{
  "filename": "ehab364.pdf",
  "title": null,
  "type": "heart_failure",
  "year": null,
  "chapters": [
    {
      "number": "1",
      "title": "1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "preamble",
        "introduction"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "2.1 Evidence review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2.2 Relationships with industry . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 1,
      "content": "2.3.1 New concepts and new sections . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2.3.2 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2.3.3 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . 11 3 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11\n",
      "keywords": [
        "industry",
        "relationships",
        "guideline",
        "review",
        "evidence"
      ],
      "tables": []
    },
    {
      "number": "3",
      "title": "3.1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 3.2 Natural history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 1,
      "content": "3.4.1 Endocardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.4.2 Epicardial pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13\n3.4.3 Cardiac resynchronization therapy (endo-and/or epicardial) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.4.4 Alternative methods (conduction system pacing, leadless pacing) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.4.4.1 Conduction system pacing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.4.4.2 Leadless pacing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.4.5 Pacing modes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.4.6 Rate-responsive pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.5 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease . . . . . . . . . . . . . . . . . . . . . . . . . . 14\n",
      "keywords": [
        "history",
        "sex",
        "natural",
        "bradycardia",
        "epidemiology"
      ],
      "tables": []
    },
    {
      "number": "4",
      "title": "4.1 History and physical examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 4.2 Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 2,
      "content": "4.3.1 Ambulatory electrocardiographic monitoring . . . . . . . . . . . . . 16 4.3.2 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4.3.3 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4.3.4 Laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 4.3.5 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17\n2 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.3.6 Sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 4.3.7 Tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 4.4 Implantable monitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 4.5 Electrophysiology study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 5 Cardiac pacing for bradycardia and conduction system disease . . . . . 21\n",
      "keywords": [
        "exercise",
        "history",
        "bradycardia",
        "genetic",
        "examination",
        "electrocardiogram",
        "physical"
      ],
      "tables": []
    },
    {
      "number": "5",
      "title": "5.1 Pacing for sinus node dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21",
      "start_page": 2,
      "end_page": 2,
      "content": "5.1.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 5.1.1.1 Sinus node dysfunction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 5.1.1.2 Bradycardia—tachycardia form of sinus node dysfunction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 5.1.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 22 5.2 Pacing for atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24\n5.2.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 5.2.1.1 First-degree atrioventricular block  . . . . . . . . . . . . . . . . . . . . . . . 24 5.2.1.2 Second-degree type I atrioventricular block (Mobitz type I or Wenckebach)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS ratio is 3:1 or higher), third-degree atrioventricular block  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 5.2.1.4 Paroxysmal atrioventricular block  . . . . . . . . . . . . . . . . . . . . . . . 24 5.2.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 25 5.2.2.1 Dual-chamber vs. ventricular pacing  . . . . . . . . . . . . . . . . . . . . 25 5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 5.3 Pacing for conduction disorders without atrioventricular block . . . 26\n5.3.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 5.3.1.1 Bundle branch block and unexplained syncope  . . . . . . . . . . . 26 5.3.1.2 Bundle branch block, unexplained syncope, and abnormal electrophysiological study  . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 5.3.1.3 Alternating bundle branch block  . . . . . . . . . . . . . . . . . . . . . . . . 27 5.3.1 Bundle branch block without symptoms  . . . . . . . . . . . . . . . . . . . 27 5.3.1.4 Patients with neuromuscular diseases  . . . . . . . . . . . . . . . . . . . 27 5.3.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 27 5.4 Pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\n5.4.1 Indications for pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 5.4.2 Pacing mode and algorithm selection . . . . . . . . . . . . . . . . . . . . . 30 5.5 Pacing for suspected (undocumented) bradycardia . . . . . . . . . . . . 30\n5.5.1 Recurrent undiagnosed syncope . . . . . . . . . . . . . . . . . . . . . . . . . 30 5.5.2 Recurrent falls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 6 Cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30\n",
      "keywords": [
        "node",
        "dysfunction",
        "sinus",
        "pacing",
        "bradycardia",
        "atrial fibrillation",
        "tachycardia",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "6",
      "title": "6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 2,
      "end_page": 2,
      "content": "6.3.1 Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy . . . . . . . . . . . 33 6.3.2 Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 6.3.3 Emerging novel modalities for CRT: role of conduction system pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35\n",
      "keywords": [
        "resynchronization",
        "biventricular",
        "epidemiology",
        "failure",
        "pacing",
        "prognosis",
        "crt",
        "heart",
        "pathophysiology",
        "ablation",
        "atrial fibrillation",
        "pacemaker",
        "cardiac",
        "therapy",
        "suitable",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "7",
      "title": "6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 2,
      "end_page": 2,
      "content": "",
      "keywords": [
        "antibradycardia",
        "patients",
        "conventional",
        "left",
        "indication",
        "pacing",
        "ejection",
        "ventricular",
        "reduced",
        "fraction"
      ],
      "tables": []
    },
    {
      "number": "8",
      "title": "7.1 Septal pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 7.2 His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 2,
      "end_page": 2,
      "content": "7.2.1 Implantation and follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 7.2.2 Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 7.2.2 Pacing for bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 7.2.2 Pace and ablate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 7.2.2 Role in cardiac resynchronization therapy . . . . . . . . . . . . . . 40 7.3 Left bundle branch area pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 7.4 Leadless pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 8 Indications for pacing in specific conditions . . . . . . . . . . . . . . . . . . . . . . . . 42\n",
      "keywords": [
        "bradycardia",
        "septal",
        "bundle",
        "pacing"
      ],
      "tables": []
    },
    {
      "number": "9",
      "title": "8.1 Pacing in acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . 42 8.2 Pacing after cardiac surgery and heart transplantation . . . . . . . . . 42",
      "start_page": 2,
      "end_page": 2,
      "content": "8.2.1 Pacing after coronary artery bypass graft and valve surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 8.2.2 Pacing after heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . 43 8.2.3 Pacing after tricuspid valve surgery . . . . . . . . . . . . . . . . . . . . . . . 43 8.3 Pacing after transcatheter aortic valve implantation . . . . . . . . . . . . 44 8.4 Cardiac pacing and cardiac resynchronization therapy in congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46\n8.4.1 Sinus node dysfunction and bradycardia—tachycardia syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 8.4.1.1 Indications for pacemaker implantation  . . . . . . . . . . . . . . . . . 46 8.4.2 Congenital atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 46 8.4.2.1 Indications for pacemaker implantation  . . . . . . . . . . . . . . . . . 46 8.4.3 Post-operative atrioventricular block . . . . . . . . . . . . . . . . . . . . . 47 8.4.3.1 Indications for pacemaker implantation  . . . . . . . . . . . . . . . . . 47 8.4.4 Cardiac resynchronization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 8.5 Pacing in hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . 47\n8.5.1 Bradyarrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 8.5.2 Pacing for the management of left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 8.5.3 Pacemaker implantation following septal myectomy and alcohol septal ablation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 8.5.4 Cardiac resynchronization therapy in end-stage hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 8.6 Pacing in rare diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\n8.6.1 LongQT syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 8.6.2 Neuromuscular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 8.6.3 Dilated cardiomyopathy with lamin A/C mutation . . . . . . . . 49 8.6.4 Mitochondrial cytopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 8.6.5 Infiltrative and metabolic diseases . . . . . . . . . . . . . . . . . . . . . . . . 49 8.6.6 Inflammatory diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 8.6.6.1 Sarcoidosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 8.7 Cardiac pacing in pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 9 Special considerations on device implantations and perioperative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50\n",
      "keywords": [
        "cardiac",
        "aortic",
        "myocardial",
        "surgery",
        "alcohol",
        "after",
        "acute",
        "tricuspid",
        "infarction",
        "pacing",
        "bradycardia",
        "heart",
        "transplantation",
        "ablation",
        "pacemaker",
        "cardiomyopathy",
        "coronary artery",
        "tachycardia"
      ],
      "tables": []
    },
    {
      "number": "10",
      "title": "9.1 General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 9.2 Antibiotic prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 2,
      "end_page": 3,
      "content": "ESC Guidelines 3\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................................................................... 9.4 Management of anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 9.5 Venous access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 9.6 Lead considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 9.7 Lead position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 9.8 Device pocket . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 10 Complications of cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53\n",
      "keywords": [
        "prophylaxis",
        "antibiotic",
        "general",
        "considerations",
        "anticoagulation"
      ],
      "tables": []
    },
    {
      "number": "11",
      "title": "10.1 General complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 10.2 Specific complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 3,
      "end_page": 3,
      "content": "10.2.1 Lead complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 10.2.2 Haematoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 10.2.3 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 10.2.4 Tricuspid valve interference . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 10.2.5 Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 11 Management considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\n",
      "keywords": [
        "tricuspid",
        "specific",
        "general",
        "complications"
      ],
      "tables": []
    },
    {
      "number": "12",
      "title": "11.1 Magnetic resonance imaging in patients with implanted cardiac devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 11.2 Radiation therapy",
      "start_page": 3,
      "end_page": 5,
      "content": "Tables of Recommendations\nRecommendations for non-invasive evaluation . . . . . . . . . . . . . . . . . . . . . . 16 Recommendation for ambulatory electrocardiographic monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Recommendations for exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Recommendations regarding imaging before implantation . . . . . . . . . . . 18 Recommendations for laboratory tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Recommendations for genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Recommendation for sleep evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Recommendation for tilt testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Recommendation for implantable loop recorders . . . . . . . . . . . . . . . . . . . 19 Recommendations for electrophysiology study . . . . . . . . . . . . . . . . . . . . . 21 Recommendations for pacing in sinus node dysfunction . . . . . . . . . . . . . 24 Recommendations for pacing for atrioventricular block . . . . . . . . . . . . . 25 Recommendations for pacing in patients with bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Recommendations for pacing for reflex syncope . . . . . . . . . . . . . . . . . . . . 30\nRecommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls . . . . . . 30 Recommendations for cardiac resynchronization therapy in patients in sinus rhythm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Recommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial fibrillation . . . . . . . . . . . . . . 35 Recommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Recommendation for patients with heart failure and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Recommendations for adding a defibrillator with cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Recommendations for using His bundle pacing . . . . . . . . . . . . . . . . . . . . . . 41 Recommendations for using leadless pacing (leadless pacemaker) . . . . 42 Recommendations for cardiac pacing after acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 Recommendations for cardiac pacing after cardiac surgery and heart transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Recommendations for cardiac pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Recommendations for cardiac pacing in patients with congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Recommendations for pacing in hypertrophic obstructive cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Recommendations for cardiac pacing in rare diseases . . . . . . . . . . . . . . . 48 Recommendation for patients with LMNA gene mutations . . . . . . . . . . 49 Recommendations for pacing in Kearns—Sayre syndrome . . . . . . . . . . 49 Recommendations for pacing in cardiac sarcoidosis . . . . . . . . . . . . . . . . . 50 Recommendations regarding device implantations and peri-operative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Recommendations for performing magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Recommendations regarding temporary cardiac pacing . . . . . . . . . . . . . 59 Recommendation when pacing is no longer indicated . . . . . . . . . . . . . . . 60 Recommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Recommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\nList of tables\nTable 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Table 3 New concepts and sections in current guidelines . . . . . . . . . . . . . 8 Table 4 New recommendations in 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Table 5 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013 . . . . . . . . . . . . . . . . . . . . . 11 Table 6 Drugs that may cause bradycardia or conduction disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Table 7 Intrinsic and extrinsic causes of bradycardia . . . . . . . . . . . . . . . . . 16 Table 8 Choice of ambulatory electrocardiographic monitoring depending on symptom frequency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Table 9 Advantages and disadvantages of a ‘backup’ ventricular lead with His bundle pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Table 10 Predictors for permanent pacing after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\n4 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................................................................... Table 11 Management of anticoagulation in pacemaker procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Table 12 Complications of pacemaker and cardiac resynchronization therapy implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 Table 13 Frequency of follow-up for routine pacemaker and cardiac resynchronization therapy, either in person alone or combined with remote device management . . . . . . . . . . . . . . . . . . . . . . . . 60 Table 14 Topics and content that may be included in patient education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Table 15 A selection of the developed quality indicators for patients undergoing cardiovascular implantable electronic device implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63\nList of figures\nFigure 1 Central Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Figure 2 Classification of documented and suspected bradyarrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Figure 3 Initial evaluation of patients with symptoms suggestive of bradycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Figure 4 Evaluation of bradycardia and conduction disease algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Figure 5 Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block . . . . . . . . . . . . . . . . . . . . . . . . 23 Figure 6 Decision algorithm for patients with unexplained syncope and bundle branch block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Figure 7 Decision pathway for cardiac pacing in patients with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Figure 8 Summary of indications for pacing in patients >40 years of age with reflex syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Figure 9 Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuitable for atrial fibrillation ablation . . . . . . . . . . . . . . . . . . . 34 Figure 10 Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pacemaker or defibrillator . . . . . . . . . . . . . . . 38 Figure 11 Three patients with different types of transitions in QRS morphology with His bundle pacing and decrementing pacing output . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Figure 12 Management of conduction abnormalities after transcatheter aortic valve implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 Figure 13 Integrated management of patients with pacemaker and cardiac resynchronization therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 Figure 14 Flowchart for evaluating magnetic resonance imaging in pacemaker patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Figure 15 Pacemaker management during radiation therapy . . . . . . . . . 58 Figure 16 Example of shared decision-making in patients considered for pacemaker/CRT implantation . . . . . . . . . . . . . . . . . . . . . . . 62\nAbbreviations and acronyms\nAF Atrial ﬁbrillation APAF Ablate and Pace in Atrial Fibrillation (trial) ATP Antitachycardia pacing AV Atrioventricular\nAVB Atrioventricular block AVJ Atrioventricular junction AVN Atrioventricular node BBB Bundle branch block BLOCK-HF Biventricular versus RV pacing in patients with AV block (trial) b.p.m. Beats per minute BRUISE CONTROL Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial BRUISE CONTROL-2 Randomized Controlled Trial of Continued Versus Interrupted Direct Oral Anti-Coagulant at the Time of Device Surgery CABG Coronary artery bypass graft CARE-HF CArdiac REsynchronization in Heart Failure (trial) CHD Congenital heart disease CI Conﬁdence interval CIED Cardiovascular implantable electronic device CMR Cardiovascular magnetic resonance COMPANION COmparison of Medical therapy, PAcing aNd deﬁbrillatION (trial) CPAP Continuous positive airway pressure CRT Cardiac resynchronization therapy CRT-D Deﬁbrillator with cardiac resynchronization therapy CRT-P Cardiac resynchronization therapy- pacemaker CSM Carotid sinus massage CSS Carotid sinus syndrome CT Computed tomography DANPACE DANish Multicenter Randomized Trial on Single Lead Atrial PACing vs. Dual Chamber Pacing in Sick Sinus Syndrome DDD Dual-chamber, atrioventricular pacing ECG Electrocardiogram/electrocardiographic Echo-CRT Echocardiography Guided Cardiac Resynchronization Therapy (trial) EF Ejection fraction EHRA European Heart Rhythm Association EMI Electromagnetic interference EORP EurObservational Research Programme EPS Electrophysiology study ESC European Society of Cardiology EuroHeart European Uniﬁed Registries On Heart Care Evaluation and Randomized Trials HBP His bundle pacing HCM Hypertrophic cardiomyopathy HF Heart failure HFmrEF Heart failure with mildly reduced ejection fraction HFpEF Heart failure with preserved ejection fraction\nESC Guidelines 5\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........................................................................................................................................................................... HFrEF Heart failure with reduced ejection fraction HOT-CRT His-optimized cardiac resynchronization therapy HR Hazard ratio HV His \u0002 ventricular interval (time from the beginning of the H deﬂection to the earliest onset of ventricular depolarization recorded in any lead, electrophysiology study of the heart) ICD Implantable cardioverter-deﬁbrillator ILR Implantable loop recorder LBBB Left bundle branch block LGE Late gadolinium contrast enhanced LQTS Long QT syndrome LV Left ventricular LVEF Left ventricular ejection fraction MADIT-CRT Multicenter Automatic Deﬁbrillator Implantation with Cardiac Resynchronization Therapy (trial) MI Myocardial infarction MIRACLE Multicenter Insync RAndomized Clinical Evaluation (trial) MOST MOde Selection Trial in Sinus-Node Dysfunction MRI Magnetic resonance imaging MUSTIC MUltisite STimulation In Cardiomyopathies (trial) NOAC Non-vitamin K antagonist oral anticoagulant NYHA New York Heart Association OAC Oral anticoagulant OMT Optimal medical therapy OR Odds ratio PATH-CHF PAcing THerapies in Congestive Heart Failure (trial) PCCD Progressive cardiac conduction disease PCI Percutaneous coronary intervention PET Positron emission tomography PM Pacemaker RA Right atrium/atrial RAFT Resynchronization \u0002 Deﬁbrillation for Ambulatory Heart Failure Trial RBBB Right bundle branch block RCT Randomized controlled trial RESET-CRT Re-evaluation of Optimal Re- synchronisation Therapy in Patients with Chronic Heart Failure (trial) REVERSE REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction (trial) RV Right ventricular/right ventricle RVA Right ventricular apical RVOT Right ventricular outﬂow tract RVS Right ventricular septum S. aureus Staphylococcus aureus\nSAR Speciﬁc absorption rate SAS Sleep apnoea syndrome SCD Sudden cardiac death SND Sinus node dysfunction SR Sinus rhythm TAVI Transcatheter aortic valve implantation VKA Vitamin K antagonist WRAP-IT World-wide Randomized Antibiotic Envelope Infection Prevention Trial\n",
      "keywords": [
        "ejection fraction",
        "echo",
        "hfmref",
        "bradycardia",
        "crt",
        "sudden cardiac death",
        "genetic",
        "guideline",
        "tavi",
        "pacemaker",
        "systolic",
        "electrocardiogram",
        "anticoagulation",
        "age",
        "anticoagulant",
        "scd",
        "nyha",
        "therapy",
        "syncope",
        "lvef",
        "radiation",
        "aortic",
        "resonance",
        "icd",
        "carotid",
        "hfref",
        "hfpef",
        "mri",
        "magnetic",
        "atrial fibrillation"
      ],
      "tables": []
    },
    {
      "number": "13",
      "title": "1 Preamble",
      "start_page": 5,
      "end_page": 7,
      "content": "Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision-making of health professionals in their daily practice. However, the final deci- sions concerning an individual patient must be made by the responsi- ble health professional(s) in consultation with the patient and caregiver, as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other soci- eties and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been estab- lished in order to make all decisions transparent to the user. The rec- ommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. In addition to the publication of Clinical Practice Guidelines, the ESC carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essen- tial to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice. Furthermore, the ESC has developed and embedded in this docu- ment a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers, and professionals to measure clinical practice as well as in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clini- cal outcomes. The Members of this Task Force were selected by the ESC, includ- ing representation from its relevant ESC subspecialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a com- prehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines Committee (CPG) policy. A critical evaluation of diagnostic and ther- apeutic procedures was performed, including assessment of the risk \u0002 benefit ratio. The level of evidence and the strength of the rec- ommendation of particular management options were weighed and graded according to pre-defined scales, as outlined below. The experts of the writing and reviewing panels provided declara- tion of interest forms for all relationships that might be perceived as\n6 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ................................... real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/ guidelines) and have been compiled in a report and published in a supplementary document simultaneously with the guidelines. This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arose during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the\nendorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions, the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publication in the  European Heart Journal . The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recom- mendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists, and an electronic version\nTable 1 Classes of recommendations\n©ESC 2021\nClasses of recommendations\nClass I  Evidence and/or general agreement  that a given treatment or procedure is\nIs recommended or is indicated\nWording to use\nClass III  Evidence or general agreement that the  given treatment or procedure is not  useful/effective, and in some cases  may be harmful .\nIs not recommended\nClass IIb\nestablished by evidence/opinion. May be considered\nClass IIa Weight of evidence/opinion is in  Should be considered\nClass II\nTable 2 Levels of evidence\nLevel of  evidence A Data derived from multiple randomized clinical trials  or meta-analyses.\nLevel of  evidence B Data derived from a single randomized clinical trial or large non-randomized studies.\nLevel of  evidence C Consensus of opinion of the experts and/or small studies,  retrospective studies, registries.\n©ESC 2021\nESC Guidelines 7\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........................................................................................ for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the EHJ website. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate, and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the out- come of disease may be favourably influenced by the thorough appli- cation of clinical recommendations. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnos- tic, or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devi- ces at the time of prescription.\n",
      "keywords": [
        "class iii",
        "recommended",
        "should be considered",
        "may be considered",
        "class i",
        "class ii",
        "preamble",
        "guideline",
        "weight"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 7",
          "page_number": 6,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is | Is recommended or is indicated",
          "bbox": [
            122.9540023803711,
            116.333984375,
            493.314990234375,
            169.80596923828125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 7",
          "page_number": 6,
          "content": "Class II |  |  | \n |  |  | \nClass IIa | Weight o | f evidence/opinion is in | Should be considered\n |  |  | \nClass IIb | establish | ed by evidence/opinion. | May be considered",
          "bbox": [
            122.9540023803711,
            175.9659423828125,
            493.314990234375,
            277.93072509765625
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 7",
          "page_number": 6,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            122.9540023803711,
            283.71197509765625,
            493.314990234375,
            336.81298828125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "8 ESC Guidelines",
          "page_number": 7,
          "content": "Concept/section |  | Section | ESC 2021\nNew section on types and modes of pacing, including con-\nduction system pacing and leadless pacing |  | 3.4 | \nNew section on sex differences in pacing |  | 3.5 | \nNew section on evaluation of patients for pacing |  | 4 | \nExpanded and updated section on CRT |  | 6 | \nNew section on alternative pacing strategies and sites |  | 7 | \nExpanded and updated section on pacing in specific con-\nditions, including detailed new sections on post TAVI,\npostoperative and pacing in the presence of tricuspid\nvalve diseases, and operations |  | 8 | \nA new section on implantation and perioperative manage-\nment, including perioperative anticoagulation |  | 9 | \nAn expanded revised section on CIED complications |  | 10 | \nA new section on various management considerations,\nincluding MRI, radiotherapy, temporary pacing, periopera-\ntive management, sport activity, and follow up |  | 11 | \nA new section on patient-centred care |  | 12 | ",
          "bbox": [
            307.86457293966544,
            439.427001953125,
            553.0789794921875,
            665.9398890904018
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "14",
      "title": "2 Introduction",
      "start_page": 7,
      "end_page": 7,
      "content": "Pacing is an important part of electrophysiology and of cardiology in general. Whereas some of the situations requiring pacing are clear and have not changed over the years, many others have evolved and have been the subject of extensive recent research, such as pacing after syn- cope ( section 5 ), pacing following transcatheter aortic valve implanta- tion (TAVI;  section 8 ), cardiac resynchronization therapy (CRT) for heart failure (HF) and for prevention of pacing-induced cardiomyop- athy ( section 6 ), and pacing in various infiltrative and inflammatory dis- eases of the heart, as well as in different cardiomyopathies ( section 8 ). Other novel topics include new diagnostic tools for decision-making on pacing ( section 4 ), as well as a whole new area of pacing the His bun- dle and the left bundle branch ( section 7 ). In addition, attention has increased in other areas, such as how to systematically minimize pro- cedural risk and avoid complications of cardiac pacing ( section 9 ), how to manage patients with pacemakers in special situations, such as when magnetic resonance imaging (MRI) or irradiation are needed ( section 11 ), how to follow patients with a pacemaker with emphasis on the use of remote monitoring, and how to include shared decision-making in caring for this patient population ( section 12 ). The last pacing guidelines of the European Society of Cardiology (ESC) were published in 2013; therefore, a new set of guidelines was felt to be timely and necessary. To address these topics, a Task Force was established to create the new guidelines. As well as receiving the input of leading experts in the field of pacing, the Task Force was enhanced by representatives from the Association for Acute CardioVascular Care, the Heart Failure Association, the European Association of Cardiothoracic Surgery, the European Association of Percutaneous Cardiovascular Interventions, the ESC Working Group on Myocardial and\nPericardial Diseases, as well as the Association of Cardiovascular Nursing & Allied Professions.\n",
      "keywords": [
        "aortic",
        "introduction",
        "mri",
        "crt",
        "tavi",
        "pacemaker",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "15",
      "title": "2.1 Evidence review This document is divided into sections, each with a section coordina- tor and several authors. They were asked to thoroughly review the recent literature on their topics, and to co",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "sections",
        "were",
        "document",
        "evidence",
        "thoroughly",
        "divided",
        "they",
        "several",
        "into",
        "recent",
        "literature",
        "their",
        "section",
        "coordina",
        "authors",
        "review",
        "each",
        "asked",
        "topics"
      ],
      "tables": []
    },
    {
      "number": "16",
      "title": "2.2 Relationships with industry All work in this document was voluntary and all co-authors were required to declare and prove that they do not have conflicts of inter- ests, as defined recently by the",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "defined",
        "work",
        "industry",
        "relationships",
        "inter",
        "conflicts",
        "ests",
        "were",
        "document",
        "voluntary",
        "recently",
        "declare",
        "prove",
        "they",
        "authors",
        "required"
      ],
      "tables": []
    },
    {
      "number": "17",
      "title": "2.3 What is new in these guidelines 2.3.1 New concepts and new sections",
      "start_page": 7,
      "end_page": 12,
      "content": "Table 3 New concepts and sections in current guidelines\nConcept/section Section\nNew section on types and modes of pacing, including con-\nduction system pacing and leadless pacing\n3.4\nNew section on sex differences in pacing 3.5\nNew section on evaluation of patients for pacing 4\nExpanded and updated section on CRT 6\nNew section on alternative pacing strategies and sites 7\nExpanded and updated section on pacing in speciﬁc con-\nditions, including detailed new sections on post TAVI,\npostoperative and pacing in the presence of tricuspid valve diseases, and operations\n8\nA new section on implantation and perioperative manage-\nment, including perioperative anticoagulation\n9\nAn expanded revised section on CIED complications 10\nA new section on various management considerations,\nincluding MRI, radiotherapy, temporary pacing, periopera-\ntive management, sport activity, and follow up\n11\nA new section on patient-centred care 12\nCIED = cardiovascular implantable electronic device; CRT = cardiac resynchroni- zation therapy; MRI = magnetic resonance imaging; TAVI = transcatheter aortic valve implantation.\nESC 2021\n. .............................................................................\n8 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n2.3.2 New recommendations in 2021\nTable 4 New recommendations in 2021\nRecommendations Class a Level b\nEvaluation of the patient with suspected or documented brady-\ncardia or conduction system disease\nMonitoring\nIn patients with infrequent (less than once a month) unexplained syncope or other symp-\ntoms suspected to be caused by bradycardia, in\nwhom a comprehensive evaluation did not dem- onstrate a cause, long-term ambulatory monitor-\ning with an ILR is recommended.\nI A\nAmbulatory electrocardiographic monitoring is\nrecommended in the evaluation of patients with suspected bradycardia to correlate rhythm dis-\nturbances with symptoms.\nI C\nCarotid massage\nOnce carotid stenosis is ruled out c , carotid sinus massage is recommended in patients with syn-\ncope of unknown origin compatible with a reﬂex\nmechanism or with symptoms related to pres- sure/manipulation of the carotid sinus area.\nI B\nTilt test\nTilt testing should be considered in patients with\nsuspected recurrent reﬂex syncope. IIa B\nExercise test\nExercise testing is recommended in patients\nwho experience symptoms suspicious of brady-\ncardia during or immediately after exertion.\nI C\nIn patients with suspected chronotropic incom-\npetence, exercise testing should be considered\nto conﬁrm the diagnosis.\nIIa B\nIn patients with intra-ventricular conduction dis- ease or AVB of unknown level, exercise testing\nmay be considered to expose infranodal block.\nIIb C\nImaging\nCardiac imaging is recommended in patients with suspected or documented symptomatic\nbradycardia to evaluate the presence of struc-\ntural heart disease, to determine left ventricular systolic function, and to diagnose potential\ncauses of conduction disturbances.\nI C\nMultimodality imaging (CMR, CT, PET) should be considered for myocardial tissue character-\nization in the diagnosis of speciﬁc pathologies\nassociated with conduction abnormalities need- ing pacemaker implantation, particularly in\npatients younger than 60 years.\nIIa C\nContinued\nLaboratory tests\nIn addition to preimplant laboratory tests, d   spe-\nciﬁc laboratory tests are recommended in\npatients with clinical suspicion for potential causes of bradycardia (e.g. thyroid function tests,\nLyme titre, digitalis level, potassium, calcium, and pH) to diagnose and treat these conditions.\nI C\nSleep evaluation\nScreening for SAS is recommended in patients\nwith symptoms of SAS and in the presence of severe bradycardia or advanced AVB during\nsleep.\nI C\nElectrophysiological study\nIn patients with syncope and bifascicular block, EPS should be considered when syncope\nremains unexplained after non-invasive evalua-\ntion or when an immediate decision about pac- ing is needed due to severity, unless empirical\npacemaker implantation is preferred (especially\nin elderly and frail patients).\nIIa B\nIn patients with syncope and sinus bradycardia, EPS may be considered when non-invasive tests\nhave failed to show a correlation between syn-\ncope and bradycardia.\nIIb B\nGenetics\nGenetic testing should be considered in patients\nwith early onset (age <50 years) of progressive\ncardiac conduction disease.\nIIa C\nGenetic testing should be considered in family\nmembers following the identiﬁcation of a patho-\ngenic genetic variant that explains the clinical phenotype of cardiac conduction disease in an\nindex case.\nIIa C\nCardiac pacing for bradycardia and conduction system disease\nPacing is indicated in symptomatic patients with the bradycardia-tachycardia form of SND to cor-\nrect bradyarrhythmias and enable pharmacologi-\ncal treatment, unless ablation of the tachyarrhythmia is preferred.\nI B\nPacing is indicated in patients with atrial arrhyth-\nmia (mainly AF) and permanent or paroxysmal\nthird- or high-degree AVB irrespective of symptoms.\nI C\nIn patients with SND and DDD PM, minimiza-\ntion of unnecessary ventricular pacing through programming is recommended.\nI A\nDual chamber cardiac pacing is indicated to\nreduce recurrent syncope in patients aged >40\nyears with severe, unpredictable, recurrent syn- cope who have: •   spontaneous documented symptomatic asys-\ntolic pause/s >3 s or asymptomatic pause/s >6 s due to sinus arrest or AVB; or •   cardioinhibitory carotid sinus syndrome; or •   asystolic syncope during tilt testing.\nI A\nContinued . ...........................................................................................................................................................................\nESC Guidelines 9\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nIn patients with recurrent unexplained falls, the\nsame assessment as for unexplained syncope\nshould be considered.\nIIa C\nAF ablation should be considered as a strategy to avoid pacemaker implantation in patients with\nAF-related bradycardia or symptomatic pre- automaticity pauses, after AF conversion, taking\ninto account the clinical situation.\nIIa C\nIn patients with the bradycardia-tachycardia var-\niant of SND, programming of atrial ATP may be considered.\nIIb B\nDual-chamber cardiac pacing may be considered\nto reduce syncope recurrences in patients with the clinical features of adenosine-sensitive\nsyncope.\nIIb B\nCardiac resynchronization therapy\nIn patients who are candidates for an ICD and who have CRT indication, implantation of a\nCRT-D is recommended.\nI A\nIn patients who are candidates for CRT, implan-\ntation of a CRT-D should be considered after individual risk assessment and using shared deci-\nsion-making.\nIIa B\nIn patients with symptomatic AF and an uncon- trolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), CRT\nrather than standard RV pacing should be con- sidered in patients with HFmrEF.\nIIa C\nIn patients with symptomatic AF and an uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), RV pac- ing should be considered in patients with HFpEF.\nIIa B\nIn patients with symptomatic AF and an uncon-\ntrolled heart rate who are candidates for AVJ ablation (irrespective of QRS duration), CRT\nmay be considered in patients with HFpEF.\nIIb B\nAlternate site pacing\nHis bundle pacing\nIn patients treated with HBP, device program- ming tailored to speciﬁc requirements of His\nbundle pacing is recommended.\nI C\nIn CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be con-\nsidered as a treatment option along with other\ntechniques such as surgical epicardial lead.\nIIa B\nIn patients treated with HBP, implantation of a right ventricular lead used as “backup” for pacing\nshould be considered in speciﬁc situations (e.g.\npacemaker-dependency, high-grade AVB, infra- nodal block, high pacing threshold, planned AVJ\nablation), or for sensing in case of issues with\ndetection (e.g. risk of ventricular undersensing or oversensing of atrial/His potentials).\nIIa C\nContinued\nHBP with a ventricular backup lead may be con-\nsidered in patients in whom a “pace-and-ablate”\nstrategy for rapidly conducted supraventricular arrhythmia is indicated, particularly when intrin-\nsic QRS is narrow.\nIIb C\nHBP may be considered as an alternative to right ventricular pacing in patients with AVB and LVEF\n>40%, who are anticipated to have >20% ven-\ntricular pacing.\nIIb C\nLeadless pacing\nLeadless pacemakers should be considered as an\nalternative to transvenous pacemakers when no\nupper extremity venous access exists or when risk of device pocket infection is particularly\nhigh, such as previous infection and patients on\nhaemodialysis.\nIIa B\nLeadless pacemakers may be considered as an alternative to standard single lead ventricular\npacing, taking into consideration life expectancy\nand using shared decision-making.\nIIb C\nIndications for pacing in speciﬁc conditions\nPacing in acute myocardial infarction\nImplantation of a permanent pacemaker is indi-\ncated with the same recommendations as in a general population ( section 5.2 ) when AVB does\nnot resolve within a waiting period of at least 5\ndays after MI.\nI C\nIn selected patients with AVB in context of ante- rior wall MI and acute HF, early device implanta-\ntion (CRT-D/CRT-P) may be considered.\nIIb C\nPacing in cardiac surgery\n1) High-degree or complete AVB after cardiac surgery. A period of clinical observation for at\nleast 5 days is indicated in order to assess\nwhether the rhythm disturbance is transient and resolves. However, in the case of complete AVB\nwith low or no escape rhythm when resolution\nis unlikely, this observation period can be shortened.\nI C\nSND after cardiac surgery and heart transplanta-\ntion. Before permanent pacemaker implantation, a period of observation for up to 6 weeks should\nbe considered.\nIIa C\nChronotropic incompetence after heart trans-\nplantation. Cardiac pacing should be considered for chronotropic incompetence persisting more\nthan 6 weeks after heart transplantation to\nimprove quality of life.\nIIa C\nContinued\n. ...........................................................................................................................................................................\n10 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nSurgery for valvular endocarditis and intraopera-\ntive complete AVB. Immediate epicardial pace-\nmaker implantation should be considered in patients with surgery for valvular endocarditis\nand complete AVB if one of the following predic-\ntors of persistence is present: preoperative con- duction abnormality,  Staphylococcus aureus\ninfection, intracardiac abscess, tricuspid valve\ninvolvement, or previous valvular surgery.\nIIa C\nPatients requiring pacing at the time of tricuspid\nvalve surgery. Transvalvular leads should be\navoided and epicardial ventricular leads used. During tricuspid valve surgery, removal of pre-\nexisting transvalvular leads should be considered\nand preferred over sewing-in the lead between the annulus and a bio-prosthesis or annuloplasty\nring. In the case of an isolated tricuspid annulo-\nplasty based on an individual risk-beneﬁt analysis, a pre-existing right ventricular lead may be left in\nplace without jailing it between ring and annulus.\nIIa C\nPatients requiring pacing after biological tricuspid\nvalve replacement/tricuspid valve ring repair. When ventricular pacing is indicated, transve-\nnous implantation of a coronary sinus lead or\nminimally invasive placement of an epicardial ventricular lead should be considered and pre-\nferred over a transvenous transvalvular\napproach.\nIIa C\nPatients requiring pacing after mechanical tricus-\npid valve replacement. Implantation of a trans-\nvalvular right ventricular lead should be avoided.\nIII C\nPacing in transcatheter aortic valve implantation\nPermanent pacing is recommended in patients\nwith complete or high-degree AVB that persists\nfor 24 - 48 h after TAVI.\nI B\nPermanent pacing is recommended in patients with new onset alternating BBB after TAVI. I C\nEarly e   permanent pacing should be considered in\npatients with pre-existing RBBB who develop any further conduction disturbance during or\nafter TAVI. f\nIIa B\nAmbulatory ECG monitoring g   or an electro-\nphysiology study h   should be considered for patients with new LBBB with QRS >150 ms or\nPR >240 ms with no further prolongation during\n>48 h after TAVI.\nIIa C\nContinued\nAmbulatory ECG monitoring g   or electrophysiol-\nogy study h   may be considered for TAVI patients\nwith pre-existing conduction abnormality who develop further prolongation of QRS or PR\n>20 ms.\nIIb C\nProphylactic permanent pacemaker implantation is not indicated before TAVI in patients with\nRBBB and no indication for permanent pacing.\nIII C\nVarious syndromes\nIn patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or\nthird-degree AVB or HV >_70 ms, with or with-\nout symptoms, permanent pacing is indicated. i\nI C\nIn patients with LMNA gene mutations, including Emery-Dreifuss and limb girdle muscular dystro-\nphies who fulﬁl conventional criteria for pace-\nmaker implantation or who have prolonged PR with LBBB, ICD implantation with pacing capabil-\nities should be considered if at least 1-year sur-\nvival is expected.\nIIa C\nIn patients with Kearns-Sayre syndrome who\nhave PR prolongation, any degree of AVB, bun-\ndle branch block, or fascicular block, permanent pacing should be considered.\nIIa C\nIn patients with neuromuscular disease such as\nmyotonic dystrophy type 1 with PR >_240 ms or\nQRS duration >_120 ms, permanent pacemaker implantation may be considered. i\nIIb C\nIn patients with Kearns-Sayre Syndrome without\ncardiac conduction disorder, permanent pacing may be considered prophylactically.\nIIb C\nSarcoidosis\nIn patients with cardiac sarcoidosis who have\npermanent or transient AVB, implantation of a device capable of cardiac pacing should be\nconsidered. i\nIIa C\nIn patients with sarcoidosis and indication for\npermanent pacing who have LVEF <50%, implan- tation of a CRT-D should be considered.\nIIa C\nSpecial considerations on device implantations and periopera-\ntive management\nAdministration of preoperative antibiotic pro- phylaxis within 1 h of skin incision is recom-\nmended to reduce risk of CIED infection.\nI A\nChlorhexidine alcohol instead of povidone- iodine alcohol should be considered for skin\nantisepsis.\nIIa B\nContinued . ......................................................................................................................................................\nESC Guidelines 11\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nFor venous access, the cephalic or axillary vein\nshould be considered as ﬁrst choice. IIa B\nFor implantation of coronary sinus leads, quadri-\npolar leads should be considered as ﬁrst choice. IIa C\nTo conﬁrm target ventricular lead position, use\nof multiple ﬂuoroscopic views should be\nconsidered.\nIIa C\nRinsing the device pocket with normal saline sol- ution before wound closure should be\nconsidered.\nIIa C\nIn patients undergoing a reintervention CIED procedure, the use of an antibiotic-eluting enve-\nlope may be considered.\nIIb B\nPacing of the mid-ventricular septum may be considered in patients with a high risk of perfora-\ntion (elderly, previous perforation).\nIIb C\nIn pacemaker implantations in patients with pos-\nsible pocket issues such as increased risk of ero- sion due to low body mass index, Twiddler’s\nsyndrome or aesthetic reasons, a submuscular\ndevice pocket may be considered.\nIIb C\nHeparin-bridging of anticoagulated patients is\nnot recommended. III A\nPermanent pacemaker implantation is not rec-\nommended in patients with fever. Pacemaker implantation should be delayed until the patient\nhas been afebrile for at least 24 h.\nIII B\nManagement considerations\nRemote monitoring\nRemote device management is recommended to\nreduce number of in-ofﬁce follow-up in patients\nwith pacemakers who have difﬁculties to attend in-ofﬁce visits (e.g. due to reduced mobility or\nother commitments or according to patient\npreference).\nI A\nRemote monitoring is recommended in case of a device component that has been recalled or is\non advisory, to enable early detection of action-\nable events in patients, particularly those who are at increased risk (e.g. in case of pacemaker-\ndependency).\nI C\nContinued\nIn-ofﬁce routine follow-up of single- and dual-\nchamber pacemakers may be spaced by up to 24\nmonths in patients on remote device management.\nIIa A\nTemporary pacing\nTemporary transvenous pacing is recommended\nin cases of haemodynamic-compromising bra- dyarrhythmia refractory to intravenous chrono-\ntropic drugs.\nI C\nTranscutaneous pacing should be considered in cases of haemodynamic compromising bradyar-\nrhythmia when temporary transvenous pacing is\nnot possible or available.\nIIa C\nTemporary transvenous pacing should be con- sidered when immediate pacing is indicated and\npacing indications are expected to be reversible,\nsuch as in the context of myocardial ischaemia, myocarditis, electrolyte disturbances, toxic\nexposure, or after cardiac surgery.\nIIa C\nTemporary transvenous pacing should be con- sidered as a bridge to permanent pacemaker\nimplantation, when this procedure is not imme-\ndiately available or possible due to concomitant infection.\nIIa C\nFor long-term temporary transvenous pacing, an\nactive ﬁxation lead inserted through the skin and\nconnected to an external pacemaker should be considered.\nIIa C\nMiscellaneous\nWhen pacing is no longer indicated, a decision\non the management strategy should be based on an individual risk-beneﬁt analysis in a shared\ndecision-making process together with the\npatient.\nI C\nMRI may be considered in pacemaker patients\nwith abandoned transvenous leads if no alterna-\ntive imaging modality is available.\nIIb C\nContinued\n. ....................................................................................................................................\n12 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .........................\n2.3.3 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013\n",
      "keywords": [
        "sections",
        "should be considered",
        "hfmref",
        "these",
        "bradycardia",
        "crt",
        "genetic",
        "guideline",
        "concepts",
        "tavi",
        "pacemaker",
        "systolic",
        "anticoagulation",
        "tachycardia",
        "age",
        "tricuspid",
        "tilt test",
        "syncope",
        "lvef",
        "aortic",
        "arrhythmia",
        "icd",
        "carotid",
        "valve replacement",
        "sex",
        "hfpef",
        "mri",
        "what",
        "guidelines",
        "level b"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 9",
          "page_number": 8,
          "content": "Laboratory tests |  |  | \nIn addition to preimplant laboratory tests,d spe-\ncific laboratory tests are recommended in\npatients with clinical suspicion for potential\ncauses of bradycardia (e.g. thyroid function tests,\nLyme titre, digitalis level, potassium, calcium, and\npH) to diagnose and treat these conditions. | I | C | \nSleep evaluation |  |  | \nScreening for SAS is recommended in patients\nwith symptoms of SAS and in the presence of\nsevere bradycardia or advanced AVB during\nsleep. | I | C | \nElectrophysiological study |  |  | \nIn patients with syncope and bifascicular block,\nEPS should be considered when syncope\nremains unexplained after non-invasive evalua-\ntion or when an immediate decision about pac-\ning is needed due to severity, unless empirical\npacemaker implantation is preferred (especially\nin elderly and frail patients). | IIa | B | \nIn patients with syncope and sinus bradycardia,\nEPS may be considered when non-invasive tests\nhave failed to show a correlation between syn-\ncope and bradycardia. | IIb | B | \nGenetics |  |  | \nGenetic testing should be considered in patients\nwith early onset (age <50 years) of progressive\ncardiac conduction disease. | IIa | C | \nGenetic testing should be considered in family\nmembers following the identification of a patho-\ngenic genetic variant that explains the clinical\nphenotype of cardiac conduction disease in an\nindex case. | IIa | C | \nCardiac pacing for bradycardia and conduction system disease |  |  | \nPacing is indicated in symptomatic patients with\nthe bradycardia-tachycardia form of SND to cor-\nrect bradyarrhythmias and enable pharmacologi-\ncal treatment, unless ablation of the\ntachyarrhythmia is preferred. | I | B | \nPacing is indicated in patients with atrial arrhyth-\nmia (mainly AF) and permanent or paroxysmal\nthird- or high-degree AVB irrespective of\nsymptoms. | I | C | \nIn patients with SND and DDD PM, minimiza-\ntion of unnecessary ventricular pacing through\nprogramming is recommended. | I | A | \nDual chamber cardiac pacing is indicated to\nreduce recurrent syncope in patients aged >40\nyears with severe, unpredictable, recurrent syn-\ncope who have:\n• spontaneous documented symptomatic asys-\ntolic pause/s >3 s or asymptomatic pause/s\n>6 s due to sinus arrest or AVB; or\n• cardioinhibitory carotid sinus syndrome; or\n• asystolic syncope during tilt testing. | I | A | ",
          "bbox": [
            311.3364264446756,
            59.86335754394531,
            556.4977101972027,
            737.7412567138672
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 9",
          "page_number": 8,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nEvaluation of the patient with suspected or documented brady-\ncardia or conduction system disease |  |  | \nMonitoring |  |  | \nIn patients with infrequent (less than once a\nmonth) unexplained syncope or other symp-\ntoms suspected to be caused by bradycardia, in\nwhom a comprehensive evaluation did not dem-\nonstrate a cause, long-term ambulatory monitor-\ning with an ILR is recommended. | I | A | \nAmbulatory electrocardiographic monitoring is\nrecommended in the evaluation of patients with\nsuspected bradycardia to correlate rhythm dis-\nturbances with symptoms. | I | C | \nCarotid massage |  |  | \nOnce carotid stenosis is ruled outc, carotid sinus\nmassage is recommended in patients with syn-\ncope of unknown origin compatible with a reflex\nmechanism or with symptoms related to pres-\nsure/manipulation of the carotid sinus area. | I | B | \nTilt test |  |  | \nTilt testing should be considered in patients with\nsuspected recurrent reflex syncope. | IIa | B | \nExercise test |  |  | \nExercise testing is recommended in patients\nwho experience symptoms suspicious of brady-\ncardia during or immediately after exertion. | I | C | \nIn patients with suspected chronotropic incom-\npetence, exercise testing should be considered\nto confirm the diagnosis. | IIa | B | \nIn patients with intra-ventricular conduction dis-\nease or AVB of unknown level, exercise testing\nmay be considered to expose infranodal block. | IIb | C | \nImaging |  |  | \nCardiac imaging is recommended in patients\nwith suspected or documented symptomatic\nbradycardia to evaluate the presence of struc-\ntural heart disease, to determine left ventricular\nsystolic function, and to diagnose potential\ncauses of conduction disturbances. | I | C | \nMultimodality imaging (CMR, CT, PET) should\nbe considered for myocardial tissue character-\nization in the diagnosis of specific pathologies\nassociated with conduction abnormalities need-\ning pacemaker implantation, particularly in\npatients younger than 60 years. | IIa | C | ",
          "bbox": [
            47.042059173583986,
            98.0393575032552,
            292.13855275800154,
            679.0011727469308
          ],
          "function_potential": "raw"
        },
        {
          "title": "10 ESC Guidelines",
          "page_number": 9,
          "content": "In patients with recurrent unexplained falls, the\nsame assessment as for unexplained syncope\nshould be considered. | IIa | C | \nAF ablation should be considered as a strategy\nto avoid pacemaker implantation in patients with\nAF-related bradycardia or symptomatic pre-\nautomaticity pauses, after AF conversion, taking\ninto account the clinical situation. | IIa | C | \nIn patients with the bradycardia-tachycardia var-\niant of SND, programming of atrial ATP may be\nconsidered. | IIb | B | \nDual-chamber cardiac pacing may be considered\nto reduce syncope recurrences in patients with\nthe clinical features of adenosine-sensitive\nsyncope. | IIb | B | \nCardiac resynchronization therapy |  |  | \nIn patients who are candidates for an ICD and\nwho have CRT indication, implantation of a\nCRT-D is recommended. | I | A | \nIn patients who are candidates for CRT, implan-\ntation of a CRT-D should be considered after\nindividual risk assessment and using shared deci-\nsion-making. | IIa | B | \nIn patients with symptomatic AF and an uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), CRT\nrather than standard RV pacing should be con-\nsidered in patients with HFmrEF. | IIa | C | \nIn patients with symptomatic AF and an uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), RV pac-\ning should be considered in patients with HFpEF. | IIa | B | \nIn patients with symptomatic AF and an uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), CRT\nmay be considered in patients with HFpEF. | IIb | B | \nAlternate site pacing |  |  | \nHis bundle pacing |  |  | \nIn patients treated with HBP, device program-\nming tailored to specific requirements of His\nbundle pacing is recommended. | I | C | \nIn CRT candidates in whom coronary sinus lead\nimplantation is unsuccessful, HBP should be con-\nsidered as a treatment option along with other\ntechniques such as surgical epicardial lead. | IIa | B | \nIn patients treated with HBP, implantation of a\nright ventricular lead used as “backup” for pacing\nshould be considered in specific situations (e.g.\npacemaker-dependency, high-grade AVB, infra-\nnodal block, high pacing threshold, planned AVJ\nablation), or for sensing in case of issues with\ndetection (e.g. risk of ventricular undersensing\nor oversensing of atrial/His potentials). | IIa | C | ",
          "bbox": [
            42.45393371582031,
            59.878027643476216,
            287.60301310221354,
            713.7541634695871
          ],
          "function_potential": "raw"
        },
        {
          "title": "10 ESC Guidelines",
          "page_number": 9,
          "content": "HBP with a ventricular backup lead may be con-\nsidered in patients in whom a “pace-and-ablate”\nstrategy for rapidly conducted supraventricular\narrhythmia is indicated, particularly when intrin-\nsic QRS is narrow. | IIb | C | \nHBP may be considered as an alternative to right\nventricular pacing in patients with AVB and LVEF\n>40%, who are anticipated to have >20% ven-\ntricular pacing. | IIb | C | \nLeadless pacing |  |  | \nLeadless pacemakers should be considered as an\nalternative to transvenous pacemakers when no\nupper extremity venous access exists or when\nrisk of device pocket infection is particularly\nhigh, such as previous infection and patients on\nhaemodialysis. | IIa | B | \nLeadless pacemakers may be considered as an\nalternative to standard single lead ventricular\npacing, taking into consideration life expectancy\nand using shared decision-making. | IIb | C | \nIndications for pacing in specific conditions |  |  | \nPacing in acute myocardial infarction |  |  | \nImplantation of a permanent pacemaker is indi-\ncated with the same recommendations as in a\ngeneral population (section 5.2) when AVB does\nnot resolve within a waiting period of at least 5\ndays after MI. | I | C | \nIn selected patients with AVB in context of ante-\nrior wall MI and acute HF, early device implanta-\ntion (CRT-D/CRT-P) may be considered. | IIb | C | \nPacing in cardiac surgery |  |  | \n1) High-degree or complete AVB after cardiac\nsurgery. A period of clinical observation for at\nleast 5 days is indicated in order to assess\nwhether the rhythm disturbance is transient and\nresolves. However, in the case of complete AVB\nwith low or no escape rhythm when resolution\nis unlikely, this observation period can be\nshortened. | I | C | \nSND after cardiac surgery and heart transplanta-\ntion. Before permanent pacemaker implantation,\na period of observation for up to 6 weeks should\nbe considered. | IIa | C | \nChronotropic incompetence after heart trans-\nplantation. Cardiac pacing should be considered\nfor chronotropic incompetence persisting more\nthan 6 weeks after heart transplantation to\nimprove quality of life. | IIa | C | ",
          "bbox": [
            306.8035024007161,
            59.878027643476216,
            551.9618225097656,
            651.3412388392857
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 11",
          "page_number": 10,
          "content": "Surgery for valvular endocarditis and intraopera-\ntive complete AVB. Immediate epicardial pace-\nmaker implantation should be considered in\npatients with surgery for valvular endocarditis\nand complete AVB if one of the following predic-\ntors of persistence is present: preoperative con-\nduction abnormality, Staphylococcus aureus\ninfection, intracardiac abscess, tricuspid valve\ninvolvement, or previous valvular surgery. | IIa | C | \nPatients requiring pacing at the time of tricuspid\nvalve surgery. Transvalvular leads should be\navoided and epicardial ventricular leads used.\nDuring tricuspid valve surgery, removal of pre-\nexisting transvalvular leads should be considered\nand preferred over sewing-in the lead between\nthe annulus and a bio-prosthesis or annuloplasty\nring. In the case of an isolated tricuspid annulo-\nplasty based on an individual risk-benefit analysis,\na pre-existing right ventricular lead may be left in\nplace without jailing it between ring and annulus. | IIa | C | \nPatients requiring pacing after biological tricuspid\nvalve replacement/tricuspid valve ring repair.\nWhen ventricular pacing is indicated, transve-\nnous implantation of a coronary sinus lead or\nminimally invasive placement of an epicardial\nventricular lead should be considered and pre-\nferred over a transvenous transvalvular\napproach. | IIa | C | \nPatients requiring pacing after mechanical tricus-\npid valve replacement. Implantation of a trans-\nvalvular right ventricular lead should be avoided. | III | C | \nPacing in transcatheter aortic valve implantation |  |  | \nPermanent pacing is recommended in patients\nwith complete or high-degree AVB that persists\nfor 24 - 48 h after TAVI. | I | B | \nPermanent pacing is recommended in patients\nwith new onset alternating BBB after TAVI. | I | C | \nEarlye permanent pacing should be considered in\npatients with pre-existing RBBB who develop\nany further conduction disturbance during or\nafter TAVI.f | IIa | B | \nAmbulatory ECG monitoringg or an electro-\nphysiology studyh should be considered for\npatients with new LBBB with QRS >150 ms or\nPR >240 ms with no further prolongation during\n>48 h after TAVI. | IIa | C | ",
          "bbox": [
            46.985221590314595,
            59.878027643476216,
            292.13853053042766,
            622.5412510463169
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 11",
          "page_number": 10,
          "content": "Ambulatory ECG monitoringg or electrophysiol-\nogy studyh may be considered for TAVI patients\nwith pre-existing conduction abnormality who\ndevelop further prolongation of QRS or PR\n>20 ms. | IIb | C | \nProphylactic permanent pacemaker implantation\nis not indicated before TAVI in patients with\nRBBB and no indication for permanent pacing. | III | C | \nVarious syndromes |  |  | \nIn patients with neuromuscular diseases such as\nmyotonic dystrophy type 1 and any second- or\nthird-degree AVB or HV >70 ms, with or with-\n_\nout symptoms, permanent pacing is indicated.i | I | C | \nIn patients with LMNA gene mutations, including\nEmery-Dreifuss and limb girdle muscular dystro-\nphies who fulfil conventional criteria for pace-\nmaker implantation or who have prolonged PR\nwith LBBB, ICD implantation with pacing capabil-\nities should be considered if at least 1-year sur-\nvival is expected. | IIa | C | \nIn patients with Kearns-Sayre syndrome who\nhave PR prolongation, any degree of AVB, bun-\ndle branch block, or fascicular block, permanent\npacing should be considered. | IIa | C | \nIn patients with neuromuscular disease such as\nmyotonic dystrophy type 1 with PR >240 ms or\n_\nQRS duration >120 ms, permanent pacemaker\n_\nimplantation may be considered.i | IIb | C | \nIn patients with Kearns-Sayre Syndrome without\ncardiac conduction disorder, permanent pacing\nmay be considered prophylactically. | IIb | C | \nSarcoidosis |  |  | \nIn patients with cardiac sarcoidosis who have\npermanent or transient AVB, implantation of a\ndevice capable of cardiac pacing should be\nconsidered.i | IIa | C | \nIn patients with sarcoidosis and indication for\npermanent pacing who have LVEF <50%, implan-\ntation of a CRT-D should be considered. | IIa | C | \nSpecial considerations on device implantations and periopera-\ntive management |  |  | \nAdministration of preoperative antibiotic pro-\nphylaxis within 1 h of skin incision is recom-\nmended to reduce risk of CIED infection. | I | A | \nChlorhexidine alcohol instead of povidone-\niodine alcohol should be considered for skin\nantisepsis. | IIa | B | ",
          "bbox": [
            311.33628312931506,
            59.878027643476216,
            556.4977669551455,
            640.5631844656808
          ],
          "function_potential": "raw"
        },
        {
          "title": "12 ESC Guidelines",
          "page_number": 11,
          "content": "For venous access, the cephalic or axillary vein\nshould be considered as first choice. | IIa | B | \nFor implantation of coronary sinus leads, quadri-\npolar leads should be considered as first choice. | IIa | C | \nTo confirm target ventricular lead position, use\nof multiple fluoroscopic views should be\nconsidered. | IIa | C | \nRinsing the device pocket with normal saline sol-\nution before wound closure should be\nconsidered. | IIa | C | \nIn patients undergoing a reintervention CIED\nprocedure, the use of an antibiotic-eluting enve-\nlope may be considered. | IIb | B | \nPacing of the mid-ventricular septum may be\nconsidered in patients with a high risk of perfora-\ntion (elderly, previous perforation). | IIb | C | \nIn pacemaker implantations in patients with pos-\nsible pocket issues such as increased risk of ero-\nsion due to low body mass index, Twiddler’s\nsyndrome or aesthetic reasons, a submuscular\ndevice pocket may be considered. | IIb | C | \nHeparin-bridging of anticoagulated patients is\nnot recommended. | III | A | \nPermanent pacemaker implantation is not rec-\nommended in patients with fever. Pacemaker\nimplantation should be delayed until the patient\nhas been afebrile for at least 24 h. | III | B | \nManagement considerations |  |  | \nRemote monitoring |  |  | \nRemote device management is recommended to\nreduce number of in-office follow-up in patients\nwith pacemakers who have difficulties to attend\nin-office visits (e.g. due to reduced mobility or\nother commitments or according to patient\npreference). | I | A | \nRemote monitoring is recommended in case of a\ndevice component that has been recalled or is\non advisory, to enable early detection of action-\nable events in patients, particularly those who\nare at increased risk (e.g. in case of pacemaker-\ndependency). | I | C | ",
          "bbox": [
            42.45381164550781,
            59.8781978062221,
            287.60292170597955,
            567.3223048618862
          ],
          "function_potential": "raw"
        },
        {
          "title": "12 ESC Guidelines",
          "page_number": 11,
          "content": "In-office routine follow-up of single- and dual-\nchamber pacemakers may be spaced by up to 24\nmonths in patients on remote device\nmanagement. | IIa | A | \nTemporary pacing |  |  | \nTemporary transvenous pacing is recommended\nin cases of haemodynamic-compromising bra-\ndyarrhythmia refractory to intravenous chrono-\ntropic drugs. | I | C | \nTranscutaneous pacing should be considered in\ncases of haemodynamic compromising bradyar-\nrhythmia when temporary transvenous pacing is\nnot possible or available. | IIa | C | \nTemporary transvenous pacing should be con-\nsidered when immediate pacing is indicated and\npacing indications are expected to be reversible,\nsuch as in the context of myocardial ischaemia,\nmyocarditis, electrolyte disturbances, toxic\nexposure, or after cardiac surgery. | IIa | C | \nTemporary transvenous pacing should be con-\nsidered as a bridge to permanent pacemaker\nimplantation, when this procedure is not imme-\ndiately available or possible due to concomitant\ninfection. | IIa | C | \nFor long-term temporary transvenous pacing, an\nactive fixation lead inserted through the skin and\nconnected to an external pacemaker should be\nconsidered. | IIa | C | \nMiscellaneous |  |  | \nWhen pacing is no longer indicated, a decision\non the management strategy should be based on\nan individual risk-benefit analysis in a shared\ndecision-making process together with the\npatient. | I | C | \nMRI may be considered in pacemaker patients\nwith abandoned transvenous leads if no alterna-\ntive imaging modality is available. | IIb | C | ",
          "bbox": [
            306.8001069099672,
            59.8781978062221,
            551.9614664713541,
            515.7313079833984
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 13",
          "page_number": 12,
          "content": "Patient-centred care |  |  | \nIn patients considered for pacemaker or CRT,\nthe decision should be based on the best\navailable evidence with consideration of\nindividual risk-benefits of each option, the\npatient\u0002s preferences, and goals of care, and it is\nrecommended to follow an integrated care\napproach and use the principles of patient-\ncentred care and shared decision making in\nthe consultation. | I | C | ESC 2021",
          "bbox": [
            47.110473814464754,
            59.880588107638886,
            292.2340037027995,
            182.14417811802454
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 13",
          "page_number": 12,
          "content": "Cardiac resynchronization therapy |  |  | \nPatients who have received a conventional pace-\nmaker or an ICD and who subsequently develop\nsymptomatic HF with LVEF <35% despite OMT\n_\nand who have a significantb proportion of RV\npacing should be considered for upgrade to\nCRT. | I | IIa | \nCRT rather than RV pacing is recommended for\npatients with HFrEF (<40%) regardless of NYHA\nclass who have an indication for ventricular pac-\ning and high-degree AVB in order to reduce\nmorbidity. This includes patients with AF. | IIa | I | \nCRT should be considered for symptomatic\npatients with HF in SR with LVEF <35%, a QRS\n_\nduration of 130\u0002149 ms, and LBBB QRS mor-\nphology despite OMT, to improve symptoms\nand reduce morbidity and mortality. | I | IIa | \nIn patients with symptomatic AF and uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), CRT is\nrecommended in patients with HFrEF. | IIa | I | \nSpecific indications for pacing |  |  | \nIn patients with congenital heart disease, pacing\nmay be considered for persistent postoperative\nbifascicular block associated with transient com-\nplete AVB. | IIa | IIb | \nManagement considerations |  |  | \nIn patients with MRI-conditional pacemaker sys-\ntemsc, MRI can be performed safely following\nmanufacturer instructions. | IIa | I | \nIn patients with non-MRI-conditional pacemaker\nsystems, MRI should be considered if no alterna-\ntive imaging mode is available and if no epicardial\nleads, abandoned or damaged leads, or lead\nadaptors/extenders are present. | IIb | IIa | ESC 2021",
          "bbox": [
            311.3354324833039,
            59.880588107638886,
            556.5508713495163,
            491.7441602434431
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 13",
          "page_number": 12,
          "content": " |  |  | \n | 2013 | 2021 | \n |  |  | \n | Classa |  | \n............................\nCardiac pacing for bradycardia and conduction system disease |  |  | \nIn patients with syncope, cardiac pacing may be\nconsidered to reduce recurrent syncope when\nasymptomatic pause(s) >6 s due to sinus arrest\nare documented. | IIa | IIb | ",
          "bbox": [
            47.110473814464754,
            623.6393086751302,
            292.2340037027995,
            722.2011849539621
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "18",
      "title": "3 Background",
      "start_page": 12,
      "end_page": 12,
      "content": "",
      "keywords": [
        "background"
      ],
      "tables": []
    },
    {
      "number": "19",
      "title": "3.1 Epidemiology The prevalence and incidence of pacemaker implantation are unknown in many countries, yet several estimations have been pub- lished based on the analysis of large observational studie",
      "start_page": 12,
      "end_page": 13,
      "content": "Patient-centred care\nIn patients considered for pacemaker or CRT,\nthe decision should be based on the best\navailable evidence with consideration of individual risk-beneﬁts of each option, the\npatient \u0002 s preferences, and goals of care, and it is recommended to follow an integrated care\napproach and use the principles of patient-\ncentred care and shared decision making in the consultation.\nI C\nAF = atrial ﬁbrillation; ATP = antitachycardia pacing; AV = atrioventricular; AVB = atrioventricular block; AVJ = atrioventricular junction; BBB = bundle branch block; BMI = body mass index; CIED = cardiovascular implantable electronic device; CMR = cardiovascular magnetic resonance; CRT = cardiac resynchroniza- tion therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; CRT-P = cardiac resynchronization therapy-pacemaker; CSM = carotid sinus massage; CT = computed tomography; DDD = dual-chamber, atrioventricular pacing; ECG = electrocardiogram; EPS = electrophysiology study; HBP = His bundle pacing; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HV = His \u0002 ventricular interval; ICD = implantable cardioverter-deﬁbrillator; ILR = implantable loop recorder; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRI = mag- netic resonance imaging; OMT = optimal medical therapy; PET = positron emis- sion tomography; PR = PR interval; QRS = Q, R, and S waves; RBBB = right bundle branch block; RV = right ventricular; SAS = sleep apnoea syndrome; SND = sinus node dysfunction; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation. a Class of recommendation. b Level of evidence. c CSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be per- formed before carotid sinus massage. If a carotid bruit is present, carotid ultra- sound should be performed to exclude carotid disease d Complete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes. e Immediately after procedure or within 24 h. f Transient high-degree AVB, PR prolongation, or QRS axis change. g Ambulatory continuous ECG monitoring (implantable or external) for 7 \u0002 30 days. h Electrophysiology study with HV >_70 ms may be considered positive for perma- nent pacing. i Whenever pacing is indicated in neuromuscular disease, an ICD should be con- sidered according to relevant guidelines.\nESC 2021\n............................\nTable 5 Changes in cardiac pacing and cardiac resynchronization therapy guideline recommendations since 2013\n2013 2021\nClass a\nCardiac pacing for bradycardia and conduction system disease\nIn patients with syncope, cardiac pacing may be considered to reduce recurrent syncope when\nasymptomatic pause(s) >6 s due to sinus arrest\nare documented.\nIIa IIb\nContinued\nCardiac resynchronization therapy\nPatients who have received a conventional pace-\nmaker or an ICD and who subsequently develop\nsymptomatic HF with LVEF <_35% despite OMT and who have a signiﬁcant b   proportion of RV\npacing should be considered for upgrade to CRT.\nI IIa\nCRT rather than RV pacing is recommended for\npatients with HFrEF (<40%) regardless of NYHA\nclass who have an indication for ventricular pac- ing and high-degree AVB in order to reduce\nmorbidity. This includes patients with AF.\nIIa I\nCRT should be considered for symptomatic patients with HF in SR with LVEF <_35%, a QRS\nduration of 130 \u0002 149 ms, and LBBB QRS mor-\nphology despite OMT, to improve symptoms and reduce morbidity and mortality.\nI IIa\nIn patients with symptomatic AF and uncon-\ntrolled heart rate who are candidates for AVJ\nablation (irrespective of QRS duration), CRT is recommended in patients with HFrEF.\nIIa I\nSpeciﬁc indications for pacing\nIn patients with congenital heart disease, pacing\nmay be considered for persistent postoperative bifascicular block associated with transient com-\nplete AVB.\nIIa IIb\nManagement considerations\nIn patients with MRI-conditional pacemaker sys- tems c , MRI can be performed safely following\nmanufacturer instructions.\nIIa I\nIn patients with non-MRI-conditional pacemaker systems, MRI should be considered if no alterna-\ntive imaging mode is available and if no epicardial\nleads, abandoned or damaged leads, or lead adaptors/extenders are present.\nIIb IIa\nAF = atrial ﬁbrillation; AVB = atrioventricular block; AVJ = atrioventricular junc- tion; CRT = cardiac resynchronization therapy; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-deﬁbrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; NYHA = New York Heart Association; OMT = optimal med- ical therapy; RV = right ventricular; SR = sinus rhythm. a Class of recommendation. b A limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which RV pacing is safe and beyond which RV pacing is harmful. c Combination of MRI conditional generator and lead(s) from the same manufacturer.\nESC 2021\n. ...................................................................................................................................................\nESC Guidelines 13\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ................................................................... pacemaker implantations per million people in Azerbaijan, Bosnia and Herzegovina, and Kyrgyzstan, to >1000 implantations per million people in France, Italy, and Sweden. 1   These differences may result from under- or overtreatment with pacemaker therapy in some countries, or from variations in sociodemographic characteristics and pathological conditions. There is a continuous growth in the use of pacemakers due to the increasing life expectancy and age- ing of populations. 2 \u0002 8   The estimated number of patients globally undergoing pacemaker implantation has increased steadily up to an annual implant rate of  \u0003 1 million devices. 2   Degeneration of the cardiac conduction system and changes in intercellular conduc- tion can be manifestations of cardiac pathology or non-cardiac disease, and are most prevalent in older patients. Therefore, most bradycardias requiring cardiac pacing are observed in the elderly, with >80% of pacemakers being implanted in patients above the age of 65 years.\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "older",
        "hfmref",
        "bradycardia",
        "crt",
        "lished",
        "guideline",
        "many",
        "tavi",
        "pacemaker",
        "electrocardiogram",
        "epidemiology",
        "unknown",
        "age",
        "estimations",
        "large",
        "incidence",
        "prevalence",
        "several",
        "nyha",
        "based",
        "syncope",
        "lvef",
        "aortic",
        "icd",
        "carotid",
        "hfref",
        "bmi",
        "hfpef"
      ],
      "tables": []
    },
    {
      "number": "20",
      "title": "3.2 Natural history High-degree atrioventricular block (AVB) and sinus node dysfunction (SND) are the most common indications for permanent pacemaker therapy. Conservatively treated (i.e. non-paced) p",
      "start_page": 13,
      "end_page": 13,
      "content": "pacemaker-treated patients. 9 \u0002 12   In contrast, SND follows an unpre- dictable course, and there is no evidence to show that pacemaker therapy results in improved prognosis. 13 \u0002 15\nImproving life expectancy is not, however, the only objective of pacemaker therapy. Quality of life is an essential metric for measuring a patient’s clinical status and outcome, and provides a holistic picture of clinical treatment effectiveness. 16   Studies have been unanimous in finding improved quality of life in patients receiving pacing therapy. 17 \u0002 22\n",
      "keywords": [
        "treated",
        "node",
        "history",
        "degree",
        "permanent",
        "dysfunction",
        "atrioventricular",
        "most",
        "sinus",
        "natural",
        "indications",
        "conservatively",
        "pacemaker",
        "common",
        "therapy",
        "paced",
        "high",
        "block"
      ],
      "tables": []
    },
    {
      "number": "21",
      "title": "3.3 Pathophysiology and classification of bradyarrhythmias considered for permanent cardiac pacing therapy Definitions of various conduction disturbances are presented in Supplementary Table 1 . Sinus",
      "start_page": 13,
      "end_page": 14,
      "content": "Preimplant evaluation\nMinimizing complication risk\nPacing for bradycardia\nPacing in patients with rare diseases\nPacing in patients after cardiac surgery\nHigh risk reflex syncope\nHBP in bradycardia or CRT\nPacing in TAVI patients CRT indications\nLeadless pacing\nNew in these guidelines\nFigure 1  The 2021 ESC Guidelines on cardiac pacing and CRT present new and updated recommendations for these treatments in relevant patient populations.\n14 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .......................................................................... system. In addition, genetic mutations have been linked to conduction disorders (see  section 4.3.5 ), and atrial cardiomyopathy 23   may be a specific disease that can result in supraventricular tachyarrhythmia, SND, and atrioventricular node (AVN) disease. 24\nIt is essential to differentiate reversible from non-reversible causes of bradycardia. Potential reversible causes of bradycardia include adverse drug effects, myocardial infarction (MI), toxic exposure, infections, surgery, and electrolyte disorders. In a study including 277 patients referred to the emergency department with bradycardia, electrolyte disorders were the underlying cause in 4%, intoxication in 6%, acute MI in 14%, and adverse drug effects in 21%. 25\nIn the case of non-reversible pathological causes of slow heart rate, the presence and severity of symptoms play an essential role in the consideration for permanent antibradycardia pacemaker therapy. This may be challenging in patients with competing mech- anisms for their symptoms. In general, candidates for pacing ther- apy can be broadly classified into two groups: patients with persistent bradycardia and patients with intermittent [with or without electrocardiographic (ECG) documentation] bradycar- dia. Persistent bradycardia usually indicates an intrinsic disease in the sinus node tissue or the atrioventricular (AV) conduction sys- tem, whereas intermittent bradycardia can be a result of a wide variety of intrinsic and extrinsic pathological processes, as illus- trated in  Figure  2 . 26 \u0002 31\n",
      "keywords": [
        "bradyarrhythmias",
        "bradycardia",
        "crt",
        "genetic",
        "tavi",
        "pacemaker",
        "supplementary",
        "various",
        "sinus",
        "pathophysiology",
        "considered",
        "therapy",
        "syncope",
        "permanent",
        "presented",
        "classification",
        "table",
        "cardiac",
        "cardiomyopathy",
        "ecg",
        "conduction",
        "definitions",
        "disturbances",
        "pacing"
      ],
      "tables": []
    },
    {
      "number": "22",
      "title": "3.4 Types and modes of pacing: general description 3.4.1 Endocardial pacing Endocardial lead-based pacemakers consist of a pulse generator com- monly placed in the pectoral region and transvenous lead",
      "start_page": 14,
      "end_page": 15,
      "content": "3.4.2 Epicardial pacing Some clinical scenarios dictate implantation of an epicardial pace- maker system. These include patients with congenital anomalies and no venous access to the heart or with an open shunt between the right and left sides of the circulation, recurrent device infections, occluded veins, and—most commonly today—in conjunction with open cardiac surgery. Epicardial leads are currently implanted using various (minimally invasive) thoracotomy or thoracoscopy and robotic techniques. 35\nPatient with bradycardia-related symptoms\nPersistent bradycardia\nY N\nSinus node disease\nDocumented arrhythmia (ECG/Holter/monitor)\nAV block\nSinus rhythm Atrial fibrillation\nIntrinsic\nParoxysmal AV block Sino-atrial block and sinus arrest a\nAtrial fibrillation with slow ventricular condition\nExtrinsic (functional) Vagally induced sinus arrest or AV block Adenosine hypersensitivity b\nIdiopathic AV block\nBBB\nReflex syncope\nCarotid sinus Tilt-induced\nUnexplained syncope\n(suspected)\nY\nN\nFigure 2  Classification of documented and suspected bradyarrhythmias. AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram. a Including the bradycardia \u0002 tachycardia form of sick sinus syndrome.  b Deharo  et al . 32  Figure adapted from Brignole  et al . 33\nESC Guidelines 15\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.4.3 Cardiac resynchronization therapy (endo- and/or epicardial) Cardiac dyssynchrony is a difference in the timing of electrical and mechanical activation of the ventricles, which can result in impaired cardiac efficiency. CRT delivers biventricular pacing to correct elec- tromechanical dyssynchrony in order to increase cardiac output. 36   In multiple trials, CRT has shown a significant morbidity and mortality benefit in specific patient groups with reduced left ventricular ejec- tion fraction (LVEF). 37 \u0002 40\n3.4.4 Alternative methods (conduction system pacing, leadless pacing) 3.4.4.1 Conduction system pacing Compared with right ventricular (RV) pacing, His bundle pacing (HBP) provides a more physiological simultaneous electrical activa- tion of the ventricles via the His \u0002 Purkinje system. HBP can restore conduction in a subset of patients with high-degree AVB, and shorten QRS duration in some patients with left bundle branch block (LBBB) or right bundle branch block (RBBB). 41 \u0002 44   More studies are ongoing and required to evaluate whether HBP has clinical benefits over CRT or RV pacing. In addition, left bundle branch area pacing is being studied as a pacing modality for patients in whom the conduction dis- ease is too distal for HBP (see  section 7.3 ).\n3.4.4.2 Leadless pacing Miniaturized, intracardiac leadless pacemakers have been introduced. These devices are inserted percutaneously through the femoral vein and implanted directly in the RV wall using customized catheter- based delivery systems. The first-generation leadless pacemakers have been proven to provide effective single-chamber pacing therapy. 45 \u0002 50   Albeit a promising technology, potential difficulty with leadless pacemaker retrieval at the end of service is a limitation. Thus far, there are no randomized controlled data available to compare clinical outcomes between leadless pacing and single-chamber trans- venous pacing.\n3.4.5 Pacing modes Technological advances in pacemaker therapy have resulted in a wide variety of pacing modalities. Pacemakers can sense the heart’s intrin- sic electrical activity and restore the rate and AV sequence of cardiac activation. Abnormal cardiac automaticity and conduction may be treated by single-lead atrial sensing/pacing, single-lead ventricular sensing/pacing, single leads that pace the right ventricle (RV) and sense both the atrium and ventricle, and dual-lead systems that sense and pace the right atrium (RA) and RV. For common pacing modes, refer to  Supplementary Table 2 . The choice of the optimal pacing mode in the presence of conduction disturbances is driven by the underlying morbidity, the impact of pacing therapy on morbidity, and the potential harmful effect of the chosen pacing modality. The choice of pacing modes in specific situations is discussed in  section 5 .\n3.4.6 Rate-responsive pacing The sinus node modulates the heart rate during different types and loads of exercise (i.e. physical exercise, emotions, postural change, and fever) proportional to the metabolic demand. Rate-responsive pacemaker systems strive to produce an appropriate compensatory\nheart rate during emotional or physical activity by sensing body motion/acceleration, minute ventilation, intracardiac impedance, or other surrogates of physical and mental stress, and are indicated in cases of chronotropic incompetence. 51 \u0002 57   Dual-sensing rate-respon- sive pacing (e.g. accelerometer and minute ventilation) may be used in selected patients. 58   A brief overview of the most commonly used rate-responsive pacing sensors is given in  Supplementary Table 3 .\n",
      "keywords": [
        "region",
        "monly",
        "generator",
        "bradycardia",
        "crt",
        "modes",
        "physical activity",
        "description",
        "electrocardiogram",
        "pacemaker",
        "tachycardia",
        "types",
        "endocardial",
        "pectoral",
        "general",
        "placed",
        "consist",
        "based",
        "syncope",
        "lvef",
        "arrhythmia",
        "carotid",
        "pacemakers",
        "pulse",
        "atrial fibrillation",
        "ecg",
        "exercise",
        "pacing",
        "lead",
        "transvenous"
      ],
      "tables": []
    },
    {
      "number": "23",
      "title": "3.5 Sex differences Pacing indications and complication rates differ between male and female patients. In male patients, primary pacemaker implantation is more often indicated for AVB and less so for ",
      "start_page": 15,
      "end_page": 15,
      "content": "Possible explanations for this are a smaller body size in women and anatomical differences, such as smaller vein diameters and RV diameters.\n",
      "keywords": [
        "primary",
        "patients",
        "often",
        "male",
        "indicated",
        "implantation",
        "indications",
        "pacing",
        "female",
        "more",
        "less",
        "between",
        "pacemaker",
        "differ",
        "differences",
        "complication",
        "rates"
      ],
      "tables": []
    },
    {
      "number": "24",
      "title": "4 Evaluation of the patient with suspected or documented bradycardia or conduction system disease",
      "start_page": 15,
      "end_page": 15,
      "content": "",
      "keywords": [
        "conduction",
        "suspected",
        "bradycardia",
        "patient",
        "documented",
        "evaluation",
        "system",
        "disease"
      ],
      "tables": []
    },
    {
      "number": "25",
      "title": "4.1 History and physical examination A careful history and physical examination are essential for the evalu- ation of patients with suspected or documented bradycardia ( Figure  3 ). Current guideline",
      "start_page": 15,
      "end_page": 17,
      "content": "A complete history should include family history, comprehensive cardiovascular risk assessment, and recent/historical diagnoses that may cause bradycardia. The history should be focused on frequency, severity, and duration of symptoms that might suggest bradycardia or conduction system disease. The relationship of symptoms to physical activity, emotional distress, positional changes, medical treatment ( Table  6 ), and typical triggers (e.g. urination, defecation, cough, pro- longed standing, and shaving) should be explored too, as well as pulse rate if measured during an episode. Family history may be especially important in young patients with progressive cardiac conduction disease either isolated or in associa- tion with cardiomyopathies and/or myopathies. 64 , 65\nPhysical examination should focus on manifestations of bradycar- dia and signs of underlying structural heart disease or systemic disor- ders ( Table  7 ). Symptomatic slow peripheral pulses should be confirmed with cardiac auscultation or ECG to ensure that other rhythms are not misrepresented as bradycardia (e.g. premature ven- tricular contractions). Autonomic regulation disorders are important in the differential diagnosis of syncope or near syncope, and, therefore, orthostatic changes in heart rate and blood pressure may help in the evaluation of the patients.\n16 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nInitial evaluation of patients with symptoms suggestive of bradycardia (SND or AV block)\nHistory Physical examination Cardiac imaging ECG\nCardiovascular risk Complete history focusing on symptoms Family history Medical treatment\nFigure 3  Initial evaluation of patients with symptoms suggestive of bradycardia. AVB = atrioventricular block; ECG = electrocardiogram; SND = sinus node dysfunction.\nTable 6 Drugs that may cause bradycardia or conduction disorders\nSinus node bradycardia AVB\nBeta-blockers 1 1\nAntihypertensives\nNon-dihydropyridine calcium channel\nblockers\n1 1\nMethyldopa 1 –\nClonidine 1 –\nAntiarrhythmics\nAmiodarone 1 1\nDronedarone 1 1\nSotalol 1 1\nFlecainide 1 1\nPropafenone 1 1\nProcainamide – 1\nDisopyramide 1 1\nAdenosine 1 1\nDigoxin 1 1\nIvabradine 1 –\nPsychoactive and neuroactive drugs\nDonepezil 1 1\nLithium 1 1\nOpioid analgesics 1 –\nPhenothiazine 1 1\nPhenytoin 1 1\nSelective serotonin reuptake inhibitors – 1\nTricyclic antidepressants – 1\nCarbamazepine 1 1\nContinued\nESC 2021\nTable 6 Continued\nSinus node bradycardia AVB\nOthers\nMuscle relaxants 1 –\nCannabis 1 –\nPropofol 1 –\nTicagrelor 1 1\nHigh-dose corticosteroids 1 –\nChloroquine – 1\nH 2  antagonists 1 1\nProton pump inhibitors 1 –\nChemotherapy\nArsenic trioxide 1 1\nBortezomib 1 1\nCapecitabine 1 –\nCisplatin 1 –\nCyclophosphamide 1 1\nDoxorubicin 1 –\nEpirubicin 1 –\n5-ﬂuorouracil 1 1\nIfosfamide 1 –\nInterleukin-2 1 –\nMethotrexate 1 –\nMitroxantrone 1 1\nPaclitaxel 1 –\nRituximab 1 1\nThalidomide 1 1\nAnthracycline – 1\nTaxane – 1\nAVB = atrioventricular block. . .......................................................................................................\nESC Guidelines 17\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nCarotid sinus massage (CSM) can be helpful in any patient >_40 years old with symptoms suggestive of carotid sinus syndrome (CSS): syncope or near syncope elicited by tight collars, shaving, or turning the head. 66 , 67   Methodology and response to CSM are described in section 4.1  in the  Supplementary data .  Diagnosis of CSS requires both the reproduction of spontaneous symptoms during CSM and clinical features of spontaneous syncope compatible with a reflex mechanism. 68 \u0002 70\n",
      "keywords": [
        "calcium channel",
        "ation",
        "family history",
        "suspected",
        "bradycardia",
        "guideline",
        "physical activity",
        "electrocardiogram",
        "orthostatic",
        "careful",
        "current",
        "blood pressure",
        "documented",
        "syncope",
        "carotid",
        "history",
        "evalu",
        "ecg",
        "essential",
        "patients",
        "figure",
        "cardiovascular risk",
        "examination",
        "physical"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 17",
          "page_number": 16,
          "content": " | Sinus node\nbradycardia | AVB\nOthers |  | \nMuscle relaxants | 1 | –\nCannabis | 1 | –\nPropofol | 1 | –\nTicagrelor | 1 | 1\nHigh-dose corticosteroids | 1 | –\nChloroquine | – | 1\nH antagonists\n2 | 1 | 1\nProton pump inhibitors | 1 | –\nChemotherapy |  | \nArsenic trioxide | 1 | 1\nBortezomib | 1 | 1\nCapecitabine | 1 | –\nCisplatin | 1 | –\nCyclophosphamide | 1 | 1\nDoxorubicin | 1 | –\nEpirubicin | 1 | –\n5-fluorouracil | 1 | 1\nIfosfamide | 1 | –\nInterleukin-2 | 1 | –\nMethotrexate | 1 | –\nMitroxantrone | 1 | 1\nPaclitaxel | 1 | –\nRituximab | 1 | 1\nThalidomide | 1 | 1\nAnthracycline | – | 1\nTaxane | – | 1",
          "bbox": [
            312.40325231719436,
            321.9019775390625,
            551.6803456624349,
            698.1934387207032
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 17",
          "page_number": 16,
          "content": " | Sinus node\nbradycardia |  | AVB\nBeta-blockers | 1 |  | 1\nAntihypertensives |  |  | \nNon-dihydropyridine calcium channel\nblockers | 1 |  | 1\nMethyldopa | 1 |  | –\nClonidine | 1 |  | –\nAntiarrhythmics |  |  | \nAmiodarone | 1 |  | 1\nDronedarone | 1 |  | 1\nSotalol | 1 |  | 1\nFlecainide | 1 |  | 1\nPropafenone | 1 |  | 1\nProcainamide | – |  | 1\nDisopyramide | 1 |  | 1\nAdenosine | 1 |  | 1\nDigoxin | 1 |  | 1\nIvabradine | 1 |  | –\nPsychoactive and neuroactive drugs |  |  | \nDonepezil | 1 |  | 1\nLithium | 1 |  | 1\nOpioid analgesics | 1 |  | –\nPhenothiazine | 1 |  | 1\nPhenytoin | 1 |  | 1\nSelective serotonin reuptake inhibitors | – |  | 1\nTricyclic antidepressants | – |  | 1\nCarbamazepine | 1 |  | 1",
          "bbox": [
            48.73195095719962,
            329.1477783203125,
            288.02253695401276,
            692.240444946289
          ],
          "function_potential": "raw"
        },
        {
          "title": "18 ESC Guidelines",
          "page_number": 17,
          "content": " | Sinus\nbradycardia\nor SND | AVJ\ndisturbances\nIntrinsic |  | \nIdiopathic (ageing, degenerative) | 1 | 1\nInfarction/ischaemia | 1 | 1\nCardiomyopathies | 1 | 1\nGenetic disorders | 1 | 1\nInfiltrative diseases |  | \nSarcoidosis | 1 | 1\nAmyloidosis | 1 | 1\nHaemochromatosis | 1 | 1\nCollagen vascular diseases |  | \nRheumatoid arthritis | 1 | 1\nScleroderma | 1 | 1\nSystemic lupus erythematosus | 1 | 1\nStorage diseases | 1 | 1\nNeuromuscular diseases | 1 | 1\nInfectious diseases |  | \nEndocarditis (perivalvular abscess) | – | 1\nChagas disease | 1 | 1\nMyocarditis | – | 1\nLyme disease | – | 1\nDiphtheria | – | 1\nToxoplasmosis | – | 1\nCongenital heart diseases | 1 | 1\nCardiac surgery |  | \nCoronary artery bypass grafting | 1 | 1\nValve surgery (including\ntranscatheter aortic valve\nreplacement) | 1 | 1\nMaze operation | 1 | –\nHeart transplant | 1 | 1\nRadiation therapy | 1 | 1\nIntended or iatrogenic AVB | – | 1\nSinus tachycardia ablation | 1 | –\nExtrinsic |  | \nPhysical training (sports) | 1 | 1\nVagal reflex | 1 | 1\nDrug effects | 1 | 1\nIdiopathic paroxysmal AVB | – | 1\nElectrolyte imbalance |  | \nHypokalaemia | 1 | 1\nHyperkalaemia | 1 | 1\nHypercalcaemia | 1 | 1\nHypermagnesaemia | 1 | 1\nMetabolic disorders |  | \nHypothyroidism | 1 | 1\nAnorexia | 1 | 1\nHypoxia | 1 | 1\nAcidosis | 1 | 1",
          "bbox": [
            43.49855434685423,
            82.68646240234375,
            283.506282739472,
            743.0459456010299
          ],
          "function_potential": "raw"
        },
        {
          "title": "18 ESC Guidelines",
          "page_number": 17,
          "content": " | Sinus\nbradycardia\nor SND | AVJ\ndisturbances | ESC 2021\nHypothermia | 1 | 1 | \nNeurological disorders |  |  | \nIncreased intracranial pressure | 1 | 1 | \nCentral nervous system tumours | 1 | 1 | \nTemporal epilepsy | 1 | 1 | \nObstructive sleep apnoea | 1 | 1 | ",
          "bbox": [
            307.54651217990454,
            82.68646240234375,
            552.3342081705729,
            192.12869926120925
          ],
          "function_potential": "raw"
        },
        {
          "title": "18 ESC Guidelines",
          "page_number": 17,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nOnce carotid stenosis is ruled out,c CSM is rec-\nommended in patients with syncope of unknown\norigin compatible with a reflex mechanism or\nwith symptoms related to pressure/manipulation\nof the carotid sinus area.68\u000270 | I | B | ESC 2021",
          "bbox": [
            307.54651217990454,
            572.4077165876116,
            552.3342081705729,
            657.8612518310547
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "26",
      "title": "4.2 Electrocardiogram Together with the history and physical examination, the resting ECG is an essential component of the initial evaluation of patients with documented or suspected bradycardia. A 12",
      "start_page": 17,
      "end_page": 17,
      "content": "",
      "keywords": [
        "patients",
        "history",
        "resting",
        "suspected",
        "bradycardia",
        "initial",
        "component",
        "evaluation",
        "examination",
        "electrocardiogram",
        "documented",
        "physical",
        "essential",
        "together"
      ],
      "tables": []
    },
    {
      "number": "27",
      "title": "4.3 Non-invasive evaluation",
      "start_page": 17,
      "end_page": 17,
      "content": "Table 7 Intrinsic and extrinsic causes of bradycardia\nSinus bradycardia or SND\nAVJ disturbances\nIntrinsic\nIdiopathic (ageing, degenerative) 1 1\nInfarction/ischaemia 1 1\nCardiomyopathies 1 1\nGenetic disorders 1 1\nInﬁltrative diseases\nSarcoidosis 1 1\nAmyloidosis 1 1\nHaemochromatosis 1 1\nCollagen vascular diseases\nRheumatoid arthritis 1 1\nScleroderma 1 1\nSystemic lupus erythematosus 1 1\nStorage diseases 1 1\nNeuromuscular diseases 1 1\nInfectious diseases\nEndocarditis (perivalvular abscess) – 1\nChagas disease 1 1\nMyocarditis – 1\nLyme disease – 1\nDiphtheria – 1\nToxoplasmosis – 1\nCongenital heart diseases 1 1\nCardiac surgery\nCoronary artery bypass grafting 1 1\nValve surgery (including\ntranscatheter aortic valve\nreplacement)\n1 1\nMaze operation 1 –\nHeart transplant 1 1\nRadiation therapy 1 1\nIntended or iatrogenic AVB – 1\nSinus tachycardia ablation 1 –\nExtrinsic\nPhysical training (sports) 1 1\nVagal reﬂex 1 1\nDrug effects 1 1\nIdiopathic paroxysmal AVB – 1\nElectrolyte imbalance\nHypokalaemia 1 1\nHyperkalaemia 1 1\nHypercalcaemia 1 1\nHypermagnesaemia 1 1\nMetabolic disorders\nHypothyroidism 1 1\nAnorexia 1 1\nHypoxia 1 1\nAcidosis 1 1\nContinued\nTable 7 Continued\nSinus bradycardia or SND\nAVJ disturbances\nHypothermia 1 1\nNeurological disorders\nIncreased intracranial pressure 1 1\nCentral nervous system tumours 1 1\nTemporal epilepsy 1 1\nObstructive sleep apnoea 1 1\nAV = atrioventricular; AVB = atrioventricular block; AVJ = atrioventricular junc- tion; SND = sinus node dysfunction. Adapted from Mangrum  et al. 71   and Da Costa  et al. 72a\nRecommendations for non-invasive evaluation\nRecommendations Class a Level b\nOnce carotid stenosis is ruled out, c   CSM is rec-\nommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or\nwith symptoms related to pressure/manipulation\nof the carotid sinus area. 68 \u0002 70\nI B\nCSM = carotid sinus massage. a Class of recommendation. b Level of evidence. c CSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be per- formed before CSM. If a carotid bruit is present, carotid ultrasound should be performed to exclude the presence of carotid disease.\n",
      "keywords": [
        "aortic",
        "carotid",
        "stenosis",
        "bradycardia",
        "genetic",
        "invasive",
        "ablation",
        "evaluation",
        "level b",
        "coronary artery",
        "tachycardia",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "28",
      "title": "ESC 2021 ESC 2021",
      "start_page": 17,
      "end_page": 20,
      "content": ". ...........................................................................................................................................................................\n18 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................................................................. 4.3.1 Ambulatory electrocardiographic monitoring The intermittent nature of most symptomatic bradycardia secondary to conduction system disease often requires prolonged ambulatory ECG monitoring to correlate rhythm disturbances with symptoms. This monitoring allows detection of interruption of AV conduction by either primary disease of the conductive system, a vagal or neuro- cardiogenic mechanism, or reflex AV block. 72 , 72a\nAmbulatory ECG identifies defects of sinus automaticity, which includes sinus pauses, sinus bradycardia, bradycardia \u0002 tachycardia syndrome, asystole post-conversion of atrial flutter or AF, and chro- notropic incompetence. Different versions of ambulatory ECG monitoring have been reviewed recently in a comprehensive expert consensus ( Supplementary Table 4 ). 73   Ambulatory ECG selection depends on the frequency and nature of the symptoms ( Table  8 ).\n4.3.2 Exercise testing Exercise testing may be useful in selected patients with suspected bradycardia during or shortly after exertion. Symptoms occurring during exercise are likely to be due to cardiac causes, whereas symp- toms occurring after exercise are usually caused by a reflex mechanism.\nExercise testing can be used to diagnose symptomatic chrono- tropic incompetence, defined as an inability to increase the heart rate commensurate with the increased metabolic demands of physical activity. 74 , 75   The most commonly used definition of chronotropic incompetence has been failure to reach 80% of the expected heart rate reserve. Expected heart rate reserve is defined as the difference between the age-predicted maximal heart rate (220  \u0002  age) and the resting heart rate. However, some medical treatments and comor- bidities cause exercise intolerance and make the diagnosis of chrono- tropic incompetence by exercise testing more difficult. In patients with exercise-related symptoms, the development or progression of AVB may occasionally be the underlying cause. Tachycardia-related exercise-induced second-degree and complete AVB have been shown to be located distal to the AVN and predict progression to permanent AVB. 76 \u0002 78   Usually, these patients show intraventricular conduction abnormalities on the resting ECG, but a normal resting ECG has also been described in such cases. 77 , 79\nExercise testing may expose advanced infranodal AVB in the pres- ence of conduction system disease of uncertain location. In rare cases, conduction disturbances induced by exercise are caused by myocardial ischaemia or coronary vasospasm, and exercise testing may reproduce the symptoms. 80 , 81\nThere are no data supporting an indication for exercise testing in patients without exercise-related symptoms. Exercise testing may be useful in selected patients to distinguish AVN from conduction dis- turbances in the His \u0002 Purkinje system below the AVN in the setting of conduction disturbance at an unclear level.\n4.3.3 Imaging In patients with suspected or documented symptomatic bradycardia, the use of cardiac imaging is recommended to evaluate the presence of structural heart disease, to determine LV systolic function, and to diagnose potential reversible causes of conduction disturbances ( Table  7 ). Echocardiography is the most commonly available imaging techni- que for evaluation of the above factors. It can also be used in the\nTable 8 Choice of ambulatory electrocardiographic monitoring depending on symptom frequency\nFrequency of symptom\nDaily 24-h Holter ECG or in-hospital telemetric\nmonitoring\nEvery 48 \u0002 72 h 24 \u0002 48 \u0002 72 h Holter ECG\nEvery week 7-day Holter ECG/external loop recorder/ external patch recorder\nEvery month External loop recorder/external patch\nrecorder/handheld ECG recorder\n< 1 per month ILR\nECG = electrocardiogram; ILR = implantable loop recorder. Adapted from Brignole  et al . 33\nESC 2021\nRecommendation for ambulatory electrocardiographic monitoring\nRecommendation Class a Level b\nAmbulatory ECG monitoring is recommended in\nthe evaluation of patients with suspected brady- cardia to correlate rhythm disturbances with\nsymptoms. 73\nI C\nECG = electrocardiogram. a Class of recommendation. b Level of evidence.\nESC 2021\nRecommendations for exercise testing\nRecommendations Class a Level b\nExercise testing is recommended in patients who experience symptoms suspicious of brady-\ncardia during or immediately after\nexertion. 62 , 74 \u0002 80\nI C\nIn patients with suspected chronotropic incom-\npetence, exercise testing should be considered\nto conﬁrm the diagnosis. 74 , 75\nIIa B\nIn patients with intraventricular conduction dis- ease or AVB of unknown level, exercise testing\nmay be considered to expose infranodal\nblock. 76 , 77 , 79\nIIb C\nAVB = atrioventricular block. a Class of recommendation. b Level of evidence.\nESC 2021\n. .........................................................................................\nESC Guidelines 19\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ...................................................................................................................\ncontext of haemodynamic instability. When coronary artery disease is suspected, coronary computed tomography (CT), angiography, or stress imaging is recommended. 82   Cardiovascular magnetic reso- nance (CMR) and nuclear imaging techniques provide information on tissue characterization (inflammation, fibrosis/scar) and should be considered before pacemaker implantation when specific aetiologies associated with conduction abnormalities are suspected (specially in young patients). Late gadolinium contrast enhanced (LGE) and T2 CMR techniques allow the diagnosis of specific causes of conduction disturbances (i.e. sarcoidosis and myocarditis). Late gadolinium con- trast enhancement CMR helps in the decision-making of individuals with arrhythmic events; the presence of large areas of LGE (scar/fib- rosis) has been linked to an increased risk of ventricular arrhythmias regardless of LVEF and may indicate the need for an implantable cardioverter-defibrillator (ICD). 83 \u0002 85   T2 CMR sequences are suited for the detection of myocardial inflammation (i.e. oedema and hyper- aemia) as a potential cause of transitory conduction abnormalities that may not need permanent pacemaker implantation. 86   Similarly, positron emission tomography (PET) combined with CMR or CT helps in the diagnosis of inflammatory activity status of infiltrative car- diomyopathies (i.e. sarcoidosis). 87 , 88\n4.3.4 Laboratory tests Laboratory tests, including full blood counts, prothrombin time, par- tial thromboplastin time, renal function, and electrolyte measure- ments, are warranted as part of pre-procedural planning for pacemaker implantation. Bradycardia or AVB may be secondary to other conditions ( Table  7 ). When suspected, laboratory data are useful for identifying and treating these conditions (e.g. thyroid function, Lyme titre to diagnose myocarditis in a young person with AVB, endocarditis, hyperkalaemia, digitalis levels, and hypercalcaemia). 89 \u0002 94\n4.3.5 Genetic testing Most cardiac conduction disorders are due to either ageing or struc- tural abnormalities of the cardiac conduction system caused by underlying structural heart disease. Genes responsible for inherited cardiac diseases associated with cardiac conduction disorders have been identified. 65 , 95 , 96\nGenetic mutations have been linked to a range of abnormalities that may present in isolated forms of cardiac conduction disorder or in association with cardiomyopathy, congenital cardiac anomalies, or extra-cardiac disorders. Most genetically mediated cardiac conduc- tion disorders have an autosomal dominant mode of inheritance 65 , 95\n( Supplementary Table 5 ). Progressive cardiac conduction disease (PCCD) may be diagnosed in the presence of unexplained progressive conduction abnormalities in young (<50 years) individuals with structurally nor- mal hearts in the absence of skeletal myopathies, especially if there is a family history of PCCD. 97   Common PCCD-associated genes are SCN5A and TRPM4 for isolated forms and LMNA for PCCD associ- ated with HF. The diagnosis of PCCD in an index patient is based on clinical data including history, family history, and 12-lead ECG. The potential pres- ence of congenital heart disease (CHD) and/or cardiomyopathy must be investigated with cardiac imaging. Early-onset PCCD, either isolated or with concomitant structural heart disease, should prompt consideration of PCCD genetic testing, particularly in patients with a positive family history of conduction abnormalities, pacemaker implants, or sudden death. 97\nA consensus panel has endorsed mutation-specific genetic testing for family members and appropriate relatives after the identification of a PCCD causative mutation in an index case. Such testing can be deferred in asymptomatic children because of the age-dependent nature of cardiac conduction diseases and incomplete penetrance. 65\nHowever, every case should be individually evaluated depending of the risk of the detected mutation. Asymptomatic family members who are positive for the family’s PCCD-associated mutation should be regularly followed for devel- opment of cardiac conduction disease-related symptoms, deteriora- tion of cardiac conduction, and beginning of HF.\nRecommendations regarding imaging before implantation\nRecommendations Class a Level b\nCardiac imaging is recommended in patients\nwith suspected or documented symptomatic bradycardia to evaluate the presence of struc-\ntural heart disease, to determine LV systolic\nfunction, and to diagnose potential causes of conduction disturbances.\nI C\nMultimodality imaging (CMR, CT, or PET) should\nbe considered for myocardial tissue character- ization in the diagnosis of speciﬁc pathologies\nassociated with conduction abnormalities need-\ning pacemaker implantation, particularly in patients younger than 60 years. 83 \u0002 86 , 88\nIIa C\nCMR = cardiovascular magnetic resonance; CT = computed tomography; LV = left ventricular; PET = positron emission tomography. a Class of recommendation. b Level of evidence.\nRecommendations for laboratory tests\nRecommendations Class a Level b\nIn addition to pre-implantation laboratory tests, c\nspeciﬁc laboratory tests are recommended in\npatients with clinical suspicion for potential\nunderlying causes of reversible bradycardia (e.g. thyroid function tests, Lyme titre, digitalis level,\npotassium, calcium, and pH) to diagnose and\ntreat these conditions. 90 \u0002 94\nI C\na Class of recommendation. b Level of evidence. c Complete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes.\nESC 2021\nESC 2021\n. ..................................................\n20 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ...........................................\n4.3.6 Sleep evaluation Nocturnal bradyarrhythmias are common in the general population. In most circumstances, these are physiological, vagally mediated asymptomatic events, which do not require intervention. 98 \u0002 100\nPatients with sleep apnoea syndrome (SAS) have a higher preva- lence of sleep-related bradycardia (both sinus and conduction system related) during apnoeic episodes. 101 , 102   SAS-induced hypoxaemia is a key mechanism leading to an increased vagal tone and bradycardic rhythm disorders. 101 , 102   Another rare mechanism of sleep-related bradycardia (usually in the form of prolonged sinus arrest) is rapid eye movement sleep-related bradycardia, unrelated to apnoea. This mechanism can also be diagnosed by polysomnography. 103   Although most cases quoted in the literature have been treated with pace- makers, the evidence for this is scant, and there is no consensus on how to treat these patients. 103\nTreatment with continuous positive airway pressure (CPAP) alle- viates obstructive sleep apnoea-related symptoms and improves car- diovascular outcomes. Appropriate treatment reduces episodes of bradycardia by 72 \u0002 89%, 104   and patients are unlikely to develop symptomatic bradycardia at long-term follow-up. 104 \u0002 106   Therefore, patients with asymptomatic nocturnal bradyarrhythmias or cardiac conduction diseases should be evaluated for SAS. If the diagnosis is confirmed, treatment of sleep apnoea with CPAP and weight loss can be effective in improving bradyarrhythmias occurring during sleep, and permanent pacing should be avoided. In patients with known or suspected SAS and symptomatic bradyarrhythmias not associated with sleep, a more complex assessment of the risks associated with bradyarrhythmias vs. the benefit of cardiac pacing is needed.\n4.3.7 Tilt testing Tilt testing should be considered to confirm a diagnosis of reflex syn- cope in patients in whom this diagnosis was suspected but not con- firmed by initial evaluation. 62 , 107   The endpoint of tilt testing is the reproduction of symptoms along with the characteristic circulatory pattern of the reflex syncope. The methodology and classification of responses are described in  section 4.2  in the  Supplementary data  and in  Supplementary Figure 1 . A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this finding is rele- vant for therapy when cardiac pacing is considered (see  section 5.4 ). Conversely, the presence of a positive vasodepressor, a mixed response, or even a negative response does not exclude asystole dur- ing spontaneous syncope. 62\n",
      "keywords": [
        "should be considered",
        "family history",
        "bradycardia",
        "genetic",
        "physical activity",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "tachycardia",
        "age",
        "syncope",
        "lvef",
        "weight",
        "icd",
        "creatinine",
        "echocardiography",
        "level b",
        "cardiomyopathy",
        "ecg",
        "exercise",
        "recommended",
        "may be considered",
        "indication",
        "angiography",
        "coronary artery"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 19",
          "page_number": 18,
          "content": "Frequency of\nsymptom |  |  | ESC 2021\nDaily |  | 24-h Holter ECG or in-hospital telemetric\nmonitoring | \nEvery 48\u000272 h |  | 24\u000248\u000272 h Holter ECG | \nEvery week |  | 7-day Holter ECG/external loop recorder/\nexternal patch recorder | \nEvery month |  | External loop recorder/external patch\nrecorder/handheld ECG recorder | \n<1 per month |  | ILR | ",
          "bbox": [
            47.7327367237636,
            310.45098876953125,
            292.51999918619794,
            435.23707111065204
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 19",
          "page_number": 18,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \nExercise testing is recommended in patients\nwho experience symptoms suspicious of brady-\ncardia during or immediately after\nexertion.62,74\u000280 | I | C | \nIn patients with suspected chronotropic incom-\npetence, exercise testing should be considered\nto confirm the diagnosis.74,75 | IIa | B | \nIn patients with intraventricular conduction dis-\nease or AVB of unknown level, exercise testing\nmay be considered to expose infranodal\nblock.76,77,79 | IIb | C | ESC 2021",
          "bbox": [
            311.4849510192871,
            413.43715515136716,
            556.6217651367188,
            572.0842808314732
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 19",
          "page_number": 18,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nAmbulatory ECG monitoring is recommended in\nthe evaluation of patients with suspected brady-\ncardia to correlate rhythm disturbances with\nsymptoms.73 | I | C | ESC 2021",
          "bbox": [
            47.7327367237636,
            523.4003772270389,
            292.51999918619794,
            596.3492344447544
          ],
          "function_potential": "raw"
        },
        {
          "title": "20 ESC Guidelines",
          "page_number": 19,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn addition to pre-implantation laboratory tests,c\nspecific laboratory tests are recommended in\npatients with clinical suspicion for potential\nunderlying causes of reversible bradycardia (e.g.\nthyroid function tests, Lyme titre, digitalis level,\npotassium, calcium, and pH) to diagnose and\ntreat these conditions.90\u000294 | I | C | ESC 2021",
          "bbox": [
            307.03785247802733,
            76.49620971679687,
            552.18525390625,
            184.64524841308594
          ],
          "function_potential": "raw"
        },
        {
          "title": "20 ESC Guidelines",
          "page_number": 19,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nCardiac imaging is recommended in patients\nwith suspected or documented symptomatic\nbradycardia to evaluate the presence of struc-\ntural heart disease, to determine LV systolic\nfunction, and to diagnose potential causes of\nconduction disturbances. | I | C | \nMultimodality imaging (CMR, CT, or PET) should\nbe considered for myocardial tissue character-\nization in the diagnosis of specific pathologies\nassociated with conduction abnormalities need-\ning pacemaker implantation, particularly in\npatients younger than 60 years.83\u000286,88 | IIa | C | ESC 2021",
          "bbox": [
            42.642042306753304,
            350.0962310791016,
            287.76658412388394,
            519.4671761648996
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 21",
          "page_number": 20,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nGenetic testing should be considered in patients\nwith early onset (age <50 years) of progressive\ncardiac conduction disease.c 65,97 | IIa | C | \nGenetic testing should be considered in family\nmembers following the identification of a patho-\ngenic genetic variant that explains the clinical\nphenotype of cardiac conduction disease in an\nindex case.65 | IIa | C | ESC 2021",
          "bbox": [
            47.201838783595875,
            76.49620971679687,
            292.3292516072591,
            197.84816414969308
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 21",
          "page_number": 20,
          "content": " |  |  | 21\nRecommendation | Classa | Levelb | \n |  |  | \nTilt testing should be considered in patients with\nsuspected recurrent reflex syncope.62 | IIa | B | ESC 20",
          "bbox": [
            311.5728332519531,
            263.2993489583333,
            556.7492858886719,
            311.46116747174943
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 21",
          "page_number": 20,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nIn patients with infrequent (less than once a\nmonth) unexplained syncope or other symp-\ntoms suspected to be caused by bradycardia, in\nwhom a comprehensive evaluation did not\ndemonstrate a cause, long-term ambulat\nory monitoring with an ILR is\nrecommended.108\u0002112 | I | A | ESC 2021",
          "bbox": [
            311.5728332519531,
            590.1338155110677,
            556.7492858886719,
            698.2832489013672
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 21",
          "page_number": 20,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nScreening for SAS is recommended in patients\nwith symptoms of SAS and in the presence of\nsevere bradycardia or advanced AVB during\nsleep.101\u0002106 | I | C | ESC 2021",
          "bbox": [
            47.201838783595875,
            636.6217915852865,
            292.3292516072591,
            708.7712315150669
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "29",
      "title": "4.4 Implantable monitors Patients with infrequent symptoms of bradycardia (less than once per month) need a longer duration of ECG monitoring. For these patients, the implantable loop recorder (ILR) i",
      "start_page": 20,
      "end_page": 20,
      "content": "Recommendations for genetic testing\nRecommendations Class a Level b\nGenetic testing should be considered in patients with early onset (age <50 years) of progressive\ncardiac conduction disease. c  65 , 97\nIIa C\nGenetic testing should be considered in family members following the identiﬁcation of a patho-\ngenic genetic variant that explains the clinical\nphenotype of cardiac conduction disease in an index case. 65\nIIa C\na Class of recommendation. b Level of evidence. c Progressive cardiac conduction disease: prolonged P wave duration, PR interval, and QRS widening with axis deviation. 96\nESC 2021\nRecommendation for sleep evaluation\nRecommendation Class a Level b\nScreening for SAS is recommended in patients with symptoms of SAS and in the presence of\nsevere bradycardia or advanced AVB during\nsleep. 101 \u0002 106\nI C\nAVB = atrioventricular block; SAS = sleep apnoea syndrome. a Class of recommendation. b Level of evidence.\nESC 2021\nRecommendation for tilt testing\nRecommendation Class a Level b\nTilt testing should be considered in patients with suspected recurrent reﬂex syncope. 62 IIa B\na Class of recommendation. b Level of evidence.\nRecommendation for implantable loop recorders\nRecommendation Class a Level b\nIn patients with infrequent (less than once a month) unexplained syncope or other symp-\ntoms suspected to be caused by bradycardia, in\nwhom a comprehensive evaluation did not demonstrate a cause, long-term ambulat\nory monitoring with an ILR is\nrecommended. 108 \u0002 112\nI A\nILR = implantable loop recorder. a Class of recommendation. b Level of evidence.\n",
      "keywords": [
        "should be considered",
        "these",
        "bradycardia",
        "genetic",
        "than",
        "age",
        "loop",
        "month",
        "less",
        "syncope",
        "monitors",
        "implantable",
        "need",
        "symptoms",
        "level b",
        "infrequent",
        "patients",
        "once",
        "recorder",
        "recommended",
        "longer",
        "monitoring",
        "duration"
      ],
      "tables": []
    },
    {
      "number": "30",
      "title": "ESC 2021 ESC 2021",
      "start_page": 20,
      "end_page": 22,
      "content": ". ...............................................................................................................................\nESC Guidelines 21\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................. 4.5 Electrophysiology study The development of non-invasive ambulatory ECG technologies has reduced the need for the electrophysiology study (EPS) as a diagnos- tic test. EPS is generally an adjunctive tool in the evaluation of patients with syncope in whom bradycardia is suspected but has not been documented after non-invasive evaluation ( Figure  4 ). The goal of an EPS in the context of bradycardia evaluation is to identify abnormal sinus node function or the anatomical location of the cardiac conduc- tion disorders (in the AVN or in the His \u0002 Purkinje system distal to the AVN).\nIn patients with syncope and sinus bradycardia, the pre-test probability of bradycardia-related syncope increases when there is a sinus bradycardia (<50 b.p.m.) or sinoatrial block. Observational studies have shown a relationship between prolonged sinus node recovery time with syncope and the effect of pacing on symptoms. 113 , 114\nIn patients with syncope and bifascicular block, a prolonged His \u0002 ventricular interval (HV) >_70 ms, or HV >_100 ms after pharma- cological stress (ajmaline, procainamide, flecainide, or disopyramide), or induction of second- or third-degree AVB by atrial pacing or by\nHistory, physical examination, 12-lead ECG and cardiac imaging\nPatient with symptoms suggestive of bradycardia or conduction system disease\nEarly onset of progressive cardiac conduction disease or family history inherited cardiac conduction disorder\nClinical suspicion for potential causes of bradycardia\nSyncope and bifascicular block\nSuspected scar or infiltrative cardiomyopathy\nSuspected recurrent reflex syncope\nBradycardia or cardiac conduction disorders during sleep\nExercise induced symptoms\nGenetic test Laboratory test\nEPS or ET for exercised- induced block or empirical pacemaker in elderly and frail patients\nFurther imaging (CMR,CT, PET etc.)\nCSM/ tilt test Polysomnography /sleep study ET\nDiagnostic\nN Y\nSND (See section 5.1)\nCCD without AV block (See section 5.3)\nAV block (See section 5.2)\nReflex syncope (See section 5.4)\nSymptoms <1 per month\nAECG monitoring ILR\nNon- diagnostic Clinical follow-up\n(non-diagnostic)\nFigure 4  Evaluation of bradycardia and conduction disease algorithm. AECG = ambulatory electrocardiographic monitoring; AV = atrioventricular; CCD = cardiac conduction disease (or disorder); CMR = cardiovascular magnetic resonance; CSM = carotid sinus massage; CT = computed tomography; ECG = electrocardiogram; EPS = electrophysiology study; ET = exercise test; ILR = implantable loop recorder; PET = positron emission tomography; SND = sinus node dysfunction.\n22 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................................................................... pharmacological stress, identifies a group at higher risk of developing AVB. 115 \u0002 122\nThe efficacy of EPS for the diagnosis of syncope is highest in patients with sinus bradycardia, bifascicular block, and suspected tachycardia, 62   and lowest in patients with syncope, a normal ECG, no structural heart disease, and no palpitations. Therefore, EPS is pre- ferred over ILR in patients with syncope who have a high pre-test probability for significant conduction disease (e.g. abnormal ECG, BBB, ischaemic heart disease, or scar-related cardiomyopathy). For patients with a low pre-test probability (no structural heart disease, normal ECG), ILR is preferred over EPS. EPS is also preferred when there is a high likelihood that another syncopal episode will be dan- gerous or life-threatening and an immediate diagnosis is likely if EPS is performed. A negative EPS does not exclude an arrhythmic syncope, and fur- ther evaluation is warranted. Approximately one-third of patients with a negative EPS in whom an ILR is implanted develop AVB at fol- low-up. 123\n",
      "keywords": [
        "exercise",
        "carotid",
        "ecg",
        "family history",
        "tilt test",
        "bradycardia",
        "genetic",
        "electrocardiogram",
        "pacemaker",
        "cardiomyopathy",
        "elderly",
        "tachycardia",
        "syncope"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 23",
          "page_number": 22,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with syncope and bifascicular block,\nEPS should be considered when syncope\nremains unexplained after non-invasive evalua-\ntion or when an immediate decision about pac-\ning is needed due to severity, unless empirical\npacemaker implantation is preferred (especially\nin elderly and frail patients).115\u0002121 | IIa | B | \nIn patients with syncope and sinus bradycardia,\nEPS may be considered when non-invasive tests\nhave failed to show a correlation between syn-\ncope and bradycardia.113,114 | IIb | B | ESC 2021",
          "bbox": [
            47.17727279663086,
            298.8457763671875,
            292.302001953125,
            456.19817025320873
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "31",
      "title": "5 Cardiac pacing for bradycardia and conduction system disease",
      "start_page": 22,
      "end_page": 22,
      "content": "",
      "keywords": [
        "conduction",
        "pacing",
        "bradycardia",
        "cardiac",
        "system",
        "disease"
      ],
      "tables": []
    },
    {
      "number": "32",
      "title": "5.1 Pacing for sinus node dysfunction SND, also known as sick sinus syndrome, comprises a wide spectrum of sinoatrial dysfunctions, ranging from sinus bradycardia, sinoatrial block, and sinus arrest t",
      "start_page": 22,
      "end_page": 25,
      "content": "An additional manifestation of SND is an inadequate chronotropic response to exercise, reported as chronotropic incompetence.\n5.1.1 Indications for pacing 5.1.1.1 Sinus node dysfunction In general, pacing for asymptomatic SND has never been shown to affect prognosis, as opposed to pacing for AVB. Therefore, SND can\nbe considered as an appropriate indication for permanent pacing only when bradycardia due to SND is symptomatic. 126   Patients with SND may manifest symptoms attributable to bradyarrhythmia and/or symptoms of accompanying atrial tachyarrhythmias in the bradycar- dia \u0002 tachycardia form of the disease. Symptoms may be present either at rest or at the end of the tachyarrhythmic episode (conver- sion pause also named pre-automaticity pause), or develop during exercise, and may range from mild fatigue to light-headedness, dizzy spells, near-syncope, to syncope. Dyspnoea on exertion may be related to chronotropic incompetence. Syncope is a common mani- festation of SND and has been reported in 50% of patients who receive a pacemaker for SND. 127\nEstablishing a correlation between symptoms and bradyarrhyth- mia is a crucial step in decision-making. However, age, concomitant heart disease, and other comorbidities may pose difficulties in establishing a clear cause \u0002 effect relationship between SND and symptoms. The effect of cardiac pacing on the natural history of bradyarrhyth- mias was evaluated in non-randomized studies undertaken at the beginning of the pacemaker era, which suggested a symptomatic improvement with cardiac pacing. 128 \u0002 131   This was confirmed by one randomized controlled trial (RCT) 14   in which 107 patients (aged 73 ± 11 years) with symptomatic SND were randomized to no treat- ment, oral theophylline, or dual-chamber (DDD) rate-responsive pacemaker therapy. In this study, the occurrence of syncope and HF was lower in the pacemaker group during a follow-up of 19 ± 14 months. In patients presenting with exercise intolerance in whom chrono- tropic incompetence has been identified, the usefulness of cardiac pacing is uncertain, and the decision to implant a pacemaker in such patients should be made on a case by case basis. In some cases, symptomatic bradyarrhythmias may be related to transient, potentially reversible, or treatable conditions ( section 4 , Table  7 ). In such cases, correction of these factors is required, whereas permanent pacing is not indicated. In clinical practice, it is crucial to distinguish physiological bradycardia (due to autonomic influences or training effects) from inappropriate bradycardia that requires permanent cardiac pacing. For example, sinus bradycardia, even when it is 40 \u0002 50 b.p.m. while at rest or as slow as 30 b.p.m. while sleeping, particularly in trained athletes, could be accepted as a physiological finding that does not require cardiac pacing. Asymptomatic bradycardia (due to either sinus pauses or AVB epi- sodes) is not uncommon and warrants interpretation in the clinical context of the patient: in healthy subjects, pauses >2.5 s are uncom- mon, but this  per se  does not necessarily constitute a clinical disorder; asymptomatic bradyarrhythmias are common in athletes. 132   In the absence of published trials, no recommendations for bradycardia detected in asymptomatic patients can be made. On the other hand, in patients investigated for syncope in whom asymptomatic pause(s) >6 s due to sinus arrest are eventually documented, pacing may be indicated. Indeed, such patients constituted a small minority of those included in an observational study and a randomized trial on pacing in reflex syncope. 133 , 134   In patients presenting with sleep-related asymptomatic intermittent bradycardia (sinus bradycardia or AVB), sleep apnoea and rapid eye movement sleep-related bradycardia should be considered as possible causes.\nRecommendations for electrophysiology study\nRecommendations Class a Level b\nIn patients with syncope and bifascicular block, EPS should be considered when syncope\nremains unexplained after non-invasive evalua-\ntion or when an immediate decision about pac- ing is needed due to severity, unless empirical\npacemaker implantation is preferred (especially\nin elderly and frail patients). 115 \u0002 121\nIIa B\nIn patients with syncope and sinus bradycardia, EPS may be considered when non-invasive tests\nhave failed to show a correlation between syn-\ncope and bradycardia. 113 , 114\nIIb B\nEPS = electrophysiology study. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 23\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ...................................................................................................................................................................... 5.1.1.2 Bradycardia \u0002 tachycardia form of sinus node dysfunction The bradycardia \u0002 tachycardia variant of SND is the most common form, and is characterized by progressive, age-related, degenerative fibrosis of the sinus node tissue and atrial myocardium. Bradyarrhythmias can be associated with various forms of atrial tachyarrhythmias, including AF. 125   In this form of SND, the bradyar- rhythmias may correspond to atrial pauses due to sinoatrial blocks or may be due to overdrive suppression after an atrial tachyarrhythmia. 135\nAtrial tachyarrhythmias may be present at the time of diagnosis, typically with sinus arrest and asystolic pauses at the termination of atrial tachyarrhythmias or after device implant. Control of atrial tachyarrhythmias in patients presenting with high ventricular rates may be difficult before implant, as drugs prescribed for rate control may worsen bradyarrhythmias. Ablation of the atrial tachyarrhythmia, mainly AF, has been proposed in lieu of pacing and continuing medi- cations for selected patients, 136 \u0002 138   but no data are available from RCTs to show whether catheter ablation of AF is non-inferior to car- diac pacing with respect to bradycardia-related symptoms in patients with bradycardia \u0002 tachycardia syndrome. 139   If drug treatment is chosen, bradyarrhythmias during drug treatment for rate or rhythm control may be managed by dose reduction or discontinuation as an alternative to cardiac pacing, but in many cases bradyarrhythmias persist.\n5.1.2 Pacing mode and algorithm selection In patients with SND, controlled studies found that DDD was supe- rior to single-chamber ventricular pacing in reducing the incidence of AF. These studies also showed some effect of DDD pacing on the occurrence of stroke. 140 , 141   Dual-chamber pacing reduces the risk of pacemaker syndrome, which may occur in more than a quarter of patients with SND. 21 , 142   Pacemaker syndrome is associated with a reduction in quality of life and usually justifies the preference for DDD vs. ventricular rate-modulated pacing in SND, when reason- able. 143   Potential exceptions are very elderly and/or frail patients with infrequent pauses who have limited functional capacity and/or a short expected survival. In these patients, the benefit of DDD(R) vs. VVIR pacing is expected to have limited or no clinical impact, and the incremental risk of complications related to the second atrial lead required in DDD(R) implants should also be considered when choosing the pacing mode. In patients with SND treated with a DDD pacemaker, programming of the AV interval and specific algorithms for minimizing RV pacing may further reduce the risk of AF and par- ticularly of persistent AF. 144   Dual-chamber pacing is safer and more sustainable than atrial-only pacing modes used in the past, 127   even though single-lead atrial pacing was found to be superior to single- lead ventricular pacing. 145 , 146   The results of studies that evaluated dif- ferent pacing modes in bradyarrhythmias, including in some cases both SND and AVB, are shown in  Supplementary Table 6 . With regard to the choice between DDD(R) and atrial pacing atrial sensing inhibited-response rate-adaptive (AAIR) pacing, an RCT with only 177 patients suggested a reduced risk of AF with AAIR. 147\nHowever, the most recent DANish Multicenter Randomized Trial on Single Lead Atrial PACing vs. Dual Chamber Pacing in Sick Sinus\nSyndrome (DANPACE), which enrolled 1415 patients followed for a mean of 5.4 years, found no difference between DDD(R) and AAIR pacing in all-cause mortality. 127   The DANPACE trial also found a higher incidence of paroxysmal AF [hazard ratio (HR) 1.27] and a two-fold increased risk of pacemaker reoperation with AAIR, with AVB developing in 0.6 \u0002 1.9% of patients every year. 127   These findings support the routine use of DDD(R) rather than AAIR pacing in patients with SND. In view of these data, DDD(R) is the pacing mode of first choice in SND ( Figure  5 ). Unnecessary RV pacing should be systematically avoided in patients with SND, because it may cause AF and deteriora- tion of HF, particularly if systolic function is impaired or border- line. 144 , 148   This can be achieved by programming of the AV interval or using specific algorithms for minimizing RV pacing. Programming an excessively long AV interval to avoid RV pacing in patients with prolonged AV conduction may be disadvantageous from a haemody- namic point of view by causing diastolic mitral regurgitation, which may lead to symptoms and/or AF. 144 , 149 , 150\nPacing algorithms for minimizing ventricular pacing are often used in SND. 144 , 151   A meta-analysis of algorithms for minimizing RV pacing failed to show a significant effect compared with conventional DDD pacing in patients with normal ventricular function with regard to endpoints such as incidence of persistent/permanent AF, all-cause hospitalization, and all-cause mortality. 152   However, the rationale for reducing unnecessary RV pacing remains strong and is coupled with the benefits of extending device longevity. 151 , 152   Some manufacturer- specific algorithms are more effective in minimizing ventricular pacing, but may confer disadvantages in allowing decoupling between atria and ventricles. 153 , 154   Rarely, algorithms designed to minimize ventric- ular pacing can cause life-threatening ventricular arrhythmias that are pause dependent or pause triggered. 155 \u0002 158   No direct comparison of these algorithms has been performed so far, but pooled data from randomized trials do not show clear-cut superiority of any specific algorithm in improving clinical outcome. 152 , 159\nIn patients with severely reduced LVEF and a SND indication for pacing, in whom a high percentage of ventricular pacing is expected, an indication for CRT or HBP should be evaluated (see  section 6  on CRT and  section 7  on HBP). The role of pacing algorithms for preventing AF has been the sub- ject of controversy. A series of algorithms for preventing/suppressing AF has been tested, such as dynamic atrial overdrive pacing, atrial pacing in response to atrial premature beats, pacing in response to exercise, and post-mode-switch pacing. The clinical evaluation of these algorithms, also applied at different atrial pacing sites, is not convincing and no clinical benefit with regard to major clinical end- points has been demonstrated. 160 , 161\nAtrial antitachycardia pacing [ATP; i.e. delivery of atrial stimuli at high frequencies to convert an atrial tachyarrhythmia to sinus rhythm (SR)] has also been tested for reducing the atrial tachyarrhythmia burden and counteracting the tendency over time towards progres- sion to permanent AF. 162   Conventional delivery of atrial ATP in a way that mirrors the delivery of ventricular ATP (bursts/ramp at arrhythmia onset) has a relatively low success rate, and indeed the tri- als based on conventional atrial ATP showed no benefit on AF bur- den or clinical events. 163   A new form of ATP delivery has been\n24 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ..................... proposed, specifically aimed at reducing atrial tachyarrhythmias, and its efficacy in reducing the progression to permanent AF was vali- dated in an RCT. 162 , 164\nIn this trial, 164   the primary composite outcome at 2 years (death, cardiovascular hospitalizations, or permanent AF) was significantly reduced in patients with a device combining ATP and algorithms for minimizing RV pacing [36% relative risk reduction compared with\nconventional DDD(R)]. The positive effect on the primary endpoint was due to a lower rate of progression to permanent AF. A post-hoc analysis indicated that this form of atrial ATP was an independent predictor of permanent or persistent AF reduction. 162 , 164 , 165   In CHD, where re-entrant atrial arrhythmias are very common, use of DDD(R) pacemakers with atrial ATP may be considered (see  section 8  on pacing in CHD).\nSND\nPersistent or paroxysmal\nDDD(R) a\nOptimal pacing mode in sinus node dysfunction and atrio-ventricular block\nY N\nSinus rhythm: DDD + AVM AF: VVI + rate hysteresis\nDDDR + AVM\nSingle chamber  AAI(R) a\nVVI(R) a\nAny reason to avoid 2 leads b\nSignificant comorbidity\nDefault option DDD + AVM DDD(R) a\n+ AVM\nSingle chamber AAIR\nSingle chamber AAI\nVVIR VVI VVI + rate hysteresis\nDDD VVIR\nVVI(R) a VDD\nVVI\nVDD\nVVI + rate hysteresis\nChronotropic incompetence?\nPersistent or paroxysmal\nno SND AF\nAV block SND\nParoxysmal Persistent Persistent Paroxysmal\nFigure 5  Optimal pacing mode and algorithm selection in sinus node dysfunction and atrioventricular block. AF = atrial fibrillation; AV = atrioventricular; AVM = atrioventricular management [i.e. AV delay programming (avoiding values >230 ms) or specific algorithms to avoid/reduce unnecessary ventricular pacing]; CRT = cardiac resynchronization therapy; SND = sinus node dysfunction.   a (R) indicates that the programming of such a pacing mode is preferred only in the case of chronotropic incompetence.   b Reasons to avoid two leads include young age and limited venous access. Note: in patients who are candi- dates for a VVI/VDD pacemaker, a leadless pacemaker may be considered (see  section  7). For combined CRT indications, see  section 6 . Adapted from Brignole  et al . 62\nESC Guidelines 25\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................\n",
      "keywords": [
        "ranging",
        "should be considered",
        "dysfunction",
        "bradycardia",
        "crt",
        "pacemaker",
        "systolic",
        "also",
        "tachycardia",
        "spectrum",
        "wide",
        "age",
        "mitral regurgitation",
        "node",
        "sick",
        "sinus",
        "syndrome",
        "comprises",
        "dysfunctions",
        "syncope",
        "lvef",
        "diastolic",
        "arrhythmia",
        "arrest",
        "atrial fibrillation",
        "level b",
        "elderly",
        "known",
        "block",
        "exercise"
      ],
      "tables": [
        {
          "title": "26 ESC Guidelines",
          "page_number": 25,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with SND and a DDD pacemaker,\nminimization of unnecessary ventricular\npacing through programming is\nrecommended.144,151,159,164,166\u0002169 | I | A | \nPacing is indicated in SND when symptoms can\nclearly be attributed to\nbradyarrhythmias.14,128\u0002131 | I | B | \nPacing is indicated in symptomatic patients with\nthe bradycardia\u0002tachycardia form of SND in\norder to correct bradyarrhythmias and enable\npharmacological treatment, unless ablation of\nthe tachyarrhythmia is\npreferred.17,20,21,136\u0002138,170,171 | I | B | \nIn patients who present chronotropic incompe-\ntence and have clear symptoms during exercise,\nDDD with rate-responsive pacing should be\nconsidered.172,173 | IIa | B | \nAF ablation should be considered as a strategy\nto avoid pacemaker implantation in patients with\nAF-related bradycardia or symptomatic pre-\nautomaticity pauses, after AF conversion, taking\ninto account the clinical situation.136\u0002139,174 | IIa | C | \nIn patients with the bradycardia\u0002tachycardia\nvariant of SND, programming of atrial ATP may\nbe considered.164,165 | IIb | B | \nIn patients with syncope, cardiac pacing may be\nconsidered to reduce recurrent syncope when\nasymptomatic pause(s) >6 s due to sinus arrest\nis documented.133,134 | IIb | C | \nPacing may be considered in SND when symp-\ntoms are likely to be due to bradyarrhythmias,\nwhen the evidence is not conclusive. | IIb | C | \nPacing is not recommended in patients with bra-\ndyarrhythmias related to SND that are asympto-\nmatic or due to transient causes that can be\ncorrected and prevented.33 | III | C | ESC 2021",
          "bbox": [
            42.5258575888241,
            76.49620971679687,
            287.6575360979353,
            542.2581372942243
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "33",
      "title": "5.2 Pacing for atrioventricular block 5.2.1 Indications for pacing Treatment of AVB aims at ameliorating symptoms and preventing syncope and sudden cardiac death (SCD). First-degree AVB is usually asy",
      "start_page": 25,
      "end_page": 27,
      "content": "AVB, manifestations of fatigue, exertional intolerance, and HF are sometimes underestimated. Deterioration of cognitive functions is often only speculative so that the possibilities of improvement after implantation of a pacemaker are unpredictable and unlikely. Death in patients with untreated AVB is due not only to HF secondary to low cardiac output, but also to SCD caused by prolonged asystole or bradycardia-triggered ventricular tachyarrhythmia. Although RCTs of pacing in AVB have not been performed, it is clear from several observational studies that pacing prevents recurrence of syncope and improves survival. 10 \u0002 12\n5.2.1.1 First-degree atrioventricular block Usually the prognosis is good in the absence of structural heart disease, and progression to high-degree block is uncommon. 175   The indication for pacing relies on an established correlation between symptoms and AVB. There is weak evidence to show that marked PR prolongation (i.e. >_300 ms), particularly when it persists or is pro- longed during exercise, can lead to symptoms similar to pacemaker syndrome and/or that these can improve with pacing. 176   Symptom correlation is crucial, although it may be difficult if these are non- specific and subtle. In the absence of a clear correlation, a pacemaker is generally not indicated.\n5.2.1.2 Second-degree type I atrioventricular block (Mobitz type I or Wenckebach) In addition to the presence or absence of symptoms, the risk of pro- gression to higher degrees of AVB should be considered. Supranodal block has a benign course, and the risk of progression to type II or a higher degree of AV block is low. Small, retrospective studies have suggested that, over the long term, this type of AVB carries a higher risk of death in patients aged >_45 years in the absence of pacemaker implantation. 177 , 178   Infranodal block (rare in this form of block) car- ries a high risk of progression to complete heart block, syncope, and sudden death, and warrants pacing even in the absence of symptoms. 179 , 180\n5.2.1.3 Second-degree Mobitz type II, 2:1, and advanced atrioventricular block (also named high-grade atrioventricular block, where the P:QRS ratio is 3:1 or higher), third-degree atrioventricular block In the absence of a reversible cause, due to the risk of occurrence of severe symptoms and/or possible progression towards a more severe or complete AVB, patients should receive a pacemaker even in the absence of symptoms. In asymptomatic patients in whom a 2:1 AVB is found incidentally, the decision for implantation should be made on a case by case basis including distinction between nodal and infranodal AVB. This distinction may be based on observations such as PR or PP interval prolongation before AVB, the effect of exercise on AV conduction, and an EPS.\n5.2.1.4 Paroxysmal atrioventricular block Because of the risk of syncope and SCD and of the potential progres- sion to permanent AVB, the indications for pacing are the same for paroxysmal as for permanent AVB. It is crucial to rule out a reversible cause and to recognize the reflex forms of AVB, which may not need pacing. Documentation of infranodal block by EPS or the documenta- tion of initiation of the block by atrial or ventricular premature beats, or increased heart rate (tachy-dependent AVB) or decreased heart\nRecommendations for pacing in sinus node dysfunction\nRecommendations Class a Level b\nIn patients with SND and a DDD pacemaker, minimization of unnecessary ventricular\npacing through programming is\nrecommended. 144 , 151 , 159 , 164 , 166 \u0002 169\nI A\nPacing is indicated in SND when symptoms can\nclearly be attributed to\nbradyarrhythmias. 14 , 128 \u0002 131\nI B\nPacing is indicated in symptomatic patients with the bradycardia \u0002 tachycardia form of SND in\norder to correct bradyarrhythmias and enable\npharmacological treatment, unless ablation of the tachyarrhythmia is\npreferred. 17 , 20 , 21 , 136 \u0002 138 , 170 , 171\nI B\nIn patients who present chronotropic incompe- tence and have clear symptoms during exercise,\nDDD with rate-responsive pacing should be\nconsidered. 172 , 173\nIIa B\nAF ablation should be considered as a strategy to avoid pacemaker implantation in patients with\nAF-related bradycardia or symptomatic pre-\nautomaticity pauses, after AF conversion, taking into account the clinical situation. 136 \u0002 139 , 174\nIIa C\nIn patients with the bradycardia \u0002 tachycardia\nvariant of SND, programming of atrial ATP may be considered. 164 , 165\nIIb B\nIn patients with syncope, cardiac pacing may be\nconsidered to reduce recurrent syncope when\nasymptomatic pause(s) >6 s due to sinus arrest is documented. 133 , 134\nIIb C\nPacing may be considered in SND when symp-\ntoms are likely to be due to bradyarrhythmias, when the evidence is not conclusive.\nIIb C\nPacing is not recommended in patients with bra-\ndyarrhythmias related to SND that are asympto-\nmatic or due to transient causes that can be corrected and prevented. 33\nIII C\nATP = antitachycardia pacing; DDD = dual-chamber, atrioventricular pacing; SND = sinus node dysfunction. a Class of recommendation. b Level of evidence.\nESC 2021\n26 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................................... rate (brady-dependent AVB), support a diagnosis of intrinsic infrano- dal AVB. 27\n5.2.2 Pacing mode and algorithm selection 5.2.2.1 Dual-chamber vs. ventricular pacing Large, randomized, parallel trials that included patients with only AVB 181   or with AVB and/or SND 140   failed to show superiority of DDD over ventricular pacing with regard to mortality, and have not consistently shown superiority in terms of quality of life or morbidity (including stroke or transient ischaemic attack and AF). 20 , 140 , 181   Dual- chamber pacing is beneficial over ventricular pacing due to the avoid- ance of pacemaker syndrome, which occurred in up to a quarter of patients with AVB in these trials. In a meta-analysis of 20 crossover trials, DDD was associated with an improved exercise capacity com- pared with ventricular pacing. However, the effect was driven by non-rate-modulated ventricular pacemakers, and no benefit was observed from the comparison of DDD with VVIR pacing. 182\nPacemaker syndrome is associated with reduction in quality of life and may require a reintervention for upgrading, justifying the prefer- ence for DDD when reasonable (i.e. in patients who do not present with significant frailty, very advanced age, significant comorbidities limiting their life expectancy, or a very limited mobility). Another con- sideration is the diagnosis of AF, which is more reliable from device data in patients with DDD pacemakers. On a case by case basis, in frail elderly patients, and/or when AVB is paroxysmal and pacing anticipated to be infrequent, VVIR pacing may be considered as it carries a lower complication rate. 140\nThere is strong evidence to show that chronic conventional RV pacing may be deleterious in some patients and may lead to LV dys- function and HF, 148   even when AV synchrony is maintained. 183   This effect is only partly explained by the abnormal activation sequence and may involve myocardial perfusion, and humoral, cellular, and molecular changes. 184 , 185   Compared with a matched control cohort, patients with a pacemaker and an RV lead have an increased risk of HF, which is also associated with older age, previous MI, kidney dis- ease, and male sex. 186   Pacing-induced cardiomyopathy occurs in 10 \u0002 20% of patients after 2 \u0002 4 years of RV pacing. 186 \u0002 188   It is associ- ated with a >20% RV pacing burden. 187 \u0002 190   However, there are no data to support that any percentage of RV pacing can be considered as defining a true limit below which RV pacing is safe and beyond which RV pacing is harmful. For discussion of potential indications for CRT and/or HBP to prevent pacing-induced cardiomyopathy, please refer to  section s  6  and  7 .\n5.2.2.2 Atrioventricular block in the case of permanent atrial fibrillation In the presence of AF, AVB should be suspected if the ventricular rate is slow and the ventricular rhythm regular. During prolonged monitoring, long ventricular pauses may be detected. 191   In patients with AF and no permanent AVB or symptoms, there is no identifiable, minimum pause duration as an indication for pacing. In the absence of a potentially reversible cause, bradycardia or inappropriate chrono- tropic response (due to either intermittent or complete AVB) associ- ated or reasonably correlated with symptoms is an indication for cardiac pacing. Any high-degree or infranodal block is also an indica- tion for pacing, even in the absence of symptoms. In the absence of\nsymptoms due to bradycardia and of high-degree or infranodal block, pacing is unlikely to be beneficial and is not indicated. In patients with AF who undergo atrioventricular junction (AVJ) ablation to control rapid ventricular rates, there is evidence to show that AVJ ablation plus RV pacing improves symptoms and quality of life. 192   In contrast, neutral results were found regarding the progres- sion of HF, hospitalization, and mortality, 193   except in one study. 194\nCompared with pharmacological rate control, AVJ ablation and CRT reduced the risks of death due to HF, hospitalization due to HF, or worsening HF by 62%, and improved specific symptoms of AF by 36% in elderly patients with permanent AF and narrow QRS. 195   In other studies, this beneficial effect was limited to patients with HF or reduced ejection fraction (EF). 166 , 196   For further discussion of the role of CRT following AVJ ablation, refer to  section  6 . There is weak evidence to support a benefit from para-Hisian and Hisian pacing after AVJ ablation for refractory AF. 197 \u0002 200   For further discussion, refer to  section  7 .\nRecommendations for pacing for atrioventricular block\nRecommendations Class a Level b\nPacing is indicated in patients in SR with perma-\nnent or paroxysmal third- or second-degree\ntype 2, infranodal 2:1, or high-degree AVB, irre- spective of symptoms. c 9 \u0002 12\nI C\nPacing is indicated in patients with atrial arrhyth-\nmia (mainly AF) and permanent or paroxysmal\nthird- or high-degree AVB irrespective of symptoms.\nI C\nIn patients with permanent AF in need of a pace-\nmaker, ventricular pacing with rate response function is recommended. 201 \u0002 204\nI C\nPacing should be considered in patients with sec-\nond-degree type 1 AVB that causes symptoms\nor is found to be located at intra- or infra-His levels at EPS. 177 \u0002 180\nIIa C\nIn patients with AVB, DDD should be preferred\nover single-chamber ventricular pacing to avoid pacemaker syndrome and to improve quality of\nlife. 20 , 140 , 181 , 182\nIIa A\nPermanent pacemaker implantation should be\nconsidered for patients with persistent symp- toms similar to those of pacemaker syndrome\nand clearly attributable to ﬁrst-degree AVB (PR\n>0.3 s). 205 \u0002 207\nIIa C\nPacing is not recommended in patients with AVB\ndue to transient causes that can be corrected\nand prevented.\nIII C\nAF = atrial ﬁbrillation; AVB = atrioventricular block; DDD = dual-chamber, atrio- ventricular pacing; EPS = electrophysiology study; SR = sinus rhythm. a Class of recommendation. b Level of evidence. c In asymptomatic narrow QRS complex and 2:1 AVB, pacing may be avoided if supra-Hisian block is clinically suspected (concomitant Wenckebach is observed and block disappears with exercise) or demonstrated at EPS.\nESC 2021\n. ..................................................................................................................\nESC Guidelines 27\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .............................................................. In patients with AF, compared with fixed rate pacing, rate- responsive pacing is associated with better exercise performance, improved daily activities, a decrease in symptoms of shortness of breath, chest pain, and palpitations, and improved quality of life. 201 \u0002 203   It has also been shown to improve heart rate and blood pressure response to mental stress compared with fixed rate pac- ing. 204   Therefore, rate-adaptive pacing is the pacing mode of first choice. Fixed-rate VVI pacing should be reserved for older sedentary patients who have very limited activity. Commonly, the minimum rate is programmed higher (e.g. 70 b.p.m.) than for patients in SR in an attempt to compensate for loss of active atrial filling.\n",
      "keywords": [
        "first",
        "ejection fraction",
        "should be considered",
        "older",
        "aims",
        "bradycardia",
        "crt",
        "pacemaker",
        "tachycardia",
        "sudden",
        "age",
        "usually",
        "death",
        "scd",
        "blood pressure",
        "syncope",
        "male",
        "sedentary",
        "atrioventricular",
        "sex",
        "preventing",
        "atrial fibrillation",
        "symptoms",
        "level b",
        "cardiomyopathy",
        "elderly",
        "cardiac",
        "degree",
        "block",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 27",
          "page_number": 26,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPacing is indicated in patients in SR with perma-\nnent or paroxysmal third- or second-degree\ntype 2, infranodal 2:1, or high-degree AVB, irre-\nspective of symptoms.c 9\u000212 | I | C | \nPacing is indicated in patients with atrial arrhyth-\nmia (mainly AF) and permanent or paroxysmal\nthird- or high-degree AVB irrespective of\nsymptoms. | I | C | \nIn patients with permanent AF in need of a pace-\nmaker, ventricular pacing with rate response\nfunction is recommended.201\u0002204 | I | C | \nPacing should be considered in patients with sec-\nond-degree type 1 AVB that causes symptoms\nor is found to be located at intra- or infra-His\nlevels at EPS.177\u0002180 | IIa | C | \nIn patients with AVB, DDD should be preferred\nover single-chamber ventricular pacing to avoid\npacemaker syndrome and to improve quality of\nlife.20,140,181,182 | IIa | A | \nPermanent pacemaker implantation should be\nconsidered for patients with persistent symp-\ntoms similar to those of pacemaker syndrome\nand clearly attributable to first-degree AVB (PR\n>0.3 s).205\u0002207 | IIa | C | \nPacing is not recommended in patients with AVB\ndue to transient causes that can be corrected\nand prevented. | III | C | ESC 2021",
          "bbox": [
            311.42217799595426,
            290.38128560384115,
            556.5634586109835,
            645.7282562255859
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "34",
      "title": "5.3 Pacing for conduction disorders without atrioventricular block This section focuses on patients with 1:1 AV conduction and QRS abnormalities caused by delayed or blocked conduction of the His \u0002 Pu",
      "start_page": 27,
      "end_page": 31,
      "content": "Isolated fascicular block and BBB are rarely associated with symp- toms; however, their presence may be a marker for underlying struc- tural heart disease. The presence or absence of symptoms referable to intermittent bradycardia will guide the evaluation of these patients.\n5.3.1 Indications for pacing 5.3.1.1 Bundle branch block and unexplained syncope Although syncope is not associated with an increased incidence of sudden death in patients with preserved cardiac function, a high inci- dence of total deaths (about one-third sudden) was observed in patients with BBB and HF, previous MI, or low EF. 208 \u0002 210   Indeed, in those with low EF, syncope is a risk factor for death. 211\nUnfortunately, ventricular-programmed stimulation does not seem to identify these patients correctly; therefore, an ICD or a defibrilla- tor with CRT (CRT-D) is indicated in patients with BBB and LVEF <35% for the prevention of SCD ( Figure  6 ). 63\n5.3.1.2 Bundle branch block, unexplained syncope, and abnormal elec- trophysiological study Electrophysiological assessment includes measurement of the HV at baseline, with stress by incremental atrial pacing or by\nDecision algorithm for patients with unexplained syncope and BBB\nBifascicular block\nLVEF  ≤  35%\nElderly and frail patients at risk of traumatic recurrrences\nICD/CRT-D Clinical follow-up Adapted therapy Pacemaker implant\nEPS/CSM\nILR\nN\nN\nNo diagnosis\nY\nY\nDiagnosis\nNo diagnosis\nDiagnosis\nFigure 6  Decision algorithm for patients with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D = defibrillator with cardiac resynchronization therapy; CSM = carotid sinus massage; EPS = electrophysiology study; ICD = implantable cardioverter-defibrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction.\n28 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .......................................................................\npharmacological provocation (ajmaline, procainamide, or flecainide). Scheinman  et al . studied the prognostic value of the HV: the progres- sion rate to AVB at 4 years was 4% in patients with HV <70 ms, 12% in patients with HV between 70 and 100 ms, and 24% in patients with HV >100 ms. 121   Development of intra- or infra-His block at incre- mental atrial pacing or by pharmacological stress test increases the sensitivity and positive predictive value of the EPS to identify patients who will develop AVB. 116 \u0002 118 , 120 , 122 , 212   A positive EPS yielded a posi- tive predictive value as high as 80% to identify patients who develop AVB. This finding has been indirectly confirmed by a study that showed a significant reduction in syncopal recurrences in patients with positive EPS treated with a pacemaker, compared with a control group of untreated patients with a negative EPS. 119   In patients with unexplained syncope and bifascicular block, EPS is highly sensitive in identifying patients with intermittent or impending high-degree AVB. However, a negative EPS cannot rule out intermittent/paroxysmal AVB as the cause of syncope. Indeed, in patients with a negative EPS, intermittent or stable AVB was documented by ILR in  \u0003 50% of cases. Therefore, elderly patients with bifascicular block and unexplained syncope might benefit from an empirical pacemaker, especially in unpredictable and recurrent syncope that exposes the patient to a high risk of traumatic recurrences. The decision to implant a pace- maker in these patients should be based on individual risk \u0002 benefit evaluation. 213\n5.3.1.3 Alternating bundle branch block This rare condition refers to situations in which there is clear ECG evidence for block in all three fascicles on successive ECGs; examples are LBBB and RBBB morphologies on successive ECGs, or RBBB with associated left anterior fascicular block on one ECG and left posterior fascicular block on another ECG. 214   There is general con- sensus that this phenomenon is associated with significant infranodal disease and that patients will progress rapidly toward AVB. Therefore, a pacemaker should be implanted as soon as the alternat- ing BBB is detected, even in the absence of symptoms.\n5.3.1.4 Bundle branch block without symptoms Permanent pacemaker implantation is not indicated for BBB without symptoms, with the exception of alternating BBB, because only a minority of these patients will develop AVB (1 \u0002 2% per year). 115 , 121 , 215   The risks of pacemaker implantation and long-term transvenous lead complications are higher than the benefits of pace- maker implantation. 216 , 217\n5.3.1.5 Patients with neuromuscular diseases In patients with neuromuscular diseases, cardiac pacing should be considered, as any degree of fascicular block can progress unpredict- ably, even in the absence of symptoms (see  section  8.5 ).\n5.3.2 Pacing mode and algorithm selection In intermittent bradycardia, pacing may be required only for short periods. In this situation, the benefits of bradycardia and pause pre- vention must be weighed against the detrimental effects of perma- nent pacing, particularly pacing-induced HF. Low base-rate programming to achieve backup pacing, and manual adaptation of AV interval, programming AV hysteresis, or other specific algorithms preventing unnecessary RV pacing, play a particularly important role in this patient group. 144 , 148\nIn patients in SR, the optimal pacing mode is DDD. The strong evi- dence of superiority of DDD vs. VVI pacing is limited to improvement in symptoms and quality of life. Conversely, there is strong evidence of non-superiority with regard to survival and morbidity. 20\nTherefore, in elderly or frail patients with intermittent bradycardia, the decision regarding the pacing mode should be made on an individ- ual basis, taking into consideration the increased complication risk and costs of DDD ( Figure  5 ). VDD may be a pacing mode alternative for patients with advanced AV conduction abnormalities and spared sinus node function. In comparison with DDD, VDD system implantation is associated with fewer complications, shorter procedure and fluoroscopy times, and a high incidence of atrial undersensing. 218   Potential atrial undersensing is contributing to the low use of this system as most operators are aiming for AV synchrony.\nRecommendations for pacing in patients with bundle branch block\nRecommendations Class a Level b\nIn patients with unexplained syncope and bifas-\ncicular block, a pacemaker is indicated in the presence of either a baseline HV of >_70 ms, sec-\nond- or third-degree intra- or infra-Hisian block\nduring incremental atrial pacing, or an abnormal response to pharmacological challenge. 119 , 120\nI B\nPacing is indicated in patients with alternating\nBBB with or without symptoms. I C\nPacing may be considered in selected patients with unexplained syncope and bifascicular block\nwithout EPS (elderly, frail patients, high-risk and/\nor recurrent syncope). 213\nIIb B\nPacing is not recommended for asymptomatic\nBBB or bifascicular block. 115 , 121 , 215 III B\nBBB = bundle branch block; EPS = electrophysiology study; HV = His \u0002 ventricular interval. a Class of recommendation. b Level of evidence.\nESC 2021\n. .........................................................................\nESC Guidelines 29\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ..................................................... 5.4 Pacing for reflex syncope Permanent pacemaker therapy may be effective if asystole is a domi- nant feature of reflex syncope. Establishing a relationship between symptoms and bradycardia should be the goal of the clinical evalua- tion of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. The fact that pacing is effec- tive does not mean it is always necessary. In patients with reflex syn- cope, cardiac pacing should be the last resort and should only be considered in highly selected patients [i.e. those >40 years of age (mostly >60 years), affected by severe forms of reflex syncope with frequent recurrences associated with a high risk of injury, often with- out a prodrome]. The 2018 ESC Guidelines on syncope 62   give a detailed description of the diagnostic pathway and indications for pacing, and provide the evidence from trials that support such rec- ommendations.  Figure  7  summarizes the suggested decision pathway. The algorithm shown in  Figure  7  has been prospectively validated in a multicentre pragmatic study, which showed a low recurrence\nrate of syncope with pacing of 15% at 2 years, significantly lower than the 37% rate observed in unpaced controls. 219   The 3-year recurrence rate was similar in patients with cardioinhibitory carotid sinus syndrome (16%), asystolic tilt response (23%), and spontane- ous asystole documented by ILR (24%), suggesting similar indica- tions and similar results for the three forms of reflex syncope. 220\nWhilst some scepticism prevails over the diagnostic accuracy of tilt testing for the diagnosis of syncope, emerging evidence supports the use of tilt testing in the assessment of reflex hypotensive sus- ceptibility. 107 , 221   Thus, tilt testing may be considered to identify patients with an associated usually antecedent hypotensive response that would be less likely to respond to permanent cardiac pacing. Patients with hypotensive susceptibility need measures directed to counteract hypotensive susceptibility in addition to car- diac pacing (e.g. physical counterpressure manoeuvres, discontinu- ation/reduction of hypotensive drugs, and administration of fludrocortisone or midodrine).\nManagement of cardiac pacing in patients with reflex syncope\nSevere, recurrent, unpredictable syncopes, age > 40 years\nCardioinhibitory carotid  sinus syndrome\nPerform carotid sinus massage and tilt table test\nPacing not indicated (Class III)\nN Y\nY\nPositive tilt-test\nY\nY\nAsystolic tilt-test\nImplantable loop recorder\nAsystole Positive tilt-test\nN\nN\nN\nY\nImplant a DDD PM and counteract hypotensive susceptibility (Class I)\nY\nY\nImplant a DDD PM (Class I)\nN\nN\nFigure 7  Decision pathway for cardiac pacing in patients with reflex syncope. DDD = dual-chamber, atrioventricular pacing. Note: cardioinhibitory carotid sinus syndrome is defined when the spontaneous syncope is reproduced by the carotid sinus massage in the presence of an asystolic pause >3 s; asystolic tilt positive test is defined when the spontaneous syncope is reproduced in the presence of an asystolic pause >3 s. A symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, atrioventricular block, or the combination of the two similarly define asystole detected by implantable loop recorder. Figure adapted from Brignole  et al . 62\n30 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ................................................................................... 5.4.1 Indications for pacing This Task Force found sufficient evidence in the literature to recom- mend pacing in highly selected patients with reflex syncope (i.e. those >40 years of age with severe recurrent unpredictable syncopal epi- sodes when asystole has been documented, induced by either CSM or tilt testing, or recorded through a monitoring system) 133 , 222 \u0002 228\n(see  Supplementary Table 7 ). There is sufficient evidence that DDD pacing should be considered in order to reduce recurrence of syn- cope in patients with dominant cardioinhibitory CSS (asystolic pause >3 s and spontaneous syncope during CSM) and in those in whom there is a correlation between spontaneous symptoms and ECG who are >40 years of age and have severe recurrent unpredictable syncope. 62   Permanent pacemaker therapy may be effective if asystole is a dominant feature of reflex syncope. Establishing a correlation between symptoms and bradycardia should be the goal of the clinical evaluation of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. A comparison of results in different settings is presented in  Supplementary Table 8 . Since the publication of the 2018 ESC Guidelines on syncope, 62\nsome trials have added relevant information regarding the subset of patients with tilt-induced asystolic vasovagal syncope. The SPAIN trial was a multicentre, randomized, controlled, crossover study, per- formed in 46 patients aged >40 years affected by severely recurrent (>5 episodes during life) syncope and cardioinhibitory tilt test response (defined as bradycardia <40 b.p.m. lasting >10 s or asystole >3 s). 226   During the 24-month follow-up, syncope recurred in 4 (9%) patients treated with a DDD pacemaker with closed loop stimulation\nvs. in 21 (46%) patients who had received a sham pacemaker pro- grammed off ( P  = 0.0001). In a propensity score-matched compari- son study, 229   the 5-year actuarial syncope-free rate was 81% in the pacing group and 53% in propensity-matched patients ( P  = 0.005; HR = 0.25). Finally, the BioSync CLS trial was a multicentre RCT that investigated the usefulness of the tilt-table test to select candidates for cardiac pacing. 228   Patients aged >_40 years who had at least two episodes of unpredictable severe reflex syncope during the past year and a tilt-induced syncope with an asystolic pause >3 s were random- ized to receive either an active (63 patients) or an inactive (64 patients) dual-chamber pacemaker with close loop stimulation. The study showed that, after a median follow-up of 11.2 months, syncope occurred in significantly fewer patients in the pacing group than in the control group [10 (16%) vs. 34 (53%), respectively; HR 0.23;  P  = 0.00005). This study supports inclusion of tilt testing as a useful method to select patients with reflex syncope for cardiac pacing. Based on the results of the above studies, sufficient evidence exists to upgrade from IIb to I the indication for pacing in patients aged >40 years with asystolic tilt response >3 s.  Figure  8  summarizes the rec- ommended indication for pacing. Although there is also a rationale for pacing in patients aged <_40 years who have the same severity cri- teria as those >40 years, this Task Force cannot make any recom- mendation due to the lack of evidence from trials addressing this specific population. There is weak evidence that DDD may be useful in reducing recur- rences of syncope in patients with the clinical features of adenosine- sensitive syncope. 62   In a small multicentre trial performed in 80 highly\nIndications for pacing in patients above age 40 with reflex syncope\nSpontaneous asystolic pause(s) Y\nY\nN\nN Test-induced asystolic pause(s)\nExtrinsic (functional) vagally-mediated or adenosine-sensitive\nPacing indicated (Class I)\nCI-CSS\nPacing indicated (Class I)\nAsystolic tilt\nPacing indicated (Class I)\nAdenosine induced AV block > 10 sec  Pacing indicated (Class IIb)\nUndocumented syncope\nPacing not indicated (Class III)\nFigure 8  Summary of indications for pacing in patients >40 years of age with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome. Note: spontaneous asystolic pause = 3 s symptomatic or 6 s asymptomatic. Adapted from Brignole  et al. 62\nESC Guidelines 31\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................................... selected elderly patients with unexplained unpredictable syncope who had induction of third-degree AVB of >_10 s to intravenous injec- tion of a bolus of 20 mg of adenosine triphosphate, DDD significantly reduced the 2-year syncope recurrence rate from 69% in the control group to 23% in the active group. 230   Finally, cardiac pacing is not indi- cated in the absence of a documented cardioinhibitory reflex. 231 , 232\n5.4.2 Pacing mode and algorithm selection Even if the quality of evidence is weak, DDD pacing is widely pre- ferred in clinical practice to single-chamber RV pacing in counteract- ing blood pressure fall and preventing symptom recurrences. In patients with tilt-induced vasovagal syncope, DDD was used mostly with a rate-drop response feature that provides rapid DDD if the device detects a rapid decrease in heart rate. A comparison between DDD closed-loop stimulation and conventional DDD has been per- formed by means of a crossover design in two small studies. Both studies showed fewer syncope recurrences with closed-loop stimula- tion, both in the acute setting during repeated tilt testing 233   and dur- ing 18-month clinical follow-up. 227   However, until a formal parallel trial is performed, no recommendation can be given regarding the selection of the pacing mode (i.e. DDD with rate-drop response or DDD with closed-loop stimulation) and its programming.\n",
      "keywords": [
        "risk factor",
        "ejection fraction",
        "should be considered",
        "class i",
        "vasovagal",
        "bradycardia",
        "crt",
        "pacemaker",
        "blocked",
        "age",
        "tilt test",
        "disorders",
        "scd",
        "blood pressure",
        "syncope",
        "lvef",
        "stress test",
        "icd",
        "carotid",
        "class iii",
        "atrioventricular",
        "section",
        "without",
        "caused",
        "level b",
        "ecg",
        "elderly",
        "focuses",
        "block",
        "conduction"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 29",
          "page_number": 28,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with unexplained syncope and bifas-\ncicular block, a pacemaker is indicated in the\npresence of either a baseline HV of >70 ms, sec-\n_\nond- or third-degree intra- or infra-Hisian block\nduring incremental atrial pacing, or an abnormal\nresponse to pharmacological challenge.119,120 | I | B | \nPacing is indicated in patients with alternating\nBBB with or without symptoms. | I | C | \nPacing may be considered in selected patients\nwith unexplained syncope and bifascicular block\nwithout EPS (elderly, frail patients, high-risk and/\nor recurrent syncope).213 | IIb | B | 21\nPacing is not recommended for asymptomatic\nBBB or bifascicular block.115,121,215 | III | B | ESC 20",
          "bbox": [
            311.46182411595396,
            82.50536092122395,
            556.5992376154119,
            278.2951856340681
          ],
          "function_potential": "raw"
        },
        {
          "title": "32 ESC Guidelines",
          "page_number": 31,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with recurrent unexplained falls, the\nsame assessment as for unexplained syncope\nshould be considered.62 | IIa | C | \nPacing is not recommended in patients with\nunexplained falls in the absence of any other\ndocumented indication.236 | III | B | \nPacing is not recommended in patients with\nunexplained syncope without evidence of SND\nor conduction disturbance.234,235 | III | C | ESC 2021",
          "bbox": [
            306.94997119903564,
            301.0000244140625,
            552.085951063368,
            435.56825583321705
          ],
          "function_potential": "raw"
        },
        {
          "title": "32 ESC Guidelines",
          "page_number": 31,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nDual-chamber cardiac pacing is indicated to\nreduce recurrent syncope in patients aged >40\nyears, with severe, unpredictable, recurrent syn-\ncope who have:\n• spontaneous documented symptomatic asys-\ntolic pause(s) >3 s or asymptomatic pause(s)\n>6 s due to sinus arrest or AVB; or\n• cardioinhibitory carotid sinus syndrome; or\n• asystolic syncope during tilt\ntesting.62,219,220,226,228,229 | I | A | \nDual-chamber cardiac pacing may be considered\nto reduce syncope recurrences in patients with\nthe clinical features of adenosine-sensitive\nsyncope.230 | IIb | B | 21\nCardiac pacing is not indicated in the absence of\na documented cardioinhibitory reflex.231,232 | III | B | ESC 20",
          "bbox": [
            42.60677194595337,
            365.5163543701172,
            287.73023478190106,
            584.097174508231
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "35",
      "title": "5.5 Pacing for suspected (undocumented) bradycardia In patients with recurrent unexplained syncope or falls at the end of the conventional work-up, ILR monitoring should be considered in an attempt to",
      "start_page": 31,
      "end_page": 31,
      "content": "5.5.1 Recurrent undiagnosed syncope In patients with unexplained syncope at the end of a complete work- up and absence of any conduction disturbance, the lack of a rationale and the negative results of small studies 234 , 235   give sufficient evidence of inefficacy of cardiac pacing. Thus, cardiac pacing is not recom- mended until a diagnosis is made ( Figure  8 ).\n5.5.2 Recurrent falls Between 15% and 20% of unexplained falls may be syncopal in nature, possibly bradyarrhythmic. Retrograde amnesia, which is frequent in the falling elderly, is responsible for misinterpretation of the event. 62\nThe management of unexplained falls should be the same as that for unexplained syncope (see  section 5.4.1 ). In a randomized double- blind trial, 236   cardiac pacing was ineffective in preventing recurrences in patients with an unexplained fall in whom carotid sinus hypersensi- tivity was unable to induce syncope.\n",
      "keywords": [
        "work",
        "patients",
        "carotid",
        "conventional",
        "attempt",
        "suspected",
        "pacing",
        "recurrent",
        "unexplained",
        "bradycardia",
        "falls",
        "monitoring",
        "should",
        "undocumented",
        "considered",
        "elderly",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "36",
      "title": "6 Cardiac resynchronization therapy",
      "start_page": 31,
      "end_page": 31,
      "content": "",
      "keywords": [
        "cardiac",
        "resynchronization",
        "therapy"
      ],
      "tables": []
    },
    {
      "number": "37",
      "title": "6.1 Epidemiology, prognosis, and pathophysiology of heart failure suitable for cardiac resynchronization therapy by biventricular pacing The prevalence of HF in the developed world approximates 1 \u0002 2%",
      "start_page": 31,
      "end_page": 32,
      "content": "There are three distinct phenotypes of HF based on the measure- ment of LVEF [<40%, HF with reduced EF (HFrEF); 40 \u0002 49%, HF with mildly reduced EF (HFmrEF); and >_50%, HF with preserved EF (HFpEF)]. 242   CRT is clinically useful mainly for patients with HFrEF and LVEF <_35%. Patients with HFrEF constitute  \u0003 50% of the entire\nRecommendations for pacing for reﬂex syncope\nRecommendations Class a Level b\nDual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40\nyears, with severe, unpredictable, recurrent syn-\ncope who have: •   spontaneous documented symptomatic asys-\ntolic pause(s) >3 s or asymptomatic pause(s)\n>6 s due to sinus arrest or AVB; or •   cardioinhibitory carotid sinus syndrome; or •   asystolic syncope during tilt\ntesting. 62 , 219 , 220 , 226 , 228 , 229\nI A\nDual-chamber cardiac pacing may be considered to reduce syncope recurrences in patients with\nthe clinical features of adenosine-sensitive\nsyncope. 230\nIIb B\nCardiac pacing is not indicated in the absence of\na documented cardioinhibitory reﬂex. 231 , 232 III B\nAVB = atrioventricular block. a Class of recommendation. b Level of evidence.\nESC 2021\nRecommendations for cardiac pacing in patients with suspected (undocumented) syncope and unexplained falls\nRecommendations Class a Level b\nIn patients with recurrent unexplained falls, the\nsame assessment as for unexplained syncope should be considered. 62\nIIa C\nPacing is not recommended in patients with\nunexplained falls in the absence of any other documented indication. 236\nIII B\nPacing is not recommended in patients with\nunexplained syncope without evidence of SND\nor conduction disturbance. 234 , 235\nIII C\nSND = sinus node dysfunction. a Class of recommendation. b Level of evidence.\nESC 2021\n. ..................................................................................................................\n32 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ population with HF, and HFrEF is less prevalent among individuals aged 70 years or older. The prognosis of HF varies according to the defined population. In contemporary clinical trials of HFrEF, 1-year mortality rates of  \u0003 6% are seen, whereas in large registry-based sur- veys, 1-year mortality rates exceed 20% in patients recently hospital- ized for HF, but are closer to 6% in those recruited with stable outpatient HF. 243   The concept of CRT is based on the fact that in patients with HF and LV systolic dysfunction, high-grade intraventric- ular conduction delays are frequently observed, with a prevalence of QRS duration >120 ms in 25 \u0002 50% of patients and of LBBB in 15 \u0002 27% of cases. Moreover, in such patients, AV dyssynchrony is also often present with prolonged PR on the surface ECG in up to 52% of cases. 244 \u0002 246   These electrical abnormalities may result in AV, interventricular, and intra-LV mechanical dyssynchrony. 247 , 248\nRecommendations for CRT are based on the results of the major RCTs of CRT, most of which have been restricted to the  \u0003 60% of HFrEF patients who are in SR. CRT is recommended (in addition to guideline-directed medical therapy) in only defined subsets of the HF patient population, the majority being symptomatic HF patients in SR with a reduced LVEF and a QRS duration >_130 ms. Other smaller groups that may be considered for CRT include New York Heart Association (NYHA) class III or IV HF patients in AF with a reduced LVEF and a QRS duration >_130 ms, provided a strategy to ensure biventricular capture is in place or the patient is expected to return to SR, and occasionally as an upgrade from a conventional pacemaker or an ICD in HFrEF patients who develop worsening HF with a high rate of ventricular pacing. A recent survey in the USA, which derived a nationally representative estimate of the entire US population of hospitalized patients, found that over a 10-year period (2003 \u0002 2012), there were an estimated 378 247 CRT-D implantations, representing \u0003 40 000 per year, or roughly 135 per million per year. 249   In Europe, previous estimates have reported that  \u0003 400 patients per million population per year might be suitable for CRT. This was based on an estimated prevalence of 35% for LVEF <_35% in a representative HF population, of which 41% of patients were estimated to have a QRS duration >_120 ms. The change to a higher threshold of QRS duration of 130 ms will reduce these estimates modestly. 250 , 251   In Sweden, a recent survey of 12 807 HFrEF patients showed that 7% had received CRT and 69% had no indication for CRT, but 24% had an indication and had not received CRT. These data highlight the underuse of CRT. 252 , 253   Finally, the Task Force stresses the point that the decision to implant CRT requires a shared decision-making with the patient.\n",
      "keywords": [
        "resynchronization",
        "developed",
        "should be considered",
        "biventricular",
        "older",
        "hfmref",
        "crt",
        "guideline",
        "heart",
        "world",
        "epidemiology",
        "pacemaker",
        "systolic",
        "prognosis",
        "prevalence",
        "pathophysiology",
        "nyha",
        "therapy",
        "syncope",
        "lvef",
        "approximates",
        "icd",
        "carotid",
        "hfref",
        "class iii",
        "hfpef",
        "failure",
        "level b",
        "cardiac",
        "ecg"
      ],
      "tables": []
    },
    {
      "number": "38",
      "title": "6.2 Indication for cardiac resynchronization therapy: patients in sinus rhythm CRT improves cardiac function, symptoms, and well-being, and reduces morbidity and mortality in an appropriately selected",
      "start_page": 32,
      "end_page": 35,
      "content": "had an ischaemic cardiomyopathy. At 7-year follow-up, the subgroup of patients with LBBB, NYHA functional class I, and ischaemic cardio- myopathy showed a non-significant trend towards lower risk of death from any cause [relative risk 0.66, 95% confidence interval (CI) 0.30 \u0002 1.42;  P  = 0.29]. Therefore, present CRT recommendations are applicable to all patients in NYHA functional class II \u0002 IV of any aetiology. The MUltisite STimulation In Cardiomyopathies (MUSTIC), 256 , 257\nMulticenter Insync RAndomized Clinical Evaluation (MIRACLE), PAcing THerapies in Congestive Heart Failure (PATH-CHF) I and II, 58 , 254 , 255 , 259 COmparison of Medical therapy, PAcing aNd defibrillatION (COMPANION), 260   and CArdiac REsynchronization in Heart Failure (CARE-HF) 39 , 261   trials compared the effect of CRT vs. guideline-directed medical therapy in NYHA functional class III or IV; in contrast, most recent trials have compared CRT-D with ICD on top of best medical therapy in NYHA functional class II. 37 , 40 , 262 \u0002 266   Few studies have compared CRT-pacemaker (CRT-P) with conventional pacing. 190 , 267 , 268   Most studies of CRT have specified that LVEF should be <_35%, but MADIT-CRT 40 and the Resynchronization \u0002 Defibrillation for Ambulatory Heart Failure Trial (RAFT) 37   considered an LVEF <_30%, and the REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction (REVERSE) trial 262   specified <_40%. Relatively few patients with an LVEF of 35 \u0002 40% have been random- ized, but an individual participant data meta-analysis suggests no dimin- ution of the effect of CRT in this group. 33\nNot all patients respond favourably to CRT. Several characteristics predict reduction in ventricular volume (reverse remodelling) and improvement in morbidity and mortality. QRS width predicts CRT response and was the inclusion criterion in all randomized trials (for ECG criteria for LBBB and RBBB, see  Supplementary Table 1 ). QRS morphology has been related to a beneficial response to CRT. Several studies have shown that patients with LBBB morphology are more likely to respond favourably, whereas there is less certainty about patients with non-LBBB morphology. Sipahi  et al. 269 , 270   per- formed a meta-analysis in which they examined 33 clinical trials inves- tigating the effect of QRS morphology on CRT, but only four (COMPANION, CARE-HF, MADIT-CRT, and RAFT) included out- comes according to QRS morphology. When they evaluated the effect of CRT on composite adverse clinical events in 3349 patients with LBBB at baseline, they observed a 36% reduction in risk with the use of CRT (relative risk 0.64, 95% CI 0.52 \u0002 0.77;  P  < 0.00001). However, such benefit was not observed in patients with non-LBBB conduction abnormalities (relative risk 0.97, 95% CI 0.82 \u0002 1.15;  P  < 0.75). When the analysis was limited to trials without ICD (CARE-HF and COMPANION), the benefit of CRT was still observed only in patients with LBBB ( P  < 0.000001). In a meta-analysis excluding COMPANION and MADIT-CRT, LBBB was not found to be a pre- dictor of mortality, in contrast to QRS duration. 266   In a recent large meta-analysis of five RCTs (COMPANION, CARE-HF, MADIT-CRT, RAFT, and REVERSE) including 6523 participants (1766 with non- LBBB QRS morphology), CRT was not associated with a reduction in death and/or HF hospitalization in patients with non-LBBB QRS mor- phology (HR 0.99, 95% CI 0.82- 1.2). 271   As patients have been aggre- gated in the non-LBBB category in nearly all studies and post-hoc analyses on the beneficial effect of QRS morphology in CRT, it is not possible to provide a separate recommendation for CRT in patients presenting with diffuse intraventricular conduction disturbance and\nESC Guidelines 33\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................ RBBB. 272 \u0002 277   Patients with RBBB do not benefit from CRT 278   unless they show a so-called masked LBBB on ECG, 277   characterized by a broad, slurred, sometimes notched R wave on leads I and aVL, together with a leftward axis deviation. Individualized positioning of the LV lead is crucial in these patients. An important recent notion is the possible role played by a pro- longed PR in HF patients with non-LBBB. A few single-centre studies and two post-hoc analyses of large RCTs (COMPANION and MADIT-CRT) indicated a potential benefit of implanting CRT in this patient subgroup. 244 , 279 , 280   In MADIT-CRT, the subgroup of non- LBBB patients who had a prolonged PR did benefit from CRT-D, with a 73% reduction in the risk of HF or death and an 81% reduction in the risk of all-cause mortality compared with ICD-only therapy. 279   In non LBBB patients with normal PR, CRT-D was associated with a trend towards an increased risk of HF or death and a >2-fold higher mortality compared with ICD therapy, suggesting a bidirectional sig- nificant interaction. However, the data are too limited to give a recommendation. 279\nThe results of the MADIT-CRT, REVERSE, and RAFT trials suggest that in patients with LBBB, there is likely to be potential benefit in all patients with LBBB regardless of QRS duration, and that no cut-off point can be identified clearly to exclude patients who will not respond according to the QRS duration. 272 , 273 , 275   In contrast, any benefit of CRT in patients with non-LBBB is evident mostly in those with a QRS duration >_150 ms. Importantly, as shown in the MADIT- CRT long-term study and RAFT, the benefit in patients with QRS <150 ms appeared later during follow-up. 265 , 273\nThe Echocardiography Guided Cardiac Resynchronization Therapy (Echo-CRT) trial suggested possible harm from CRT when baseline echocardiographic mechanical dyssynchrony in patients with QRS duration <130 ms is used. 264 , 281   Therefore, selection of CRT patients based solely on the use of cardiac imaging data is strongly dis- couraged in patients with so-called ‘narrow’ QRS (i.e. <130 ms). Individual patient data pooled from three CRT-D vs. ICD trials enrolling predominantly patients with NYHA class II HF showed that women are more likely to respond than men. 282   In the US Food and Drug Administration meta-analysis of patient-level data, Zusterzeel  et al . 283   found that the main difference occurred in patients with LBBB and a QRS of 130 \u0002 149 ms. In this group, women had a 76% reduc- tion in HF or death [absolute CRT-D to ICD difference, 23% (HR 0.24, 95% CI 0.11 \u0002 0.53;  P  < 0.001)] and a 76% reduction in death alone [absolute difference 9% (HR 0.24, 95% CI 0.06 \u0002 0.89;  P  = 0.03)], whereas there was no significant benefit in men for HF or death [absolute difference 4% (HR 0.85, 95% CI 0.60 \u0002 1.21;  P  = 0.38)] or death alone [absolute difference 2% (HR 0.86, 95% CI 0.49 \u0002 1.52;  P  = 0.60)]. A possible explanation for the greater benefit of CRT in women has been attributed to sex difference in LV size, as sex-specific differences in response disappear when QRS duration is normalized to LV end-diastolic volume. 284   Recently, computer mod- elling confirmed that sex differences in the LV size account for a sig- nificant proportion of the sex difference in QRS duration, and provided a possible mechanistic explanation for the sex difference in CRT response. 285 , 286   Simulations accounting for the smaller LV size in female CRT patients predict 9 - 13 ms lower QRS duration thresh- olds for females. As with other ECG parameters (e.g. duration of QT and corrected QT), it is conceivable that QRS duration also has to reflect sex difference.\nECG criteria of intraventricular conduction disturbance, LBBB, and non-LBBB have not been consistently defined and reported in any of the past CRT studies. 287 , 288   Similarly, the modality of QRS measure- ment (automatic or manual, and ECG recording machine) was not reported in CRT studies. However, the selection of ECG criteria appears to influence hard endpoints. 287 \u0002 290   Similarly, ECG recording modality and ECG manufacturer have been shown to possibly affect the automatically measured QRS duration. Finally, CRT is considered in patients on optimal medical treatment (OMT), including beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and mineralocorticoid receptor antagonists. However, a study raises the question of the timing of CRT, because the efficacy of the medical treatment can be limited in patients with LBBB, suggesting considering CRT sooner. 291\nMoreover, whereas everyday clinical practice supports the use of sacubitril/valsartan, ivabradine, and sodium \u0002 glucose co-transporter- 2 inhibitors, it must be emphasized that in the landmark trials documenting the efficacy of these drugs, very few patients had an indication for CRT. Thus, there are no strong data to support the mandatory use of these drugs before considering CRT. 292 \u0002 295\nRecommendations for cardiac resynchronization ther- apy in patients in sinus rhythm\nRecommendations Class a Level b\nLBBB QRS morphology\nCRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration\n>_150 ms, and LBBB QRS morphology despite\nOMT, in order to improve symptoms and reduce morbidity and mortality. 37 , 39 , 40 , 254 \u0002 266 , 283 , 284\nI A\nCRT should be considered for symptomatic\npatients with HF in SR with LVEF <_35%, QRS\nduration 130 \u0002 149 ms, and LBBB QRS morphol- ogy despite OMT, in order to improve symp-\ntoms and reduce morbidity and\nmortality. 37 , 39 , 40 , 254 \u0002 266 , 283 , 284\nIIa B\nNon-LBBB QRS morphology\nCRT should be considered for symptomatic\npatients with HF in SR with LVEF <_35%, QRS\nduration >_150 ms, and non-LBBB QRS morphol- ogy despite OMT, in order to improve symp-\ntoms and reduce morbidity. 37 , 39 , 40 , 254 \u0002 266 , 283 , 284\nIIa B\nCRT may be considered for symptomatic patients with HF in SR with LVEF <_35%, QRS\nduration 130 \u0002 149 ms, and non-LBBB QRS mor-\nphology despite OMT, in order to improve symptoms and reduce morbidity. 273 \u0002 278 , 281\nIIb B\nQRS duration\nCRT is not indicated in patients with HF and\nQRS duration <130 ms without an indication for RV pacing. 264 , 282\nIII A\nCRT = cardiac resynchronization therapy; HF = heart failure; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; SR = sinus rhythm. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...............................................................................................................\n34 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 6.3 Patients in atrial fibrillation This section considers indications for CRT in patients with perma- nent AF or persistent AF unsuitable for AF ablation or after unsuc- cessful AF ablation. AF ablation has been reported to improve LVEF and reduce the HF hospitalization rate in selected patients. In particu- lar, AF ablation is recommended for reversing LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly prob- able, regardless of symptoms. 296   Therefore, CRT should be consid- ered in those patients with persistent AF and HFrEF when AF ablation cannot be performed or is declined by the patient. With regard to indications for rate control therapy and in particular to AVJ ablation, refer to the ESC Guidelines for the management of AF. 296\n6.3.1 Patients with atrial fibrillation and heart failure who are candidates for cardiac resynchronization therapy A major determinant of the success of CRT is the effective delivery of biventricular pacing. A particular aspect of AF patients is that AF rhythm with fast ventricular rate and irregularity may interfere with adequate biventricular pacing delivery. AF may reduce the rate of effective biventricular capture by creating spontaneous, fusion, or pseudo-fusion beats. A high rate of biventricular pacing is not reached in two-thirds of patients with persistent or permanent AF. 297\nData from large registries show that AF patients undergoing CRT have an increased risk of mortality even after adjusting for several clinical variables. 297 \u0002 299   In most AF patients with intact AV conduc- tion, an adequate biventricular pacing delivery can be achieved only by means of AVJ ablation. 300 \u0002 302   A substudy of the RAFT trial 300   was unable to show benefit of CRT without AVJ ablation with regard to the combined endpoint of death or hospitalization for HF; notably, only 47% of the patients had a biventricular capture >90%. The deci- sion to perform AVJ ablation is still a matter of debate, but most stud- ies have shown improvements in LV function, functional capacity, exercise capacity, and survival (with the same magnitude as in patients with SR). 301   Gasparini  et al. 302   compared total mortality of 443 AF patients who received AVJ ablation ( n  = 443) and of 895 AF patients who received rate-slowing drugs with the mortality of 6046 patients who were in SR. The long-term survival after CRT among patients with AF and AVJ ablation was similar to that observed among patients in SR (HR 0.93); the mortality was higher for AF patients treated with rate-slowing drugs (HR 1.52). The most common rate- controlling drugs used in AF are beta-blockers; although safe even in the context of AF and HFrEF, they do not necessarily have the same benefit as in patients with SR 303   and the benefit \u0002 risk ratio is influ- enced by other cardiovascular comorbidities. 304 , 305   In a systematic review and meta-analysis, 306   AVJ ablation, compared with no AVJ ablation, reduced mortality by 37% and reduced the rate of non- response by 59% in patients with biventricular pacing <90%, but showed no benefit in those with >_90% biventricular pacing. Similarly, Tolosana  et al.  observed the same rate of responders (defined as >_10% decrease in end-systolic volume) in AF patients who received AVJ ablation or rate-slowing drugs and patients in SR who had adequate biventricular pacing (97, 94, and 97%, respectively). 307\nImportantly, AVJ ablation did not improve survival for patients in AF treated with CRT compared with those treated with rate-slowing drugs when an adequate biventricular pacing was achieved either with ablation (97%) or with drugs (94%). 308\nIn conclusion, despite the weak evidence due to lack of large, randomized trials, the prevailing opinion of experts is in favour of the usefulness of CRT in patients with permanent AF and NYHA class III and IV with the same indications as for patients in SR, provided that AVJ ablation is added in those patients with incomplete (<90 - 95%) biventricular capture due to AF ( Figure  9 ). However, there are other causes for incomplete biventricular pacing such as frequent prema- ture ventricular beats, which may need to be treated (with drugs or ablation) before considering AVJ ablation. Importantly, evaluation of the biventricular pacing percentage is mainly given by the percentage of biventricular pacing using device memory, which does not reflect exactly the rate of effective biventricular capture. Holter monitoring may help to assess the real biventricular capture percentage. 309 , 310   A new algorithm has been developed that can continuously assess the effective biventricular pacing. 311\nFor patients with permanent AF, there are no data supporting the difference in the magnitude of response to CRT according to the QRS morphology or a QRS duration cut-off of 150 ms. It is important to remember that limited data are available for patients in NYHA class II.\n6.3.2 Patients with uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration) AVJ ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control ther- apy, or who are ineligible for AF ablation, accepting that these patients will become pacemaker dependent. 296   In particular, AVJ ablation combined with CRT may be preferred to AF ablation in severely symptomatic patients with permanent AF and at least one hospitalization for HF. 296\nAVJ ablation and permanent pacing from the RV apex provides highly efficient rate control and regularization of the ventricular response in AF, and improves symptoms in selected patients. 192   A large study with a propensity score-matched control group 194\nshowed a 53% reduction in total mortality in patients who underwent AVJ ablation compared with those treated with pharmacological rate control therapy. A class IIa indication is provided in the 2020 ESC Guidelines on AF. 296\nThe downside of RV pacing, however, is that it induces LV dyssyn- chrony in  \u0003 50% of patients, 312   and that this may lead to worsening of HF symptoms in a minority. In the majority of patients, AVJ ablation improves LVEF even with RV apical (RVA) pacing due to amelioration of tachycardia-induced LV dysfunction, which commonly exists in these patients. CRT may prevent RV pacing-induced LV dyssyn- chrony. The multicentre, randomized, prospective Ablate and Pace in Atrial Fibrillation (APAF) trial 313   included 186 patients in whom a CRT or RV pacing device was implanted, followed by AVJ ablation. During a median follow-up of 20 months, CRT significantly reduced by 63% the primary composite endpoint of death due to HF, hospital- ization due to HF, or worsening of HF. The beneficial effects of CRT were similar in patients with an EF <_35%, NYHA class >_III, and QRS width >_120 ms, and in other patients with EF>35% or NYHA class < III or narrow QRS. Compared with the RV pacing group, respond- ers increased from 63% to 83% ( P  ¼  0.003). 314   A meta-analysis of 696 patients from five trials showed a 62% reduction in\nESC Guidelines 35\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................ hospitalization for HF and a modest improvement in LVEF compared with RV pacing, but not in 6-min walked distance and quality of life assessed by means of the Minnesota Living with Heart Failure ques- tionnaire. 315   In the APAF-CRT RCT, 102 elderly patients (mean age 72 years) with permanent AF, a narrow QRS (<_110 ms), and at least one hospitalization for HF in the previous year were randomized to AVJ ablation and CRT or to pharmacological rate control therapy. 195\nAfter a median follow-up of 16 months, the primary composite out- come of HF death, hospitalization due to HF, or worsening HF had occurred in 10 patients (20%) in the ablation (AVJ) plus CRT arm and in 20 patients (38%) in the drug control arm (HR 0.38;  P  = 0.013). The results were mostly driven by a reduction in hospitalization for HF. The HR was 0.18 ( P  = 0.01) in patients with LVEF <_35% and 0.62 ( P  = 0.36) in those with LVEF >35%. Furthermore, patients undergoing AVJ ablation and CRT had a 36% reduction in the specific symptoms and\nphysical limitations of AF at 1-year follow-up ( P  = 0.004). In contrast to the main composite endpoint, the greatest symptomatic improve- ments were observed in patients with LVEF >35% ( P  = 0.0003). In conclusion, there is evidence from randomized trials of an addi- tional benefit of performing CRT pacing in patients with reduced EF, who are candidates for AVJ ablation for rate control to reduce hospi- talization and improve quality of life. There is evidence that CRT is superior to RV pacing in relieving symptoms, but not mortality and hospitalization in patients with mid-range reduced systolic function ( Figure  9 ).\n6.3.3 Emerging novel modalities for CRT: role of conduction system pacing HBP, alone or in conjunction with coronary sinus pacing, is a promising novel technique for delivering CRT, useful in AF patients\nOR\nControlled heart rate\nCandidate for CRT Candidate for AVJ ablation\n",
      "keywords": [
        "resynchronization",
        "ejection fraction",
        "should be considered",
        "echo",
        "class i",
        "reduces",
        "selected",
        "crt",
        "guideline",
        "pacemaker",
        "systolic",
        "tachycardia",
        "rhythm",
        "age",
        "mortality",
        "glucose",
        "function",
        "sinus",
        "well",
        "nyha",
        "therapy",
        "lvef",
        "diastolic",
        "icd",
        "class iii",
        "hfref",
        "sex",
        "being",
        "atrial fibrillation",
        "echocardiography"
      ],
      "tables": [
        {
          "title": "34 ESC Guidelines",
          "page_number": 33,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nLBBB QRS morphology |  |  | \nCRT is recommended for symptomatic patients\nwith HF in SR with LVEF <35%, QRS duration\n_\n>150 ms, and LBBB QRS morphology despite\n_\nOMT, in order to improve symptoms and reduce\nmorbidity and mortality.37,39,40,254\u0002266,283,284 | I | A | \nCRT should be considered for symptomatic\npatients with HF in SR with LVEF <35%, QRS\n_\nduration 130\u0002149 ms, and LBBB QRS morphol-\nogy despite OMT, in order to improve symp-\ntoms and reduce morbidity and\nmortality.37,39,40,254\u0002266,283,284 | IIa | B | \nNon-LBBB QRS morphology |  |  | \nCRT should be considered for symptomatic\npatients with HF in SR with LVEF <35%, QRS\n_\nduration >150 ms, and non-LBBB QRS morphol-\n_\nogy despite OMT, in order to improve symp-\ntoms and reduce morbidity.37,39,40,254\u0002266,283,284 | IIa | B | \nCRT may be considered for symptomatic\npatients with HF in SR with LVEF <35%, QRS\n_\nduration 130\u0002149 ms, and non-LBBB QRS mor-\nphology despite OMT, in order to improve\nsymptoms and reduce morbidity.273\u0002278,281 | IIb | B | \nQRS duration |  |  | \nCRT is not indicated in patients with HF and\nQRS duration <130 ms without an indication for\nRV pacing.264,282 | III | A | ESC 2021",
          "bbox": [
            306.8847686767578,
            333.93828633626305,
            552.0238749186198,
            690.5101514543805
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "39",
      "title": "Management of atrio-ventricular junction ablation in patients with:",
      "start_page": 35,
      "end_page": 36,
      "content": "Y N\nPersistent AF unsuitable for atrial fibrillation ablation  Permanent AF  OR\nCRT if QRS  ≥  130 ms (Class IIa)\nBiV > 90 – 95% a BiV < 90 – 95% a\nNo AVJ ablation AVJ ablation (Class IIa)\nCRT (Class I) CRT (Class IIa)\nCRT (Class IIb)\nLVEF < 40% (HFrEF)\n40%  ≤ LVEF  LVEF < 50% (HFmrEF)\nLVEF < 50%\nHBP (Class IIb)\nAVJ ablation\nY N\nRV pacing (Class IIa)\nHBP (Class IIb)\nFigure 9  Indication for atrioventricular junction ablation in patients with symptomatic permanent atrial fibrillation or persistent atrial fibrillation unsuit- able for atrial fibrillation ablation. AF = atrial fibrillation; AVJ = atrioventricular junction; BiV = biventricular; CRT = cardiac resynchronization therapy; ESC = European Society of Cardiology; HBP = His bundle pacing; HFmrEF = heart failure with mildly reduced ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; QRS = Q, R, and S waves; RV = right ventricular/right ventricle.   a Due to a rapid ventric- ular response. Note: the figure is based on the recommendations in the ESC Guidelines on AF. 296\n36 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ..................................................................................................................... undergoing AVJ ablation. 198 , 199 , 316 \u0002 318   Non-conventional CRT using HBP coronary sinus pacing (so-called ‘His-optimized CRT’) or left bundle branch area pacing, in comparison with conventional CRT, can achieve a narrower QRS with a ‘quasi-normal’ axis morphology, echocardiographic improvement of mechanical resynchronization indexes, and a better short-term clinical outcome. 319 \u0002 321   In general, the potential benefit of HBP depends on the ability to achieve a narrow QRS complex that is similar to the native QRS complex, rather than on the LVEF. Widespread adoption of this technique relies upon further validation of its efficacy in large RCTs and improvements in lead design, delivery tools, and devices (see section  7 ).\n",
      "keywords": [
        "patients",
        "hfref",
        "ejection fraction",
        "indication",
        "class i",
        "hfmref",
        "crt",
        "atrio",
        "ventricular",
        "atrial fibrillation",
        "ablation",
        "management",
        "junction",
        "lvef",
        "heart failure"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 37",
          "page_number": 36,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \n1) In patients with HF with permanent AF who are candidates\nfor CRT: |  |  | \n1A) CRT should be considered for patients with\nHF and LVEF <35% in NYHA class III or IV\n_\ndespite OMT if they are in AF and have intrinsic\nQRS >130 ms, provided a strategy to ensure\n_\nbiventricular capture is in place, in order to\nimprove symptoms and reduce morbidity and\nmortality.302,306,307,322 | IIa | C | \n1B) AVJ ablation should be added in the case of\nincomplete biventricular pacing (<90\u000295%) due\nto conducted AF.297\u0002302 | IIa | B | \n2) In patients with symptomatic AF and an uncontrolled heart\nrate who are candidates for AVJ ablation (irrespective of QRS\nduration): |  |  | \n2A) CRT is recommended in patients with\nHFrEF.196,197,306,308 | I | B | \n2B) CRT rather than standard RV pacing should\nbe considered in patients with HFmrEF. | IIa | C | \n2C) RV pacing should be considered in patients\nwith HFpEF.188,196,323 | IIa | B | 021\n2D) CRT may be considered in patients with\nHFpEF. | IIb | C | ESC 2",
          "bbox": [
            47.07401173909505,
            244.1768351236979,
            292.20211452907984,
            551.6118001937866
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 37",
          "page_number": 36,
          "content": "Recommendation | Classa | Levelb | \n |  |  | \nPatients who have received a conventional pace-\nmaker or an ICD and who subsequently develop\nsymptomatic HF with LVEF <35% despite OMT,\n_\nand who have a significantc proportion of RV\npacing, should be considered for upgrade to\nCRT.37,148,185,190,324\u0002352 | IIa | B | ESC 2021",
          "bbox": [
            311.5728332519531,
            551.6118001937866,
            556.7208862304688,
            646.0061776297433
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "40",
      "title": "6.4 Patients with conventional pacemaker or implantable cardioverter defibrillator who need upgrade to cardiac resynchronization therapy Several studies have demonstrated the deleterious effect of chr",
      "start_page": 36,
      "end_page": 37,
      "content": "hospitalizations, which may be reduced by programming to maximize intrinsic conduction or prevented by CRT. 148 , 183 , 190 , 324   Previously, the benefit of CRT upgrade had been investigated only by observatio- nal controlled trials and registries, 325 \u0002 339   mainly comparing upgrade with  de novo  CRT; in early, small, observational pre- vs. post-CRT studies; 340 \u0002 346   and in crossover trials, 347 \u0002 350   providing only limited clinical outcome data. Based on a recent meta-analysis of observational studies, mostly single-centre, 351   echocardiographic and functional response as well as the risk of mortality or HF events was similar in patients after  de novo  vs. upgrade CRT; however, in previous subgroup analyses from large, randomized, prospective trials such as RAFT, 37   morbidity or mortality benefit was not confirmed. Clinical outcomes are also influenced by the clinical characteristics of patients referred to CRT upgrade. Based on data from the European CRT Survey II, 352   a high-volume registry, and clinical char- acteristics from previous studies, 351   patients referred for a CRT upgrade differ from patients referred for  de novo  CRT implantation: they are older (even compared with those in RCTs), mainly male patients, and have more comorbidities such as AF, ischaemic heart disease, anaemia, and renal failure. On average, the number of upgrade procedures reaches 23% of total CRT implantations, 60% from a conventional device and 40% from an ICD 352   in ESC countries, showing significant regional differ- ences regarding the type of implanted device, such as CRT-P or CRT-D. 352 , 353\nRegarding procedure-related complications, several studies described a higher burden during upgrade procedures, ranging from 6.8% to 20.9% compared with  de novo  implantations. 339 , 354   This was not confirmed in a recent analysis of registry data, where upgrades had similar complication rates to  de novo  implantations. 352   Notably, 82% of these procedures were performed in high-volume centres. However, data on the long-term infection rates or lead revisions after CRT upgrade are scarce. 354 , 355\nThe first prospective, randomized trial, the BUDAPEST CRT Upgrade study, is still ongoing, but may clarify these questions. 356\nRecommendations for cardiac resynchronization therapy in patients with persistent or permanent atrial ﬁbrillation\nRecommendations Class a Level b\n1) In patients with HF with permanent AF who are candidates\nfor CRT:\n1A)  CRT should be considered for patients with\nHF and LVEF <_35% in NYHA class III or IV despite OMT if they are in AF and have intrinsic\nQRS >_130 ms, provided a strategy to ensure\nbiventricular capture is in place, in order to improve symptoms and reduce morbidity and\nmortality. 302 , 306 , 307 , 322\nIIa C\n1B)  AVJ ablation should be added in the case of incomplete biventricular pacing (<90 \u0002 95%) due\nto conducted AF. 297 \u0002 302\nIIa B\n2) In patients with symptomatic AF and an uncontrolled heart\nrate who are candidates for AVJ ablation (irrespective of QRS duration):\n2A)  CRT is recommended in patients with\nHFrEF. 196 , 197 , 306 , 308 I B\n2B)  CRT rather than standard RV pacing should be considered in patients with HFmrEF. IIa C\n2C ) RV pacing should be considered in patients\nwith HFpEF. 188 , 196 , 323 IIa B\n2D)  CRT may be considered in patients with HFpEF. IIb C\nAF = atrial ﬁbrillation; AVJ = atrioventricular junction; CRT = cardiac resynchroniza- tion therapy; EF = ejection fraction; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%); HFmrEF = heart failure with mildly reduced ejection fraction (40- 49%); HFpEF = heart failure with preserved ejection fraction (>_50%) according to the 2021 ESC HF Guidelines; 242   LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RV = right ventricular. a Class of recommendation. b Level of evidence.\nRecommendation for upgrade from right ventricular pacing to cardiac resynchronization therapy\nRecommendation Class a Level b\nPatients who have received a conventional pace-\nmaker or an ICD and who subsequently develop symptomatic HF with LVEF <_35% despite OMT,\nand who have a signiﬁcant c   proportion of RV\npacing, should be considered for upgrade to CRT. 37 , 148 , 185 , 190 , 324 \u0002 352\nIIa B\nCRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction; OMT = opti- mal medical therapy; RV = right ventricular. a Class of recommendation. b Level of evidence. c A limit of 20% RV pacing for considering interventions for pacing-induced HF is supported by observational data. However, there are no data to support that any percentage of RV pacing can be considered as deﬁning a true limit below which RV pacing is safe and beyond which RV pacing is harmful.\nESC 2021\nESC 2021\n. ......................................................\nESC Guidelines 37\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 6.5 Pacing in patients with reduced left ventricular ejection fraction and a conventional indication for antibradycardia pacing Three randomized trials proved the superiority of biventricular pac- ing over RV pacing in patients with moderate to severe systolic dys- function who required antibradycardia pacing to improve quality of life, NYHA class, and echocardiographic response. 190 , 357 , 358   In the Biventricular versus RV pacing in patients with AV block (BLOCK HF) trial, 691 patients with AVN disease and an indication for pace- maker with a mildly reduced EF (<50% by inclusion criteria, average 42.9% in the pacemaker group) were randomized to biventricular or RV pacing with or without an ICD, and followed for an average of 37 months. 190   The primary endpoint (a composite of >_15% increase in the LV end-systolic volume, HF events, or mortality) was significantly improved in those assigned to CRT. CRT response is high among patients with systolic dysfunction and expected frequent RV pacing. Based on the MOde Selection Trial in Sinus-Node Dysfunction (MOST), 183   at least 40% RV pacing is associated with an increased risk of HF hospitalization or AF. For patients with normal or preserved EF, data on benefit of CRT are conflicting with respect to hospitalization, and no mortality bene- fit was shown. 166 , 268 , 323 , 359   However, adverse remodelling caused by RV pacing was prevented by biventricular pacing, especially during long-term follow up. 323 , 359 , 360   A single-centre study showed that >20% RV pacing was associated with deleterious LV remodelling in patients with AVB and preserved LVEF. 188   Frailty should also be taken into account in deciding on CRT implantation, because of the higher costs and high complication rates of this procedure.\n",
      "keywords": [
        "resynchronization",
        "ejection fraction",
        "should be considered",
        "older",
        "hfmref",
        "crt",
        "pacemaker",
        "systolic",
        "demonstrated",
        "cardioverter",
        "several",
        "nyha",
        "effect",
        "therapy",
        "lvef",
        "deleterious",
        "icd",
        "class iii",
        "hfref",
        "male",
        "implantable",
        "hfpef",
        "defibrillator",
        "need",
        "level b",
        "cardiac",
        "upgrade",
        "heart failure",
        "systolic dysfunction",
        "patients"
      ],
      "tables": [
        {
          "title": "38 ESC Guidelines",
          "page_number": 37,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nCRT rather than RV pacing is recommended for\npatients with HFrEF (<40%) regardless of NYHA\nclass who have an indication for ventricular pac-\ning and high-degree AVB in order to reduce\nmorbidity. This includes patients with\nAF.183,190,196,268,313,323,357\u0002359,361,362 | I | A | ESC 2021",
          "bbox": [
            42.6984748840332,
            457.2457794189453,
            287.83201293945314,
            553.4261670793805
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "41",
      "title": "6.6 Benefit of adding implantable cardioverter defibrillator in patients with indications for cardiac resynchronization therapy The mortality benefit of CRT-D over CRT-P is still unclear, mostly becau",
      "start_page": 37,
      "end_page": 38,
      "content": "over CRT-P by reducing arrhythmic death, it does also add ICD- specific risks such as lead failure and inappropriate shocks, as well as costs. COMPANION is the only trial to randomize patients to CRT-P or CRT-D, but was designed to assess the effects of CRT compared with OMT. 260   Crucially, it was not designed to compare CRT-D and CRT-P. CRT-P was associated with a marginally non-significant reduction in the risk of all-cause mortality (HR 0.76, 95% CI 0.58 - 1.01;  P  = 0.06), whereas CRT-D was associated with a signifi- cant, 36% risk reduction (HR 0.64, 95% CI 0.48 \u0002 0.86;  P  = 0.004). Analysis of cause-specific mortality showed that SCD was significantly reduced by CRT-D (HR 0.44, 95% CI 0.23 - 0.86;  P  = 0.02) but not CRT-P (HR 1.21, 95% CI 0.7 \u0002 2.07;  P  = 0.50). 363\nNevertheless, the CARE-HF extension study proved that CRT-P alone reduced the risk of dying suddenly by 5.6%. 261   In line with these findings, subgroup analyses from RCTs in mild HF consistently found a reduction in ventricular arrhythmias with CRT. 364 \u0002 368   These effects were especially observed among CRT responders, suggesting that the reduction in SCD risk is related to the extent of reverse LV remodelling with CRT. Meta-analyses have drawn different conclusions on the matter. In the study by Al-Majed  et al. , 369   the survival benefit of CRT was largely driven by a reduction in HF-related mortality, but SCD was not reduced. Lam  et al . 370   showed that CRT-D significantly reduced mor- tality compared with medical therapy alone [odds ratio (OR) 0.57, 95% CI 0.40 \u0002 0.80], but not when compared with ICD without CRT (OR 0.82, 95% CI 0.57 \u0002 1.18) or CRT-P (OR 0.85, 95% CI 0.60 \u0002 1.22). However, more recently, a network meta-analysis of 13 randomized trials including >12 000 patients found that CRT-D reduced total mortality by 19% (95% CI 1 \u0002 33%, unadjusted) com- pared with CRT-P. 275\nSome recent large observational studies highlighted the impor- tance of HF aetiology in the assessment of potential benefits of CRT- D over CRT-P. 371 \u0002 373   CRT-D was associated with a significant risk reduction in all-cause mortality compared with CRT-P in patients with ischaemic cardiomyopathy. However, this difference was not found in patients with non-ischaemic cardiomyopathy. These findings are consistent with the results from the DANISH study, which assigned 1116 patients with HF and non-ischaemic cardi- omyopathy to receive either a primary prophylactic ICD or usual clinical care alone. 374   In both groups, 58% of patients also had CRT. Subgroup analysis showed that CRT-D was not superior to CRT-P in reducing the primary outcome of all-cause mortality (HR 0.91, 95% CI 0.64 \u0002 1.29;  P  = 0.59) after a median follow-up of 67.6 months. However, in a large multicentre registry of >50 000 patients, CRT-D was associated with a significantly lower observed mortality. 375\nSimilar results were found in a recent propensity-matched cohort, where CRT-D was associated with a significantly lower all-cause mortality than CRT-P in patients with ischaemic aetiology and in patients with non-ischaemic HF under 75 years old. 376   Furthermore, the CeRtiTuDe Cohort study 377   showed better survival in CRT-D vs. CRT-P mainly due to a reduction of non-SCD. In an Italian multi- centre CRT registry, the only independent predictor of mortality was the lack of an ICD. 378   Whereas these studies are limited by their observational design, important novel information on the issue of CRT-D vs. CRT-P is expected to come from an ongoing randomized trial, Re-evaluation of Optimal Re-synchronisation Therapy in\nRecommendation for patients with heart failure and atrioventricular block\nRecommendation Class a Level b\nCRT rather than RV pacing is recommended for\npatients with HFrEF (<40%) regardless of NYHA class who have an indication for ventricular pac-\ning and high-degree AVB in order to reduce\nmorbidity. This includes patients with AF. 183 , 190 , 196 , 268 , 313 , 323 , 357 \u0002 359 , 361 , 362\nI A\nAF = atrial ﬁbrillation; AVB = atrioventricular block; CRT = cardiac resynchroni- zation therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction (<40%) according to the 2021 ESC HF Guidelines; 242   NYHA = New York Heart Association; RV = right ventricular. a Class of recommendation. b Level of evidence.\nESC 2021\n38 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................................................................... Patients with Chronic Heart Failure (RESET-CRT; ClinicalTrials.gov Identifier NCT03494933). In conclusion, prospective randomized trials are lacking, and avail- able data are insufficient to firmly prove a superiority of CRT-D over CRT-P. However, it is important to consider that CRT trials in mild HF almost exclusively included patients with an ICD, 37 , 40 , 262   and that survival benefit of CRT without an ICD is uncertain in this particular group. Furthermore, observational data point towards significant sur- vival benefits by CRT-D over CRT-P in patients with ischaemic cardi- omyopathy, while no clear benefit has been shown in those with non-ischaemic cardiomyopathy. Further predictive power concerning the risk of ventricular arrhythmia may be derived by contrast-enhanced CMR-guided scar characterization. 379 , 380   When discussing the choice between CRT-D and CRT-P, it is particularly important to consider general predictors of ICD effectiveness such as age and comorbidities associated with a mortality risk that competes with sudden arrhythmic death. Thus, the addition of ICD to CRT should be considered, especially in younger patients with a good survival prognosis, ischaemic aetiology, and a favourable comorbidity profile or presence of myocardial fibrosis ( Figure  10 ). Moreover, the benefit of the ICD is governed by the bal- ance between the risk of SCD and the risk of death from other causes, as well as comorbidities. Generally, the rate of sudden arrhythmic death in primary prevention appears to be declining (1%/ year). Owing to the complexity of the matter and the lack of clear evi- dence, it is particularly important that the choice between CRT-P and CRT-D is guided by a process of shared decision-making between patients and clinicians, taking into account both medical facts and patient values.\n",
      "keywords": [
        "resynchronization",
        "ejection fraction",
        "should be considered",
        "crt",
        "becau",
        "age",
        "cardioverter",
        "mortality",
        "scd",
        "benefit",
        "nyha",
        "therapy",
        "arrhythmia",
        "icd",
        "hfref",
        "implantable",
        "defibrillator",
        "still",
        "level b",
        "cardiomyopathy",
        "cardiac",
        "adding",
        "heart failure",
        "primary prevention",
        "over",
        "patients",
        "recommended",
        "indication",
        "indications",
        "unclear"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 39",
          "page_number": 38,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients who are candidates for an ICD and\nwho have CRT indication, implantation of a\nCRT-D is recommended.260,369,370,381 | I | A | \nIn patients who are candidates for CRT, implan-\ntation of a CRT-D should be considered after\nindividual risk assessment and using shared deci-\nsion-making.382,383 | IIa | B | ESC 2021",
          "bbox": [
            47.17727279663086,
            459.7967864990234,
            292.302001953125,
            569.1871534075055
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "42",
      "title": "6.7 Factors influencing the efficacy of cardiac resynchronization therapy: role of imaging techniques The role of cardiac imaging in selecting HF patients for CRT has been evaluated mostly in observat",
      "start_page": 38,
      "end_page": 39,
      "content": "of the LV in relation to the LV lead position 389 , 390   have been associ- ated with response to CRT. LVEF is the only parameter included in the guidelines for the selection of patients for CRT and is key to define the type of HF (<40%, HFrEF; 40 \u0002 49%, HFmrEF; and >_50%, HFpEF). 242   Echocardiography is the imaging technique of first choice for the assessment of LVEF. However, when intravenous contrast is not available and the acoustic window does not allow accurate assessment of LVEF, CMR or nuclear imaging should be consid- ered. 242   Strain imaging (based on echocardiography or CMR) to quantify LV systolic function has shown incremental prognostic value in HF, and allows assessment of LV mechanical dys- synchrony. 384 , 391 \u0002 393   CMR with LGE techniques (which show the presence of myocardial scar tissue) provide the best resolution to dif- ferentiate ischaemic cardiomyopathy and non-ischaemic cardiomy- opathy. 394   The location (posterolateral) and extent (transmural vs. non-transmural and percentage of LV mass) of LGE on CMR or with nuclear techniques has been associated with the benefit from CRT. 380 , 387 , 395 , 396   Severe mitral regurgitation, 397   lack of significant electromechanical LV dyssynchrony, 384 , 385 , 392   and RV systolic dys- function 398   have been associated with less improvement in clinical symptoms and reduced survival after CRT. Several imaging techni- ques have been tested to assess LV mechanical dyssynchrony, but most measures of LV dyssynchrony have not been tested in random- ized trials including patients with HFrEF and wide QRS. 399   The pres- ence of septal flash and apical rocking, 400   time differences based on radial strain and patterns of regional longitudinal strain, 384 , 392 , 401 \u0002 403\nnon-invasive and invasive ECG mapping, 385 , 404   and vector-cardiogra- phy 405   have been proposed as novel techniques to predict response to CRT. Furthermore, LV myocardial work assessed with speckle- tracking echocardiography has been associated with survival in CRT recipients. 406   Coronary sinus venography is commonly performed to detect a suitable coronary vein in which to deploy an LV lead. Randomized trials have not systematically demonstrated that the guidance of LV lead implantation based on imaging (assessing myocar- dial scar or site of latest activation) is superior to standard prac- tice. 389 , 390 , 407 , 408   Initial experience on using artificial intelligence to combine clinical, electrical, and imaging parameters to define pheno- types of patients that will benefit from CRT is promising, but more data are needed. 409\nSignificant (moderate to severe and severe) secondary mitral regurgitation is frequent among candidates for CRT and has been shown to affect long-term survival as well as response to ther- apy. 406 , 410   CRT can improve mitral regurgitation in as many as 40% of patients. 406   However, in 60% of patients, significant mitral regurgita- tion is not corrected and, at long-term follow-up, progression of the underlying disease may lead to further deterioration of mitral valve function and poor prognosis. Transcatheter edge-to-edge mitral valve repair has been demonstrated to improve the response to CRT in registries. 411 \u0002 414   However, results from recent RCTs including patients with symptomatic severe secondary mitral regurgitation despite guideline-directed medical therapy (including CRT when indi- cated) have not consistently shown a benefit from transcatheter edge-to-edge mitral valve repair. 415 , 416\nTherefore, selection of patients for CRT based on imaging is lim- ited to the measurement of LVEF, whereas the assessment of other factors such as extent of myocardial scar, presence of mitral\nRecommendations for adding a deﬁbrillator with car- diac resynchronization therapy\nRecommendations Class a Level b\nIn patients who are candidates for an ICD and\nwho have CRT indication, implantation of a CRT-D is recommended. 260 , 369 , 370 , 381\nI A\nIn patients who are candidates for CRT, implan-\ntation of a CRT-D should be considered after individual risk assessment and using shared deci-\nsion-making. 382 , 383\nIIa B\nCRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 39\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ..................................................................................... regurgitation, or RV systolic function is important in identifying potential non-responders that may need additional treatment (mitral valve intervention, for example). Alternatives to conventional coronary sinus pacing for CRT (epi- cardial, endocardial) are described in  section 6.1  in the  Supplementary data .\n",
      "keywords": [
        "resynchronization",
        "should be considered",
        "hfmref",
        "crt",
        "valve repair",
        "guideline",
        "systolic",
        "efficacy",
        "mitral regurgitation",
        "therapy",
        "lvef",
        "icd",
        "hfref",
        "observat",
        "influencing",
        "role",
        "hfpef",
        "echocardiography",
        "level b",
        "cardiomyopathy",
        "ecg",
        "cardiac",
        "selecting",
        "patients",
        "factors",
        "recommended",
        "indication",
        "imaging",
        "techniques",
        "evaluated"
      ],
      "tables": []
    },
    {
      "number": "43",
      "title": "7 Alternative pacing strategies and sites",
      "start_page": 39,
      "end_page": 39,
      "content": "Alternative RV pacing sites (as opposed to RVA pacing) include pac- ing from the RV outflow tract (RVOT), the mid and high RV septum (RVS), HBP, para-Hisian pacing, and left bundle branch area pacing, which includes LV septal pacing and left bundle branch pacing.\n",
      "keywords": [
        "alternative",
        "pacing",
        "strategies",
        "sites"
      ],
      "tables": []
    },
    {
      "number": "44",
      "title": "7.1 Septal pacing Since the 2013 ESC Guidelines, 33   two randomized trials found no dif- ference in clinical outcomes between RVS and RVA pacing in the set- ting of AVB 417   or CRT, 418   respective",
      "start_page": 39,
      "end_page": 39,
      "content": "",
      "keywords": [
        "clinical",
        "found",
        "trials",
        "outcomes",
        "septal",
        "pacing",
        "respective",
        "since",
        "randomized",
        "ting",
        "guidelines",
        "between",
        "ference"
      ],
      "tables": []
    },
    {
      "number": "45",
      "title": "7.2 His bundle pacing HBP was first reported in humans in 2000, 199   and is steadily gaining interest for providing a more physiological alternative to RV pacing. It may also correct intraventricular",
      "start_page": 39,
      "end_page": 39,
      "content": "7.2.1 Implantation and follow-up The use of guiding catheters to deliver leads has facilitated implanta- tion, with success rates exceeding 80%. 422   In an international registry, implant success was 87% after a learning curve of 40 cases. 423\nSelective HBP is easily recognized by an isoelectric interval (corre- sponding to the HV) between the pacing spike and QRS onset, whereas with non-selective HBP, a ‘pseudo-delta’ wave is observed due to capture of local myocardium. 424   In addition, correction of BBB may be observed ( Figure  11 ). It is important to distinguish non- selective HBP from para-Hisian pacing (where there is no capture of conduction tissue) by evaluating transitions in QRS morphology by reducing pacing output or with pacing manoeuvres. 425\nPatient with indication for CRT\nCRT-P\nCRT-D\n+ - Myocardial Fibrosis on CMR\nAge\n-\n+\n",
      "keywords": [
        "first",
        "providing",
        "age",
        "indication",
        "alternative",
        "intraventricular",
        "pacing",
        "humans",
        "more",
        "crt",
        "physiological",
        "correct",
        "steadily",
        "also",
        "gaining",
        "bundle",
        "interest",
        "reported"
      ],
      "tables": []
    },
    {
      "number": "46",
      "title": "Other factors in favor of choosing  CRT-P rather than CRT-D:",
      "start_page": 39,
      "end_page": 42,
      "content": "Non-ischaemic cardiomyopathy Short life expectancy Major comorbidities Poor renal function Patient preference\nShared decision making\nShared decision making\nAge\n-\n+\nFigure 10  Patient’s clinical characteristics and preference to be considered for the decision-making between cardiac resynchronization therapy pace- maker or defibrillator. CRT-P = cardiac resynchronization therapy-pacemaker; CRT-D = defibrillator with cardiac resynchronization therapy; CMR = car- diovascular magnetic resonance.\n40 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n0\n1\n2\n3\n4\n5\n6\n7\n8\nNS-HBP\nS-HBP\nLOC\nNS-HBP\nS-HBP corr-\nS-HBP corr+\nMyo\nLOC LOC\nA\nB\nC\nThresholds\nHis\nMyocardium\nBundle branch\nNS-HBP S-HBP\nV\nNS-HBP Myo\nV\nS-HBP corr+ S-HBP corr-\nV A B C\nOutput  (V/0.5ms)\nFigure 11  Three patients with different types of transitions in QRS morphology with His bundle pacing and decrementing pacing output. BBB = bundle branch block; Corr± = with/without correction of bundle branch block; LBBB = left bundle branch block; LOC = loss of capture; Myo = myocardium; NSHBP = non-selective His bundle pacing; S-HBP = selective His bundle pacing. ( A ) Non-selective to selective His capture. Note the presence of a ‘pseudo-delta’ wave with non-selective capture and an isoelectric interval after the pacing spike with selective capture. ( B ) Non-selective His capture to myocardial capture only. ( C ) Selective His capture with correction of BBB to selective His capture with LBBB. Note: the graph on the right of the panel shows a schematic representation of the different thresholds in the three instances.\nESC Guidelines 41\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................\nCompared with RV pacing, HBP capture thresholds are on average higher and sensing amplitudes lower. A recent observational study raised concern with regard to increasing HBP pacing thresholds with intermediate follow-up. 426   The higher capture thresholds lead to shorter battery longevity (at 5 years there were 9% generator changes with HBP compared with 1% with RVP). 427   Capture thresh- olds of HBP at implantation should aim to be <2.0 V/1 ms (or <2.5 V/ 0.4 ms) and bipolar R-wave sensing amplitude >2.0 mV. With experi- ence, thresholds decrease as implanters gain confidence to reposition leads. Sensing issues include not only ventricular undersensing, but also oversensing of atrial or His potentials (which may be potentially lethal in a pacemaker-dependent patient). An RV backup lead should be considered if the implanter is inex- perienced, or if there are high capture thresholds or sensing issues in pacemaker-dependent patients, in those scheduled for AVN ablation (where there is a risk of compromising HBP), or in patients with high- degree or infranodal block. Pros and cons are listed in  Table  9 . Several series have shown that the rate of mid-term lead revision is relatively high at  \u0003 7%, 318 , 423 , 427 , 428   (and reported to be as high as 11% 426 ), and is higher than RV pacing, which is 2 \u0002 3%. 427 , 429\nTherefore, it is advisable to follow-up these patients at least once every 6 months or place them on remote monitoring (ensuring that automatic threshold measurements correspond to those measured manually, as this may not be the case and depends on device configu- ration). 430   Device programming should take into account specific requirements for HBP, which are covered in detail elsewhere. 431 , 432\n7.2.2 Indications 7.2.2.1 Pacing for bradycardia One study reported that in patients with AVB and normal baseline LVEF, the incidence of RV pacing-induced cardiomyopathy was 12.3% and the risk was increased if the percentage of ventricular pac- ing was >_20% (HR 6.76;  P  = 0.002). 188   However, there are no data to support that any percentage of RV pacing can be considered as defin- ing a true limit below which RV pacing is safe and beyond which RV pacing is harmful. Observational data indicate that patients with HBP\nfare better in terms of HF hospitalizations than patients with RV pac- ing if the percentage of ventricular pacing is >20% (HR 0.54;  P  = 0.01). 42   Of note, the average baseline LVEF in patients with HBP in that study was 55% and the average QRS duration was 105 ms. HBP may therefore avoid clinical deterioration in these patients, particu- larly if the intrinsic QRS is narrow or if BBB is corrected by HBP. In a series of 100 patients with AVB undergoing HBP by experi- enced operators, implantation was successful in 41/54 (76%) patients with infranodal AVB and higher in the case of nodal block (93%;  P  < 0.05). 433   Over a mean follow-up of 19 ± 12 months, lead revision was necessary in 2/41 (5%) patients with infranodal block and in 3/43 (7%) with nodal block. Notably, the average LVEF in this series was 54%, and there are no data reported specifically on HBP in patients with AVB and reduced LVEF. HBP is an option in patients with a nar- row QRS or if HBP corrects BBB, but otherwise biventricular pacing is indicated. There is a need for RCTs to compare the safety and efficacy of HBP with RV pacing. It is important to balance the potential benefits of HBP with the aforementioned issues of higher capture thresholds and shorter battery longevity, a higher rate of lead revision, and more frequent sensing issues, compared with RV pacing. It is also important to consider the operator’s experience and expertise with HBP, and whether a backup ventricular pacing lead is indicated. The patient’s safety should be first and foremost in decision-making.\n7.2.2.2 Pace and ablate Seven observational series, totalling >240 patients treated with a ‘pace-and-ablate’ strategy for rapidly conducted AF, found an improvement in LVEF and NYHA class compared with baseline with HBP. 197 \u0002 199 , 434   Long-term results with a median of 3 years of follow- up have been reported, with favourable outcomes. 434   A single- blinded, randomized, crossover study in 16 patients compared HBP with RVA pacing over 6 months and found better NYHA and 6-min walk distance with HBP, without differences in echocardiographic parameters. 200   However, only four patients in this study had con- firmed HBP (with para-Hisian pacing in the remaining patients). These studies included patients with reduced as well as preserved LVEF, 197 , 198   and QRS width was on average <120 ms. HBP is of par- ticular interest in patients with a normal baseline QRS morphology as it preserves intrinsic ventricular synchrony, However, a caveat is that AVJ ablation may result in an increase in HBP capture thresholds or in lead dislodgments in a minority of patients. 197 , 199 , 318 , 426   Owing to these issues and risk of HBP lead failure, a backup RV lead should be considered.\n7.2.2.3 Role in cardiac resynchronization therapy In 1977, Narula showed that pacing of the His bundle can correct LBBB in a subset of patients, implying a proximal site of conduction disturbance with longitudinal dissociation within the His bundle. 435   A recent mapping study reported intra-Hisian block in 46% of patients with LBBB, in whom 94% were corrected by temporary HBP. 436   HBP may therefore be used in lieu of biventricular pacing for HBP-based CRT, as some data have shown that results are comparable (see Supplementary Table 10 ). 437 \u0002 439   Nevertheless, especially in CRT can- didates with LBBB, biventricular pacing has more solid evidence of efficacy and safety, and therefore remains first-line therapy. However, HBP should be considered as a bailout solution in the case of failed\nTable 9 Advantages and disadvantages of a ‘backup’ ventricular lead with His bundle pacing\nAdvantages •   Increased safety (in case of loss of capture of the HBP lead) •   Can be used for sensing (lower risk of ventricular undersensing, no risk of His or atrial oversensing) •   Programming of pacing output with lower safety margins •   May serve to narrow the QRS with fusion pacing in the case of selec- tive-HBP with uncorrected RBBB\nDisadvantages •   Higher cost •   More transvenous hardware •   Risk associated with the additional lead (e.g. ventricular perforation) •   More complex programming •   “Off-label” use (current regulatory approval and MRI-conditionality for HBP is only granted for His leads connected to the RV port)\nHBP = His bundle pacing; MRI = magnetic resonance imaging; RBBB = right bun- dle branch block.\nESC 2021\n42 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .........................................................................................................................................\nLV lead implantation along with other options such as surgical epicar- dial leads 424 , 440   (see  section  6.7 ). An interesting population is patients with RBBB, who are known to respond less well to biventricular pac- ing, in whom HBP has shown promising preliminary results in a series of 37 patients. 441   HBP may sometimes incompletely correct BBB, and can be used in conjunction with RV, LV, or biventricular pacing, as in the HOT-CRT study. 319   This is of particular interest in patients with permanent AF, in whom a His lead may be connected to the vacant atrial port, thus offering additional therapeutic options.\n",
      "keywords": [
        "favor",
        "choosing",
        "rather",
        "factors",
        "age",
        "should be considered",
        "other",
        "mri",
        "bradycardia",
        "crt",
        "ablation",
        "pacemaker",
        "nyha",
        "than",
        "cardiomyopathy",
        "lvef"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 41",
          "page_number": 40,
          "content": " |  | \n | NS-HBP | NS-HBP\n |  | ",
          "bbox": [
            203.58199310302734,
            507.34999084472656,
            298.6031882546165,
            550.2459716796875
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 41",
          "page_number": 40,
          "content": " |  | \n | S-HBP | \nLOC\nLOC |  | \n |  | LOC",
          "bbox": [
            203.58199310302734,
            564.3479881286621,
            298.6031882546165,
            621.9103881835938
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 43",
          "page_number": 42,
          "content": "HBP may be considered as an alternative to RV\npacing in patients with AVB and LVEF >40%,\nwho are anticipated to have >20% ventricular\npacing.42,433 | IIb | C | ESC 2021",
          "bbox": [
            311.31485748291016,
            59.87817600795201,
            556.8698933919271,
            108.95418221609933
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 43",
          "page_number": 42,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients treated with HBP, device program-\nming tailored to specific requirements of HBP is\nrecommended.430,431 | I | C | \nIn CRT candidates in whom coronary sinus lead\nimplantation is unsuccessful, HBP should be con-\nsidered as a treatment option along with other\ntechniques such as surgical epicardial\nlead.318,424,440,443 | IIa | B | \nIn patients treated with HBP, implantation of an\nRV lead used as ‘backup’ for pacing should be\nconsidered in specific situations (e.g. pacemaker\ndependency, high-grade AVB, infranodal block,\nhigh pacing threshold, planned AVJ ablation) or\nfor sensing in the case of issues with detection\n(e.g. risk of ventricular undersensing or over-\nsensing of atrial/His potentials).423,426,444 | IIa | C | \nHBP with a ventricular backup lead may be con-\nsidered in patients in whom a ‘pace-and-ablate’\nstrategy for rapidly conducted supraventricular\narrhythmia is indicated, particularly when the\nintrinsic QRS is narrow.197,199,200,318 | IIb | C | ",
          "bbox": [
            47.11779724924188,
            439.44422302246096,
            292.1385498046875,
            719.2022617885044
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "47",
      "title": "7.3 Left bundle branch area pacing With left bundle branch area pacing, the lead is implanted slightly dis- tal to the His bundle and is screwed deep in the LV septum, ideally to capture the left bund",
      "start_page": 42,
      "end_page": 42,
      "content": "",
      "keywords": [
        "capture",
        "implanted",
        "screwed",
        "left",
        "bund",
        "pacing",
        "area",
        "lead",
        "septum",
        "branch",
        "deep",
        "slightly",
        "bundle",
        "ideally"
      ],
      "tables": []
    },
    {
      "number": "48",
      "title": "7.4 Leadless pacing Leadless pacemakers have been developed to address limitations typ- ically related to pulse generator pocket and transvenous leads of con- ventional pacemaker systems. Currently, t",
      "start_page": 42,
      "end_page": 43,
      "content": "Leadless pacemakers that only function in the VVI(R) mode restrict indications to patients with AF or very infrequent pacing (e.g. paroxysmal AVB). Recently, VDD pacing (by detection of atrial con- traction by the accelerometer) has been introduced, which extends indications to patients with AVB with preserved sinus node function. AV synchrony is maintained 70 \u0002 90% of the time, depending on the patient’s position and activity, based on data from two studies includ- ing 73 patients in SR and high-degree AV block. 448   There may in future be an alternative to standard DDD pacemakers in selected patients if the potential benefits of leadless pacing outweigh the potential benefits of 100% AV synchrony, atrial pacing, and atrial arrhythmia monitoring. Indications for leadless pacemakers include obstruction of the venous route used for standard pacemaker implantation (e.g. bilateral venous thoracic outlet syndrome or chronic obstruction of the supe- rior vena cava), pocket issues (e.g. in the case of cachexia or demen- tia), or particularly increased infection risk [e.g. in the case of dialysis\nRecommendations for using His bundle pacing\nRecommendations Class a Level b\nIn patients treated with HBP, device program-\nming tailored to speciﬁc requirements of HBP is recommended. 430 , 431\nI C\nIn CRT candidates in whom coronary sinus lead\nimplantation is unsuccessful, HBP should be con-\nsidered as a treatment option along with other techniques such as surgical epicardial\nlead. 318 , 424 , 440 , 443\nIIa B\nIn patients treated with HBP, implantation of an RV lead used as ‘backup’ for pacing should be\nconsidered in speciﬁc situations (e.g. pacemaker\ndependency, high-grade AVB, infranodal block, high pacing threshold, planned AVJ ablation) or\nfor sensing in the case of issues with detection\n(e.g. risk of ventricular undersensing or over- sensing of atrial/His potentials). 423 , 426 , 444\nIIa C\nHBP with a ventricular backup lead may be con-\nsidered in patients in whom a ‘pace-and-ablate’ strategy for rapidly conducted supraventricular\narrhythmia is indicated, particularly when the\nintrinsic QRS is narrow. 197 , 199 , 200 , 318\nIIb C\nContinued\nHBP may be considered as an alternative to RV\npacing in patients with AVB and LVEF >40%,\nwho are anticipated to have >20% ventricular pacing. 42 , 433\nIIb C\nAVB = atrioventricular block; AVJ = atrioventricular junction; CRT = cardiac resynchronization therapy; HBP = His bundle pacing; LVEF = left ventricular ejec- tion fraction; RV = right ventricular. a Class of recommendation. b Level of evidence.\nESC 2021\n. ................................\nESC Guidelines 43\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................... or previous cardiovascular implantable electronic device (CIED) infection]. Observational data showed that a leadless pacemaker was a safe pacing alternative in patients with previous device infection and explant, and in patients on chronic haemodialysis. Whereas observa- tional data indicate high efficacy and low complication rates with lead- less pacemakers, 50   there are currently no data from RCTs documenting the long-term safety and efficacy of leadless vs. standard transvenous pacemakers, and therefore the indication for a leadless pacemaker should be carefully considered on a case by case basis. The absence of long-term data on leadless pacemaker performance and limited data on retrievability and end-of-life strategy 449   require careful consideration before selecting leadless pacemaker therapy, especially for younger patients (e.g. with a life expectancy >20 years).\n",
      "keywords": [
        "developed",
        "generator",
        "crt",
        "ventional",
        "pacemaker",
        "address",
        "leads",
        "pocket",
        "leadless",
        "related",
        "lvef",
        "arrhythmia",
        "limitations",
        "currently",
        "pacemakers",
        "pulse",
        "level b",
        "systems",
        "recommended",
        "may be considered",
        "indication",
        "pacing",
        "ically",
        "transvenous",
        "ablation"
      ],
      "tables": [
        {
          "title": "44 ESC Guidelines",
          "page_number": 43,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nLeadless pacemakers should be considered as an\nalternative to transvenous pacemakers when no\nupper extremity venous access exists or when\nrisk of device pocket infection is particularly\nhigh, such as previous infection and patients on\nhaemodialysis.45,47\u000250,450 | IIa | B | \nLeadless pacemakers may be considered as an\nalternative to standard single-lead ventricular\npacing, taking into consideration life expectancy\nand using shared decision-making.45,47\u000250 | IIb | C | ESC 2021",
          "bbox": [
            42.642042306753304,
            258.25335896809895,
            287.76658412388394,
            403.5859159581801
          ],
          "function_potential": "raw"
        },
        {
          "title": "44 ESC Guidelines",
          "page_number": 43,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nImplantation of a permanent pacemaker is indi-\ncated with the same recommendations as in a\ngeneral population (section 5.2) when AVB does\nnot resolve within a waiting period of at least 5\ndays after MI. | I | C | \nIn selected patients with AVB in the context of\nanterior wall MI and acute HF, early device\nimplantation (CRT-D/CRT-P) may be\nconsidered.471 | IIb | C | 021\nPacing is not recommended if AVB resolves after\nrevascularization or spontaneously.454\u0002456,458 | III | B | ESC 2",
          "bbox": [
            306.94997119903564,
            397.8882232666016,
            552.085951063368,
            556.4372406005859
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "49",
      "title": "8 Indications for pacing in specific conditions",
      "start_page": 43,
      "end_page": 43,
      "content": "",
      "keywords": [
        "specific",
        "indications",
        "pacing",
        "conditions"
      ],
      "tables": []
    },
    {
      "number": "50",
      "title": "8.1 Pacing in acute myocardial infarction In patients with acute MI, significant bradyarrhythmia may occur due to autonomic influences or damage of the conduction system by ischaemia and/or reperfusio",
      "start_page": 43,
      "end_page": 43,
      "content": "The incidence of high-degree AVB in patients with ST-segment ele- vation MI has declined to 3 \u0002 4% in the primary percutaneous coro- nary intervention era. 458 \u0002 460   High-degree AVB is most frequent in inferior or inferolateral infarctions. 455 , 458 \u0002 461\nPatients with high-degree AVB have higher clinical risk and larger infarctions especially when AVB complicates an anterior infarction. 458 \u0002 460 , 462 , 463   New-onset intraventricular conduction dis- turbance is also associated with larger infarctions. 464 \u0002 467\nSinus bradycardia and AVB at presentation can be vagally me- diated and may respond to atropine. 455 , 468   Revascularization is\nrecommended in patients with AVB who have not yet received reperfusion therapy. 469   AVB may require temporary pacing in the presence of refractory symptoms or haemodynamic compromise, but most often resolves spontaneously within a few days and only a minority of patients require permanent pacing. 451 , 454 , 456 , 458 , 462   In patients with persistent intraventricular conduction abnormalities and transient AVB in whom permanent pacing was recommended in the past, there is no evidence that permanent cardiac pacing improves outcome. 454 , 470   These patients frequently have HF and poor LV function, and should be evaluated for ICD, CRT-P, or CRT- D rather than conventional pacing if an early device implantation is considered. 471\nIf AVB does not resolve within 10 days, a permanent pacemaker should be implanted. In the absence of robust scientific data, the wait- ing period before pacemaker implantation has to be decided individu- ally. It may last up to 10 days but can be shortened to 5 days depending on the occluded vessel, time delay, and success of revascu- larization. Conditions favouring consideration of earlier pacemaker implantation include unsuccessful or late revascularization, anterior MI, bifascicular block or AV block before MI, and progression of AV block within the first days after MI. Sick sinus syndrome after occlu- sion of the right coronary artery resolves in most cases. If revasculari- zation is incomplete, pacemaker implantation can usually still be postponed and implantation only be performed if symptoms due to sinus bradycardia persist.\n",
      "keywords": [
        "bradycardia",
        "crt",
        "pacemaker",
        "ischaemia",
        "occur",
        "significant",
        "reperfusio",
        "myocardial",
        "influences",
        "icd",
        "damage",
        "infarction",
        "autonomic",
        "system",
        "conduction",
        "patients",
        "recommended",
        "acute",
        "pacing",
        "bradyarrhythmia",
        "coronary artery"
      ],
      "tables": []
    },
    {
      "number": "51",
      "title": "8.2 Pacing after cardiac surgery and heart transplantation 8.2.1 Pacing after coronary artery bypass graft and valve surgery AVB may occur in 1 \u0002 4% of cases after cardiac surgery and in \u0003 8% after re",
      "start_page": 43,
      "end_page": 45,
      "content": "Recommendations for using leadless pacing (leadless pacemaker)\nRecommendations Class a Level b\nLeadless pacemakers should be considered as an\nalternative to transvenous pacemakers when no upper extremity venous access exists or when\nrisk of device pocket infection is particularly\nhigh, such as previous infection and patients on haemodialysis. 45 , 47 \u0002 50 , 450\nIIa B\nLeadless pacemakers may be considered as an\nalternative to standard single-lead ventricular pacing, taking into consideration life expectancy\nand using shared decision-making. 45 , 47 \u0002 50\nIIb C\na Class of recommendation. b Level of evidence.\nESC 2021\nRecommendations for cardiac pacing after acute myo- cardial infarction\nRecommendations Class a Level b\nImplantation of a permanent pacemaker is indi- cated with the same recommendations as in a\ngeneral population ( section 5.2 ) when AVB does\nnot resolve within a waiting period of at least 5 days after MI.\nI C\nIn selected patients with AVB in the context of\nanterior wall MI and acute HF, early device implantation (CRT-D/CRT-P) may be\nconsidered. 471\nIIb C\nPacing is not recommended if AVB resolves after\nrevascularization or spontaneously. 454 \u0002 456 , 458 III B\nAVB = atrioventricular block; CRT-D = deﬁbrillator with cardiac resynchroniza- tion therapy; CRT-P = cardiac resynchronization therapy-pacemaker; MI = myo- cardial infarction. a Class of recommendation. b Level of evidence.\nESC 2021\n. .........................................................................................\n44 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ....................................................................................................................................................... Pacemaker implantation is more frequent after valvular than after coronary artery bypass graft (CABG) surgery. 477   In clinical practice, an observation period of 3 \u0002 7 days is usually applied before implant- ing a permanent pacemaker 473   to allow regression of transient brady- cardias. The ideal timing of pacemaker implantation after cardiac surgery remains a topic of controversy, due to the fact that 60 \u0002 70% of patients implanted for SND and up to 25% of those implanted for AVB are not pacemaker dependent at follow-up. 473 , 478   In the case of complete AVB occurring within the first 24 h after valvular surgery and persisting for 48 h, resolution within the next 1 \u0002 2 weeks is unlikely and earlier implantation of a pacemaker may be consid- ered. 479 , 480   The same approach appears reasonable for complete AVB with a low rate of escape rhythm. 473   The situation in CHD sur- gery and in children may be different (see  section 8.4 ). In valvular endocarditis, predictors of AVB after surgery are pre- operative conduction abnormalities,  Staphylococcus aureus  infection, intracardiac abscess, tricuspid valve involvement, and previous valvu- lar surgery. 481   In patients with endocarditis and peri-operative AVB, early pacemaker implantation is reasonable, especially when one or more predicting factors are present. In light of the infected state of the patient, intra-operative implantation of an epicardial pacemaker system during valvular surgery may be reasonable despite the absence of solid data on infection rates of epicardial vs. transvenous pacemaker systems.\n8.2.2 Pacing after heart transplantation SND is common and leads to permanent pacemaker implantation after heart transplantation in 8% of patients. 473   Possible causes of SND include surgical trauma, sinus node artery damage, or ischaemia and prolonged cardiac ischaemic times. 482 , 483   AVB is less common, and is probably related to inadequate preservation of the donor heart. 473 , 483 , 484   Chronotropic incompetence is always present fol- lowing standard orthotopic heart transplantation, as a result of loss of autonomic control. As sinus node and AVN function improve dur- ing the first few weeks after transplantation, an observation period before pacemaker implantation may allow spontaneous improve- ment of bradycardia. 485   There is general consensus that patients in whom symptomatic bradycardia persists after the third post- operative week may require permanent pacemaker implantation. DDD(R) mode with minimized ventricular pacing in the case of intact AVN conduction is recommended. 483\n8.2.3 Pacing after tricuspid valve surgery An underestimated aspect of the surgical management of tricuspid valve disease is to address trans-tricuspid pacemaker or ICD leads. Such leads can interfere with the function of a repaired tricuspid valve or tricuspid valve prosthesis. Placing an epicardial RV lead at the time of tricuspid valve surgery is the most straightforward alternative in cases with type II second-\nor third-degree AVB. There have been doubts about the long-term performance of epicardial leads, but recent data indicate, at least for epicardial LV leads, performance comparable with transvenous leads. 486\nVentricular pacing after mechanical tricuspid valve replacement using a coronary sinus lead appears safe and feasible, but only results from small patient cohorts have been published. Procedural success of implantation was 100% in 23 patients; after 5.3 ± 2.8 years, 96% of leads were functional with stable pacing and sensing parameters. 487\nHBP is emerging as a more physiological method of ventricular pacing and may evolve into a possible solution in patients with AV conduction disease after tricuspid valve surgery. One study investi- gating 30 patients with HBP after cardiac valve operations reported successful permanent HBP in 93% of these patients. 488   This study included 10 patients with tricuspid valve annuloplasty. After replacement by a mechanical valve, transvalvular lead placement is contraindicated, and implanting either a coronary sinus lead for ventricular pacing or epicardial leads, which may be placed minimally invasively, is recommended. To avoid damaging a repaired tricuspid valve or a tricuspid bioprosthesis, the optimal solution in patients needing ventricular pacing after such surgery should not include transvalvular lead implantation. Implanting a cor- onary sinus lead for ventricular pacing or minimally invasively placed epicardial leads is judged to be the preferred choice. However, as indicated in observational reports, transvalvular lead implantation was used with acceptable results, 489   and still may be considered in selected patients after tricuspid valve annuloplasty, other types of repair, and replacement of a tricuspid valve by a bioprosthesis. Performing tricuspid valve replacement in a patient with an exist- ing RV lead, removal of the old RV lead and implantation of an epi- cardial RV lead should be preferred over sewing in the existing lead between a bioprosthesis and annulus. The reasons are that sewing in the lead may be associated with higher risk of lead failure and, in the case of future need for lead extraction, such a procedure is likely to require open heart surgery, which will be a reintervention with higher operative risk. In cases of tricuspid valve repair with a current annuloplasty ring with an open segment and without con- comitant leaflet procedures, an existing RV lead may be left in place without sewing it in between the ring and the annulus. However, even in isolated annuloplasty procedures, an existing RV lead should ideally be removed to avoid future lead-related complications to the repaired tricuspid valve and an epicardial RV lead should be implanted. Particularly in patients not in need of a dual-chamber device, the use of a leadless pacemaker for ventricular pacing may serve as a feasible future alternative after tricuspid valve repair or replacement by a bioprosthesis. However, experience is very lim- ited, and no long-term data are available in this cohort. Crossing a mechanical tricuspid valve with the delivery sheath and a leadless pacemaker is contraindicated.\nESC Guidelines 45\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................................................................................................................................\n",
      "keywords": [
        "should be considered",
        "bradycardia",
        "crt",
        "valve repair",
        "heart",
        "valve",
        "pacemaker",
        "surgery",
        "occur",
        "tricuspid",
        "coronary",
        "icd",
        "valve replacement",
        "bypass",
        "artery",
        "transplantation",
        "level b",
        "cardiac",
        "cases",
        "recommended",
        "may be considered",
        "after",
        "pacing",
        "coronary artery",
        "graft"
      ],
      "tables": [
        {
          "title": "46 ESC Guidelines",
          "page_number": 45,
          "content": "7) Patients requiring pacing after mechan-\nical tricuspid valve replacement\nImplantation of a transvalvular RV lead should\nbe avoided. | III | C | ESC 2021",
          "bbox": [
            306.77988052368164,
            59.87817600795201,
            552.3342081705729,
            109.28630921898818
          ],
          "function_potential": "raw"
        },
        {
          "title": "46 ESC Guidelines",
          "page_number": 45,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \n1) High-degree or complete AVB after\ncardiac surgery\nA period of clinical observation of at least 5\ndays is indicated to assess whether the rhythm\ndisturbance is transient and resolves.\nHowever, in the case of complete AVB with\nlow or no escape rhythm when resolution is\nunlikely, this observation period can be\nshortened.473,478 | I | C | \n2) Surgery for valvular endocarditis and\nintraoperative complete AVB\nImmediate epicardial pacemaker implantation\nshould be considered in patients with surgery\nfor valvular endocarditis and complete AVB if\none of the following predictors of persistence is\npresent: pre-operative conduction abnormality,\nStaphylococcus aureus infection, intracardiac\nabscess, tricuspid valve involvement, or previous\nvalvular surgery.481 | IIa | C | \n3) SND after cardiac surgery and heart\ntransplantation\nBefore permanent pacemaker implantation, a\nperiod of observation of up to 6 weeks should\nbe considered.473 | IIa | C | \n4) Chronotropic incompetence after\nheart transplantation\nCardiac pacing should be considered for chro-\nnotropic incompetence persisting for >6 weeks\nafter heart transplantation to improve quality of\nlife.485 | IIa | C | \n5) Patients requiring pacing at the time of\ntricuspid valve surgery\nTransvalvular leads should be avoided and epi-\ncardial ventricular leads used. During tricuspid\nvalve surgery, removal of pre-existing transvalv-\nular leads should be considered and preferred\nover sewing in the lead between the annulus\nand a bioprosthesis or annuloplasty ring. In the\ncase of an isolated tricuspid annuloplasty based\non an individual risk\u0002benefit analysis, a pre-\nexisting RV lead may be left in place without jail-\ning it between ring and annulus. | IIa | C | \n6) Patients requiring pacing after biologi-\ncal tricuspid valve replacement/tricuspid\nvalve ring repair\nWhen ventricular pacing is indicated, transve-\nnous implantation of a coronary sinus lead or\nminimally invasive placement of an epicardial\nventricular lead should be considered and pre-\nferred over a transvenous transvalvular\napproach.487 | IIa | C | ",
          "bbox": [
            42.55175018310547,
            86.47422485351562,
            287.60301310221354,
            728.6641366141183
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "52",
      "title": "8.3 Pacing after transcatheter aortic valve implantation For extended literature on patients with pre-procedural RBBB and post-procedural LBBB see sections 8.3.1 and 8.3.2 in the Supplementary data . ",
      "start_page": 45,
      "end_page": 47,
      "content": "Recommendations for cardiac pacing after cardiac sur- gery and heart transplantation\nRecommendations Class a Level b\n1) High-degree or complete AVB after\ncardiac surgery A period of clinical observation of at least 5\ndays is indicated to assess whether the rhythm\ndisturbance is transient and resolves. However, in the case of complete AVB with\nlow or no escape rhythm when resolution is\nunlikely, this observation period can be shortened. 473 , 478\nI C\n2) Surgery for valvular endocarditis and\nintraoperative complete AVB Immediate epicardial pacemaker implantation\nshould be considered in patients with surgery\nfor valvular endocarditis and complete AVB if one of the following predictors of persistence is\npresent: pre-operative conduction abnormality,\nStaphylococcus aureus  infection, intracardiac abscess, tricuspid valve involvement, or previous\nvalvular surgery. 481\nIIa C\n3) SND after cardiac surgery and heart\ntransplantation Before permanent pacemaker implantation, a\nperiod of observation of up to 6 weeks should\nbe considered. 473\nIIa C\n4) Chronotropic incompetence after\nheart transplantation\nCardiac pacing should be considered for chro- notropic incompetence persisting for >6 weeks\nafter heart transplantation to improve quality of\nlife. 485\nIIa C\n5) Patients requiring pacing at the time of tricuspid valve surgery\nTransvalvular leads should be avoided and epi-\ncardial ventricular leads used. During tricuspid valve surgery, removal of pre-existing transvalv-\nular leads should be considered and preferred\nover sewing in the lead between the annulus and a bioprosthesis or annuloplasty ring. In the\ncase of an isolated tricuspid annuloplasty based\non an individual risk \u0002 beneﬁt analysis, a pre- existing RV lead may be left in place without jail-\ning it between ring and annulus.\nIIa C\n6) Patients requiring pacing after biologi- cal tricuspid valve replacement/tricuspid\nvalve ring repair\nWhen ventricular pacing is indicated, transve- nous implantation of a coronary sinus lead or\nminimally invasive placement of an epicardial\nventricular lead should be considered and pre- ferred over a transvenous transvalvular\napproach. 487\nIIa C\nContinued\n7) Patients requiring pacing after mechan-\nical tricuspid valve replacement\nImplantation of a transvalvular RV lead should be avoided.\nIII C\nAVB = atrioventricular block; RV = right ventricular; SND = sinus node dysfunction. a Class of recommendation. b Level of evidence.\nESC 2021\n. ..........................\n46 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nTable 10 Predictors for permanent pacing after transcatheter aortic valve implantation\nCharacteristics References\nECG\nRight BBB 512 \u0002 528\nPR-interval prolongation 517 , 521 , 525 , 527\nLeft anterior hemiblock 517 , 525\nPatient\nOlder age (per 1-year increase) 529\nMale sex 518 , 519 , 525 , 529\nLarger body mass index (per 1-unit increase) 529\nAnatomical\nSevere mitral annular calciﬁcation 512 , 515\nLV outﬂow tract calciﬁcations 522\nMembranous septum length 528 , 530\nPorcelain aorta 531\nHigher mean aortic valve gradient 519\nProcedural\nSelf-expandable valve 512 , 513 , 525 , 529 , 531\nDeeper valve implantation 517 , 518 , 520 , 522 , 528 , 532\nLarger ratio between prosthesis diameter versus annulus or LV outﬂow tract diameter 524 , 529 , 532\nBalloon post-dilatation 519 , 521 , 529\nTAVI in native valve vs. valve-in-valve procedure 531\nAVB = atrioventricular block; BBB = bundle branch block; ECG = electrocardiogram; LV = left ventricular; TAVI = transcatheter aortic valve implantation. For more detailed data, see  Supplementary Tables 14  and  15 .\nManagement of conduction abnormalities in patients afterTAVI\nPersistent a\nhigh degree AVB New onset alternating BBB\nPre-existing RBBB with new post-procedure conduction disturbance b\nPersistent new LBBB with QRS > 150 ms or PR > 240 ms with no further prolongation during > 48h after procedure c\nPre-existing conduction abnormality with prolongation of QRS (> 20 ms) or  PR (> 20 ms) f\nAmbulatory ECG monitoring d\n(Class IIa)\nAmbulatory ECG monitoring d\n(Class IIb)\nOR OR\nEPS e\n(Class IIa)\nEPS e\n(Class IIb)\nPermanent PM\n(Class I)\nPermanent PM\n(Class IIa)\nFigure 12  Management of conduction abnormalities after transcatheter aortic valve implantation. AF = atrial fibrillation; AV = atrioventricular; AVB = atrioventricular block; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiology study; HV = His \u0002 ventricular interval; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; PM = pacemaker; QRS = Q, R, and S waves; RBBB = right bundle branch block; TAVI = transcatheter aortic valve implantation.   a 24-48 h post-procedure.   b Transient high-degree AVB, PR prolongation, or axis change.   c High-risk parameters for high-degree AV block in patients with new-onset LBBB include: AF, prolonged PR interval, and LVEF <40%.   d Ambulatory continuous ECG monitoring for 7 - 30 days.   e EPS with HV >_70 ms may be considered positive for permanent pacing.   f With no further prolongation of QRS or PR during 48-h observation.\nESC 2021\nESC Guidelines 47\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ <150 ms may not require further evaluation during hospitalization. When EPS is contemplated, it should be performed >_3 days post- procedure and after the conduction abnormalities have stabilized. The type of permanent pacemaker implanted should follow stand- ard guidance (see  sections 5 ,  6 , and  7 ). Given the low rates of long- term dependency on pacing, 544 , 545   algorithms promoting spontane- ous AV conduction should be used.\n8.4. Cardiac pacing and cardiac resynchronization therapy in congenital heart disease Permanent pacing in patients with moderate or complex CHD should be performed in centres with a multidisciplinary team and expertise in CHD-related device therapy. Generally, decision-making\nfor pacemaker therapy in patients with CHD is based on expert con- sensus and individual evaluation due to lack of evidence from RCTs. In the presence of an intracardiac shunt between the systemic and pulmonary circulation, endovascular lead placement is relatively con- traindicated due to the risk of arterial embolism. 551\nThe clinical presentation may vary considerably; even severe bra- dycardia in congenital AVB may remain oligosymptomatic or asymp- tomatic. Periodic Holter recordings may be useful for patients at specific risk of bradyarrhythmia.\n8.4.1 Sinus node dysfunction and bradycardia \u0002 tachycardia syndrome There is no evidence that SND directly leads to increased mortality in CHD. However, it may be associated with a higher rate of post- operative atrial flutter, with 1:1 AV conduction in CHD, and thus lead to morbidity and potentially mortality. 552 , 553\n8.4.1.1 Indications for pacemaker implantation In patients with symptomatic chronotropic incompetence, pace- maker implantation is justified when other causes (see  section  4 ) have been ruled out. 554 , 555   Increasing the heart rate through permanent pacing to prevent atrial arrhythmias may be considered. 556   The underlying evidence is weak, as the benefit of atrial-based pacing observed in patients without structural heart disease could not be validated in CHD. 21 , 557 , 558   The general consensus is that if permanent pacing is necessary, single-lead atrial-based pacing should be pre- ferred to limit the number of leads, especially in young patients with adequate AV conduction. 559   In patients with congenitally corrected transposition of the great arteries requiring ventricular pacing because of high-degree AVB, CRT should be considered. Current evidence to use devices with atrial antitachycardia pacing to treat intra-atrial re-entrant tachycardias in patients with CHD 560 , 561   is too limited to make general recommendations.\n8.4.2 Congenital atrioventricular block A number of maternal or fetal factors can cause congenital heart block, particularly autoimmune diseases such as systemic lupus eryth- ematosus and Sjo¨gren syndrome ( Supplementary Table 16 ). Patients presenting with congenital AVB may be asymptomatic or may present with reduced exercise capacity, syncopal attacks, con- gestive HF, ventricular dysfunction, and dilatation. Rarely, in SCD, congenital AVB is diagnosed as the cause. 562 , 563   SCD may occur through increased propensity to develop bradycardia-related ventric- ular arrhythmias such as torsades-de-pointes.\n8.4.2.1 Indications for pacemaker implantation There is general consensus that prophylactic pacing is indicated in asymptomatic patients with any of the following risk factors: mean daytime heart rate <50 b.p.m., pauses greater than three times the cycle length of the ventricular escape rhythm, a broad QRS escape rhythm, prolonged QT interval, or complex ventricular ectopy. 564 \u0002 566   Clinical symptoms, such as syncope, pre-syncope, HF, or chronotropic incompetence, are indications for pacemaker implantation. 564 , 567 , 568   If ventricular dysfunction is attributed to hae- modynamic compromise caused by bradycardia, permanent pacing may be indicated. 518 , 567   Despite a modest quality of evidence, there\nRecommendations for cardiac pacing after transcath- eter aortic valve implantation\nRecommendations Class a Level b\nPermanent pacing is recommended in patients\nwith complete or high-degree AVB that persists for 24 - 48 h after TAVI. 546\nI B\nPermanent pacing is recommended in patients\nwith new-onset alternating BBB after TAVI. 533 , 547\nI C\nEarly c   permanent pacing should be considered in\npatients with pre-existing RBBB who develop\nany further conduction disturbance during or after TAVI. d\nIIa B\nAmbulatory ECG monitoring e   or EPS f   should be\nconsidered for patients with new LBBB with QRS >150 ms or PR >240 ms with no further\nprolongation during the >48 h after\n",
      "keywords": [
        "sections",
        "ejection fraction",
        "should be considered",
        "older",
        "class i",
        "bradycardia",
        "crt",
        "valve",
        "tavi",
        "pacemaker",
        "electrocardiogram",
        "tachycardia",
        "supplementary",
        "age",
        "tricuspid",
        "scd",
        "procedural",
        "post",
        "syncope",
        "lvef",
        "aortic",
        "literature",
        "male",
        "valve replacement",
        "extended",
        "lbbb",
        "sex",
        "atrial fibrillation",
        "level b",
        "ecg"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 47",
          "page_number": 46,
          "content": "Characteristics |  | References | ESC 2021\nECG |  |  | \nRight BBB |  | 512\u0002528 | \nPR-interval prolongation |  | 517,521,525,527 | \nLeft anterior hemiblock |  | 517,525 | \nPatient |  |  | \nOlder age (per 1-year increase) |  | 529 | \nMale sex |  | 518,519,525,529 | \nLarger body mass index (per 1-unit increase) |  | 529 | \nAnatomical |  |  | \nSevere mitral annular calcification |  | 512,515 | \nLV outflow tract calcifications |  | 522 | \nMembranous septum length |  | 528,530 | \nPorcelain aorta |  | 531 | \nHigher mean aortic valve gradient |  | 519 | \nProcedural |  |  | \nSelf-expandable valve |  | 512,513,525,529,531 | \nDeeper valve implantation |  | 517,518,520,522,528,532 | \nLarger ratio between prosthesis diameter versus annulus or LV outflow tract diameter |  | 524,529,532 | \nBalloon post-dilatation |  | 519,521,529 | \nTAVI in native valve vs. valve-in-valve procedure |  | 531 | ",
          "bbox": [
            48.031925164736236,
            73.92803955078125,
            557.6139526367188,
            348.4586966378348
          ],
          "function_potential": "raw"
        },
        {
          "title": "48 ESC Guidelines",
          "page_number": 47,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPermanent pacing is recommended in patients\nwith complete or high-degree AVB that persists\nfor 24 - 48 h after TAVI.546 | I | B | \nPermanent pacing is recommended in patients\nwith new-onset alternating BBB after\nTAVI.533,547 | I | C | \nEarlyc permanent pacing should be considered in\npatients with pre-existing RBBB who develop\nany further conduction disturbance during or\nafter TAVI.d | IIa | B | \nAmbulatory ECG monitoringe or EPSf should be\nconsidered for patients with new LBBB with\nQRS >150 ms or PR >240 ms with no further\nprolongation during the >48 h after\nTAVI.536,537,548 | IIa | C | \nAmbulatory ECG monitoringe or EPSf may be\nconsidered for patients with a pre-existing con-\nduction abnormality who develop prolongation\nof QRS or PR >20 ms.g | IIb | C | \nProphylactic permanent pacemaker implantation\nis not indicated before TAVI in patients with\nRBBB and no indication for permanent pacing. | III | C | ESC 2021",
          "bbox": [
            42.55175018310547,
            183.7022277832031,
            287.679345703125,
            477.8612583705357
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "53",
      "title": "TAVI. 536 , 537 , 548",
      "start_page": 47,
      "end_page": 48,
      "content": "IIa C\nAmbulatory ECG monitoring e   or EPS f   may be considered for patients with a pre-existing con-\nduction abnormality who develop prolongation\nof QRS or PR >20 ms. g\nIIb C\nProphylactic permanent pacemaker implantation\nis not indicated before TAVI in patients with\nRBBB and no indication for permanent pacing.\nIII C\nAF = atrial ﬁbrillation; AVB = atrioventricular block; BBB = bundle branch block; CRT = cardiac resynchronization therapy; ECG = electrocardiogram; EPS = elec- trophysiology study; HV = His \u0002 ventricular interval; LBBB = left bundle branch block; RBBB = right bundle branch block; SR = sinus rhythm; TAVI = transcath- eter aortic valve implantation. For the deﬁnition of alternating BBB, see  section 5.3.1 . a Class of recommendation. b Level of evidence. c Immediately after procedure or within 24 h. d Transient high-degree AVB, PR prolongation, or QRS axis change. e Ambulatory continuous ECG monitoring (implantable or external) for 7 \u0002 30 days. 536 , 549\nf EPS should be performed >_3 days after TAVI. Conduction delay with HV >_70 ms may be considered positive for permanent pacing. 540 , 541 , 550\ng With no further prolongation of QRS or PR during 48-h observation. Note: CRT in patients requiring pacing after TAVI has the same indication as for general patients (see  section 6 ).\nESC 2021\n48 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................\nis strong consensus that patients with third- or second-degree AVB (Mobitz type II) must receive permanent cardiac pacing therapy if symptomatic or with risk factors. In asymptomatic patients without risk factors, opinion on the benefit of cardiac pacing diverges, and permanent pacing may be considered. 567 , 569\n8.4.3 Post-operative atrioventricular block Post-operative high-degree AVB is estimated to occur in 1 \u0002 3% of patients undergoing surgery for CHD. 518 , 569 , 570   In children, transient early post-operative AVB usually resolves within 7 \u0002 10 days. 571   In adults with CHD, there are no data to support a different waiting period before deciding for permanent pacing post-operatively than after other cardiac surgery. After recovery from complete AVB, bifas- cicular block occasionally persists, which is associated with an increased risk of late recurrent AVB and sudden death. 572   The prog- nosis is poor for patients with untreated post-operative complete AVB. 573\n8.4.3.1 Indications for pacemaker implantation There is a strong recommendation for permanent pacing in patients with persistent second- or third-degree AVB. In patients with persis- tent bifascicular block associated with transient AVB or permanent prolonged PR interval, consensus for pacemaker implantation is mod- est. Post-operative HV interval determination may help to estimate the risk in patients with prolonged PR or bifascicular block. 573   In patients with bifascicular block and long PR after surgery for CHD, the risk of extensive damage to the conduction system is high, 572\ntherefore pacemaker implantation may be indicated even without HV measurement. Implantation of epicardial leads should be consid- ered during surgery in patients with complex CHD and a high lifetime risk of pacemaker implantation, in order to reduce the rate of reoperation.\n8.4.4 Cardiac resynchronization Standard indications for CRT may be considered in CHD, taking into account that the anatomy, morphology of the systemic ventricle, and cause of dyssynchrony, as well as QRS morphology, may be atypi- cal. 574   Multidisciplinary teams in experienced centres should be involved in the decision-making process.\n",
      "keywords": [
        "aortic",
        "may be considered",
        "electrocardiogram",
        "indication",
        "lifetime risk",
        "crt",
        "tavi",
        "pacemaker",
        "ecg"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 49",
          "page_number": 48,
          "content": "In patients with persistent post-operative bifas-\ncicular block associated with transient complete\nAVB, permanent pacing may be considered.572 | IIb | C | \nIn patients with complex CHD and asympto-\nmatic bradycardia (awake resting heart rate <40\nb.p.m. or pauses >3 s), permanent pacing may be\nconsidered on an individual basis. | IIb | C | ESC 2021",
          "bbox": [
            311.3249816894531,
            59.87817600795201,
            556.7210815429687,
            146.14418465750558
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 49",
          "page_number": 48,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with congenital complete or high-\ndegree AVB, pacing is recommended if one of\nthe following risk factors is present:\na. Symptoms\nb. Pauses >3\u0004 the cycle length of the ventricu-\nlar escape rhythm\nc. Broad QRS escape rhythm\nd. Prolonged QT interval\ne. Complex ventricular ectopy\nf. Mean daytime heart rate <50 b.p.m. | I | C | \nIn patients with congenital complete or high-\ndegree AVB, permanent pacing may be consid-\nered even if no risk factors are present.566 | IIb | C | ",
          "bbox": [
            47.17727279663086,
            495.2297882080078,
            292.1385759626116,
            676.6201847621372
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "54",
      "title": "8.5 Pacing in hypertrophic cardiomyopathy 8.5.1 Bradyarrhythmia AVB in hypertrophic cardiomyopathy (HCM) should generally be treated according to the recommendations in this guideline (see  sec- tion ",
      "start_page": 48,
      "end_page": 49,
      "content": "8.5.2 Pacing for the management of left ventricular outflow tract obstruction In patients with symptoms caused by LV outflow tract obstruction, treatment options include drugs, surgery, septal alcohol ablation, and AV sequential pacing with a short AV delay. Three small, randomized, placebo-controlled studies and several long-term observational stud- ies reported reductions in LV outflow tract gradients, and variable improvement in symptoms and quality of life with AV sequential pacing. 577 \u0002 582   Myectomy achieved superior haemodynamic results compared with DDD pacing, 583   but is a more invasive and higher risk intervention. In one trial, a subgroup analysis suggested that older patients (>65 years) are more likely to benefit from DDD AV sequential pacing. 579   A recent meta-analysis—comprising 34 studies and 1135 patients—found that pacing reduced the LV outflow gra- dient by 35%, with a non-significant trend towards reduction in NYHA class. 584\nShared decision-making should be employed when considering the treatment of choice for patients with obstructive HCM.\nRecommendations for cardiac pacing in patients with congenital heart disease\nRecommendations Class a Level b\nIn patients with congenital complete or high-\ndegree AVB, pacing is recommended if one of the following risk factors is present:\na. Symptoms\nb. Pauses >3 \u0004  the cycle length of the ventricu- lar escape rhythm\nc. Broad QRS escape rhythm\nd. Prolonged QT interval e. Complex ventricular ectopy\nf. Mean daytime heart rate <50 b.p.m.\nI C\nIn patients with congenital complete or high- degree AVB, permanent pacing may be consid-\nered even if no risk factors are present. 566\nIIb C\nContinued\nIn patients with persistent post-operative bifas-\ncicular block associated with transient complete\nAVB, permanent pacing may be considered. 572\nIIb C\nIn patients with complex CHD and asympto- matic bradycardia (awake resting heart rate <40\nb.p.m. or pauses >3 s), permanent pacing may be considered on an individual basis.\nIIb C\nAVB = atrioventricular block; BBB = bundle branch block; b.p.m. = beats per minute; CHD = congenital heart disease; ECG = electrocardiogram. a Class of recommendation. b Level of evidence.\nESC 2021\n. ......................................\nESC Guidelines 49\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .....................................................................................................................\n8.5.3 Pacemaker implantation following septal myectomy and alcohol septal ablation In a study involving 2482 patients with obstructive HCM, 2.3% devel- oped AVB after septal myectomy 588   (only 0.6% in those with normal baseline conduction vs. 34.8% in patients with pre-existing RBBB). Alcohol septal ablation causes AVB in 7 \u0002 20% of patients; 576   those with pre-existing conduction defects, mainly LBBB, are at highest risk. 585\n8.5.4 Cardiac resynchronization therapy in end-stage hypertrophic cardiomyopathy Based on the findings of a small cohort study, 589   CRT was given both a class IIa and a class IIb recommendation in previous guidelines for patients with HCM, HF, LBBB, and LVEF <50%. 576 , 590   More recent studies did not demonstrate sustained efficacy of this therapy. 591 \u0002 593\nUntil further evidence becomes available, standard criteria for CRT are recommended in patients with HCM ( section 6 ).\n",
      "keywords": [
        "older",
        "bradycardia",
        "crt",
        "guideline",
        "electrocardiogram",
        "pacemaker",
        "treated",
        "hypertrophic",
        "nyha",
        "recommendations",
        "lvef",
        "tion",
        "should",
        "level b",
        "cardiomyopathy",
        "ecg",
        "alcohol",
        "recommended",
        "may be considered",
        "according",
        "pacing",
        "bradyarrhythmia",
        "ablation",
        "generally"
      ],
      "tables": [
        {
          "title": "50 ESC Guidelines",
          "page_number": 49,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAV sequential pacing with short AV delay may\nbe considered in patients in SR who have other\npacing or ICD indications if drug-refractory\nsymptoms or baseline or provocable LV outflow\ntract gradients >50 mmHg are\n_\npresent.576\u0002581,584 | IIb | B | \nAV sequential pacing with short AV delay may be\nconsidered in selected adults with drug-refractory\nsymptoms, >50 mmHg baseline or provocable LV\n_\noutflow tract gradient, in SR, who are unsuitable\nfor or unwilling to consider other invasive septal\nreduction therapies.576\u0002581,584 | IIb | B | \nAV sequential pacing with short AV delay may\nbe considered in selected patients with drug-\nrefractory symptoms, >50 mmHg baseline or\n_\nprovocable LV outflow tract gradients, in SR, at\nhigh risk of developing AVB during septal\nablation.585,586 | IIb | C | ESC 2021",
          "bbox": [
            42.60677194595337,
            86.47422485351562,
            287.73023478190106,
            329.04225485665455
          ],
          "function_potential": "raw"
        },
        {
          "title": "50 ESC Guidelines",
          "page_number": 49,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with neuromuscular diseases such as\nmyotonic dystrophy type 1 and any second- or\nthird-degree AVB or HV >70 ms, with or without\n_\nsymptoms, permanent pacing is indicated.c 599\u0002602 | I | C | \nIn patients with neuromuscular disease such as\nmyotonic dystrophy type 1 with PR >240 ms or\n_\nQRS duration >120 ms, permanent pacemaker\n_\nimplantation may be considered.c 600,603,604 | IIb | C | ESC 2021",
          "bbox": [
            306.9837716909555,
            557.818770345052,
            552.1214163643973,
            679.171162196568
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "55",
      "title": "8.6 Pacing in rare diseases 8.6.1 Long QT syndrome There are multiple inter-relationships between the different forms of long QT syndrome (LQTS) and bradycardia: LQTS can be associated with sinus brad",
      "start_page": 49,
      "end_page": 51,
      "content": "As current ICDs provide all pacemaker functions, a standalone pacemaker is rarely indicated in LQTS today. However, in individ- ual patients with LQTS and catecholamine-induced torsades-de- pointes, shock therapy may be disadvantageous or even fatal; in these cases, pacing and beta-blocker therapy alone without an ICD may be used. Pacemaker instead of ICD implantation repre- sents a treatment option in neonates and small infants with LQTS, 594   and an alternative in LQTS patients with symptomatic bradycardia (spontaneous or due to beta-blockers) if ventricular tachyarrhythmias are unlikely or if ICD implantation is not desired (e.g. patient preference). An indication for a pacemaker in LQTS exists in neonates and infants with a 2:1 AVB due to excessive corrected QT prolongation with long myocardial refractory periods. 595\nTemporary pacing at an increased rate (usually 90- 120 b.p.m.) is an important treatment in LQTS patients with electrical storm, because an increase in the basic heart rate shortens the window of vulnerability for reinduction of torsade de pointes ventricular tachycardia.\n8.6.2 Neuromuscular diseases Neuromuscular diseases are a group of heterogeneous inherited dis- orders affecting the skeletal muscle and frequently also involve the heart (for extended literature on conduction disorders in neuromus- cular disease, see the supplementary literature on pacing in rare dis- ease and  Supplementary Table 17 ). The cardiac phenotype variably includes all types of cardiomyopathies, conduction defects with or without cardiomyopathies, and supraventricular and ventricular tachyarrhythmias. 596 \u0002 598   Duchenne, Becker, and limb-girdle types 2C, 2F, and 2I are muscular dystrophies in which the development of dilated cardiomyopathy is common and usually the predominant fea- ture. Arrhythmias and conduction disease can be associated with the development of cardiomyopathy. 596 \u0002 598   Such patients are consid- ered for pacemakers or ICDs on the basis of guidelines used for other non-ischaemic cardiomyopathies. 242   Myotonic dystrophy types 1 and 2, Emery \u0002 Dreifuss, and limb-girdle type 1B often present with conduction disease and associated arrhythmias, and variably with car- diomyopathy. 596 , 597   The recommendations present guidance in the instances where the recommendations for cardiac pacing differ from those used for other patients with bradycardia.\nRecommendations for pacing in hypertrophic obstruc- tive cardiomyopathy\nRecommendations Class a Level b\nAV sequential pacing with short AV delay may\nbe considered in patients in SR who have other pacing or ICD indications if drug-refractory\nsymptoms or baseline or provocable LV outﬂow\ntract gradients >_50 mmHg are present. 576 \u0002 581 , 584\nIIb B\nAV sequential pacing with short AV delay may be\nconsidered in selected adults with drug-refractory symptoms, >_50 mmHg baseline or provocable LV\noutﬂow tract gradient, in SR, who are unsuitable\nfor or unwilling to consider other invasive septal reduction therapies. 576 \u0002 581 , 584\nIIb B\nAV sequential pacing with short AV delay may\nbe considered in selected patients with drug-\nrefractory symptoms, >_50 mmHg baseline or provocable LV outﬂow tract gradients, in SR, at\nhigh risk of developing AVB during septal\nablation. 585 , 586\nIIb C\nAV = atrioventricular; AVB = atrioventricular block; ICD = implantable cardi- overter-deﬁbrillator; LV = left ventricular; SR = sinus rhythm. a Class of recommendation. b Level of evidence. Pacing parameters should be optimized to achieve maximum pre-excitation of the RV apex with minimal compromise of LV ﬁlling (typically achieved with a rest- ing sensed AV interval of 100 ± 30 ms). 587\nESC 2021\nRecommendations for cardiac pacing in rare diseases\nRecommendations Class a Level b\nIn patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or\nthird-degree AVB or HV >_70 ms, with or without\nsymptoms, permanent pacing is indicated. c  599 \u0002 602\nI C\nIn patients with neuromuscular disease such as\nmyotonic dystrophy type 1 with PR >_240 ms or\nQRS duration >_120 ms, permanent pacemaker implantation may be considered. c  600 , 603 , 604\nIIb C\nAVB = atrioventricular block; CRT = cardiac resynchronization therapy; HV = His \u0002 ventricular interval; ICD = implantable cardioverter-deﬁbrillator. a Class of recommendation. b Level of evidence. c Whenever pacing is indicated in neuromuscular disease, CRT or an ICD should be considered according to relevant guidelines.\nESC 2021\n. .....................................................\n50 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........ 8.6.3 Dilated cardiomyopathy with lamin A/C mutation Mutations in the LMNA gene, which encodes lamin A and C inter- mediate filaments of the nuclear envelope, cause a variety of inherited diseases defined as ‘laminopathies’. 605 \u0002 607   According to the type of mutation, they can lead to isolated cardiac disorders or additional systemic or musculoskeletal disorders such as the Emery \u0002 Dreifuss autosomal dominant variant or limb-girdle dystrophy. Around 5 \u0002 10% of dilated cardiomyopathies are induced by LMNA gene mutations, manifested as cardiac conduction disease, tachyarrhyth- mias, or impaired myocardial contractility. 596 , 606 \u0002 620   SND and con- duction disease are frequently the first manifestation, in many cases with preserved LV size and function. 613 , 614   LMNA-related cardiomy- opathy is more malignant than most other cardiomyopathies, carry- ing a higher risk of SCD in asymptomatic mutation carriers with preserved or only mildly decreased LV contractility. 610 \u0002 615\nPacemaker implantation does not reduce the risk of SCD in these patients. A meta-analysis of mode of death in LMNA mutations dem- onstrated that 46% of patients who died suddenly had an implanted pacemaker. Sudden death rates were similar in those with isolated cardiomyopathy and those with an additional neuromuscular pheno- type. 611   Complex ventricular arrhythmias are common in patients with conduction disturbances. 612 , 613 , 615   In two studies, patients with LMNA mutations and an indication for permanent pacing underwent ICD implantation, and appropriate ICD therapies occurred in 42% and 52% of patients within 3 and 5 years, respectively. 612 , 613   These findings led to the clinical practice to consider ICD rather than pace- maker implantation in LMNA-related conduction disease. 614 , 620   For additional clinical risk factors for ventricular tachyarrhythmias and sudden death found in patients with dilated cardiomyopathy due to LMNA gene mutations, see  Supplementary Table 18 . CRT(D) should be considered if the patient has AVB and LVEF <50%, and a high fre- quency of ventricular pacing is expected ( section  6  and  Supplementary Table 18 ). The risk score of life-threatening ventricular arrhythmia in laminopathies can be predicted by a recently developed and validated module (https://lmna-risk-vta.fr/). 616\n8.6.4 Mitochondrial cytopathies Mitochondrial cytopathies are a heterogeneous group of hereditary disorders, in which cardiomyopathies, conduction defects, and ven- tricular arrhythmias are the most common cardiac\npresentations. 621 , 622   In Kearns \u0002 Sayre syndrome, the most common cardiac manifestation is conduction disease, which may progress to complete AVB and cause SCD. 623 \u0002 625\n8.6.5 Infiltrative and metabolic diseases Infiltrative cardiomyopathy is secondary to abnormal deposition and accumulation of pathological products in the myocardial interstitium, while storage diseases lead to their intracellular accumulation. The main cause of infiltrative cardiomyopathy is amyloidosis, while stor- age diseases include haemochromatosis, Fabry’s disease, and glycogen storage diseases. In patients with cardiac amyloid, conduction defects, tachyarrhythmias, and SCD are common. Based upon current knowl- edge, conventional indications should be used for pacing in this group of patients.\n8.6.6 Inflammatory diseases Infections (viral, bacterial including Borreliosis, protozoa, fungal, para- sites), autoimmune (e.g. giant cell myocarditis, sarcoidosis, rheumatic heart disease, connective tissue disease, eosinophilic myocarditis), toxic (alcohol, cocaine, cancer therapies, especially monoclonal anti- bodies), and physical reactions (radiation therapy) can cause inflam- matory heart disease. Involvement of the AVN and the conduction system is more frequent than that of the sinus node. AVB may indi- cate involvement of the septum in the inflammatory process and is a predictor of adverse outcome. Ventricular arrhythmias may also occur because of myocardial pathology. When inflammatory heart disease is complicated by bradycardia, especially AVB, specific therapy should be applied if available, eventu- ally backed-up by temporary pacing or intravenous administration of isoprenaline. Otherwise, immunosuppressive therapy or awaiting spontaneous resolution may be sufficient. If bradycardia does not resolve within a clinically reasonable period or cannot be expected to resolve (e.g. after radiation therapy), permanent pacing is indi- cated. Before choosing a device type, the indication for an ICD and/ or CRT rather than a single-chamber or DDD pacemaker should be\nRecommendation for patients with LMNA gene muta- tions (for references, see  Supplementary Table 18 )\nRecommendation Class a Level b\nIn patients with LMNA gene mutations, including\nEmery \u0002 Dreifuss and limb-girdle muscular dys-\ntrophies who fulﬁl conventional criteria for pace- maker implantation or who have prolonged PR\ninterval with LBBB, ICD implantation with pacing\ncapabilities should be considered if at least 1- year survival is expected. 616\nIIa C\nICD = implantable cardioverter-deﬁbrillator; LBBB, left bundle branch block. a Class of recommendation. b Level of evidence.\nRecommendations for pacing in Kearns \u0002 Sayre syndrome\nRecommendations Class a Level b\nIn patients with Kearns \u0002 Sayre syndrome who\nhave PR prolongation, any degree of AVB, BBB, or fascicular block, permanent pacing should be\nconsidered. c  621 \u0002 625\nIIa C\nIn patients with Kearns \u0002 Sayre syndrome with- out cardiac conduction disorder, permanent\npacing may be considered\nprophylactically. c  621 \u0002 625\nIIb C\nAVB = atrioventricular block; BBB = bundle branch block; CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-deﬁbrillator; PR = PR interval. a Class of recommendation. b Level of evidence. c Whenever pacing is indicated, CRT or an ICD should be considered according to the relevant guidelines.\nESC 2021\nESC 2021\n. .................................................................................................................................................................\nESC Guidelines 51\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .......................................................................................................................................................................... considered because most causes of inflammatory disease causing bra- dycardia may also result in reduced myocardial contractility and ven- tricular fibrosis.\n8.6.6.1 Sarcoidosis Persistent or intermittent AVB can occur in sarcoidosis, which shows a propensity to involve the basal intraventricular septum. In a Finnish registry, 143 of 325 patients (44%) diagnosed with cardiac sarcoidosis had Mobitz II second- or third-degree AVB in the absence of other explanatory cardiac disease. 626   A history of syncope, pre-syncope, or palpitations points towards bradycardia, but also to potential ventric- ular tachyarrhythmia. AVB is the most common clinical presentation in patients with clinically evident cardiac sarcoidosis. 627 , 628   Diagnostic steps include ECG monitoring, echocardiography, cardiac MRI, and myocardial or other involved tissue biopsy. Fluorodeoxyglucose- positron emission tomography may be useful. 629   The chances and time course of resolution of AVB with immunosuppressive therapy are not clear, 630   but may be low. 88   Long-term data are available mainly from a Canadian prospective study (32 patients), 627   a Japanese retrospective study (22 patients), 628   and a Finnish registry (325 patients). 626   Reversibility of conduction disorder is unpredictable and, even in patients with transient AVB, permanent pacing should be considered. 631   Immunosuppressive treatment may increase risk of device infection. However, there are no firm data to support device implantation before initiation of immunosuppressive medication. Patients with cardiac sarcoidosis and AVB are at high risk of SCD dur- ing long-term follow-up, even if LVEF is >35%. 626   Patients with even a mild or moderate decrease in LVEF (35 \u0002 49%) are at increased risk of SCD. 632 , 633   Therefore, in patients with cardiac sarcoidosis who have an indication for cardiac pacing and LVEF <50%, a CRT-D should be considered rather than a pacemaker 634   ( section 6 ).\n",
      "keywords": [
        "should be considered",
        "bradycardia",
        "crt",
        "lqts",
        "pacemaker",
        "tachycardia",
        "rare",
        "different",
        "there",
        "age",
        "forms",
        "sinus",
        "syndrome",
        "scd",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "arrhythmia",
        "icd",
        "inter",
        "relationships",
        "hereditary",
        "mri",
        "brad",
        "between",
        "echocardiography",
        "level b",
        "cardiomyopathy",
        "ecg",
        "multiple"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 51",
          "page_number": 50,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with Kearns\u0002Sayre syndrome who\nhave PR prolongation, any degree of AVB, BBB,\nor fascicular block, permanent pacing should be\nconsidered.c 621\u0002625 | IIa | C | \nIn patients with Kearns\u0002Sayre syndrome with-\nout cardiac conduction disorder, permanent\npacing may be considered\nprophylactically.c 621\u0002625 | IIb | C | ESC 2021",
          "bbox": [
            311.5187518780048,
            136.93081461588542,
            556.6571655273438,
            258.2892368861607
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 51",
          "page_number": 50,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nIn patients with LMNA gene mutations, including\nEmery\u0002Dreifuss and limb-girdle muscular dys-\ntrophies who fulfil conventional criteria for pace-\nmaker implantation or who have prolonged PR\ninterval with LBBB, ICD implantation with pacing\ncapabilities should be considered if at least 1-\nyear survival is expected.616 | IIa | C | ESC 2021",
          "bbox": [
            47.23377456665039,
            518.4002888997396,
            292.3674011230469,
            626.5601392473493
          ],
          "function_potential": "raw"
        },
        {
          "title": "52 ESC Guidelines",
          "page_number": 51,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with cardiac sarcoidosis who have\npermanent or transient AVB, implantation of a\ndevice capable of cardiac pacing should be con-\nsidered.c 88,629,630 | IIa | C | \nIn patients with sarcoidosis and an indication for\npermanent pacing who have LVEF <50%, implan-\ntation of a CRT-D should be considered.631,634 | IIa | C | ESC 2021",
          "bbox": [
            42.642042306753304,
            454.8472890218099,
            287.76658412388394,
            564.1981876918247
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "56",
      "title": "8.7 Cardiac pacing in pregnancy Vaginal delivery carries no extra risks in a mother with congenital complete heart block, unless contraindicated for obstetric rea- sons. 635   For women who have a sta",
      "start_page": 51,
      "end_page": 51,
      "content": "pauses >3 \u0004  the cycle length of the ventricular escape rhythm, wide QRS escape rhythm, prolonged QT interval, complex ventricular ectopy, mean daytime heart rate <50 b.p.m.) is present. However, women with complete heart block who exhibit a slow, wide QRS complex escape rhythm should undergo pacemaker implantation during pregnancy. The risks of pacemaker implantation are generally low and can be performed safely, especially if the foetus is beyond 8 weeks gestation. A pacemaker for the alleviation of symptomatic bra- dycardia can be implanted at any stage of pregnancy using echo guid- ance or electroanatomic navigation minimizing fluoroscopy. 636 , 637\n",
      "keywords": [
        "risks",
        "pregnancy",
        "echo",
        "heart",
        "carries",
        "sons",
        "pacemaker",
        "delivery",
        "mother",
        "obstetric",
        "unless",
        "extra",
        "vaginal",
        "cardiac",
        "congenital",
        "block",
        "complete",
        "pacing",
        "contraindicated",
        "women"
      ],
      "tables": []
    },
    {
      "number": "57",
      "title": "9 Special considerations on device implantations and peri-operative management",
      "start_page": 51,
      "end_page": 51,
      "content": "",
      "keywords": [
        "special",
        "device",
        "operative",
        "management",
        "considerations",
        "implantations",
        "peri"
      ],
      "tables": []
    },
    {
      "number": "58",
      "title": "9.1 General considerations Patients with clinical signs of active infection and/or fever should not undergo a permanent pacemaker (including leadless pacemaker) implantation until they have been afebr",
      "start_page": 51,
      "end_page": 51,
      "content": "",
      "keywords": [
        "clinical",
        "undergo",
        "patients",
        "permanent",
        "infection",
        "until",
        "implantation",
        "signs",
        "general",
        "fever",
        "afebr",
        "including",
        "leadless",
        "active",
        "they",
        "considerations",
        "pacemaker",
        "should"
      ],
      "tables": []
    },
    {
      "number": "59",
      "title": "9.2 Antibiotic prophylaxis The use of pre-operative systemic antibiotic prophylaxis is re- commended as the standard of care in pacemaker implantation procedures. The risk of infection is significantl",
      "start_page": 51,
      "end_page": 51,
      "content": "In contrast, post-operative antibiotic prophylaxis does not reduce the incidence of infection. 644 , 645\n",
      "keywords": [
        "prophylaxis",
        "standard",
        "significantl",
        "infection",
        "risk",
        "implantation",
        "antibiotic",
        "operative",
        "procedures",
        "commended",
        "systemic",
        "pacemaker",
        "care"
      ],
      "tables": []
    },
    {
      "number": "60",
      "title": "9.3 Operative environment and skin antisepsis The pacemaker implantation procedure should be performed in an operating environment that meets the standards of sterility as required for other surgical ",
      "start_page": 51,
      "end_page": 52,
      "content": "Recommendations for pacing in cardiac sarcoidosis\nRecommendations Class a Level b\nIn patients with cardiac sarcoidosis who have\npermanent or transient AVB, implantation of a\ndevice capable of cardiac pacing should be con- sidered. c  88 , 629 , 630\nIIa C\nIn patients with sarcoidosis and an indication for\npermanent pacing who have LVEF <50%, implan-\ntation of a CRT-D should be considered. 631 , 634\nIIa C\nAVB = atrioventricular block; CRT-D = deﬁbrillator with cardiac resynchroniza- tion therapy; ICD = implantable cardioverter-deﬁbrillator; LVEF = left ventricular ejection fraction. a Class of recommendation. b Level of evidence. c Whenever pacing is indicated in sarcoidosis, an ICD should be considered according to the relevant guidelines.\nESC 2021\n52 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .......................................................................................... Based on data from surgical and intravascular catheter procedures, skin antisepsis should be performed using chlorhexidine \u0002 alcohol instead of povidone-iodine \u0002 alcohol. 647 , 648   In a large RCT comprising 2546 patients, chlorhexidine \u0002 alcohol was associated with a lower incidence of short-term intravascular catheter-related infections (HR 0.15, 95% CI 0.05 - 0.41;  P  = 0.0002). 647\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "skin",
        "other",
        "operative",
        "environment",
        "crt",
        "pacemaker",
        "antisepsis",
        "standards",
        "performed",
        "procedure",
        "lvef",
        "sterility",
        "icd",
        "surgical",
        "should",
        "level b",
        "required",
        "alcohol",
        "operating",
        "indication",
        "implantation",
        "meets"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 53",
          "page_number": 52,
          "content": " | Dual antiplatelet therapy655,656 |  | NOAC652 | VKA650 | OAC 1 antiplatelet657 | ESC 2021\n | Thrombotic risk after PCI |  |  |  |  | \n | Intermediate or low\n>1 month PCI\n>6 months acute coronary\nsyndrome at index PCI | High\n<1 month PCI\n<6 months acute coronary\nsyndrome at index PCI |  |  |  | \nLow procedural\nbleeding risk First\nimplant | Continue aspirin AND\nDiscontinue P2Y inhibi-\n12\ntors: Ticagrelor at least\n3 days before surgery\nClopidogrel at least 5 days\nbefore surgery Prasugrel at\nleast 7 days before surgery | Elective surgery: Consider\npostponement Otherwise:\n• Continue aspirin\n• Continue P2Y\n12\ninhibitor | Continue or interrupt as\nper operator preference. If\ninterruption, then based on\nCrCl and specific NOAC | Continuea | Continue OAC (VKAa or\nNOAC). Discontinue anti-\nplatelet per patient-specific\nrisk/benefit analysis | \nHigh procedural\nbleeding risk Device\nexchange, upgrade/\nrevision procedure |  | Continue aspirin AND\nDiscontinue P2Y inhibi-\n12\ntors: Ticagrelor at least 3\ndays before surgery,\nClopidogrel at least 5 days\nbefore surgery, Prasugrel at\nleast 7 days before surgery.\nBridging with GP IIb/IIIa\ninhibitors |  |  |  | ",
          "bbox": [
            47.99954395294189,
            453.23021507263184,
            559.8819580078125,
            699.2256602411685
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "61",
      "title": "9.4 Management of anticoagulation It is well known that the development of a pocket haematoma after the implantation of a pacemaker system significantly increases the risk for subsequent pocket infect",
      "start_page": 52,
      "end_page": 52,
      "content": "Regarding non-vitamin K antagonist oral anticoagulants, the Randomized Controlled Trial of Continued Versus Interrupted Direct Oral Anti-Coagulant at the Time of Device Surgery (BRUISE CONTROL-2) was stopped prematurely due to futility because the event rate was far lower than anticipated; however, it suggested that,\ndepending on the clinical scenario and concomitant antiplatelet ther- apy, either stopping or continuing non-vitamin K antagonist oral anti- coagulants might be reasonable at the time of device implantation. 652\nPatients on dual antiplatelet therapy have a significantly increased risk of post-operative pocket haematoma compared with patients treated with aspirin alone or without antiplatelet therapy. In such cases, P2Y 12  receptor inhibitors should be discontinued for 3 \u0002 7 days (according to the specific drug) before the procedure where possible and based on an individualized risk assessment. 638 , 653 , 654   For more details on the management of anticoagulation in the pacemaker procedure, refer to  Table  11 .\n",
      "keywords": [
        "subsequent",
        "development",
        "after",
        "implantation",
        "risk",
        "pocket",
        "haematoma",
        "significantly",
        "infect",
        "well",
        "management",
        "pacemaker",
        "increases",
        "known",
        "anticoagulation",
        "system"
      ],
      "tables": []
    },
    {
      "number": "62",
      "title": "9.5 Venous access Transvenous lead implantation for pacemaker implantation is com- monly performed by venous access via the cephalic, subclavian, or axillary vein. In the case of clinical signs of ven",
      "start_page": 52,
      "end_page": 53,
      "content": "Table 11 Management of anticoagulation in pacemaker procedures\nDual antiplatelet therapy 655 , 656 NOAC 652 VKA 650 OAC  1  antiplatelet 657\nThrombotic risk after PCI\nIntermediate or low >1 month PCI\n>6 months acute coronary\nsyndrome at index PCI\nHigh <1 month PCI\n<6 months acute coronary\nsyndrome at index PCI\nLow procedural\nbleeding risk  First\nimplant\nContinue aspirin AND\nDiscontinue P2Y 12  inhibi-\ntors: Ticagrelor at least 3 days before surgery\nClopidogrel at least 5 days\nbefore surgery Prasugrel at least 7 days before surgery\nElective surgery: Consider\npostponement Otherwise: •   Continue aspirin •   Continue P2Y 12 inhibitor\nContinue or interrupt as\nper operator preference. If\ninterruption, then based on CrCl and speciﬁc NOAC\nContinue a Continue OAC (VKA a   or\nNOAC). Discontinue anti-\nplatelet per patient-speciﬁc risk/beneﬁt analysis\nHigh procedural\nbleeding risk  Device exchange, upgrade/\nrevision procedure\nContinue aspirin AND\nDiscontinue P2Y 12  inhibi- tors: Ticagrelor at least 3\ndays before surgery,\nClopidogrel at least 5 days before surgery, Prasugrel at\nleast 7 days before surgery.\nBridging with GP IIb/IIIa inhibitors\nCrCl = creatinine clearance; GP = glycoprotein; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; PCI = percutaneous coronary intervention; VKA = vitamin K antagonist. a Target international normalized ratio within therapeutic range.\nESC 2021\nESC Guidelines 53\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ increased risk of pneumothorax. 658   Prospective data on axillary vein puncture suggest a lower risk of access-related complications com- pared with subclavian puncture. 659   Ultrasound guidance for axillary vein puncture has been described as a helpful technique for achieving a safe and uncomplicated puncture. 660\nWith regards to lead failure after implantation, there is evidence that the axillary vein route is associated with a lower rate of lead fail- ures in long-term follow-up. In a retrospective study comprising 409 patients and mean follow-up of 73.6 ± 33.1 months, lead failure occurred in 1.2% of patients with contrast-guided axillary vein punc- ture, 2.3% of patients with cephalic vein cutdown, and 5.6% of patients with subclavian vein puncture. In multivariable regression analysis, the only predictor of lead failure was subclavian vein punc- ture instead of axillary vein access (HR 0.26, 95% CI 0.071 \u0002 0.954;  P = 0.042). When analysing the success rates of the different venous access approaches, the cephalic vein approach showed the lowest success rate (78.2% vs. axillary vein 97.6% and subclavian vein 96.8%; P  < 0.001). 661\n",
      "keywords": [
        "clinical",
        "cephalic",
        "anticoagulant",
        "implantation",
        "monly",
        "signs",
        "axillary",
        "lead",
        "performed",
        "creatinine",
        "transvenous",
        "subclavian",
        "access",
        "pacemaker",
        "vein",
        "anticoagulation",
        "case",
        "venous"
      ],
      "tables": []
    },
    {
      "number": "63",
      "title": "9.6 Lead considerations In choosing between active or passive fixation pacemaker leads in the RA or RV, one should consider the potential for perforation and peri- carditis, as well as extractability.",
      "start_page": 53,
      "end_page": 53,
      "content": "Lead stability and phrenic nerve stimulation are important aspects of coronary sinus lead implantation. With regards to both, quadripo- lar leads seem to have relevant advantages. The rate of phrenic nerve stimulation requiring lead revision is significantly lower compared with that in bipolar coronary sinus leads. 665 , 666   Furthermore, lead stability is increased because quadripolar leads can usually be implanted in the wedged position. If implanted in an apical position due to wedging, the use of the proximal poles avoids apical stimula- tion. Therefore, quadripolar leads are recommended for coronary sinus lead implantation. Active fixation LV leads via a side helix have been developed, and results have proved reliable stability, easy access to the target pacing site, and stable LV pacing threshold in the long term. In comparison with passive fixation quadripolar leads, active fix- ation bipolar and quadripolar leads achieved similar results. The lead design with an active fixation mechanism via a side helix was\ndeveloped to allow for full extractability in the long term. However, the ease of extractability at long term has not yet been proven. 667 \u0002 669\n",
      "keywords": [
        "perforation",
        "choosing",
        "fixation",
        "extractability",
        "recommended",
        "leads",
        "consider",
        "passive",
        "lead",
        "potential",
        "active",
        "between",
        "well",
        "considerations",
        "pacemaker",
        "should",
        "carditis",
        "peri"
      ],
      "tables": []
    },
    {
      "number": "64",
      "title": "9.7 Lead position Ventricular pacing has traditionally been performed from the RV apex. Since the introduction of active fixation leads, alternative pacing sites such as the RVOT septum or the mid-sep",
      "start_page": 53,
      "end_page": 53,
      "content": "Placing the lead on the mid-septum may be challenging (even more so in the RVOT septum, which is a smaller target area). The use of multiple fluoroscopic views and specially shaped stylets is useful for this purpose and is outlined in a recent EHRA consensus paper. 34   In this context, it is important to mention that the accuracy and repro- ducibility of fluoroscopic assessment of RV lead positions is often inaccurate. 421\nMultiple fluoroscopic views are also recommended for placing RVA leads, to ensure there is no inadvertent placement of the lead in a coronary sinus tributary or in the LV via an intracardiac shunt or arterial access. The coronary sinus may be used for LV pacing without the need to cross the tricuspid valve. It may also be used in the case of other diffi- culties in deploying an RV lead (e.g. in the case of a tricuspid valve prosthesis). In selected patients, the outcome is similar to RV pacing. 675 , 676\nThe RA appendage is usually the preferred site for atrial pacing. The lateral atrium may carry a risk of phrenic nerve capture. 677 , 678\nAlternative pacing sites to avoid AF such as Bachman’s bundle and the region of the coronary sinus ostium have not shown benefit and are not to be recommended in routine practice. 679 , 680\n",
      "keywords": [
        "fixation",
        "since",
        "septum",
        "leads",
        "tricuspid",
        "alternative",
        "performed",
        "apex",
        "active",
        "position",
        "such",
        "traditionally",
        "introduction",
        "rvot",
        "recommended",
        "pacing",
        "sites",
        "lead",
        "ventricular"
      ],
      "tables": []
    },
    {
      "number": "65",
      "title": "9.8 Device pocket In recent years, there has been increasing awareness of the device pocket as a source of complications. Avoidance of pocket infections has become a special focus in device therapy. T",
      "start_page": 53,
      "end_page": 54,
      "content": "54 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................\nHistorical data from 1000 patients with ICD implants showed signifi- cantly shorter procedural times for patients with subcutaneous device pockets. No significant differences with regard to pocket hae- matomas were found. There were no significant differences in the cumulative percentages of patients free from complication during fol- low-up. 682\nPocket irrigation at the end of the procedure with normal saline leads to dilution of possible contaminants and eliminates debris from the wound before closure. 683 , 684   Addition of antibiotics to the rinsing solution does not reduce the risk of device infections. 683\nThe World-wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT study) investigated the effect of an absorbable antibiotic-eluting envelope on the development of post- operative CIED infections. A total of 6983 patients undergoing a CIED pocket revision, generator replacement, or system upgrade, or initial implantation of a CRT-D were randomly assigned, in a 1:1 ratio, to receive the antibiotic envelope or not. The rate of CIED infection in patients who had the antibacterial envelope was 0.7% vs. 1.2% in the control group (HR 0.6, 95% CI 0.36 \u0002 0.98;  P  = 0.04). 685   No effect on infection rate was observed in the subgroup with pacemakers. 685\nConsidering cost-effectiveness aspects, the use of an antibiotic enve- lope may be considered in pacemaker patients at high risk for CIED infections. Risk factors to be considered in this context are end-stage renal disease, chronic obstructive pulmonary disease, diabetes melli- tus, and device replacement, revision, or upgrade procedures. 638\n",
      "keywords": [
        "device",
        "years",
        "crt",
        "awareness",
        "pacemaker",
        "there",
        "diabetes",
        "avoidance",
        "complications",
        "pocket",
        "become",
        "increasing",
        "therapy",
        "infections",
        "icd",
        "recent",
        "special",
        "may be considered",
        "source",
        "focus"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 55",
          "page_number": 54,
          "content": "In pacemaker implantations in patients with pos-\nsible pocket issues such as increased risk of ero-\nsion due to low body mass index, Twiddler’s\nsyndrome, or for aesthetic reasons, a submuscu-\nlar device pocket may be considered. | IIb | C | \nHeparin bridging of anticoagulated patients is\nnot recommended.650,689 | III | A | \nPermanent pacemaker implantation is not rec-\nommended in patients with fever. Pacemaker\nimplantation should be delayed until the patient\nhas been afebrile for at least 24 h.638,639 | III | B | ESC 2021",
          "bbox": [
            311.3290313720703,
            59.87787927900042,
            556.6573050362723,
            195.35414559500558
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 55",
          "page_number": 54,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAdministration of pre-operative antibiotic pro-\nphylaxis within 1 h of skin incision is recom-\nmended to reduce risk of CIED\ninfection.641,643.686 | I | A | \nChlorhexidine\u0002alcohol instead of povidone-\niodine\u0002alcohol should be considered for skin\nantisepsis.647,648 | IIa | B | \nFor venous access, the cephalic or axillary vein\nshould be considered as first choice.658,659 | IIa | B | \nTo confirm target ventricular lead position, use\nof multiple fluoroscopic views should be\nconsidered. | IIa | C | \nFor implantation of coronary sinus leads, quadri-\npolar leads should be considered as first\nchoice.665,666,687 | IIa | C | \nRinsing the device pocket with normal saline sol-\nution before wound closure should be\nconsidered.683,684 | IIa | C | \nIn patients undergoing a reintervention CIED\nprocedure, the use of an antibiotic-eluting enve-\nlope may be considered.685,688 | IIb | B | \nPacing of the mid-ventricular septum may be\nconsidered in patients at high risk of perforation\n(e.g. elderly, previous perforation, low body\nmass index, women).420,674 | IIb | C | ",
          "bbox": [
            47.06791453207693,
            405.088232421875,
            292.13853053042766,
            737.6781812395368
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "66",
      "title": "10 Complications of cardiac pacing and cardiac resynchronization therapy",
      "start_page": 54,
      "end_page": 54,
      "content": "",
      "keywords": [
        "resynchronization",
        "pacing",
        "complications",
        "cardiac",
        "therapy"
      ],
      "tables": []
    },
    {
      "number": "67",
      "title": "10.1 General complications Cardiac pacing and CRT are associated with a substantial risk of com- plications ( Table  12 ), most of which occur in the perioperative phase, 429 , 690   but a sizable ris",
      "start_page": 54,
      "end_page": 55,
      "content": "Complication rates after dual-chamber pacemaker implantation in the MOST trial were 4.8% at 30 days, 5.5% at 90 days, and 7.5% at 3 years. 692   However, ‘real-life’ data indicate a higher risk. 690 , 693   In a recent study of >81 000 patients receiving  de novo  CIED implanta- tions, major complications occurred in 8.2% within 90 days of hospi- tal discharge. 694   Mortality in hospital (0.5%) and within 30 days (0.8%) was low. Complication risks generally increase with the complexity of the device and are more common in the context of a device upgrade or lead revisions compared with  de novo  implantation. In a Danish population-based cohort study, complications were observed in 9.9% of patients at first device implantation and in 14.8% upon upgrade or lead revision. 354   Procedures limited to replacement of the generator had a lower complication risk (5.9%). In the prospec- tive REPLACE registry, a similar proportion (4%) of complication risks in the setting of generator replacement was reported, but much higher risks were found in those with one or more additional lead insertions (up to 15.3%). 695   Accordingly, major complications were particularly more common with CRT upgrade procedures, a finding that was corroborated in a large US inpatient cohort 339   and a pro- spective Italian observational study. 696   The rate of procedural com- plications also increases with comorbidity burden. 697\nThus, careful shared decision-making is warranted when consider- ing upgrades to more complex systems. This also applies to prophy- lactic replacement of recalled CIED generators and leads, a scenario in which procedural risks should be carefully weighed against the risks associated with device or lead failure. 698\nOverall, complication rates are closely linked to individual and centre implantation volumes. 429 , 658 , 693   Complications were increased by 60% in inexperienced operators who had performed fewer than\nRecommendations regarding device implantations and peri-operative management\nRecommendations Class a Level b\nAdministration of pre-operative antibiotic pro-\nphylaxis within 1 h of skin incision is recom- mended to reduce risk of CIED\ninfection. 641 , 643 . 686\nI A\nChlorhexidine \u0002 alcohol instead of povidone- iodine \u0002 alcohol should be considered for skin\nantisepsis. 647 , 648\nIIa B\nFor venous access, the cephalic or axillary vein\nshould be considered as ﬁrst choice. 658 , 659 IIa B\nTo conﬁrm target ventricular lead position, use\nof multiple ﬂuoroscopic views should be\nconsidered.\nIIa C\nFor implantation of coronary sinus leads, quadri- polar leads should be considered as ﬁrst\nchoice. 665 , 666 , 687\nIIa C\nRinsing the device pocket with normal saline sol- ution before wound closure should be\nconsidered. 683 , 684\nIIa C\nIn patients undergoing a reintervention CIED\nprocedure, the use of an antibiotic-eluting enve- lope may be considered. 685 , 688\nIIb B\nPacing of the mid-ventricular septum may be\nconsidered in patients at high risk of perforation (e.g. elderly, previous perforation, low body\nmass index, women). 420 , 674\nIIb C\nContinued\nIn pacemaker implantations in patients with pos-\nsible pocket issues such as increased risk of ero-\nsion due to low body mass index, Twiddler’s syndrome, or for aesthetic reasons, a submuscu-\nlar device pocket may be considered.\nIIb C\nHeparin bridging of anticoagulated patients is not recommended. 650 , 689 III A\nPermanent pacemaker implantation is not rec-\nommended in patients with fever. Pacemaker\nimplantation should be delayed until the patient has been afebrile for at least 24 h. 638 , 639\nIII B\nCIED = cardiovascular implantable electronic device. a Class of recommendation. b Level of evidence.\nESC 2021\n. ....................................................\nESC Guidelines 55\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 25 implantations. 429   Data from a large national quality assurance pro- gramme for pacemakers and CRT-P showed that the annual hospital implantation volume was inversely related to complication rates, with the greatest difference observed between the lowest (1- 50 implantations/year) and the second lowest quintile (51 \u0002 90 implanta- tions/year). 699   Furthermore, emergency and out-of-hours proce- dures are associated with increased complication rates. 354   These data clearly suggest that CIED procedures should be performed by operators and centres with a sufficient procedural volume.\n",
      "keywords": [
        "should be considered",
        "crt",
        "pacemaker",
        "sizable",
        "occur",
        "phase",
        "perioperative",
        "risk",
        "general",
        "complications",
        "which",
        "plications",
        "table",
        "level b",
        "cardiac",
        "elderly",
        "substantial",
        "most",
        "associated",
        "alcohol",
        "recommended",
        "may be considered",
        "pacing"
      ],
      "tables": [
        {
          "title": "56 ESC Guidelines",
          "page_number": 55,
          "content": "Incidence of complications after CIED therapy |  | % | ESC 2021\nLead-related reintervention354,639,690,692,695,700,701\n(including dislodgement, malposition, subclavian crush\nsyndrome, etc.) |  | 1.0\u00025.9 | \nCIED-related infections, <12\nmonths354,639,641,645,685,695,702 |  | 0.7\u00021.7 | \nSuperficial infection354 |  | 1.2 | \nPocket infections354 |  | 0.4 | \nSystemic infections354 |  | 0.5 | \nCIED-related infections, >12 months702\u0002709 |  | 1.1\u00024.6 | \nPocket infections702 |  | 1.3 | \nSystemic infections702,705 |  | 0.5\u00021.2 | \nPneumothorax354,658,690,692,700,701,707 |  | 0.5\u00022.2 | \nHaemothorax695 |  | 0.1 | \nBrachial plexus injury695 |  | <0.1 | \nCardiac perforation354,663,690,692,695 |  | 0.3\u00020.7 | \nCoronary sinus dissection/perforation710,288 |  | 0.7\u00022.1 | \nRevision due to pain/discomfort354,690 |  | 0.1\u00020.4 | \nDiaphragmatic stimulation requiring\nreintervention711,712,665,713 |  | 0.5\u00025 | \nHaematoma354,639,650,652,654,690,700,714,715 |  | 2.1\u00025.3 | \nTricuspid regurgitation716\u0002718 |  | 5\u000215 | \nPacemaker syndrome146,701,719 |  | 1\u000220 | \nGenerator/lead problem354,639,690 |  | 0.1\u00021.5 | \nDeep venous thrombosis (acute or\nchronic)354,720,721 |  | 0.1\u00022.6 | \nAny complication354,639,690,692,695,707,722,723 |  | 5\u000215 | \nMortality (<30 days)354,694 |  | 0.8\u00021.4 | ",
          "bbox": [
            43.52258937916857,
            368.2770690917969,
            288.7480163574219,
            729.1599731445312
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "68",
      "title": "10.2 Specific complications 10.2.1 Lead complications Pacemaker leads are a frequent source of complications due to dis- lodgement, insulation defects, lead fractures, and sensing or threshold problem",
      "start_page": 55,
      "end_page": 56,
      "content": "passive fixation RA lead (OR 2.2) were the most important risk predictors. A meta-analysis of 25 CRT trials noted mechanical complications in 3.2% (including coronary sinus dissection or perforation, pericar- dial effusion or tamponade, pneumothorax, and haemothorax), other lead problems in 6.2%, and infections in 1.4%. Peri-implantation deaths occurred in 0.3%. 369\n10.2.2 Haematoma Pocket haematoma is a frequent complication (2.1 \u0002 9.5%), which can usually be managed conservatively. Evacuation, required in 0.3 \u0002 2% of cases, is associated with an  \u0003 15 times increased risk of infection. 639\nMoreover, patients developing pocket haematoma stay in hospital longer and have a higher in-hospital mortality rate (2.0% vs. 0.7%). 724\nHence, appropriate precautions are critical, and reoperation should be limited to patients with severe pain, persistent bleeding, distension of the suture line, and imminent skin necrosis. Many haematomas can be avoided by careful haemostasis and optimal management of anti- platelet and anticoagulant drugs.\n10.2.3 Infection Infection is one of the most worrying CIED complications, causing significant morbidity, mortality, and healthcare costs. 725 , 726   Infection rates are higher with device replacement or upgrade procedures, 695\nas well as CRT or ICD implants compared with simple pacemaker implantation. 727   Olsen  et al. 702   reported the lifetime risk of system infection in patients with: a pacemaker (1.19%), ICD (1.91%), CRT-P (2.18%), and CRT-D (3.35%). Specifically, patients undergoing reop- erations, those with a previous device-related infection, men, and younger patients had a significantly higher risk of infection. Similar findings have been reported in a large cohort of patients receiving an ICD, with infection rates of 1.4% for single, 1.5% for dual, and 2.0% for biventricular ICDs. 728   In addition, early reintervention (OR 2.70), previous valvular surgery (OR 1.53), reimplantation (OR 1.35), renal failure on dialysis (OR 1.34), chronic lung disease (OR 1.22), cerebrovascular disease (OR 1.17), and warfarin use (OR 1.16) were associated with an increased risk of infection. 702   Infections also occur more frequently with use of temporary pacing or other proce- dures before implantation (OR 2.5 and 5.8, respectively), early rein- terventions (OR 15), and lack of antibiotic prophylaxis (OR 2.5). 639 , 729\nFurther comprehensive information on how to prevent, diagnose, and treat CIED infections has been provided in a recent EHRA con- sensus document. 642\n10.2.4 Tricuspid valve interference CIED leads may interfere with tricuspid valve function intra- operatively by causing damage to the tricuspid valve leaflets or the subvalvular apparatus, or chronically after operation or lead extrac- tion. This damage has been linked to haemodynamic deterioration and an adverse clinical outcome. 730   In fact, moderate to severe tricus- pid regurgitation is generally associated with excess mortality 731 , 732\nand occurs at a significantly higher rate in CIED patients. 733   The prev- alence of significant tricuspid regurgitation (defined as grade 2 or above) following CIED implantation varies between 10% and 39%. Most studies attribute a greater harm with ICD leads and in the\nTable 12 Complications of pacemaker and cardiac resynchronization therapy implantation\nIncidence of complications after CIED therapy %\nLead-related reintervention 354 , 639 , 690 , 692 , 695 , 700 , 701\n(including dislodgement, malposition, subclavian crush syndrome, etc.)\n1.0 \u0002 5.9\nCIED-related infections,  < 12\nmonths 354 , 639 , 641 , 645 , 685 , 695 , 702\n0.7 \u0002 1.7\nSuperﬁcial infection 354 1.2\nPocket infections 354 0.4\nSystemic infections 354 0.5\nCIED-related infections,  > 12 months 702 \u0002 709 1.1 \u0002 4.6\nPocket infections 702 1.3\nSystemic infections 702 , 705 0.5 \u0002 1.2\nPneumothorax 354 , 658 , 690 , 692 , 700 , 701 , 707 0.5 \u0002 2.2\nHaemothorax 695 0.1\nBrachial plexus injury 695 <0.1\nCardiac perforation 354 , 663 , 690 , 692 , 695 0.3 \u0002 0.7\nCoronary sinus dissection/perforation 710 , 288 0.7 \u0002 2.1\nRevision due to pain/discomfort 354 , 690 0.1 \u0002 0.4\nDiaphragmatic stimulation requiring reintervention 711 , 712 , 665 , 713\n0.5 \u0002 5\nHaematoma 354 , 639 , 650 , 652 , 654 , 690 , 700 , 714 , 715 2.1 \u0002 5.3\nTricuspid regurgitation 716 \u0002 718 5 \u0002 15\nPacemaker syndrome 146 , 701 , 719 1 \u0002 20\nGenerator/lead problem 354 , 639 , 690 0.1 \u0002 1.5\nDeep venous thrombosis (acute or chronic) 354 , 720 , 721\n0.1 \u0002 2.6\nAny complication 354 , 639 , 690 , 692 , 695 , 707 , 722 , 723 5 \u0002 15\nMortality ( < 30 days) 354 , 694 0.8 \u0002 1.4\nCIED = cardiovascular implantable electronic device.\nESC 2021\n56 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ presence of multiple RV leads. 45 , 46 , 49 , 445 , 642 , 685 , 697 , 709 , 728 , 730 \u0002 732   The issue of lead interference with bioprosthetic tricuspid valves or after annuloplasty or repair is debated. Furthermore, there is no firm evi- dence supporting that pacing-induced RV dyssynchrony significantly contributes to tricuspid regurgitation. A recent study randomizing 63 patients to pacing lead positions in the RV apex, RVS, or LV pacing via the coronary sinus did not affect the development of tricuspid regur- gitation. 734   The diagnostic work-up of CIED lead-related tricuspid regurgitation based on clinical, haemodynamic, and in particular echo- cardiographic (2D, 3D, and Doppler) evaluation is often challeng- ing. 735   While clear guidance for the management of tricuspid regurgitation in the presence of CIED leads is still lacking, a high level of clinical suspicion is required, not discounting the possibility that worsening HF may be a consequence of the mechanical effect on tri- cuspid leaflet mobility or coaptation. 730   General treatment options include medical therapy aiming to relieve congestion and lead extrac- tion with careful replacement, or use of alternative pacing strategies, such as LV pacing via the coronary sinus or epicardial leads. However, transvenous lead extraction itself carries a risk of damage to the tricuspid valve and, hence, worsening tricuspid regurgitation. While leadless pacing eliminates the need for transvalvular leads, it may still negatively affect tricuspid valve function, potentially due to mechanical interference and abnormal electrical and mechanical ven- tricular activation. 736   Indications for surgical valve repair or replace- ment in the context of CIED-induced tricuspid regurgitation follow current recommendations based on the presence of symptoms, severity of tricuspid regurgitation, and RV function. When consider- ing tricuspid valve surgery, management of the RV lead should follow the recommendations outlined in  section 8.2.3 . 737   Methods for percu- taneous tricuspid repair have recently gained major attention, but evi- dence in favour of such interventions in the context of lead-related tricuspid regurgitation is still limited. 738\n10.2.5 Other Increased complication risks have been observed in women (mainly pneumothorax and cardiac perforation) and in those with a low body mass index. 354 , 739   Patients older than 80 years were also found to have a lower risk of lead-related reinterventions compared with patients aged 60 \u0002 79 years (1.0% vs. 3.1%). 354\nFinally, suboptimal atrioventricular synchrony may lead to the pacemaker syndrome, giving rise to cannon waves caused by simulta- neous atrial and ventricular contractions and symptoms of fatigue, dizziness, and hypotension (see  section 5 ). Long-term RV pacing indu- ces a dyssynchronous ventricular activation pattern that may pro- mote progressive LV dysfunction and clinical HF. Strategies to avoid and resolve the adverse effect of RV pacing have been discussed above ( section  6 ).\n",
      "keywords": [
        "echo",
        "older",
        "problem",
        "crt",
        "valve repair",
        "pacemaker",
        "specific",
        "threshold",
        "frequent",
        "leads",
        "anticoagulant",
        "tricuspid",
        "lifetime risk",
        "complications",
        "insulation",
        "sensing",
        "fractures",
        "icd",
        "lodgement",
        "source",
        "lead",
        "defects"
      ],
      "tables": []
    },
    {
      "number": "69",
      "title": "11 Management considerations",
      "start_page": 56,
      "end_page": 56,
      "content": "Integrated management of pacemaker and CRT patients, delivered by an interdisciplinary team in partnership with the patient and family, should be adopted in order to deliver comprehensive treatment across the continuum of healthcare (see  section 12 ). The integrated- care approach is indicated in pacemaker and CRT patients to ensure a patient-centred approach and patient involvement in shared\ndecision-making. The integrated-care approach has its origins in the chronic care model developed by Wagner  et al ., 740   and has the potential to improve clinical and patient outcomes in arrhythmia management 741 \u0002 743   (see  section 12 ). Relevant specialists to be included in the interdisciplinary team are included according to the patient’s needs and local service availability ( Figure  13 ).\n",
      "keywords": [
        "arrhythmia",
        "crt",
        "management",
        "considerations",
        "pacemaker"
      ],
      "tables": []
    },
    {
      "number": "70",
      "title": "11.1 Magnetic resonance imaging in patients with implanted cardiac devices MRI is a frequent requirement in patients with implanted pacemakers. It may cause adverse effects such as inappropriate devic",
      "start_page": 56,
      "end_page": 59,
      "content": "ESC Guidelines 57\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................. Evaluation must be made on a case by case basis by balancing the advantages of MRI with the potential risks and availability of alterna- tive imaging methods and using shared decision-making. In general, MRIs should always be performed in the context of a rigorously applied standardized institutional workflow, following the appropriate conditions of use (including programming). 744 , 746 , 753 \u0002 755\nA flowchart summarizing the management of patients with a pace- maker undergoing MRI is shown in  Figure  14 . There is evidence indicating that 1.5 T MRIs may be performed in patients with temporary epicardial wires 756   as well as with transve- nous pacemaker active fixation leads implanted to externalized pace- makers used for temporary pacing. 751\nIntegrated management of patients with pacemaker and CRT\nEmphasising patient-centred care and shared decision making\nEnsure optimal device selection and implantation\nPre-implant assessment and adherence to low-risk implantation surgery\nProvide physiological pacing and symptom control\nStructured follow-up with tailored device programming (remote monitoring and in-office)\nManagement of underlying cardiac disease\nIncluding stroke prevention in atrial fibrillation and heart failure optimization\nPatient education/ self-management  Including personal goals and/or action plan\nHealthcare professional education\nIncluding certifications for optimal quality in relevant specialities\nLifestyle modification Smoking cessation, alcohol, dietary and exercise interventions\nPsychosocial management and support Psychological assessment and/or treatment\nStrategies to promote medical adherence\nEducate patients about what to expect from the device and medical treatment using available technologies\nMultidisciplinary team approach\nIncluding different disciplines when relevant; electrophysiologists, cardiologists, nurses, allied professionals, psychologist, dietician and pharmacist\nClear communication between primary and secondary care\nIncluding timely end-of-life discussions\nFigure 13  Integrated management of patients with pacemaker and cardiac resynchronization therapy. CRT = cardiac resynchronization therapy.\n58 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........................................................... 11.2 Radiation therapy in pacemaker patients An increasing number of patients with CIEDs are referred for radio- therapy, 757   with a reported annual rate of 4.33 treatments per 100 000 person-years. Radiotherapy uses high-energy ionizing radiation including X-rays, gamma rays, and charged particles, which might cause software and hardware errors in CIEDs, especially when pho- ton radiation beam energy exceeds 6 \u0002 10 MV, and the radiation dose to the device is high (>2 \u0002 10 Gy). 758 , 759   Hard errors are rare, and are most often due to direct irradiation to the device. This can cause irre- versible hardware damage, requiring device replacement. Soft errors are more common, and are associated with secondary neutron pro- duction by irradiation. 760   Such errors typically include resets of the device without causing structural damage, and can be solved without replacement. 757 , 759\nElectromagnetic interference during radiotherapy can cause oversensing, although this very rarely occurs in clinical practice. 760\nDevice relocation before radiotherapy is very rarely recom- mended, and only if the current location of the device interferes\nEvaluating magnetic resonance imaging in pacemaker patients\nMRI following conditions of use and standardized workflow (Class I)\nMRI Alternative imaging technique\nMRI following appropriate standardized workflow (Class IIa)\nMRI only if benefits outweigh risk (max. 1.5T, SAR < 1.5 W/Kg) (Class IIb) (Class IIa)\nPresence of abandoned leads\nMRI-conditional system\nPast exemption period after implementation\nAlternative imaging mode available\nN\nY\nPresence of epicardial leads, or connected fractured leads, or lead adaptors/extenders\nY\nN\nN\nN\nStrongly reconsider MRI a\nY\nY\nN\nY\nFigure 14  Flowchart for evaluating magnetic resonance imaging in pacemaker patients. MRI = magnetic resonance imaging; SAR = specific absorption rate.   a Consider only if there is no imaging alternative and the result of the test is crucial for applying life-saving therapies for the patient.\nRecommendations for performing magnetic resonance imaging in pacemaker patients\nRecommendations Class a Level b\nIn patients with MRI-conditional pacemaker sys-\ntems, c   MRIs can be performed safely following the manufacturer’s instructions. 745 , 753 \u0002 755\nI A\nIn patients with non-MRI-conditional pacemaker\nsystems, MRI should be considered if no alterna- tive imaging mode is available and if no epicardial\nleads, abandoned or damaged leads, or lead\nadaptors/extenders are present. 744 , 746\nIIa B\nMRI may be considered in pacemaker patients with abandoned transvenous leads if no alterna-\ntive imaging modality is available. 748 \u0002 751\nIIb C\nMRI = magnetic resonance imaging. a Class of recommendation. b Level of evidence. c Combination of MRI-conditional generator and lead(s) from the same manufacturer.\nESC 2021\nESC Guidelines 59\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................................................................... with adequate tumour treatment or in very selected high-risk cases. 757 , 761\n",
      "keywords": [
        "should be considered",
        "smoking",
        "class i",
        "devic",
        "crt",
        "pacemaker",
        "frequent",
        "requirement",
        "adverse",
        "cause",
        "effects",
        "resonance",
        "pacemakers",
        "mri",
        "inappropriate",
        "such",
        "atrial fibrillation",
        "level b",
        "cardiac",
        "heart failure",
        "exercise",
        "patients",
        "alcohol",
        "implanted",
        "may be considered",
        "imaging",
        "magnetic",
        "devices"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 59",
          "page_number": 58,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with MRI-conditional pacemaker sys-\ntems,c MRIs can be performed safely following\nthe manufacturer’s instructions.745,753\u0002755 | I | A | \nIn patients with non-MRI-conditional pacemaker\nsystems, MRI should be considered if no alterna-\ntive imaging mode is available and if no epicardial\nleads, abandoned or damaged leads, or lead\nadaptors/extenders are present.744,746 | IIa | B | \nMRI may be considered in pacemaker patients\nwith abandoned transvenous leads if no alterna-\ntive imaging modality is available.748\u0002751 | IIb | C | ESC 2021",
          "bbox": [
            47.262596933465254,
            530.0960286458334,
            292.26566908094617,
            688.6452484130859
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "71",
      "title": "According to published recommendations for CIED patients, 745 , 759 , 762   the risk of malfunction (or adverse events) is higher in the following situations for pacemaker patients:",
      "start_page": 59,
      "end_page": 59,
      "content": "•   With photon radiation applying energy  > 6 \u0002 10 MV : the risk of mal- functions (usually soft errors) is due to secondary neutron pro- duction, is not associated with the target zone, and cannot be shielded. •   With a cumulative dose reaching the device  > 2 Gy (moderate risk) or > 10 Gy (high-risk) : the dose reaching the pacemaker can be esti- mated before and measured during treatment, is correlated with the target zone, and can be shielded. •   If the patient is pacemaker dependent.\nAppropriate decision-making is suggested in  Figure  15 . Experience with proton radiation therapy in CIED patients is lim- ited. However, compared with photon irradiation, this radiation modality produces more secondary neutrons, which may affect the risk of device errors or failure. 763   Currently, no specific guidance can be given regarding proton radiation therapy in CIED patients. The specific recommendations of CIED manufacturers are reported in  Supplementary Table 23 .\n",
      "keywords": [
        "higher",
        "patients",
        "following",
        "malfunction",
        "risk",
        "according",
        "adverse",
        "published",
        "cied",
        "events",
        "situations",
        "pacemaker",
        "recommendations"
      ],
      "tables": []
    },
    {
      "number": "72",
      "title": "11.3 Temporary pacing Temporary pacing can provide electronic cardiac stimulation in patients with acute life-threatening bradycardia or can be placed",
      "start_page": 59,
      "end_page": 60,
      "content": "prophylactically when the need for pacing is anticipated (e.g. after car- diac surgery). 764 , 765   Modalities for emergency temporary pacing include transvenous, epicardial, and transcutaneous approaches. The transvenous approach often requires fluoroscopic guidance, although echo-guided placement is also feasible. 766   Balloon-tipped floating catheters are easier to insert, more stable, and safer than semi-rigid catheters. 767 , 768   Patients who undergo transvenous temporary car- diac pacing have a high risk for procedure-related complications (e.g. cardiac perforation, bleeding, malfunction, arrhythmias, and acciden- tal electrode displacement) and complications related to immobiliza- tion (e.g. infection, delirium, and thrombotic events). 764 , 765 , 769 \u0002 775   In addition, previous temporary pacing is associated with an increased risk of permanent pacemaker infection. 639 , 641   A percutaneous trans- venous active fixation lead connected to an external device is safer and more comfortable for patients requiring prolonged temporary pacing. 776 \u0002 779   There are no good data that support either a jugular or axillar/subclavian access; however, intrathoracic subclavian punc- ture should be avoided to reduce the risk of pneumothorax. A jugular access should be preferred if implantation of a permanent ipsilateral device is planned. In selected cases where fast and efficient pacing is needed, a femoral access may be used. Owing to instability of passive leads placed through the femoral vein and immobilization of the patient, the duration of this approach should be as short as possible until bradycardia has resolved or a more permanent solution has been established. The epicardial approach is mostly used following cardiac surgery. Removal of these leads is associated with complica- tions such as bleeding and tamponade. 780 \u0002 782   Transcutaneous tem- porary pacing is a fast and effective non-invasive method, but is not as\nPacemaker management in patients undergoing radiation therapy\nAvoid direct radiation Limit cumulative dose Reduce beam energy to minimize direct neutron radiation\nDevice-specific treatment planning considerations: a\nN\nComprehensive PM evaluation before radiation therapy\nNeutron-producing treatment ( > 10 MV)\nWeekly comprehensive PM evaluation Comprehensive PM evaluation after end of radiation therapy\nY\nFigure 15  Pacemaker management during radiation therapy ECG = electrocardiographic; PM = pacemaker.   a Relocation of the device, continuous ECG monitoring, reprogramming, or magnet application are very rarely indicated.\n60 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........................................................................................................................................................... stable as the transvenous approach, and is limited by the need for continuous sedation. 783   This modality should only be used in emer- gency settings or when no other option is available, and under close haemodynamic monitoring. 784   Before starting temporary pacing, chronotropic medication should be considered, taking into account side effects, contraindications, and interactions with other medication. This Task Force concludes that temporary transvenous pacing should be avoided if possible; when it is required, the lead should remain  in situ  for as short a time as possible. The use of temporary pacing should be limited to the emergency treatment of patients with severe bradyarrhythmia causing syncope and/or haemodynamic com- promise, and to cases in whom those bradyarrhythmias are antici- pated. Temporary transvenous pacing is recommended when pacing indications are reversible, such as in the context of antiarrhythmic drug use, myocardial ischaemia, myocarditis, electrolyte disturbances, toxic exposure, after cardiac surgery, or as a bridge to permanent pacemaker implantation when this procedure is not immediately available or possible due to concomitant infection. Lastly, if a patient meets the permanent pacemaker implantation criteria, this proce- dure should be performed promptly.\n",
      "keywords": [
        "electronic",
        "patients",
        "stimulation",
        "recommended",
        "should be considered",
        "temporary",
        "echo",
        "provide",
        "acute",
        "pacing",
        "life",
        "threatening",
        "bradycardia",
        "placed",
        "pacemaker",
        "cardiac",
        "ecg",
        "syncope"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 61",
          "page_number": 60,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nTemporary transvenous pacing is recommended\nin cases of haemodynamic-compromising bra-\ndyarrhythmia refractory to intravenous chrono-\ntropic drugs.764,765 | I | C | \nTranscutaneous pacing should be considered in\ncases of haemodynamic-compromising bradyar-\nrhythmia when temporary transvenous pacing is\nnot possible or available.783\u0002785 | IIa | C | \nTemporary transvenous pacing should be con-\nsidered when immediate pacing is indicated and\npacing indications are expected to be reversible,\nsuch as in the context of myocardial ischaemia,\nmyocarditis, electrolyte disturbances, toxic\nexposure, or after cardiac surgery.771\u0002773 | IIa | C | \nTemporary transvenous pacing should be con-\nsidered as a bridge to permanent pacemaker\nimplantation when this procedure is not immedi-\nately available or possible due to concomitant\ninfection.771\u0002773 | IIa | C | \nFor long-term temporary transvenous pacing, an\nactive fixation lead inserted through the skin and\nconnected to an external pacemaker should be\nconsidered.641,776,777,779 | IIa | C | ESC 2021",
          "bbox": [
            47.100224928422406,
            343.23634643554686,
            292.2265413724459,
            648.1662445068359
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "73",
      "title": "11.4 Peri-operative management in patients with cardiovascular implantable electronic devices Advisory documents to help manage patients with CIEDs in the peri- operative period have been issued by se",
      "start_page": 60,
      "end_page": 60,
      "content": "•   Electromagnetic interference (EMI) may induce oversensing (more likely with unipolar leads), activation of rate-responsive sensors, device resetting, or other damage. The most common source of EMI is electrocautery, although it is rare during bipolar electrocautery >5 cm from the CIED and monopolar electro- cautery below the umbilicus. 790   To reduce the risk of EMI, monopolar electrocautery should be applied in short (<5 s) pulses, with the skin patches away from the area of the device. Other sources of EMI include radiofrequency procedures, nerve stimulators, and other electronic devices. •   The peri-operative strategy should be tailored based on the indi- vidual needs and values of patients, procedure, and device. 786 \u0002 789   Most procedures will not require any interven- tion. 791   In pacemaker-dependent patients, a magnet should be applied during delivery of diathermy pulses, or, if EMI is likely to occur or magnet stability cannot be guaranteed, the device should be reprogrammed to an asynchronous mode (VOO/ DOO). The response to magnet application may differ between device manufactures. CIEDs with a rate-responsive function using an active sensor may also require magnet application or disabling of this function to prevent inappropriate rapid pacing. Post-operative CIED interrogation is recommended if malfunc- tion is suspected or if the device has been exposed to strong EMI.\n",
      "keywords": [
        "electronic",
        "period",
        "patients",
        "recommended",
        "manage",
        "issued",
        "implantable",
        "operative",
        "help",
        "cardiovascular",
        "advisory",
        "management",
        "documents",
        "pacemaker",
        "cieds",
        "devices",
        "peri"
      ],
      "tables": []
    },
    {
      "number": "74",
      "title": "11.5 Cardiovascular implantable electronic devices and sports activity Regular exercise is strongly recommended for prevention of cardio- vascular disease. 792 \u0002 795   Restrictions to patients with a ",
      "start_page": 60,
      "end_page": 61,
      "content": "There is consensus that contact sports (e.g. rugby or martial arts) should be avoided so as not to risk damage of device components or haematoma at the implantation site. For participation in sports such as football, basketball, or baseball, special protective shields are rec- ommended to reduce the risk of trauma to the device. Sport inter- ests and right or left arm dominance should be considered when selecting the implantation site, and submuscular placement can be considered to reduce the risk of impact. A lateral vascular access is\nRecommendations regarding temporary cardiac pacing\nRecommendations Class a Level b\nTemporary transvenous pacing is recommended in cases of haemodynamic-compromising bra-\ndyarrhythmia refractory to intravenous chrono-\ntropic drugs. 764 , 765\nI C\nTranscutaneous pacing should be considered in\ncases of haemodynamic-compromising bradyar-\nrhythmia when temporary transvenous pacing is not possible or available. 783 \u0002 785\nIIa C\nTemporary transvenous pacing should be con-\nsidered when immediate pacing is indicated and\npacing indications are expected to be reversible, such as in the context of myocardial ischaemia,\nmyocarditis, electrolyte disturbances, toxic\nexposure, or after cardiac surgery. 771 \u0002 773\nIIa C\nTemporary transvenous pacing should be con-\nsidered as a bridge to permanent pacemaker\nimplantation when this procedure is not immedi- ately available or possible due to concomitant\ninfection. 771 \u0002 773\nIIa C\nFor long-term temporary transvenous pacing, an\nactive ﬁxation lead inserted through the skin and connected to an external pacemaker should be\nconsidered. 641 , 776 , 777 , 779\nIIa C\na Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 61\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .............................................................................................................. preferable to prevent the risk of subclavian crush of the lead associ- ated with arm exercises above shoulder level. It is recommended to abstain from vigorous exercise and ipsilateral arm exercise for 4 \u0002 6 weeks post-device implantation. Of note, recommendations regarding sports activity in patients with an ICD differ from those in pacemaker patients. 797 , 798\n",
      "keywords": [
        "should be considered",
        "activity",
        "sports",
        "pacemaker",
        "restrictions",
        "disease",
        "cardio",
        "electronic",
        "cardiovascular",
        "regular",
        "strongly",
        "icd",
        "implantable",
        "level b",
        "exercise",
        "patients",
        "recommended",
        "prevention",
        "vascular",
        "devices"
      ],
      "tables": [
        {
          "title": "62 ESC Guidelines",
          "page_number": 61,
          "content": " | In-office only | In-office 1 remote | ESC 2021\nAll devices | Within 72 h and\n2\u000212 weeks after\nimplantation | In-office within 72 h and\n2\u000212 weeks after\nimplantation | \nCRT-P or\nHBP | Every 6 months | Remote every 6 months and\nin-office every 12 monthsa | \nSingle/dual-\nchamber | Every 12 months then every\n3 - 6 months at signs of bat-\ntery depletion | Remote every 6 months and\nin-office every 18 - 24\nmonthsa | ",
          "bbox": [
            307.84238891601564,
            550.5449829101562,
            553.0789794921875,
            660.6786693226207
          ],
          "function_potential": "raw"
        },
        {
          "title": "62 ESC Guidelines",
          "page_number": 61,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nWhen pacing is no longer indicated, the decision\non management strategy should be based on an\nindividual risk\u0002benefit analysis in a shared deci-\nsion-making process together with the patient. | I | C | ESC 2021",
          "bbox": [
            42.6984748840332,
            580.779355875651,
            287.83201293945314,
            652.9282618931362
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "75",
      "title": "11.6 When pacing is no longer indicated Different management options are available in patients with implanted pacemaker systems in whom pacing is no longer indicated:",
      "start_page": 61,
      "end_page": 61,
      "content": "Leave pacemaker generator and pacemaker leads  in situ . Explant pacemaker generator and abandon leads. Explant pacemaker generator and leads. The feasibility of option 1 depends on the end-of-life behaviour of the implanted generator, which is manufacturer dependent, and may be erratic and lead to complications in rare cases. 799   Option 1 is the preferred approach to selected frail and elderly patients. Option 2 comes with a low procedural risk but may be associated with the disadvantages of lead abandonment, including future MRI. Especially in young patients, the potential necessary future require- ment for lead extraction of abandoned leads due to infection and the associated elevated procedural risk due to longer duration of implan- tation procedure need to be taken into account. Several studies have shown increased complexity, lower procedural success, and higher complication rates of lead extraction procedures of abandoned leads. 800 \u0002 803\nOption 3 comes with the highest initial procedural risk, but elimi- nates all possibilities of future device-related complications. When performed in specialized high-volume centres with current extrac- tion tools, lead extraction procedures can be carried out with high complete procedural success rates and low complication rates. 802\nThis approach may be appropriate for the combination of a young patient, low risk for extraction, and an experienced extractor. As part of a patient-centred approach, the decision in such situa- tions has to be based on an individual risk \u0002 benefit analysis in a shared decision-making process together with the patient and his/her carers. This includes providing sufficient information to achieve an informed decision-making. Important factors to take into consideration are patient age, patient condition, comorbidities, pacemaker system, lead implant duration, and the patient’s life expectancy.\n",
      "keywords": [
        "options",
        "patients",
        "age",
        "implanted",
        "systems",
        "indicated",
        "longer",
        "pacing",
        "mri",
        "whom",
        "management",
        "pacemaker",
        "when",
        "elderly",
        "available",
        "different"
      ],
      "tables": []
    },
    {
      "number": "76",
      "title": "11.7 Device follow-up General principles of follow-up are covered here, as in-depth recom- mendations are beyond the scope of this document. The patient and",
      "start_page": 61,
      "end_page": 62,
      "content": "the device should be treated as a single entity, with programming tail- ored to meet the patient’s needs. The goals are to (i) ensure patient safety; (ii) provide physiological pacing; (iii) improve patient quality of life; (iv) improve patient clinical management; and (v) maximize device longevity. Requirement for follow-up of the underlying cardiac disease should not be overlooked. In addition to the technical check and opti- mization of programming, proper counselling of the patient and his/her family are necessary to meet these goals. The frequency of follow-up depends on the type of device (CRT and HBP are associated with more clinical or technical issues and need closer surveillance) and whether they are on remote device management ( Table  13 ).\n•   Remote device management includes  remote follow-up  with full remote device interrogation at scheduled intervals (to replace in-office visits),  remote monitoring  with unscheduled transmission of pre-defined alert events, and  patient-initiated follow-up  with unscheduled interrogations as a result of a patient experiencing a real or perceived clinical event. Most studies have focused on patients with ICDs and CRT-Ds, and have shown a significant reduction in delay between event detection/clinical decision, and fewer inappropriate shocks. 804   Two randomized non-inferiority trials with single-chamber 805   or DDD 805 , 806   pacemakers (no CRT-P) showed that in-office visits can be safely spaced to 18 \u0002 24 month intervals if patients are on remote monitoring with devices having automatic threshold algorithms. Spacing of scheduled in-office visits is particularly convenient for elderly patients with limited mobility, but also for young or midlle-aged patients with full-time jobs, family commitments, etc., and in spe- cific situations (e.g. to avoid exposure during a pandemic). •   It is important to conduct remote device management with an appropriate set-up that delivers a structured approach to remote follow-up and a timely response to alerts. Third-party providers can be useful to triage alerts and assist with this task. 807 Importantly, compliance with the General Data Protection Regulation should be respected, as outlined in a recent ESC regulatory affairs/EHRA document. 808\nRecommendation when pacing is no longer indicated\nRecommendation Class a Level b\nWhen pacing is no longer indicated, the decision on management strategy should be based on an\nindividual risk \u0002 beneﬁt analysis in a shared deci-\nsion-making process together with the patient.\nI C\na Class of recommendation. b Level of evidence.\nTable 13 Frequency of follow-up for routine pacemaker and cardiac resynchronization therapy, either in person alone or combined with remote device management\nIn-office only In-office  1  remote\nAll devices Within 72 h and 2 \u0002 12 weeks after\nimplantation\nIn-ofﬁce within 72 h and 2 \u0002 12 weeks after\nimplantation\nCRT-P or HBP Every 6 months Remote every 6 months and in-ofﬁce every 12 months a\nSingle/dual-\nchamber\nEvery 12 months then every\n3 - 6 months at signs of bat-\ntery depletion\nRemote every 6 months and\nin-ofﬁce every 18 - 24\nmonths a\nCRT-P = cardiac resynchronization therapy-pacemaker; HBP = His bundle pacing. a Remote follow-up can only replace in-ofﬁce visits if automatic capture threshold algorithms perform accurately (and are previously veriﬁed in-ofﬁce). Note: additional in-ofﬁce follow-up may be required (e.g. to verify the clinical effect of modiﬁcation of programming, or for follow-up a technical issue). Remote monitoring (i.e. of pre-deﬁned alerts) should be implemented in all instances along with remote follow-ups.\nESC 2021\nESC 2021\n. ................................................................\n62 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ................................................................\n",
      "keywords": [
        "follow",
        "depth",
        "here",
        "covered",
        "device",
        "general",
        "document",
        "crt",
        "principles",
        "beyond",
        "patient",
        "pacemaker",
        "elderly",
        "scope",
        "mendations",
        "recom",
        "level b"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 63",
          "page_number": 62,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nRemote device management is recommended to\nreduce the number of in-office follow-ups in\npatients with pacemakers who have difficulties\nto attend in-office visits (e.g. due to reduced\nmobility or other commitments, or according to\npatient preference).805,806,809 | I | A | \nRemote monitoring is recommended in the case\nof a device component that has been recalled or\nis on advisory, to enable early detection of\nactionable events in patients, particularly those\nwho are at increased risk (e.g. in the case of\npacemaker dependency). | I | C | \nIn-office routine follow-up of single- and dual-\nchamber pacemakers may be spaced by up to 24\nmonths in patients on remote device\nmanagement.805,806 | IIa | A | \nRemote device management of pacemakers\nshould be considered in order to provide earlier\ndetection of clinical problems (e.g. arrhythmias)\nor technical issues (e.g. lead failure or battery\ndepletion).806,810 | IIa | B | ESC 2021",
          "bbox": [
            47.11779724924188,
            86.47422485351562,
            292.24254816228694,
            366.62326229319854
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 63",
          "page_number": 62,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nIn patients considered for pacemaker or CRT,\nthe decision should be based on the best avail-\nable evidence with consideration of individual\nrisk\u0002benefits of each option, the patient’s pref-\nerences, and goals of care, and it is recom-\nmended to follow an integrated care approach\nand use the principles of patient-centred care\nand shared decision-making in the\nconsultation.831\u0002836 | I | C | ESC 2021",
          "bbox": [
            311.5728332519531,
            351.04295349121094,
            556.7208862304688,
            483.1902313232422
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "77",
      "title": "12 Patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy",
      "start_page": 62,
      "end_page": 62,
      "content": "Providing patient-centred care is a holistic process that emphasizes partnerships in health between patient and clinician, acknowledging the patient’s needs, beliefs, expectations, healthcare preferences, goals, and values. 811 \u0002 813   In patient-centred care, the focus is on shared decision-making, accepting that patients generally prefer to take an active role in decisions about their health. 814 , 815   This approach has been shown to improve health outcomes and health- care experiences. 814 , 816   Clinicians have a duty to define and explain the healthcare problem and make recommendations about the best available evidence across all available options at the time, including no treatment, while ensuring that the patient’s values and preferences are considered ( Figure  16 ). 817 \u0002 820\nDecision aids, such as written information and/or the use of inter- active websites or web-based applications, can complement the clini- cians’ counselling and thus facilitate shared decision-making. 822   When decision aids are used, patients feel more knowledgeable, have more accurate risk perceptions, and take a more active part in the deci- sion. 823   In patients with poor language or literacy skills, as well as in those with cognitive impairment, communication strategies, including the help of a qualified interpreter, is recommended, as this helps the\npatient to make a balanced decision. 824 \u0002 826   Choosing the appropri- ate educational material is an important component of promoting the learning process of patients. 827 \u0002 830   Based on the patient’s needs and preferences, the education should be performed before implan- tation, at discharge, and during follow-up using a person-centred approach ( Table  14 ). All patients should receive a brochure provided by the manufacturer as well as a device identification card before discharge. This Task Force emphasizes the importance of patient-centred care and shared decision-making between patients and clinicians. The decision to implant a pacemaker/CRT should be based on the best available evidence with consideration of the individual risk \u0002 benefits of each option, the patient’s preferences, and goals of care. The con- sultation should include whether the patient is a good candidate for pacemaker/CRT treatment, and possible alternative treatment options should be discussed in a way that can be understood by everyone involved in the discussion. Using the principles of shared decision-making and informed consent/refusal, patients with decision-making capacity have the right to refuse pacemaker therapy, even if they are pacemaker dependent.\n",
      "keywords": [
        "resynchronization",
        "recommended",
        "centred",
        "pacing",
        "crt",
        "decision",
        "making",
        "patient",
        "shared",
        "pacemaker",
        "cardiac",
        "therapy",
        "care"
      ],
      "tables": []
    },
    {
      "number": "78",
      "title": "13 Quality indicators",
      "start_page": 62,
      "end_page": 64,
      "content": "Quality indicators are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes. 837   They may also serve as a mechanism for enhancing adherence to guideline recommendations through quality assurance endeavours and bench- marking of care providers. 838   As such, the role of quality indicators in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations, payers, and the public. 839\nThe ESC recognizes the need for measuring and reporting quality and outcomes of cardiovascular care. One aspect of this is the devel- opment and implementation of quality indicators for cardiovascular disease. The methodology by which the ESC quality indicators are\nRecommendations for pacemaker and cardiac resynch- ronization therapy-pacemaker follow-up\nRecommendations Class a Level b\nRemote device management is recommended to\nreduce the number of in-ofﬁce follow-ups in patients with pacemakers who have difﬁculties\nto attend in-ofﬁce visits (e.g. due to reduced\nmobility or other commitments, or according to patient preference). 805 , 806 , 809\nI A\nRemote monitoring is recommended in the case\nof a device component that has been recalled or is on advisory, to enable early detection of\nactionable events in patients, particularly those\nwho are at increased risk (e.g. in the case of pacemaker dependency).\nI C\nIn-ofﬁce routine follow-up of single- and dual-\nchamber pacemakers may be spaced by up to 24\nmonths in patients on remote device management. 805 , 806\nIIa A\nRemote device management of pacemakers\nshould be considered in order to provide earlier detection of clinical problems (e.g. arrhythmias)\nor technical issues (e.g. lead failure or battery\ndepletion). 806 , 810\nIIa B\na Class of recommendation. b Level of evidence.\nESC 2021\nRecommendation regarding patient-centred care and shared decision-making in cardiac pacing and cardiac resynchronization therapy\nRecommendation Class a Level b\nIn patients considered for pacemaker or CRT,\nthe decision should be based on the best avail-\nable evidence with consideration of individual risk \u0002 beneﬁts of each option, the patient’s pref-\nerences, and goals of care, and it is recom-\nmended to follow an integrated care approach and use the principles of patient-centred care\nand shared decision-making in the\nconsultation. 831 \u0002 836\nI C\nCRT = cardiac resynchronization therapy. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................\nESC Guidelines 63\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nSeek the patient’s participation\nDefine and explain the healthcare problem and communicate that a choice exists. Discuss possible alternative treatment options, including that  patients with decision-making capacity have the right to refuse PM/CRT therapy, even if the patient is pacemaker dependent. The consultation should be discussed in a way that can be understood by everyone involved in the discussion. Encourage the patient to become involved in the consultation and invite family to participate.\nHelp the patient explore and compare treatment options\nProvide an overview of the implantation process, and address all aspects of how the device works and the conditions it treats. Discuss the benefits and risks with each option, including potential complications and treatment refusal.\nAccess the patient’s values and preferences\nSupplement the counselling with different decision aids to facilitate SDM. In patients with poor language skills, cognitive impairment, or low health literacy, a variety of communication strategies should be used in order for the patient to make a deliberate decision. Take into account the patient´s preferences and goals of care, and what matters most to the patient.\nReach a decision with the patient\nMake evidence based recommendations with consideration of individual risk-benefits of each option, while ensuring that the patient's beliefs, expectations, values, goals, and preferences are considered. Decide together on the best available option.\nEvaluate the patient’s decision\nEvaluate if the decision is reasonable and understood. Based on the patient´s needs and preferences, the education should be repeated prior discharge, and at the follow-up appointments using a person centred approach.\nFigure 16  Example of shared decision-making in patients considered for pacemaker/CRT implantation. Modified from the principles of the SHARE Approach. 821 CRT = Cardiac resynchronization therapy; PM = pacemaker; SDM = Shared Decision Making.\nTable 14 Topics and content that may be included in patient education\nTopics Content that may be included in patient education\nBiophysiological Disease/condition, pacemaker indication, implantation process, possible periprocedural or late complications and malfunction,\npacemaker/CRT function and technical aspects, patient notiﬁer (if applicable), battery replacement Demonstration of pacemaker dummies\nFunctional Daily activities: mobility, physical activities and sports, possible physical restrictions (arm movements), sexual activities, driving\nrestrictions, travelling, wound care, medication use Normal postoperative signs and symptoms and self-care; pain, stiffness in the shoulder, swelling or tenderness around the\npacemaker pocket\nFinancial Costs of treatment and rights in the social security system, insurance issues, sick leave\nEmotional Possible emotions and reactions to pacemaker treatment: anxiety, worries, body image\nSocial Available support: telephone-based support, face-to-face group sessions, patient forums, and peer-support groups Possible employment restrictions and electromagnetic interference\nEthical Rights and duties of patients and healthcare providers: consent/refusal of pacemaker or CRT therapy, or withdrawal\nof therapy Information about registration in the national pacemaker registry\nPractical Pacemaker identiﬁcation card contact information to the pacemaker clinic\nFollow-up routines: remotely or/and hospital based\nWhere to get more information: reliable web-based information/sources, which organizations provide reliable health information\nCRT = cardiac resynchronization therapy.\nESC 2021\n64 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................. developed has been published. 839   To date, a suite of quality indicators for an initial tranche of cardiovascular conditions has been pro- duced. 839 , 840   To facilitate quality improvement initiatives, the disease- specific ESC quality indicators are included in corresponding ESC Clinical Practice Guidelines. 296 , 841   This is further enhanced by way of their integration in the ESC registries, such as the EurObservational Research Programme (EORP) and the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart) project. 842\nA number of registries exist for patients undergoing CIED implan- tation, 843   providing ‘real-world’ data about the quality and outcomes of CIED care. 702   However, there is a lack of a widely agreed set of quality indicators that encompasses the multifaceted nature of CIED care, and that serves as a bridge between clinical registries and guideline recommendations. Thus, and in parallel with the writing of these guidelines, a suite of quality indicators for patients undergoing CIED implantation was developed. The full list of these quality indica- tors, as well as their specifications and development methodology, has been published elsewhere, 844   with a selection presented in Table  15 .\n",
      "keywords": [
        "quality",
        "recommended",
        "should be considered",
        "indication",
        "crt",
        "guideline",
        "indicators",
        "pacemaker",
        "level b"
      ],
      "tables": [
        {
          "title": "64 ESC Guidelines",
          "page_number": 63,
          "content": "Topics |  | Content that may be included in patient education | \nBiophysiological |  | Disease/condition, pacemaker indication, implantation process, possible periprocedural or late complications and malfunction,\npacemaker/CRT function and technical aspects, patient notifier (if applicable), battery replacement\nDemonstration of pacemaker dummies | \nFunctional |  | Daily activities: mobility, physical activities and sports, possible physical restrictions (arm movements), sexual activities, driving\nrestrictions, travelling, wound care, medication use\nNormal postoperative signs and symptoms and self-care; pain, stiffness in the shoulder, swelling or tenderness around the\npacemaker pocket | \nFinancial |  | Costs of treatment and rights in the social security system, insurance issues, sick leave | \nEmotional |  | Possible emotions and reactions to pacemaker treatment: anxiety, worries, body image | \nSocial |  | Available support: telephone-based support, face-to-face group sessions, patient forums, and peer-support groups\nPossible employment restrictions and electromagnetic interference | \nEthical |  | Rights and duties of patients and healthcare providers: consent/refusal of pacemaker or CRT therapy, or withdrawal\nof therapy\nInformation about registration in the national pacemaker registry | \nPractical |  | Pacemaker identification card contact information to the pacemaker clinic\nFollow-up routines: remotely or/and hospital based\nWhere to get more information: reliable web-based information/sources, which organizations provide reliable health\ninformation | ",
          "bbox": [
            43.46977981567383,
            501.39208984375,
            547.841618290654,
            736.314683702257
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 65",
          "page_number": 64,
          "content": "Quality indicator |  | Domain | ESC 2021\nCentres providing CIED services should participate in at least one CIED registry |  | Structural quality indicatora | \nNumerator: Number of centres participating in at least one registry for CIED |  |  | \nCentres providing CIED services should monitor and report the volume of procedures performed by individ-\nual operators on an annual basis |  | Structural quality indicator | \nNumerator: Number of centres monitoring and reporting the volume of procedures performed by individual operators |  |  | \nCentres providing CIED services should have available resources (ambulatory ECG monitoring, echocardio-\ngram) to stratify patients according to their risk for ventricular arrhythmias |  | Structural quality indicator | \nNumerator: Number of centres with an available ambulatory ECG and echocardiogram service |  |  | \nCentres providing CIED services should have a preprocedural checklist to ensure discussion with the patient\nregarding risks, benefits, and alternative treatment options |  | Structural quality indicator | \nNumerator: Number of centres that have a checklist to ensure discussion with patient regarding risks, benefits, and alternative treatment options before\nCIED implantation |  |  | \nCentres providing CIED services should have established protocols to follow-up patients within 2 - 12 weeks\nfollowing implantation |  | Structural quality indicator | \nNumerator: Number of centres that have an established protocol to follow up patients within 2 - 12 weeks following CIED implantation |  |  | \nProportion of patients considered for CIED implantation who receive prophylactic antibiotics 1 h before their\nprocedure |  | Patient assessment | \nNumerator: Number of patients who receive antibiotics 1 h before their CIED implantation procedure\nDenominator: Number of patients undergoing CIED implantation procedure |  |  | \nAnnual rate of procedural complicationsb 30 days following CIED implantation |  | Outcomes | \nNumerator: Number of patients who develop one or more procedural complicationsb within 30 days of CIED implantation\nDenominator: Number of patients undergoing CIED implantation procedure |  |  | ",
          "bbox": [
            48.02908470756129,
            91.33294677734375,
            557.6139526367188,
            382.6300354003906
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "79",
      "title": "14 Key messages",
      "start_page": 64,
      "end_page": 65,
      "content": "•   In the evaluation of candidates for permanent pacemaker implan- tation, a thorough and detailed pre-operative evaluation is rec- ommended. This should always include careful history taking and physical examination, laboratory testing, documentation of the type of bradyarrhythmia requiring treatment, and cardiac imag- ing. In selected cases, additional tests, EPS, and/or genetic testing are indicated. •   Ambulatory ECG monitoring is useful in the evaluation of patients with suspected bradycardia or cardiac conduction disor- der, to correlate rhythm disturbances with symptoms. Choice of type of monitoring should be based on frequency and nature of symptoms and patient preferences. •   In patients with SND including those with bradycar- dia \u0002 tachycardia type of SND, when symptoms can clearly be attributed to bradyarrhythmia, cardiac pacing is indicated. •   In patients with SR and permanent or paroxysmal third- or second-degree type 2 or high-degree AVB, cardiac pacing is indi- cated irrespective of symptoms.\nTable 15 A selection of the developed quality indicators for patients undergoing cardiovascular implantable electronic device implantation\nQuality indicator Domain\nCentres providing CIED services should participate in at least one CIED registry Structural quality indicator a\nNumerator : Number of centres participating in at least one registry for CIED\nCentres providing CIED services should monitor and report the volume of procedures performed by individ- ual operators on an annual basis Structural quality indicator\nNumerator : Number of centres monitoring and reporting the volume of procedures performed by individual operators\nCentres providing CIED services should have available resources (ambulatory ECG monitoring, echocardio-\ngram) to stratify patients according to their risk for ventricular arrhythmias\nStructural quality indicator\nNumerator : Number of centres with an available ambulatory ECG and echocardiogram service\nCentres providing CIED services should have a preprocedural checklist to ensure discussion with the patient\nregarding risks, beneﬁts, and alternative treatment options\nStructural quality indicator\nNumerator : Number of centres that have a checklist to ensure discussion with patient regarding risks, beneﬁts, and alternative treatment options before CIED implantation\nCentres providing CIED services should have established protocols to follow-up patients within 2 - 12 weeks\nfollowing implantation\nStructural quality indicator\nNumerator : Number of centres that have an established protocol to follow up patients within 2 - 12 weeks following CIED implantation\nProportion of patients considered for CIED implantation who receive prophylactic antibiotics 1 h before their procedure Patient assessment\nNumerator : Number of patients who receive antibiotics 1 h before their CIED implantation procedure\nDenominator:  Number of patients undergoing CIED implantation procedure\nAnnual rate of procedural complications b   30 days following CIED implantation Outcomes\nNumerator : Number of patients who develop one or more procedural complications b   within 30 days of CIED implantation\nDenominator:  Number of patients undergoing CIED implantation procedure\nCIED = cardiovascular implantable electronic device; ECG = electrocardiogram. a Structural quality indicators are binary measurements (yes/no), and thus only the numerator is deﬁned. b CIED-related bleeding, pneumothorax, cardiac perforation, tamponade, pocket haematoma, lead displacement (all requiring intervention), or infection.\nESC 2021\nESC Guidelines 65\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ......................................................................................................................................................................... •   In patients with permanent AF and permanent or paroxysmal AVB, single-lead ventricular pacing is indicated. •   In patients with syncope and unexplained falls, the diagnosis should be ascertained using the available diagnostic methods before pacemaker treatment is considered. •   In patients with symptomatic HF and LVEF <_35% despite OMT who are in SR and have LBBB QRS morphology, CRT is recom- mended when QRS duration is >_150 ms, and should be consid- ered when QRS duration is 130 \u0002 149 ms. For patients with non- LBBB QRS morphology, evidence for benefit of CRT is less con- vincing, especially with normal PR and QRS duration <150 ms. CRT should not be used in patients with HF and QRS duration <130 ms, unless there is need for ventricular pacing. •   Selection of patients for CRT based on imaging is limited to the measurement of LVEF, whereas the assessment of other factors, such as extent of myocardial scar, presence of mitral regurgita- tion, or RV systolic function, is important to anticipate potential non-responders who may need additional treatments (e.g. mitral valve intervention). •   In patients with permanent AF, symptomatic HF, LVEF <_35%, and QRS >_130 ms who remain in NYHA class III or ambulatory IV despite OMT, CRT should be considered. •   For patients with AF and CRT, AVJ ablation should be consid- ered when at least 90 \u0002 95% effective biventricular pacing cannot be achieved. •   For patients with high-degree AVB and an indication for cardiac pacing who have HFrEF (LVEF <40%), CRT rather than RV pac- ing is recommended. •   HBP may result in normal or near-normal ventricular activation, and is an attractive alternative to RV pacing. To date, no data from randomized trials support that HBP is non-inferior to RV pacing with respect to safety and efficacy. Therefore, HBP may be considered for selected patients with AVB and LVEF >40%, who are anticipated to have >20% ventricular pacing. •   In patients offered HBP, implantation of an RV lead used as ‘backup’ for pacing should be considered individually. •   HBP may correct ventricular conduction in a subset of patients with LBBB and may therefore be used in lieu of biventricular pac- ing for HBP-based CRT in selected patients. •   In patients treated with HBP, device programming tailored to specific requirements of HBP must be ensured. •   Implanting a leadless pacemaker should be considered when no upper extremity venous access exists, when risk of device pocket infection is particularly increased, and in patients on haemodialysis. •   Patients undergoing TAVI are at increased risk of developing AVB. Decisions regarding cardiac pacing after TAVI should be taken based upon pre-existing and new conduction disturbances. Ambulatory ECG monitoring for 7 \u0002 30 days or EPS may be con- sidered in patients post-TAVI with new LBBB or progression of pre-existing conduction anomaly, but not yet any indication for a pacemaker. •   In patients undergoing surgery for endocarditis or tricuspid valve surgery who have or develop AVB under surgery, placement of epicardial pacing leads during surgery should be considered. •   To reduce the risk of complications, pre-operative anti- biotics must be administered before CIED procedures,\nchlorhexidine \u0002 alcohol should be preferred for skin antisepsis, and cephalic or axillary vein access should be attempted as first choice. •   Heparin bridging should be avoided in CIED procedures to mini- mize the risk of haematoma and pocket infection. •   In patients undergoing a CIED reintervention procedure, using an antibiotic-eluting envelope may be considered to reduce the risk of infection. •   In the majority of patients with a pacemaker or CRT, a well- indicated MRI can be performed if no epicardial leads, aban- doned or damaged leads, or lead adaptors/extenders are present, and certain precautions are taken. •   Radiation therapy can be offered to patients with a pacemaker or CRT if an individualized treatment planning and risk stratifica- tion is done beforehand and the device is interrogated as recom- mended around the period of radiation therapy. •   Remote device management is valuable for earlier detection of clinical problems and technical issues, and may allow longer spac- ing between in-office follow-ups. •   The principles of patient-centred care and shared decision- making should be used in the consultation both pre-operatively and during follow-up for patients considered for or living with a pacemaker or CRT.\n",
      "keywords": [
        "should be considered",
        "bradycardia",
        "crt",
        "genetic",
        "electrocardiogram",
        "tavi",
        "pacemaker",
        "systolic",
        "tachycardia",
        "tricuspid",
        "nyha",
        "syncope",
        "lvef",
        "class iii",
        "hfref",
        "mri",
        "ecg",
        "messages",
        "alcohol",
        "recommended",
        "may be considered",
        "indication",
        "ablation"
      ],
      "tables": []
    },
    {
      "number": "80",
      "title": "15 Gaps in evidence",
      "start_page": 65,
      "end_page": 68,
      "content": "Clinicians responsible for managing pacemaker and CRT candidates, and patients, must frequently make treatment decisions without adequate evidence or consensus of expert opinion. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.\n•   Best pre-implant evaluation programme, including when to apply advanced imaging methods to ensure optimal choice of CIED for each patient. •   Benefit of implementing genetic testing of CIED patients and their relatives when conduction tissue disease is diagnosed. •   Whether use of rate-adaptive pacing in general is beneficial in patients with SND. •   Whether catheter ablation of AF without pacemaker implanta- tion is non-inferior to pacemaker implantation with respect to freedom from bradycardia-related symptoms in patients with symptomatic conversion pauses after AF. •   In patients with reflex syncope, studies of which pacing mode is superior are needed. •   In patients with an indication for VVI pacing, the long-term effi- cacy and safety of choosing leadless pacing need to be docu- mented in RCTs. •   In patients with HF, it remains to be shown that CRT improves outcome in patients without LBBB. •   In patients with permanent/persistent AF, HF, and BBB, any ben- eficial effects of CRT remain to be proven in RCTs. •   There is a lack of RCTs documenting the effect of CRT in patients with HF treated with novel HF drugs including sacubitril/ valsartan, ivabradine, and sodium \u0002 glucose co-transporter-2 inhibitors.\n66 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ........................................................................................ •   The beneficial effects of upgrading to CRT from a standard pace- maker or ICD in patients with HF and a high frequency of RV pacing need to be documented. •   When implanting the LV electrode, it is unknown whether tar- geting the latest local activation mechanically or electrically causes an improved effect of CRT and a better patient outcome. •   It is unknown whether employing any type of pre-implant imag- ing to decide about LV and RV lead placement in CRT may cause better a patient outcome. •   In patients with an indication for permanent pacing and need for a high frequency of RV pacing because of AVB, it is not known which patient and treatment characteristics predict development of pacing-induced cardiomyopathy or HF. •   In patients with AVB and an indication for cardiac pacing, the long-term efficacy and safety of HBP as an alternative to RV pac- ing need to be proven in RCTs. In addition, the selection of patients most likely to benefit from HBP is not yet defined. •   In patients with HF and an indication for CRT, the long-term effi- cacy and safety of implementing HBP as an alternative to or ele- ment of CRT with biventricular pacing need to be proven in RCTs. In addition, the selection of CRT candidates who are most likely to benefit from HBP is not yet defined. •   Further studies are needed to determine whether HBP could be used to improve response in CRT non-responders. •   The efficacy and safety of left bundle branch area pacing remain to be documented. •   Superiority of a specific location for the RV lead (i.e. septal, out- flow tract, or apical) has not been documented for standard pac- ing indicated for bradycardia or for CRT. •   Better prediction of who will develop AVB after TAVI is needed.\n•   In symptomatic patients with end-stage HCM and LBBB, there is a need to better define the criteria for CRT implantation and document the clinical features associated with sustained benefit from the procedure. •   Optimal treatment including cardiac pacing for patients with congenital AVB should be investigated. •   In pacemaker candidates with cardiomyopathies with >1 year expected survival who do not fulfil standard criteria for ICD implantation, criteria for ICD instead of pacemaker implantation should be better defined. •   The optimal pre-operative handling in CIED implantations and potential use of pre-operative skin disinfection and/or pre- hospitalization decolonization in  S. aureus  carriers remains to be determined. •   The optimal approach for the different operational procedure elements in CIED implantations, especially for choice of venous access, active or passive fixation leads in right-sided chambers, specific pacing sites, use of haemostatic agents in the pocket, choice of suture types, and application of pressure dressing at the end of the procedure remains to be determined. •   Patients with a need for immediate cardiac pacing occasionally present with fever and infection; typically, treatment includes temporary transvenous pacing and antibiotics, followed by implantation of a permanent pacemaker after the infection has resolved. It is unknown whether immediate implantation of a permanent pacemaker after initiation of antibiotics would be inferior. •   The role of patient education, patient-centred care, and shared decision-making should be studied in CIED populations.\n16 ‘What to do’ and ‘what not to do’ messages from the Guidelines\n............ ............ Recommendations Class a Level b\nEvaluation of the patient with suspected or documented bradycardia or conduction system disease\nMonitoring\nAmbulatory ECG monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm\ndisturbances with symptoms. I C\nCarotid massage\nOnce carotid stenosis is ruled out, c   CSM is recommended in patients with syncope of unknown origin compatible with a reﬂex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area. I B\nExercise test\nExercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after\nexertion. I C\nImaging\nCardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the pres-\nence of structural heart disease, to determine LV systolic function, and to diagnose potential causes of conduction\ndisturbances.\nI C\nLaboratory tests\nIn addition to pre-implant laboratory tests, d   speciﬁc laboratory tests are recommended in patients with clinical suspicion for\npotential causes of bradycardia (e.g. thyroid function tests, Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose\nand treat these conditions.\nI C\nContinued\nESC Guidelines 67\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nSleep evaluation\nScreening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced\nAVB during sleep. I C\nRecommendation for implantable loop recorder\nIn patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bra- dycardia in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulatory monitoring with an ILR is\nrecommended.\nI A\nCardiac pacing for bradycardia and conduction system disease\nIn patients with SND and a DDD pacemaker, minimization of unnecessary ventricular pacing through programming is recommended. I A\nPacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias. I B\nPacing is indicated in symptomatic patients with the bradycardia \u0002 tachycardia form of SND to correct bradyarrhythmias and\nenable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred. I B\nPacing is not recommended in patients with bradyarrhythmias related to SND which are asymptomatic or due to transient\ncauses that can be corrected and prevented. III C\nPacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or high-\ndegree AVB, irrespective of symptoms. e I C\nPacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB,\nirrespective of symptoms. I C\nIn patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended. I C\nPacing is not recommended in patients with AVB due to transient causes that can be corrected and prevented. III C\nIn patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV interval of >_70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or abnormal response\nto pharmacological challenge.\nI B\nPacing is indicated in patients with alternating BBB with or without symptoms. I C\nPacing is not recommended for asymptomatic BBB or bifascicular block. III B\nRecommendations for pacing for reﬂex syncope\nDual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40 years, with severe, unpredictable,\nrecurrent syncope who have: •   spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest or AVB; or •   cardioinhibitory carotid sinus syndrome; or •   asystolic syncope during tilt testing.\nI A\nCardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex. III B\nPacing is not recommended in patients with unexplained falls in the absence of any other documented indication. III B\nPacing is not recommended in patients with unexplained syncope without evidence of SND or conduction disturbance. III C\nCRT\nCRT is recommended for symptomatic patients with HF in SR with LVEF <_35%, QRS duration >_150 ms, and LBBB QRS mor- phology despite OMT, to improve symptoms and reduce morbidity and mortality. I A\nCRT is not indicated in patients with HF and a QRS duration <130 ms without indication for RV pacing. III A\nIn patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS\nduration), CRT is recommended in patients with HFrEF. I B\nCRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA class who have an indica- tion for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with AF. I A\nIn patients who are candidates for an ICD, and who have CRT indication, implantation of a CRT-D is recommended. I A\nRecommendations for using His bundle pacing\nIn patients treated with His bundle pacing, device programming tailored to speciﬁc requirements of His bundle pacing is recommended. I C\nPacing in acute myocardial infarction\nImplantation of a permanent pacemaker is indicated with the same recommendations as in a general population ( section 5.2 )\nwhen AVB does not resolve within a waiting period of at least 5 days after MI. I C\nPacing is not recommended if AVB resolves after revascularization or spontaneously. III B\nContinued\n68 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\nRecommendations for cardiac pacing after cardiac surgery and heart transplantation\nHigh-degree or complete AVB after cardiac surgery: a period of clinical observation of at least 5 days is indicated to assess\nwhether the rhythm disturbance is transient and resolves. However, this observation period can be shortened in the case of\ncomplete AVB with low or no escape rhythm when resolution is unlikely.\nI C\nPatients requiring pacing after mechanical tricuspid valve replacement: implantation of a transvalvular RV lead should be avoided. III C\nRecommendations for cardiac pacing after TAVI\nPermanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI. I B\nPermanent pacing is recommended in patients with new-onset alternating BBB after TAVI. I C\nProphylactic permanent pacemaker implantation is not indicated before TAVI in patients with RBBB and no indication for per- manent pacing. III C\nRecommendations for cardiac pacing in patients with congenital heart disease\n",
      "keywords": [
        "bradycardia",
        "crt",
        "genetic",
        "tavi",
        "pacemaker",
        "systolic",
        "gaps",
        "tachycardia",
        "evidence",
        "glucose",
        "tricuspid",
        "nyha",
        "syncope",
        "lvef",
        "arrhythmia",
        "icd",
        "hfref",
        "carotid",
        "valve replacement",
        "level b",
        "cardiomyopathy",
        "ecg",
        "exercise",
        "recommended",
        "stenosis",
        "indication",
        "ablation"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 67",
          "page_number": 66,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n | ............ | ............ | \nEvaluation of the patient with suspected or documented bradycardia or conduction system disease |  |  | \nMonitoring |  |  | \nAmbulatory ECG monitoring is recommended in the evaluation of patients with suspected bradycardia to correlate rhythm\ndisturbances with symptoms. | I | C | \nCarotid massage |  |  | \nOnce carotid stenosis is ruled out,c CSM is recommended in patients with syncope of unknown origin compatible with a\nreflex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area. | I | B | \nExercise test |  |  | \nExercise testing is recommended in patients who experience symptoms suspicious of bradycardia during or immediately after\nexertion. | I | C | \nImaging |  |  | \nCardiac imaging is recommended in patients with suspected or documented symptomatic bradycardia to evaluate the pres-\nence of structural heart disease, to determine LV systolic function, and to diagnose potential causes of conduction\ndisturbances. | I | C | \nLaboratory tests |  |  | \nIn addition to pre-implant laboratory tests,d specific laboratory tests are recommended in patients with clinical suspicion for\npotential causes of bradycardia (e.g. thyroid function tests, Lyme titre, digitalis level, potassium, calcium, and pH) to diagnose\nand treat these conditions. | I | C | ",
          "bbox": [
            47.058835682116054,
            467.73377888997396,
            556.4976461659307,
            719.8832244873047
          ],
          "function_potential": "raw"
        },
        {
          "title": "68 ESC Guidelines",
          "page_number": 67,
          "content": "Sleep evaluation |  |  | \nScreening for SAS is recommended in patients with symptoms of SAS and in the presence of severe bradycardia or advanced\nAVB during sleep. | I | C | \nRecommendation for implantable loop recorder |  |  | \nIn patients with infrequent (less than once a month) unexplained syncope or other symptoms suspected to be caused by bra-\ndycardia in whom a comprehensive evaluation did not demonstrate a cause, long-term ambulatory monitoring with an ILR is\nrecommended. | I | A | \nCardiac pacing for bradycardia and conduction system disease |  |  | \nIn patients with SND and a DDD pacemaker, minimization of unnecessary ventricular pacing through programming is\nrecommended. | I | A | \nPacing is indicated in SND when symptoms can clearly be attributed to bradyarrhythmias. | I | B | \nPacing is indicated in symptomatic patients with the bradycardia\u0002tachycardia form of SND to correct bradyarrhythmias and\nenable pharmacological treatment, unless ablation of the tachyarrhythmia is preferred. | I | B | \nPacing is not recommended in patients with bradyarrhythmias related to SND which are asymptomatic or due to transient\ncauses that can be corrected and prevented. | III | C | \nPacing is indicated in patients in SR with permanent or paroxysmal third- or second-degree type 2, infranodal 2:1, or high-\ndegree AVB, irrespective of symptoms.e | I | C | \nPacing is indicated in patients with atrial arrhythmia (mainly AF) and permanent or paroxysmal third- or high-degree AVB,\nirrespective of symptoms. | I | C | \nIn patients with permanent AF in need of a pacemaker, ventricular pacing with rate response function is recommended. | I | C | \nPacing is not recommended in patients with AVB due to transient causes that can be corrected and prevented. | III | C | \nIn patients with unexplained syncope and bifascicular block, a pacemaker is indicated in the presence of either a baseline HV\ninterval of >70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or abnormal response\n_\nto pharmacological challenge. | I | B | \nPacing is indicated in patients with alternating BBB with or without symptoms. | I | C | \nPacing is not recommended for asymptomatic BBB or bifascicular block. | III | B | \nRecommendations for pacing for reflex syncope |  |  | \nDual-chamber cardiac pacing is indicated to reduce recurrent syncope in patients aged >40 years, with severe, unpredictable,\nrecurrent syncope who have:\n• spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest or AVB;\nor\n• cardioinhibitory carotid sinus syndrome; or\n• asystolic syncope during tilt testing. | I | A | \nCardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex. | III | B | \nPacing is not recommended in patients with unexplained falls in the absence of any other documented indication. | III | B | \nPacing is not recommended in patients with unexplained syncope without evidence of SND or conduction disturbance. | III | C | \nCRT |  |  | \nCRT is recommended for symptomatic patients with HF in SR with LVEF <35%, QRS duration >150 ms, and LBBB QRS mor-\n_ _\nphology despite OMT, to improve symptoms and reduce morbidity and mortality. | I | A | \nCRT is not indicated in patients with HF and a QRS duration <130 ms without indication for RV pacing. | III | A | \nIn patients with symptomatic AF and an uncontrolled heart rate who are candidates for AVJ ablation (irrespective of QRS\nduration), CRT is recommended in patients with HFrEF. | I | B | \nCRT rather than RV pacing is recommended for patients with HFrEF (<40%) regardless of NYHA class who have an indica-\ntion for ventricular pacing and high-degree AVB in order to reduce morbidity. This includes patients with AF. | I | A | \nIn patients who are candidates for an ICD, and who have CRT indication, implantation of a CRT-D is recommended. | I | A | \nRecommendations for using His bundle pacing |  |  | \nIn patients treated with His bundle pacing, device programming tailored to specific requirements of His bundle pacing is\nrecommended. | I | C | \nPacing in acute myocardial infarction |  |  | \nImplantation of a permanent pacemaker is indicated with the same recommendations as in a general population (section 5.2)\nwhen AVB does not resolve within a waiting period of at least 5 days after MI. | I | C | \nPacing is not recommended if AVB resolves after revascularization or spontaneously. | III | B | ",
          "bbox": [
            42.452862218483205,
            59.86335754394531,
            551.9618192232572,
            722.1441781180246
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 69",
          "page_number": 68,
          "content": "Recommendations for cardiac pacing after cardiac surgery and heart transplantation |  |  | \nHigh-degree or complete AVB after cardiac surgery: a period of clinical observation of at least 5 days is indicated to assess\nwhether the rhythm disturbance is transient and resolves. However, this observation period can be shortened in the case of\ncomplete AVB with low or no escape rhythm when resolution is unlikely. | I | C | \nPatients requiring pacing after mechanical tricuspid valve replacement: implantation of a transvalvular RV lead should be avoided. | III | C | \nRecommendations for cardiac pacing after TAVI |  |  | \nPermanent pacing is recommended in patients with complete or high-degree AVB that persists for 24 - 48 h after TAVI. | I | B | \nPermanent pacing is recommended in patients with new-onset alternating BBB after TAVI. | I | C | \nProphylactic permanent pacemaker implantation is not indicated before TAVI in patients with RBBB and no indication for per-\nmanent pacing. | III | C | \nRecommendations for cardiac pacing in patients with congenital heart disease |  |  | \nIn patients with congenital complete or high-degree AVB, pacing is recommended if one of the following risk factors is present:\ni. Symptoms\nii. Pauses >3\u0004 the cycle length of the ventricular escape rhythm\niii. Broad QRS escape rhythm\niv. Prolonged QT interval\nv. Complex ventricular ectopy\nvi. Mean daytime heart rate <50 b.p.m. | I | C | \nRecommendations for cardiac pacing in rare diseases |  |  | \nIn patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >70\n_\nms, with or without symptoms, permanent pacing is indicated.f | I | C | \nRecommendations regarding device implantations and peri-operative management |  |  | \nAdministration of pre-operative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce the risk of CIED infection. | I | A | \nHeparin bridging of anticoagulated patients is not recommended. | III | A | \nPermanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed\nuntil the patient has been afebrile for at least 24 h. | III | B | \nRecommendations for performing magnetic resonance imaging in pacemaker patients |  |  | \nIn patients with MRI-conditional pacemaker systems,g MRI can be performed safely following the manufacturer’s instructions. | I | A | \nRecommendations regarding temporary cardiac pacing |  |  | \nTemporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to\nintravenous chronotropic drugs. | I | C | \nRecommendation when pacing is no longer indicated |  |  | \nWhen pacing is no longer indicated, the decision on management strategy should be based on an individual risk\u0002benefit anal-\nysis in a shared decision-making process together with the patient. | I | C | \nRecommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up |  |  | \nRemote device management is recommended to reduce the number of in-office follow-up visits in patients with pacemakers who\nhave difficulties in attending in-office visits (e.g. due to reduced mobility or other commitments, or according to patient preference). | I | A | \nRemote monitoring is recommended in the case of a device component that has been recalled or is on advisory, to enable early\ndetection of actionable events in patients, particularly those who are at increased risk (e.g. in case of pacemaker dependency). | I | C | \nRecommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy |  |  | \nIn patients considered for a pacemaker or CRT, the decision should be based on the best available evidence with considera-\ntion of individual risk\u0002benefits of each option, the patient’s preferences, and goals of care, and it is recommended to follow\nan integrated care approach and use the principles of patient-centred care and shared decision-making in the consultation. | I | C | ESC 2021",
          "bbox": [
            46.987617927261546,
            59.86335754394531,
            556.5187377929688,
            606.9441724504743
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "81",
      "title": "In patients with congenital complete or high-degree AVB, pacing is recommended if one of the following risk factors is present:",
      "start_page": 68,
      "end_page": 69,
      "content": "i. Symptoms ii. Pauses >3 \u0004  the cycle length of the ventricular escape rhythm\niii. Broad QRS escape rhythm\niv. Prolonged QT interval v. Complex ventricular ectopy\nvi. Mean daytime heart rate <50 b.p.m.\nI C\nRecommendations for cardiac pacing in rare diseases\nIn patients with neuromuscular diseases such as myotonic dystrophy type 1 and any second- or third-degree AVB or HV >_70 ms, with or without symptoms, permanent pacing is indicated. f I C\nRecommendations regarding device implantations and peri-operative management\nAdministration of pre-operative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce the risk of CIED infection. I A\nHeparin bridging of anticoagulated patients is not recommended. III A\nPermanent pacemaker implantation is not recommended in patients with fever. Pacemaker implantation should be delayed until the patient has been afebrile for at least 24 h. III B\nRecommendations for performing magnetic resonance imaging in pacemaker patients\nIn patients with MRI-conditional pacemaker systems, g   MRI can be performed safely following the manufacturer’s instructions. I A\nRecommendations regarding temporary cardiac pacing\nTemporary transvenous pacing is recommended in cases of haemodynamic-compromising bradyarrhythmia refractory to intravenous chronotropic drugs. I C\nRecommendation when pacing is no longer indicated\nWhen pacing is no longer indicated, the decision on management strategy should be based on an individual risk \u0002 beneﬁt anal-\nysis in a shared decision-making process together with the patient. I C\nRecommendations for pacemaker and cardiac resynchronization therapy-pacemaker follow-up\nRemote device management is recommended to reduce the number of in-ofﬁce follow-up visits in patients with pacemakers who\nhave difﬁculties in attending in-ofﬁce visits (e.g. due to reduced mobility or other commitments, or according to patient preference). I A\nRemote monitoring is recommended in the case of a device component that has been recalled or is on advisory, to enable early\ndetection of actionable events in patients, particularly those who are at increased risk (e.g. in case of pacemaker dependency). I C\nRecommendation regarding patient-centred care in cardiac pacing and cardiac resynchronization therapy\nIn patients considered for a pacemaker or CRT, the decision should be based on the best available evidence with considera-\ntion of individual risk \u0002 beneﬁts of each option, the patient’s preferences, and goals of care, and it is recommended to follow\nan integrated care approach and use the principles of patient-centred care and shared decision-making in the consultation.\nI C\nAF = atrial ﬁbrillation; AVB = atrioventricular block; AVJ = atrioventricular junction; BBB = bundle branch block; b.p.m. = beats per minute; CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; CRT-D = deﬁbrillator with cardiac resynchronization therapy; CSM = carotid sinus massage; DDD = dual-chamber, atrioventricular pacing; ECG = electrocardiogram; EPS = electrophysiology study; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HV = His \u0002 ventricular interval; ICD = implantable cardioverter-deﬁbrillator; ILR = implantable loop recorder; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ven- tricular ejection fraction; MI = myocardial infarction; MRI = magnetic resonance imaging; NYHA = New York Heart Association; OMT = optimal medical therapy; RBBB = right bundle branch block; RV = right ventricular; SAS = sleep apnoea syndrome; SND = sinus node dysfunction; SR = sinus rhythm; TAVI = transcatheter aortic valve implantation. a Class of recommendation. b Level of evidence. c CSM should not be undertaken in patients with previous transient ischaemic attack, stroke, or known carotid stenosis. Carotid auscultation should be performed before CSM. If a carotid bruit is present, carotid ultrasound should be performed to exclude carotid disease. d Complete blood counts, prothrombin time, partial thromboplastin time, serum creatinine, and electrolytes. e In asymptomatic narrow QRS complex and 2:1 AVB, pacing may be avoided if supra-Hisian block is clinically suspected (concomitant Wenckebach is observed and block disap- pears with exercise) or demonstrated at EPS. f Whenever pacing is indicated in neuromuscular disease, CRT or an implantable cardioverter-deﬁbrillator should be considered according to relevant guidelines. g Combination of MRI conditional generator and lead(s) from the same manufacturer.\nESC 2021\nESC Guidelines 69\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 17 Supplementary data\nSupplementary data  with additional Supplementary Figures, Tables, and text complementing the full text are available on the  European Heart Journal  website and via the ESC website at https://www.escardio.org/ guidelines.\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "crt",
        "electrocardiogram",
        "tavi",
        "pacemaker",
        "risk",
        "present",
        "nyha",
        "lvef",
        "high",
        "aortic",
        "icd",
        "carotid",
        "hfref",
        "following",
        "mri",
        "creatinine",
        "degree",
        "ecg",
        "congenital",
        "heart failure",
        "exercise",
        "patients",
        "complete",
        "factors",
        "recommended",
        "stenosis",
        "pacing"
      ],
      "tables": []
    },
    {
      "number": "82",
      "title": "18 Author Information",
      "start_page": 69,
      "end_page": 69,
      "content": "Author/Task Force Member Affiliations: Mads Brix Kronborg , Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark;  Yoav Michowitz , Jesselson Integrated Heart Center, Faculty of Medicine, Hebrew University, Shaare Zedek Medical Center, Jerusalem, Israel;  Angelo Auricchio , Department of Cardiology, Istituto Cardiocentro Ticino, Lugano, Switzerland; Israel Moshe Barbash,  Leviev Heart Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel;  Jose´ A. Barrabe´s , Department of Cardiology, Vall d’Hebron Hospital Universitari, Universitat Autonoma de Barcelona, CIBERCV, Barcelona, Spain; Giuseppe Boriani , Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy;  Frieder Braunschweig , Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden;  Michele Brignole , Cardiology, IRCCS Istituto Auxologico Italiano, Milan, Italy;  Haran Burri , Cardiology, University Hospital of Geneva, Geneva, Switzerland; Andrew J. S. Coats , Faculty of Medicine, University of Warwick, Coventry, United Kingdom;  Jean-Claude Deharo , Cardiology La Timone, Aix Marseille Universite´, Marseille, France;  Victoria Delgado , Cardiology, Leiden University Medical Center, Leiden, Netherlands;  Gerhard-Paul Diller , Department of Cardiology III, Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Muenster, Germany;  Carsten W. Israel , Department of Medicine-Cardiology, Diabetology and Nephrology, Bethel-Clinic, Bielefeld, Germany;  Andre Keren , Cardiology, Hadassah-Hebrew University Hospital, Jerusalem, Israel; Reinoud E. Knops , Cardiology and Electrophysiology, Amsterdam University Medical Center, Amsterdam, Netherlands;  Dipak Kotecha , Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom;  Christophe Leclercq , Department of Cadiology, Rennes University Hospital, Rennes, France;  Be´la Merkely , Heart and Vascular Center, Semmelweis University, Budapest, Hungary; Christoph Starck , Department of Cardiothoracic & Vascular Surgery, German Heart Center Berlin, Berlin, Germany;  Ingela Thyle´n , Department of Health, Medicine and Caring Sciences, Linko¨ping University, Linko¨ping, Sweden;  Jose´ Maria Tolosana , Arrhythmia Section, Cardiovascular Institute, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain.\n",
      "keywords": [
        "author",
        "arrhythmia",
        "information"
      ],
      "tables": []
    },
    {
      "number": "83",
      "title": "19 Appendix",
      "start_page": 69,
      "end_page": 70,
      "content": "ESC Scientific Document Group Includes Document Reviewers and ESC National Cardiac Societies.\nDocument Reviewers: Francisco Leyva (CPG Review Coordinator) (United Kingdom), Cecilia Linde (CPG Review\nCoordinator) (Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Gonzalo Bar \u0002 on-Esquivias (Spain), Johann Bauersachs (Germany), Mauro Biffi (Italy), Ulrika Birgersdotter-Green (United States of America ), Maria Grazia Bongiorni (Italy), Michael A. Borger (Germany), Jelena \u0003 Celutkien _ e (Lithuania), Maja Cikes (Croatia), Jean-Claude Daubert (France), Inga Drossart (Belgium), Kenneth Ellenbogen (United States of America), Perry M. Elliott (United Kingdom), Larissa Fabritz (United Kingdom), Volkmar Falk (Germany), Laurent Fauchier (France), Francisco Fern \u0002 andez-Avile´s (Spain), Dan Foldager (Denmark), Fredrik Gadler (Sweden), Pastora Gallego Garcia De Vinuesa (Spain), Bulent Gorenek (Turkey), Jose M. Guerra (Spain), Kristina Hermann Haugaa (Norway), Jeroen Hendriks (Netherlands), Thomas Kahan (Sweden), Hugo A. Katus (Germany), Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Hannah Law (United Kingdom), Basil S. Lewis (Israel), Nicholas John Linker (United Kingdom), Maja-Lisa Løchen (Norway), Joost Lumens (Netherlands), Julia Mascherbauer (Austria), Wilfried Mullens (Belgium), KlaudiaVivien Nagy (Hungary), Eva Prescott (Denmark), Pekka Raatikainen (Finland), Amina Rakisheva (Kazakhstan), Tobias Reichlin (Switzerland), Renato Pietro Ricci (Italy), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Richard Sutton (Monaco), Piotr Suwalski (Poland), Jesper Hastrup Svendsen (Denmark), Rhian M. Touyz (United Kingdom), Isabelle C. Van Gelder (Netherlands), Kevin Vernooy (Netherlands), Johannes Waltenberger (Germany), Zachary Whinnett (United Kingdom), Klaus K. Witte (United Kingdom).\nESC National Cardiac Societies  actively involved in the review process of the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:  Algeria:  Algerian Society of Cardiology, Brahim Kichou;  Armenia:  Armenian Cardiologists Association, Armen Khachatryan;  Austria:  Austrian Society of Cardiology, Daniel Scherr; Belarus: Belorussian Scientific Society of Cardiologists, Alexandr Chasnoits;  Belgium:  Belgian Society of Cardiology, Georges H. Mairesse;  Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Mugdim Bajric;  Bulgaria:  Bulgarian Society of Cardiology, Vasil Velchev; Croatia:  Croatian Cardiac Society, Vedran Velagic;  Cyprus: Cyprus Society of Cardiology, Elias Papasavvas;  Czech Republic: Czech Society of Cardiology, Milos Taborsky;  Denmark:  Danish Society of Cardiology, Michael Vinther;  Egypt:  Egyptian Society of Cardiology, John Kamel Zarif Tawadros;  Estonia:  Estonian Society of Cardiology, Ju¨ri Voitk;  Finland:  Finnish Cardiac Society, Jarkko Karvonen;  France:  French Society of Cardiology, Paul Milliez; Georgia:  Georgian Society of Cardiology, Kakhaber Etsadashvili; Germany:  German Cardiac Society, Christian Veltmann;  Greece: Hellenic Society of Cardiology, Nikolaos Fragakis;  Hungary: Hungarian Society of Cardiology, Laszlo Alajos Gelle´r;  Ireland:  Irish Cardiac Society, Richard Sheahan;  Israel:  Israel Heart Society, Avishag Laish-Farkash;  Italy:  Italian Federation of Cardiology, Massimo Zecchin;  Kazakhstan:  Association of Cardiologists of Kazakhstan, Ayan Abdrakhmanov;  Kosovo (Republic of):  Kosovo Society of Cardiology, Ibadete Bytyc¸i;  Kyrgyzstan:  Kyrgyz Society of Cardiology, Kurbanbek Kalysov;  Latvia:  Latvian Society of Cardiology, Oskars Kalejs; Lebanon: Lebanese Society of Cardiology, Bernard Abi-Saleh;  Lithuania:  Lithuanian Society of\n70 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Cardiology, Germanas Marinskis; Luxembourg: Luxembourg Society of Cardiology, Laurent Groben;  Malta:  Maltese Cardiac Society, Mark Adrian Sammut;  Moldova (Republic of):  Moldavian Society of Cardiology, Mihail Rizov;  Montenegro:  Montenegro Society of Cardiology, Mihailo Vukmirovic;  Morocco:  Moroccan Society of Cardiology, Rachida Bouhouch; Netherlands : Netherlands Society of Cardiology, Mathias Meine; North Macedonia : North Macedonian Society of Cardiology, Lidija Poposka;  Norway:  Norwegian Society of Cardiology, Ole Christian Mjølstad; Poland: Polish Cardiac Society, Maciej Sterlinski; Portugal:  Portuguese Society of Cardiology, Nat \u0002 alia Ant \u0002 onio; Romania:  Romanian Society of Cardiology, Calin Siliste;  Russian Federation:  Russian Society of Cardiology, Sergey Valentinovich Popov;  San Marino:  San Marino Society of Cardiology, Roberto Bini;  Serbia:  Cardiology Society of Serbia, Goran Milasinovic; Slovakia:  Slovak Society of Cardiology, Peter Margitfalvi;  Slovenia: Slovenian Society of Cardiology, Igor Zupan;  Spain:  Spanish Society of Cardiology, \u0002 Oscar Cano; Sweden: Swedish Society of Cardiology, Rasmus Borgquist;  Switzerland:  Swiss Society of Cardiology, Tobias Reichlin;  Syrian Arab Republic:  Syrian Cardiovascular Association, Ahmad Rasheed Al Saadi;  Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Abdeddayem Haggui;  Turkey:  Turkish Society of Cardiology, Ilyas Atar;  United Kingdom of Great Britain and Northern Ireland:  British Cardiovascular Society, Anthony W. C. Chow.\nESC Clinical Practice Guidelines Committee (CPG):  Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena \u0003 Celutkien _ e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark); Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United Kingdom).\n",
      "keywords": [
        "appendix"
      ],
      "tables": []
    },
    {
      "number": "84",
      "title": "19 References",
      "start_page": 70,
      "end_page": 70,
      "content": "",
      "keywords": [
        "references"
      ],
      "tables": []
    },
    {
      "number": "85",
      "title": "1. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P, ESC Scientific Document Group. European Society of Cardiology: cardio",
      "start_page": 70,
      "end_page": 70,
      "content": "",
      "keywords": [
        "gale",
        "maniadakis",
        "society",
        "townsend",
        "cardiology",
        "flather",
        "wright",
        "scientific",
        "document",
        "blum",
        "wilkins",
        "grobbee",
        "group",
        "european",
        "timmis",
        "vardas",
        "pinto",
        "cardio"
      ],
      "tables": []
    },
    {
      "number": "86",
      "title": "6. Ector H, Rickards AF, Kappenberger L, Linde C, Vardas P, Oto A, Santini M, Sutton R, Working Group on Cardiac Pacing. The World Survey of Cardiac Pacing and Implantable Cardioverter Defibrillators:",
      "start_page": 70,
      "end_page": 72,
      "content": "ESC Guidelines 71\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 30. Brignole M, Menozzi C, Gianfranchi L, Oddone D, Lolli G, Bertulla A. Neurally mediated syncope detected by carotid sinus massage and head-up tilt test in sick sinus syndrome.  Am J Cardiol  1991; 68 :1032 \u0002 1036. 31. Brignole M, Deharo JC, De Roy L, Menozzi C, Blommaert D, Dabiri L, Ruf J, Guieu R. Syncope due to idiopathic paroxysmal atrioventricular block: long-term follow-up of a distinct form of atrioventricular block.  J Am Coll Cardiol 2011; 58 :167 \u0002 173. 32. Deharo JC, Brignole M, Guieu R. Adenosine hypersensitivity and atrioventricular block.  Herzschrittmacherther Elektrophysiol  2018; 29 :166 \u0002 170. 33. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, ESC Committee for Practice Guidelines. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchroniza- tion therapy of the European Society of Cardiology (ESC). Developed in collabo- ration with the European Heart Rhythm Association (EHRA).  Eur Heart J 2013; 34 :2281 \u0002 2329. 34. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D’Avila ALR, Deharo JC, Glikson M, Israel C, Lau CAR, Leclercq C, Love C, Nielsen JC, Vernooy K, Reviewers, Dagres NRC, Boveda SRC, Butter C, Marijon E, Braunschweig F, Mairesse GH, Gleva M, Defaye P, Zanon F, Lopez-Cabanillas N, Guerra JM, Vassilikos VP, Martins Oliveira M. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS).  Europace  2021;doi: 10.1093/europace/euaa367. 35. Belott P, Reynolds D. Permanent pacemaker and implantable cardioverter- defibrillator implantation in adults. In: Ellenbogen KA, Wilcoff BL, Kay NG, Lau CP, Auricchio A, eds.  Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy . 5th ed. Elsevier; 2017. p631 \u0002 691. 36. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 1999; 99 :2993 \u0002 3001. 37. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynch- ronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363 :2385 \u0002 2395. 38. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114 :2766 \u0002 2772. 39. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure.  N Engl J Med  2005; 352 :1539 \u0002 1549. 40. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events.  N Engl J Med  2009; 361 :1329 \u0002 1338. 41. Verma N, Knight BP. Update in cardiac pacing.  Arrhythm Electrophysiol Rev 2019; 8 :228 \u0002 233. 42. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren JW, Dandamudi G, Vijayaraman P. Clinical outcomes of His bundle pacing com- pared to right ventricular pacing.  J Am Coll Cardiol  2018; 71 :2319 \u0002 2330. 43. Bhatt AG, Musat DL, Milstein N, Pimienta J, Flynn L, Sichrovsky T, Preminger MW, Mittal S. The efficacy of his bundle pacing: lessons learned from implemen- tation for the first time at an experienced electrophysiology center.  JACC Clin Electrophysiol  2018; 4 :1397 \u0002 1406. 44. Ali N, Keene D, Arnold A, Shun-Shin M, Whinnett ZI, Afzal Sohaib SM. His bun- dle pacing: a new frontier in the treatment of heart failure.  Arrhythm Electrophysiol Rev  2018; 7 :103 \u0002 110. 45. Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C, Steinwender C, Brugada J, Lloyd M, Roberts PR, Sagi V, Hummel J, Bongiorni MG, Knops RE, Ellis CR, Gornick CC, Bernabei MA, Laager V, Stromberg K, Williams ER, Hudnall JH, Ritter P, Micra Transcatheter Pacing Study Group. A leadless intracardiac transcatheter pacing system. N Engl J Med 2016; 374 :533 \u0002 541. 46. Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, Friedman PA, Estes NA 3rd, Ip J, Niazi I, Plunkitt K, Banker R, Porterfield J, Ip JE, Dukkipati SR, Leadless II Study Investigators. Percutaneous implantation of an entirely intra- cardiac leadless pacemaker.  N Engl J Med  2015; 373 :1125 \u0002 1135. 47. Knops RE, Tjong FV, Neuzil P, Sperzel J, Miller MA, Petru J, Simon J, Sediva L, de Groot JR, Dukkipati SR, Koruth JS, Wilde AA, Kautzner J, Reddy VY. Chronic\nperformance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial.  J Am Coll Cardiol  2015; 65 :1497 \u0002 1504. 48. Sperzel J, Defaye P, Delnoy PP, Garcia Guerrero JJ, Knops RE, Tondo C, Deharo JC, Wong T, Neuzil P. Primary safety results from the LEADLESS Observational Study.  Europace  2018; 20 :1491 \u0002 1497. 49. Roberts PR, Clementy N, Al Samadi F, Garweg C, Martinez-Sande JL, Iacopino S, Johansen JB, Vinolas Prat X, Kowal RC, Klug D, Mont L, Steffel J, Li S, Van Osch D, El-Chami MF. A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm 2017; 14 :1375 \u0002 1379. 50. El-Chami MF, Al-Samadi F, Clementy N, Garweg C, Martinez-Sande JL, Piccini JP, Iacopino S, Lloyd M, Vinolas Prat X, Jacobsen MD, Ritter P, Johansen JB, Tondo C, Liu F, Fagan DH, Eakley AK, Roberts PR. Updated performance of the Micra trans- catheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control.  Heart Rhythm  2018; 15 :1800 \u0002 1807. 51. Ovsyshcher I, Guetta V, Bondy C, Porath A. First derivative of right ventricular pressure, dP/dt, as a sensor for a rate adaptive VVI pacemaker: initial experience. Pacing Clin Electrophysiol  1992; 15 :211 \u0002 218. 52. Lau CP, Butrous GS, Ward DE, Camm AJ. Comparison of exercise performance of six rate-adaptive right ventricular cardiac pacemakers.  Am J Cardiol  1989; 63 :833 \u0002 838. 53. Lau CP, Antoniou A, Ward DE, Camm AJ. Initial clinical experience with a minute ventilation sensing rate modulated pacemaker: improvements in exercise capacity and symptomatology.  Pacing Clin Electrophysiol  1988; 11 :1815 \u0002 1822. 54. Benditt DG, Mianulli M, Fetter J, Benson DW Jr, Dunnigan A, Molina E, Gornick CC, Almquist A. Single-chamber cardiac pacing with activity-initiated chrono- tropic response: evaluation by cardiopulmonary exercise testing.  Circulation 1987; 75 :184 \u0002 191. 55. Landzberg JS, Franklin JO, Mahawar SK, Himelman RB, Botvinick EH, Schiller NB, Springer MJ, Griffin JC. Benefits of physiologic atrioventricular synchronization for pacing with an exercise rate response.  Am J Cardiol  1990; 66 :193 \u0002 197. 56. Iwase M, Hatano K, Saito F, Kato K, Maeda M, Miyaguchi K, Aoki T, Yokota M, Hayashi H, Saito H, Murase M. Evaluation by exercise Doppler echocardiography of maintenance of cardiac output during ventricular pacing with or without chro- notropic response.  Am J Cardiol  1989; 63 :934 \u0002 938. 57. Buckingham TA, Woodruff RC, Pennington DG, Redd RM, Janosik DL, Labovitz AJ, Graves R, Kennedy HL. Effect of ventricular function on the exercise hemo- dynamics of variable rate pacing.  J Am Coll Cardiol  1988; 11 :1269 \u0002 1277. 58. Padeletti L, Pieragnoli P, Di Biase L, Colella A, Landolina M, Moro E, Orazi S, Vicentini A, Maglia G, Pensabene O, Raciti G, Barold SS. Is a dual-sensor pace- maker appropriate in patients with sino-atrial disease? Results from the DUSISLOG study.  Pacing Clin Electrophysiol  2006; 29 :34 \u0002 40. 59. Nowak B, Misselwitz B, Expert committee ‘Pacemaker Institute of Quality Assurance Hessen’, Erdogan A, Funck R, Irnich W, Israel CW, Olbrich HG, Schmidt H, Sperzel J, Zegelman M. Do gender differences exist in pacemaker implantation?—results of an obligatory external quality control program. Europace  2010; 12 :210 \u0002 215. 60. Mohamed MO, Volgman AS, Contractor T, Sharma PS, Kwok CS, Rashid M, Martin GP, Barker D, Patwala A, Mamas MA. Trends of sex differences in out- comes of cardiac electronic device implantations in the United States.  Can J Cardiol  2020; 36 :69 \u0002 78. 61. Moore K, Ganesan A, Labrosciano C, Heddle W, McGavigan A, Hossain S, Horton D, Hariharaputhiran S, Ranasinghe I. Sex differences in acute complica- tions of cardiac implantable electronic devices: implications for patient safety.  J Am Heart Assoc  2019; 8 :e010869. 62. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG. 2018 ESC Guidelines for the diagnosis and management of syn- cope.  Eur Heart J  2018; 39 :1883 \u0002 1948. 63. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).  Eur Heart J  2015; 36 :2793 \u0002 2867. 64. Kaess BM, Andersson C, Duncan MS, Larson MG, Aasbjerg K, Gislason GH, Torp-Pedersen C, Vasan RS. Familial clustering of cardiac conduction defects and pacemaker insertion.  Circ Arrhythm Electrophysiol  2019; 12 :e007150. 65. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies.  Heart Rhythm 2011; 8 :1308 \u0002 1339.\n72 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 66. Kerr SR, Pearce MS, Brayne C, Davis RJ, Kenny RA. Carotid sinus hypersensitivity in asymptomatic older persons: implications for diagnosis of syncope and falls. Arch Intern Med  2006; 166 :515 \u0002 520. 67. Puggioni E, Guiducci V, Brignole M, Menozzi C, Oddone D, Donateo P, Croci F, Solano A, Lolli G, Tomasi C, Bottoni N. Results and complications of the carotid sinus massage performed according to the ‘method of symptoms’.  Am J Cardiol 2002; 89 :599 \u0002 601. 68. Brignole M, Ungar A, Casagranda I, Gulizia M, Lunati M, Ammirati F, Del Rosso A, Sasdelli M, Santini M, Maggi R, Vitale E, Morrione A, Francese GM, Vecchi MR, Giada F. Prospective multicentre systematic guideline-based management of patients referred to the Syncope Units of general hospitals.  Europace  2010; 12 :109 \u0002 118. 69. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Brignole M. Clinical context and outcome of carotid sinus syndrome diagnosed by means of the ‘method of symptoms’.  Europace  2014; 16 :928 \u0002 934. 70. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Wieling W, Brignole M. Assessment of the vasodepressor reflex in carotid sinus syndrome. Circ Arrhythm Electrophysiol  2014; 7 :505 \u0002 510. 71. Mangrum JM, DiMarco JP. The evaluation and management of bradycardia.  N Engl J Med  2000; 342 :703 \u0002 709. 72. Sutton R. Reflex atrioventricular block.  Front Cardiovasc Med  2020; 7 :48. 72a.Da Costa D, Brady WJ, Edhouse J. Bradycardias and atrioventricular conduction block.  BMJ  2002; 324 :535 \u0002 538. 73. Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, Cantillon DJ, Dilaveris P, Dubner SJ, El-Sherif N, Krol J, Kurpesa M, La Rovere MT, Lobodzinski SS, Locati ET, Mittal S, Olshansky B, Piotrowicz E, Saxon L, Stone PH, Tereshchenko L, Turitto G, Wimmer NJ, Verrier RL, Zareba W, Piotrowicz R. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and exter- nal cardiac monitoring/telemetry.  Heart Rhythm  2017; 14 :e55-e96. 74. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management.  Circulation  2011; 123 :1010 \u0002 1020. 75. Savonen KP, Kiviniemi V, Laukkanen JA, Lakka TA, Rauramaa TH, Salonen JT, Rauramaa R. Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart disease.  Eur Heart J  2008; 29 :1896 \u0002 1902. 76. Byrne JM, Marais HJ, Cheek GA. Exercise-induced complete heart block in a patient with chronic bifascicular block.  J Electrocardiol  1994; 27 :339 \u0002 342. 77. Wissocq L, Ennezat PV, Mouquet F. Exercise-induced high-degree atrioventricu- lar block.  Arch Cardiovasc Dis  2009; 102 :733 \u0002 735. 78. Woelfel AK, Simpson RJ Jr, Gettes LS, Foster JR. Exercise-induced distal atrio- ventricular block.  J Am Coll Cardiol  1983; 2 :578 \u0002 581. 79. Sumiyoshi M, Nakata Y, Yasuda M, Tokano T, Ogura S, Nakazato Y, Yamaguchi H. Clinical and electrophysiologic features of exercise-induced atrioventricular block.  Am Heart J  1996; 132 :1277 \u0002 1281. 80. Oliveros RA, Seaworth J, Weiland FL, Boucher CA. Intermittent left anterior hemiblock during treadmill exercise test. Correlation with coronary arteriogram. Chest  1977; 72 :492 \u0002 494. 81. Bharati S, Dhingra RC, Lev M, Towne WD, Rhimtoola SH, Rosen KM. Conduction system in a patient with Prinzmetal’s angina and transient atrioven- tricular block.  Am J Cardiol  1977; 39 :120 \u0002 125. 82. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the diagnosis and manage- ment of chronic coronary syndromes.  Eur Heart J  2019; 41 :407 \u0002 477. 83. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardi- omyopathy and mild and moderate left ventricular systolic dysfunction. Circulation  2017; 135 :2106 \u0002 2115. 84. Kazmirczak F, Chen KA, Adabag S, von Wald L, Roukoz H, Benditt DG, Okasha O, Farzaneh-Far A, Markowitz J, Nijjar PS, Velangi PS, Bhargava M, Perlman D, Duval S, Akcakaya M, Shenoy C. Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis.  Circ Arrhythm Electrophysiol  2019; 12 :e007488. 85. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra M, Barison A, Di Bella G. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study.  J Am Coll Cardiol 2017; 70 :1977 \u0002 1987. 86. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommen- dations.  J Am Coll Cardiol  2018; 72 :3158 \u0002 3176. 87. Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival.  Chest  2017; 151 :139 \u0002 148.\n",
      "keywords": [
        "linde",
        "older",
        "defibrillators",
        "bradycardia",
        "crt",
        "sudden cardiac death",
        "genetic",
        "guideline",
        "world",
        "pacemaker",
        "systolic",
        "gender",
        "age",
        "cardioverter",
        "sutton",
        "tilt test",
        "santini",
        "ector",
        "syncope",
        "survey",
        "carotid",
        "rickards",
        "sex",
        "implantable",
        "echocardiography",
        "group",
        "cardiac",
        "ecg",
        "working",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "87",
      "title": "88. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults.  Circ Arrhythm Electrophysiol  2011; 4 :303 \u0002 ",
      "start_page": 72,
      "end_page": 75,
      "content": "ESC Guidelines 73\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 112. Sulke N, Sugihara C, Hong P, Patel N, Freemantle N. The benefit of a remotely monitored implantable loop recorder as a first line investigation in unexplained syncope: the EaSyAS II trial.  Europace  2016; 18 :912 \u0002 918. 113. Gann D, Tolentino A, Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia: a long-term follow-up study. Ann Intern Med 1979; 90 :24 \u0002 29. 114. Menozzi C, Brignole M, Alboni P, Boni L, Paparella N, Gaggioli G, Lolli G. The natural course of untreated sick sinus syndrome and identification of the varia- bles predictive of unfavorable outcome.  Am J Cardiol  1998; 82 :1205 \u0002 1209. 115. McAnulty JH, Rahimtoola SH, Murphy E, DeMots H, Ritzmann L, Kanarek PE, Kauffman S. Natural history of ‘high-risk’ bundle-branch block: final report of a prospective study.  N Engl J Med  1982; 307 :137 \u0002 143. 116. Gronda M, Magnani A, Occhetta E, Sauro G, D’Aulerio M, Carfora A, Rossi P. Electrophysiological study of atrio-ventricular block and ventricular conduction defects. Prognostic and therapeutical implications. G Ital Cardiol 1984; 14 :768 \u0002 773. 117. Bergfeldt L, Edvardsson N, Rosenqvist M, Vallin H, Edhag O. Atrioventricular block progression in patients with bifascicular block assessed by repeated elec- trocardiography and a bradycardia-detecting pacemaker. Am J Cardiol 1994; 74 :1129 \u0002 1132. 118. Kaul U, Dev V, Narula J, Malhotra AK, Talwar KK, Bhatia ML. Evaluation of patients with bundle branch block and ‘unexplained’ syncope: a study based on comprehensive electrophysiologic testing and ajmaline stress.  Pacing Clin Electrophysiol  1988; 11 :289 \u0002 297. 119. Moya A, Garcia-Civera R, Croci F, Menozzi C, Brugada J, Ammirati F, Del Rosso A, Bellver-Navarro A, Garcia-Sacristan J, Bortnik M, Mont L, Ruiz-Granell R, Navarro X. Diagnosis, management, and outcomes of patients with syncope and bundle branch block.  Eur Heart J  2011; 32 :1535 \u0002 1541. 120. Twidale N, Heddle WF, Tonkin AM. Procainamide administration during elec- trophysiology study—utility as a provocative test for intermittent atrioventricu- lar block.  Pacing Clin Electrophysiol  1988; 11 :1388 \u0002 1397. 121. Scheinman MM, Peters RW, Suave MJ, Desai J, Abbott JA, Cogan J, Wohl B, Williams K. Value of the H \u0002 Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. Am J Cardiol 1982; 50 :1316 \u0002 1322. 122. Roca-Luque I, Oristrell G, Francisco-Pasqual J, Rodriguez-Garcia J, Santos- Ortega A, Martin-Sanchez G, Rivas-Gandara N, Perez-Rodon J, Ferreira- Gonzalez I, Garcia-Dorado D, Moya-Mitjans A. Predictors of positive electrophysiological study in patients with syncope and bundle branch block: PR interval and type of conduction disturbance.  Clin Cardiol  2018; 41 :1537 \u0002 1542. 123. Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, Errazquin F, Beiras J, Bottoni N, Donateo P. Mechanism of syncope in patients with bun- dle branch block and negative electrophysiological test. Circulation 2001; 104 :2045 \u0002 2050. 124. Rubenstein JJ, Schulman CL, Yurchak PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome.  Circulation  1972; 46 :5 \u0002 13. 125. Short DS. The syndrome of alternating bradycardia and tachycardia.  Br Heart J 1954; 16 :208 \u0002 214. 126. Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bradycardia for subsequent pacemaker implantation and mortality in patients >60 years of age.  Am J Cardiol  2011; 108 :857 \u0002 861. 127. Nielsen JC, Thomsen PE, Hojberg S, Moller M, Vesterlund T, Dalsgaard D, Mortensen LS, Nielsen T, Asklund M, Friis EV, Christensen PD, Simonsen EH, Eriksen UH, Jensen GV, Svendsen JH, Toff WD, Healey JS, Andersen HR, DANPACE Investigators. A comparison of single-lead atrial pacing with dual- chamber pacing in sick sinus syndrome.  Eur Heart J  2011; 32 :686 \u0002 696. 128. Breivik K, Ohm OJ, Segadal L. Sick sinus syndrome treated with permanent pacemaker in 109 patients. A follow-up study. Acta Med Scand 1979; 206 :153 \u0002 159. 129. Hartel G, Talvensaari T. Treatment of sinoatrial syndrome with permanent car- diac pacing in 90 patients.  Acta Med Scand  1975; 198 :341 \u0002 347. 130. Rasmussen K. Chronic sinus node disease: natural course and indications for pacing.  Eur Heart J  1981; 2 :455 \u0002 459. 131. Sasaki Y, Shimotori M, Akahane K, Yonekura H, Hirano K, Endoh R, Koike S, Kawa S, Furuta S, Homma T. Long-term follow-up of patients with sick sinus syndrome: a comparison of clinical aspects among unpaced, ventricular inhibited paced, and physiologically paced groups. Pacing Clin Electrophysiol 1988; 11 :1575 \u0002 1583. 132. Senturk T, Xu H, Puppala K, Krishnan B, Sakaguchi S, Chen LY, Karim R, Dickinson O, Benditt DG. Cardiac pauses in competitive athletes: a systematic review examining the basis of current practice recommendations.  Europace 2016; 18 :1873 \u0002 1879. 133. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R, International Study on Syncope of Uncertain Etiology Investigators. Pacemaker therapy in patients with\nneurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial.  Circulation 2012; 125 :2566 \u0002 2571. 134. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W, Andresen D, Benditt DG, Vardas P, International Study on Syncope of Uncertain Etiology Group. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope.  Eur Heart J  2006; 27 :1085 \u0002 1092. 135. Asseman P, Berzin B, Desry D, Vilarem D, Durand P, Delmotte C, Sarkis EH, Lekieffre J, Thery C. Persistent sinus nodal electrograms during abnormally pro- longed postpacing atrial pauses in sick sinus syndrome in humans: sinoatrial block vs overdrive suppression.  Circulation  1983; 68 :33 \u0002 41. 136. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis AB, Davies DW, Day JD, d’Avila A, Natasja de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T, Document Reviewers. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical abla- tion of atrial fibrillation.  Europace  2018; 20 :e1 \u0002 e160. 137. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, Yu RH, Tang RB, Guo XY, Yan XL, Nie JG, Du X, Dong JZ, Ma CS. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia \u0002 bradycardia syndrome?  Pacing Clin Electrophysiol  2014; 37 :403 \u0002 411. 138. Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M, Narui R, Ito K, Tanigawa S, Yamashita S, Tokuda M, Matsuo S, Shibayama K, Miyanaga S, Date T, Sugimoto K, Yoshimura M. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up.  Europace  2014; 16 :208 \u0002 213. 139. Jackson LR, 2nd, Rathakrishnan B, Campbell K, Thomas KL, Piccini JP, Bahnson T, Stiber JA, Daubert JP. Sinus node dysfunction and atrial fibrillation: a reversi- ble phenomenon?  Pacing Clin Electrophysiol  2017; 40 :442 \u0002 450. 140. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000; 342 :1385 \u0002 1391. 141. Healey JS, Toff WD, Lamas GA, Andersen HR, Thorpe KE, Ellenbogen KA, Lee KL, Skene AM, Schron EB, Skehan JD, Goldman L, Roberts RS, Camm AJ, Yusuf S, Connolly SJ. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data.  Circulation  2006; 114 :11 \u0002 17. 142. Ross RA, Kenny RA. Pacemaker syndrome in older people.  Age Ageing 2000; 29 :13 \u0002 15. 143. Mitsuoka T, Kenny RA, Yeung TA, Chan SL, Perrins JE, Sutton R. Benefits of dual chamber pacing in sick sinus syndrome.  Br Heart J  1988; 60 :338 \u0002 347. 144. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick D, Sheldon T, Lamas GA, Search AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction Trial. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease.  N Engl J Med  2007; 357 :1000 \u0002 1008. 145. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350 :1210 \u0002 1216. 146. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet  1994; 344 :1523 \u0002 1528. 147. Kristensen L, Nielsen JC, Mortensen PT, Pedersen OL, Pedersen AK, Andersen HR. Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome. Heart  2004; 90 :661 \u0002 666. 148. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A, Dual Chamber VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implant- able defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.  JAMA  2002; 288 :3115 \u0002 3123. 149. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, Benjamin EJ, Vasan RS, Wang TJ. Long-term outcomes in individuals with pro- longed PR interval or first-degree atrioventricular block. JAMA 2009; 301 :2571 \u0002 2577. 150. Nielsen JC, Thomsen PE, Hojberg S, Moller M, Riahi S, Dalsgaard D, Mortensen LS, Nielsen T, Asklund M, Friis EV, Christensen PD, Simonsen EH, Eriksen UH,\n74 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Jensen GV, Svendsen JH, Toff WD, Healey JS, Andersen HR, DANPACE Investigators. Atrial fibrillation in patients with sick sinus syndrome: the associa- tion with PQ-interval and percentage of ventricular pacing. Europace 2012; 14 :682 \u0002 689. 151. Auricchio A, Ellenbogen KA. Reducing ventricular pacing frequency in patients with atrioventricular block: is it time to change the current pacing paradigm? Circ Arrhythm Electrophysiol  2016; 9 :e004404. 152. Shurrab M, Healey JS, Haj-Yahia S, Kaoutskaia A, Boriani G, Carrizo A, Botto G, Newman D, Padeletti L, Connolly SJ, Crystal E. Reduction in unnecessary ven- tricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis.  Europace  2017; 19 :282 \u0002 288. 153. Jankelson L, Bordachar P, Strik M, Ploux S, Chinitz L. Reducing right ventricular pacing burden: algorithms, benefits, and risks.  Europace  2019; 21 :539 \u0002 547. 154. Pascale P, Pruvot E, Graf D. Pacemaker syndrome during managed ventricular pacing mode: what is the mechanism? J Cardiovasc Electrophysiol 2009; 20 :574 \u0002 576. 155. Mansour F, Khairy P. Electrical storm due to managed ventricular pacing.  Heart Rhythm  2012; 9 :842 \u0002 843. 156. Sekita G, Hayashi H, Nakazato Y, Daida H. Ventricular fibrillation induced by short \u0002 long \u0002 short sequence during managed ventricular pacing.  J Cardiovasc Electrophysiol  2011; 22 :1181. 157. Vavasis C, Slotwiner DJ, Goldner BG, Cheung JW. Frequent recurrent polymor- phic ventricular tachycardia during sleep due to managed ventricular pacing. Pacing Clin Electrophysiol  2010; 33 :641 \u0002 644. 158. van Mechelen R, Schoonderwoerd R. Risk of managed ventricular pacing in a patient with heart block.  Heart Rhythm  2006; 3 :1384 \u0002 1385. 159. Stockburger M, Boveda S, Moreno J, Da Costa A, Hatala R, Brachmann J, Butter C, Garcia Seara J, Rolando M, Defaye P. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.  Eur Heart J  2015; 36 :151 \u0002 157. 160. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke.  N Engl J Med  2012; 366 :120 \u0002 129. 161. Munawar DA, Mahajan R, Agbaedeng TA, Thiyagarajah A, Twomey DJ, Khokhar K, O’Shea C, Young GD, Roberts-Thomson KC, Munawar M, Lau DH, Sanders P. Implication of ventricular pacing burden and atrial pacing therapies on the progression of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.  Heart Rhythm  2019; 16 :1204 \u0002 1214. 162. Padeletti L, Purerfellner H, Mont L, Tukkie R, Manolis AS, Ricci R, Inama G, Serra P, Scheffer MG, Martins V, Warman EN, Vimercati M, Grammatico A, Boriani G, MINERVA Investigators. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: results from the MINERVA randomized multicenter international trial.  Heart Rhythm  2015; 12 :1717 \u0002 1725. 163. Pujol-Lopez M, San Antonio R, Tolosana JM, Mont L. Programming pacemakers to reduce and terminate atrial fibrillation.  Curr Cardiol Rep  2019; 21 :127. 164. Boriani G, Tukkie R, Manolis AS, Mont L, Purerfellner H, Santini M, Inama G, Serra P, de Sousa J, Botto GL, Mangoni L, Grammatico A, Padeletti L, MINERVA Investigators. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhyth- mias: the MINERVA randomized multicentre international trial.  Eur Heart J 2014; 35 :2352 \u0002 2362. 165. Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol  2019; 42 :970 \u0002 979. 166. Stockburger M, Gomez-Doblas JJ, Lamas G, Alzueta J, Fernandez-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-Lopez F, de Teresa E. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF).  Eur J Heart Fail  2011; 13 :633 \u0002 641. 167. Stockburger M, Defaye P, Boveda S, Stancak B, Lazarus A, Sipotz J, Nardi S, Rolando M, Moreno J. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity—a sub-study of the ANSWER trial.  Europace  2016; 18 :739 \u0002 746. 168. Thibault B, Simpson C, Gagne CE, Blier L, Senaratne M, McNicoll S, Stuglin C, Williams R, Pinter A, Khaykin Y, Nitzsche R. Impact of AV conduction disorders on SafeR mode performance. Pacing Clin Electrophysiol 2009; 32 Suppl 1 :S231 \u0002 235. 169. Thibault B, Ducharme A, Baranchuk A, Dubuc M, Dyrda K, Guerra PG, Macle L, Mondesert B, Rivard L, Roy D, Talajic M, Andrade J, Nitzsche R, Khairy P, CAN-SAVE R Study Investigators. Very low ventricular pacing rates can be achieved safely in a heterogeneous pacemaker population and provide clinical benefits: the CANadian Multi-Centre Randomised Study-Spontaneous\nAtrioVEntricular Conduction pReservation (CAN-SAVE R)  Trial. J Am Heart Assoc  2015; 4 :e001983 170. Bellocci F, Spampinato A, Ricci R, Puglisi A, Capucci A, Dini P, Boriani G, Botto G, Curnis A, Moracchini PV, Nicotra G, Lisi F, Nigro P. Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence: a prospective, multicentre study.  Europace  1999; 1 :220 \u0002 225. 171. Santini M, Ricci R, Puglisi A, Mangiameli S, Proclemer A, Menozzi C, De Fabrizio G, Leoni G, Lisi F, De Seta F. Long-term haemodynamic and antiarrhythmic benefits of DDIR versus DDI pacing mode in sick sinus syndrome and chrono- tropic incompetence.  G Ital Cardiol  1997; 27 :892 \u0002 900. 172. Capucci A, Boriani G, Specchia S, Marinelli M, Santarelli A, Magnani B. Evaluation by cardiopulmonary exercise test of DDDR versus DDD pacing. Pacing Clin Electrophysiol  1992; 15 :1908 \u0002 1913. 173. Lamas GA, Knight JD, Sweeney MO, Mianulli M, Jorapur V, Khalighi K, Cook JR, Silverman R, Rosenthal L, Clapp-Channing N, Lee KL, Mark DB. Impact of rate- modulated pacing on quality of life and exercise capacity—evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT).  Heart Rhythm  2007; 4 :1125 \u0002 1132. 174. Hocini M, Sanders P, Deisenhofer I, Jais P, Hsu LF, Scavee C, Weerasoriya R, Raybaud F, Macle L, Shah DC, Garrigue S, Le Metayer P, Clementy J, Haissaguerre M. Reverse remodeling of sinus node function after catheter abla- tion of atrial fibrillation in patients with prolonged sinus pauses.  Circulation 2003; 108 :1172 \u0002 1175. 175. Mymin D, Mathewson FA, Tate RB, Manfreda J. The natural history of primary first-degree atrioventricular heart block.  N Engl J Med  1986; 315 :1183 \u0002 1187. 176. Barold SS, Ilercil A, Leonelli F, Herweg B. First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & conse- quences during cardiac resynchronization. J Interv Card Electrophysiol 2006; 17 :139 \u0002 152. 177. Shaw DB, Gowers JI, Kekwick CA, New KH, Whistance AW. Is Mobitz type I atrioventricular block benign in adults?  Heart  2004; 90 :169 \u0002 174. 178. Coumbe AG, Naksuk N, Newell MC, Somasundaram PE, Benditt DG, Adabag S. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block.  Heart  2013; 99 :334 \u0002 338. 179. Strasberg B, Amat YLF, Dhingra RC, Palileo E, Swiryn S, Bauernfeind R, Wyndham C, Rosen KM. Natural history of chronic second-degree atrioventric- ular nodal block.  Circulation  1981; 63 :1043 \u0002 1049. 180. Dhingra RC, Denes P, Wu D, Chuquimia R, Rosen KM. The significance of sec- ond degree atrioventricular block and bundle branch block. Observations regarding site and type of block.  Circulation  1974; 49 :638 \u0002 646. 181. Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block.  N Engl J Med  2005; 353 :145 \u0002 155. 182. Castelnuovo E, Stein K, Pitt M, Garside R, Payne E. The effectiveness and cost- effectiveness of dual-chamber pacemakers compared with single-chamber pace- makers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation.  Health Technol Assess  2005; 9 :iii, xi \u0002 xiii, 1 \u0002 246. 183. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107 :2932 \u0002 2937. 184. Nahlawi M, Waligora M, Spies SM, Bonow RO, Kadish AH, Goldberger JJ. Left ventricular function during and after right ventricular pacing.  J Am Coll Cardiol 2004; 44 :1883 \u0002 1888. 185. Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing.  J Am Coll Cardiol  2006; 47 :282 \u0002 288. 186. Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, Gislason G, Risum N, Torp-Pedersen C, Kober L, Kragholm KH. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.  Eur Heart J  2019; 40 :3641 \u0002 3648. 187. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, Frankel DS. Incidence and predictors of right ventricular pacing-induced cardiomyop- athy.  Heart Rhythm  2014; 11 :1619 \u0002 1625. 188. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM, Saliba WI, Varma N, Wilkoff BL, Cantillon DJ. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function.  Heart Rhythm  2016; 13 :2272 \u0002 2278. 189. Khurshid S, Obeng-Gyimah E, Supple GE, Schaller R, Lin D, Owens AT, Epstein AE, Dixit S, Marchlinski FE, Frankel DS. Reversal of pacing-induced cardiomyop- athy following cardiac resynchronization therapy.  JACC Clin Electrophysiol 2018; 4 :168 \u0002 177.\nESC Guidelines 75\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 190. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368 :1585 \u0002 1593. 191. Pitcher D, Papouchado M, James MA, Rees JR. Twenty four hour ambulatory electrocardiography in patients with chronic atrial fibrillation.  Br Med J (Clin Res Ed)  1986; 292 :594. 192. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review.  Circ Arrhythm Electrophysiol  2012; 5 :68 \u0002 76. 193. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344 :1043 \u0002 1051. 194. Garcia B, Clementy N, Benhenda N, Pierre B, Babuty D, Olshansky B, Fauchier L. Mortality after atrioventricular nodal radiofrequency catheter ablation with permanent ventricular pacing in atrial fibrillation: outcomes from a controlled nonrandomized study.  Circ Arrhythm Electrophysiol  2016; 9 . 195. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, Quartieri F, Cal \u0004 o L, Ungar A, Mont L. A randomized controlled trial of atrio- ventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018; 39 :3999 \u0002 4008. 196. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA, PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16 :1160 \u0002 1165. 197. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. Benefits of per- manent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ven- tricular ejection fraction.  J Am Heart Assoc  2017; 6 :e005309. 198. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing.  Europace  2017; 19 :iv10-iv16. 199. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His \u0002 Purkinje activation.  Circulation  2000; 101 :869 \u0002 877. 200. Occhetta E, Bortnik M, Magnani A, Francalacci G, Piccinino C, Plebani L, Marino P. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing.  J Am Coll Cardiol  2006; 47 :1938 \u0002 1945. 201. Lau CP, Rushby J, Leigh-Jones M, Tam CY, Poloniecki J, Ingram A, Sutton R, Camm AJ. Symptomatology and quality of life in patients with rate-responsive pacemakers: a double-blind, randomized, crossover study. Clin Cardiol 1989; 12 :505 \u0002 512. 202. Leung SK, Lau CP. Developments in sensor-driven pacing.  Cardiol Clin 2000; 18 :113 \u0002 155, ix. 203. Oto MA, Muderrisoglu H, Ozin MB, Korkmaz ME, Karamehmetoglu A, Oram A, Oram E, Ugurlu S. Quality of life in patients with rate responsive pace- makers: a randomized, cross-over study. Pacing Clin Electrophysiol 1991; 14 :800 \u0002 806. 204. Proietti R, Manzoni G, Di Biase L, Castelnuovo G, Lombardi L, Fundaro C, Vegliante N, Pietrabissa G, Santangeli P, Canby RA, Sagone A, Viecca M, Natale A. Closed loop stimulation is effective in improving heart rate and blood pres- sure response to mental stress: report of a single-chamber pacemaker study in patients with chronotropic incompetent atrial fibrillation. Pacing Clin Electrophysiol  2012; 35 :990 \u0002 998. 205. Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III?  Pacing Clin Electrophysiol  1996; 19 :747 \u0002 751. 206. Brecker SJ, Xiao HB, Sparrow J, Gibson DG. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet 1992; 340 :1308 \u0002 1312. 207. Carroz P, Delay D, Girod G. Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block.  Europace  2010; 12 :594 \u0002 596. 208. Englund A, Bergfeldt L, Rehnqvist N, Astrom H, Rosenqvist M. Diagnostic value of programmed ventricular stimulation in patients with bifascicular block: a pro- spective study of patients with and without syncope.  J Am Coll Cardiol 1995; 26 :1508 \u0002 1515. 209. Morady F, Higgins J, Peters RW, Schwartz AB, Shen EN, Bhandari A, Scheinman MM, Sauve MJ. Electrophysiologic testing in bundle branch block and unex- plained syncope.  Am J Cardiol  1984; 54 :587 \u0002 591. 210. Tabrizi F, Rosenqvist M, Bergfeldt L, Englund A. Long-term prognosis in patients with bifascicular block—the predictive value of noninvasive and invasive assess- ment.  J Intern Med  2006; 260 :31 \u0002 38.\n",
      "keywords": [
        "myocarditis",
        "ejection fraction",
        "older",
        "class i",
        "bradycardia",
        "giant",
        "pacemaker",
        "systolic",
        "tachycardia",
        "sarcoidosis",
        "age",
        "circ",
        "syncope",
        "ventricular tachycardia",
        "causes",
        "atrioventricular",
        "aged",
        "lehtonen",
        "arrhythm",
        "atrial fibrillation",
        "young",
        "cardiomyopathy",
        "elderly",
        "kandolin",
        "cardiac",
        "cell",
        "heart failure",
        "block",
        "systolic dysfunction",
        "middle"
      ],
      "tables": []
    },
    {
      "number": "88",
      "title": "211. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators",
      "start_page": 75,
      "end_page": 78,
      "content": "76 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 231. Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, Morillo C, Gent M, VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA 2003; 289 :2224 \u0002 2229. 232. Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M, Vasovagal Syncope Pacing Trial Investigators. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE).  Eur Heart J  2004; 25 :1741 \u0002 1748. 233. Palmisano P, Dell’Era G, Russo V, Zaccaria M, Mangia R, Bortnik M, De Vecchi F, Giubertoni A, Patti F, Magnani A, Nigro G, Rago A, Occhetta E, Accogli M. Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in Closed-loop Stimulation multicentre, prospective, single blind, randomized study.  Europace  2018; 20 :859 \u0002 866. 234. Proclemer A, Facchin D, Feruglio GA. [Syncope of unknown origin after elec- trophysiologic study: is the treatment with pacemaker useful?].  G Ital Cardiol 1990; 20 :195 \u0002 201. 235. Raviele A, Proclemer A, Gasparini G, Di Pede F, Delise P, Piccolo E, Feruglio GA. Long-term follow-up of patients with unexplained syncope and negative electrophysiologic study.  Eur Heart J  1989; 10 :127 \u0002 132. 236. Parry SW, Steen N, Bexton RS, Tynan M, Kenny RA. Pacing in elderly recurrent fallers with carotid sinus hypersensitivity: a randomised, double-blind, placebo controlled crossover trial.  Heart  2009; 95 :405 \u0002 409. 237. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93 :1137 \u0002 1146. 238. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case \u0002 control study.  Am J Med  2009; 122 :1023 \u0002 1028. 239. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure.  N Engl J Med 2002; 347 :305 \u0002 313. 240. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjornsdottir S. Risk fac- tors, mortality, and cardiovascular outcomes in patients with type 2 diabetes.  N Engl J Med  2018; 379 :633 \u0002 644. 241. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and pat- terns in heart failure incidence: a population-based study of 4 million individuals. Lancet  2018; 391 :572 \u0002 580. 242. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bo¨hm M, Burri H, Butler J,   \u0003 Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.  Eur Heart J  2021;doi:10.1093/ eurheartj/ehab368. 243. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.  Eur J Heart Fail  2016; 18 :613 \u0002 625. 244. Olshansky B, Day JD, Sullivan RM, Yong P, Galle E, Steinberg JS. Does cardiac resynchronization therapy provide unrecognized benefit in patients with pro- longed PR intervals? The impact of restoring atrioventricular synchrony: an anal- ysis from the COMPANION Trial.  Heart Rhythm  2012; 9 :34 \u0002 39. 245. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A, Freemantle N, Cleland JG, Tavazzi L, Daubert C, CARE-HF investigators. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial.  Eur J Heart Fail 2009; 11 :699 \u0002 705. 246. Friedman DJ, Bao H, Spatz ES, Curtis JP, Daubert JP, Al-Khatib SM. Association Between a Prolonged PR interval and outcomes of cardiac resynchronization therapy: a report from the National Cardiovascular Data Registry.  Circulation 2016; 134 :1617 \u0002 1628. 247. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization.  J Am Coll Cardiol  2002; 39 :194 \u0002 201. 248. Leclercq C, Hare JM. Ventricular resynchronization: current state of the art. Circulation  2004; 109 :296 \u0002 299. 249. Patel N, Viles-Gonzalez J, Agnihotri K, Arora S, Patel NJ, Aneja E, Shah M, Badheka AO, Pothineni NV. Frequency of in-hospital adverse outcomes and cost\nutilization associated with cardiac resynchronization therapy defibrillator implanta- tion in the United States.  J Cardiovasc Electrophysiol  2018; 29 :1425 \u0002 1435. 250. Khan NK, Goode KM, Cleland JG, Rigby AS, Freemantle N, Eastaugh J, Clark AL, de Silva R, Calvert MJ, Swedberg K, Komajda M, Mareev V, Follath F. Prevalence of ECG abnormalities in an international survey of patients with sus- pected or confirmed heart failure at death or discharge.  Eur J Heart Fail 2007; 9 :491 \u0002 501. 251. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The national heart failure audit for England and Wales 2008 \u0002 2009.  Heart  2011; 97 :876 \u0002 886. 252. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.  Eur J Heart Fail  2017; 19 :1270 \u0002 1279. 253. Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomstrom Lundqvist C, Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C, Margitfalvi P, Cano O, Plummer C, Sarigul NU, Sterlinski M, Linde C. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?  Eur J Heart Fail  2018; 20 :1039 \u0002 1051. 254. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, Schondube F, Wolfhard U, Bocker D, Krahnefeld O, Kirkels H. Long-term clini- cal effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay.  J Am Coll Cardiol 2002; 39 :2026 \u0002 2033. 255. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, Block M, Kirkels JH, Kramer A, Huvelle E. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay.  J Am Coll Cardiol  2003; 42 :2109 \u0002 2116. 256. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.  N Engl J Med  2001; 344 :873 \u0002 880. 257. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, McKenna W, Fitzgerald M, Deharo JC, Alonso C, Walker S, Braunschweig F, Bailleul C, Daubert JC. Long-term benefits of biventricular pacing in congestive heart fail- ure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol  2002; 40 :111 \u0002 118. 258. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure.  N Engl J Med  2002; 346 :1845 \u0002 1853. 259. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, O’Connell JB, Schroeder JS, Wheelan KR. Effects of cardiac resynchro- nization on disease progression in patients with left ventricular systolic dysfunc- tion, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.  Circulation  2004; 110 :2864 \u0002 2868. 260. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynch- ronization therapy with or without an implantable defibrillator in advanced chronic heart failure.  N Engl J Med  2004; 350 :2140 \u0002 2150. 261. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortal- ity in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase].  Eur Heart J  2006; 27 :1928 \u0002 1932. 262. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart fail- ure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.  J Am Coll Cardiol  2008; 52 :1834 \u0002 1843. 263. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok T, Linde C. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.  J Am Coll Cardiol  2009; 54 :1837 \u0002 1846. 264. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J. Cardiac- resynchronization therapy in heart failure with a narrow QRS complex.  N Engl J Med  2013; 369 :1395 \u0002 1405. 265. Goldenberg I, Kutyifa V, Moss AJ. Survival with cardiac-resynchronization ther- apy.  N Engl J Med  2014; 371 :477 \u0002 478. 266. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.  Eur Heart J 2013; 34 :3547 \u0002 3556.\nESC Guidelines 77\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 267. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P, Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC. Comparative effects of per- manent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation.  Eur Heart J  2002; 23 :1780 \u0002 1787. 268. Funck RC, Mueller HH, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg M, Wuensch D, Blanc JJ. Characteristics of a large sample of candidates for per- manent ventricular pacing included in the Biventricular Pacing for Atrio- ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace  2014; 16 :354 \u0002 362. 269. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS dura- tion on clinical event reduction with cardiac resynchronization therapy: meta- analysis of randomized controlled trials.  Arch Intern Med  2011; 171 :1454 \u0002 1462. 270. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163 :260 \u0002 267.e263. 271. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A, Ahmed FZ, Mamas MA. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials.  Heart  2015; 101 :1456 \u0002 1462. 272. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).  Circulation  2011; 123 :1061 \u0002 1072. 273. Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F, Thibault B, Wells G, Tang A. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).  Circ Heart Fail  2013; 6 :1190 \u0002 1198. 274. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block mor- phology and other predictors of outcome after cardiac resynchronization ther- apy in Medicare patients.  Circulation  2010; 122 :2022 \u0002 2030. 275. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR. Individual patient data network meta- analysis of mortality effects of implantable cardiac devices. Heart 2015; 101 :1800 \u0002 1806. 276. Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, St John Sutton M, Daubert JC. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.  Circulation  2012; 126 :822 \u0002 829. 277. Fantoni C, Kawabata M, Massaro R, Regoli F, Raffa S, Arora V, Salerno-Uriarte JA, Klein HU, Auricchio A. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system.  J Cardiovasc Electrophysiol  2005; 16 :112 \u0002 119; discussion 120 \u0002 121. 278. Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review.  Heart Rhythm  2011; 8 :1083 \u0002 1087. 279. Kutyifa V, Stockburger M, Daubert JP, Holmqvist F, Olshansky B, Schuger C, Klein H, Goldenberg I, Brenyo A, McNitt S, Merkely B, Zareba W, Moss AJ. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. Circ Arrhythm Electrophysiol 2014; 7 :645 \u0002 651. 280. Kewcharoen J, Kanitsoraphan C. Prolonged PR interval and outcome in cardiac resynchronization therapy.  Arq Bras Cardiol  2019; 113 :109 \u0002 110. 281. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J, Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial.  Eur Heart J  2015; 36 :1983 \u0002 1989. 282. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial.  J Am Coll Cardiol  2011; 57 :813 \u0002 820. 283. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM, Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data.  JAMA Intern Med  2014; 174 :1340 \u0002 1348. 284. Zweerink A, Friedman DJ, Klem I, van de Ven PM, Vink C, Biesbroek PS, Hansen SM, Emerek K, Kim RJ, van Rossum AC, Atwater BD, Nijveldt R, Allaart CP. Size Matters: Normalization of QRS duration to left ventricular dimension\nimproves prediction of long-term cardiac resynchronization therapy outcome. Circ Arrhythm Electrophysiol  2018; 11 :e006767. 285. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy.  Am J Cardiol  2011; 107 :927 \u0002 934. 286. Lee AWC, O’Regan DP, Gould J, Sidhu B, Sieniewicz B, Plank G, Warriner DR, Lamata P, Rinaldi CA, Niederer SA. Sex-dependent QRS guidelines for cardiac resynchronization therapy using computer model predictions.  Biophysical Journal 2019; 117 :2375 \u0002 2381. 287. Caputo ML, van Stipdonk A, Illner A, D’Ambrosio G, Regoli F, Conte G, Moccetti T, Klersy C, Prinzen FW, Vernooy K, Auricchio A. The definition of left bundle branch block influences the response to cardiac resynchronization therapy.  Int J Cardiol  2018; 269 :165 \u0002 169. 288. van Stipdonk AMW, Vanbelle S, Ter Horst IAH, Luermans JG, Meine M, Maass AH, Auricchio A, Prinzen FW, Vernooy K. Large variability in clinical judgement and definitions of left bundle branch block to identify candidates for cardiac resynchronisation therapy.  Int J Cardiol  2019; 286 :61 \u0002 65. 289. Tomlinson DR, Bashir Y, Betts TR, Rajappan K. Accuracy of manual QRS dura- tion assessment: its importance in patient selection for cardiac resynchroniza- tion and implantable cardioverter defibrillator therapy. Europace 2009; 11 :638 \u0002 642. 290. Vancura V, Wichterle D, Ulc I, Smid J, Brabec M, Zarybnicka M, Rokyta R. The variability of automated QRS duration measurement. Europace 2017; 19 :636 \u0002 643. 291. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired recovery of left ventricular func- tion in patients with cardiomyopathy and left bundle branch block.  J Am Coll Cardiol  2018; 71 :306 \u0002 317. 292. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.  Lancet 2010; 376 :875 \u0002 885. 293. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators Committees. Angiotensin \u0002 neprilysin inhibition versus enalapril in heart failure. N Engl J Med  2014; 371 :993 \u0002 1004. 294. Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, Bruckers L, Voros G, Willems R, Vandervoort PM, Dupont M, Mullens W. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy.  J Am Coll Cardiol  2020; 75 :1426 \u0002 1438. 295. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E, Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis Nielsen J, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H, Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchroniza- tion therapy: a call for action for referral and optimization of care: a joint posi- tion statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology.  Eur J Heart Fail 2020; 22 :2349 \u0002 2369. 296. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).  Eur Heart J  2020; 42 :373 \u0002 498. 297. Ousdigian KT, Borek PP, Koehler JL, Heywood JT, Ziegler PD, Wilkoff BL. The epidemic of inadequate biventricular pacing in patients with persistent or per- manent atrial fibrillation and its association with mortality.  Circ Arrhythm Electrophysiol  2014; 7 :370 \u0002 376. 298. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart fail- ure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing neces- sary?  J Am Coll Cardiol  2009; 53 :355 \u0002 360. 299. Hayes DL, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Seth M, Jones PW, Saxon LA. Cardiac resynchronization therapy and the relationship of per- cent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8 :1469 \u0002 1475. 300. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS. Cardiac resynchronization ther- apy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).  Circ Heart Fail 2012; 5 :566 \u0002 570. 301. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with\n78 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ coexistent atrial fibrillation and heart failure a systematic review.  J Am Coll Cardiol  2012; 59 :719 \u0002 726. 302. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani G, Lamp B, Proclemer A, Curnis A, Klersy C, Leyva F. Cardiac resynchroniza- tion therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail  2013; 1 :500 \u0002 507. 303. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrilla- tion: an individual-patient data meta-analysis.  Lancet  2014; 384 :2235 \u0002 2243. 304. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment.  BMC Med  2020; 18 :103. 305. Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K, Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.  Eur J Heart Fail  2020; 22 :528 \u0002 538. 306. Yin J, Hu H, Wang Y, Xue M, Li X, Cheng W, Li X, Yan S. Effects of atrioven- tricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis.  Clin Cardiol 2014; 37 :707 \u0002 715. 307. Tolosana JM, Arnau AM, Madrid AH, Macias A, Lozano IF, Osca J, Quesada A, Toquero J, France´s RM, Bolao IG, Berruezo A, Sitges M, Alcal \u0002 a MG, Brugada J, Mont L. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response?  Eur J Heart Fail  2012; 14 :635 \u0002 641. 308. Tolosana JM, Trucco E, Khatib M, Doltra A, Borras R, Castel M, Berruezo A, Arbelo E, Sitges M, Matas M, Guasch E, Brugada J, Mont L. Complete atrioven- tricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy.  Eur J Heart Fail 2013; 15 :1412 \u0002 1418. 309. Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF, Mandava A, Mittal S, Steinberg JS. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy.  J Am Coll Cardiol  2009; 53 :1050 \u0002 1055. 310. Hernandez-Madrid A, Facchin D, Klepfer RN, Ghosh S, Matia R, Moreno J, Locatelli A. Device pacing diagnostics overestimate effective cardiac resynchro- nization therapy pacing results of the hOLter for Efficacy analysis of CRT (OLE CRT) study.  Heart Rhythm  2017; 14 :541 \u0002 547. 311. Plummer CJ, Frank CM, B \u0002 ari Z, Al Hebaishi YS, Klepfer RN, Stadler RW, Ghosh S, Liu S, Mittal S. A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: the CRTee randomized crossover trial.  Heart Rhythm  2018; 15 :369 \u0002 375. 312. Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ven- tricular pacing can induce ventricular dyssynchrony in patients with atrial fibrilla- tion after atrioventricular node ablation.  J Am Coll Cardiol  2006; 48 :1642 \u0002 1648. 313. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibril- lation: a randomized trial.  Eur Heart J  2011; 32 :2420 \u0002 2429. 314. Brignole M, Botto GL, Mont L, Oddone D, Iacopino S, De Marchi G, Campoli M, Sebastiani V, Vincenti A, Garcia Medina D, Osca Asensi J, Mocini A, Grovale N, De Santo T, Menozzi C. Predictors of clinical efficacy of ‘Ablate and Pace’ therapy in patients with permanent atrial fibrillation.  Heart  2012; 98 :297 \u0002 302. 315. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-anal- ysis.  Europace  2012; 14 :1490 \u0002 1497. 316. Sharma PS, Vijayaraman P, Ellenbogen KA. Permanent His bundle pacing: shaping the future of physiological ventricular pacing.  Nat Rev Cardiol  2020; 17 :22 \u0002 36. 317. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. A Novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block.  Can J Cardiol  2017; 33 :1736.e1 \u0002 1736.e73. 318. Sharma PS, Dandamudi G, Herweg B, Wilson D, Singh R, Naperkowski A, Koneru JN, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a mul- ticenter experience.  Heart Rhythm  2018; 15 :413 \u0002 420. 319. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: a feasibility study.  Circ Arrhythm Electrophysiol  2019; 12 :e006934. 320. Boczar K, Sławuta A, Za˛bek A, De R  bski M, Vijayaraman P, Gajek J, Lelakowski J, Małecka B. Cardiac resynchronization therapy with His bundle pacing.  Pacing Clin Electrophysiol . 2019; 42 :374 \u0002 380.\n",
      "keywords": [
        "esvem",
        "ejection fraction",
        "older",
        "vasovagal",
        "crt",
        "obesity",
        "electrocardiographic",
        "significance",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "investigators",
        "mason",
        "diabetes",
        "tilt test",
        "trial",
        "hahn",
        "syncope",
        "clinical",
        "carotid",
        "sex",
        "atrial fibrillation",
        "prater",
        "cardiomyopathy",
        "ecg",
        "elderly",
        "hartz",
        "heart failure",
        "systolic dysfunction",
        "versus"
      ],
      "tables": []
    },
    {
      "number": "89",
      "title": "321. Coluccia G, Vitale E, Corallo S, Aste M, Odaglia F, Donateo P, Oddone D, Brignole M. Additional benefits of nonconventional modalities of cardiac resynchronization therapy using His bundle pacing",
      "start_page": 78,
      "end_page": 79,
      "content": "ESC Guidelines 79\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 341. Baker CM, Christopher TJ, Smith PF, Langberg JJ, Delurgio DB, Leon AR. Addition of a left ventricular lead to conventional pacing systems in patients with congestive heart failure: feasibility, safety, and early results in 60 consecu- tive patients.  Pacing Clin Electrophysiol  2002; 25 :1166 \u0002 1171. 342. Valls-Bertault V, Fatemi M, Gilard M, Pennec PY, Etienne Y, Blanc JJ. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation.  Europace  2004; 6 :438 \u0002 443. 343. Eldadah ZA, Rosen B, Hay I, Edvardsen T, Jayam V, Dickfeld T, Meininger GR, Judge DP, Hare J, Lima JB, Calkins H, Berger RD. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging.  Heart Rhythm  2006; 3 :435 \u0002 442. 344. Shimano M, Tsuji Y, Yoshida Y, Inden Y, Tsuboi N, Itoh T, Suzuki H, Muramatsu T, Okada T, Harata S, Yamada T, Hirayama H, Nattel S, Murohara T. Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block.  Europace  2007; 9 :869 \u0002 874. 345. Laurenzi F, Achilli A, Avella A, Peraldo C, Orazi S, Perego GB, Cesario A, Valsecchi S, De Santo T, Puglisi A, Tondo C. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors.  Pacing Clin Electrophysiol  2007; 30 :1096 \u0002 1104. 346. Vatankulu MA, Goktekin O, Kaya MG, Ayhan S, Kucukdurmaz Z, Sutton R, Henein M. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices.  Am J Cardiol  2009; 103 :1280 \u0002 1284. 347. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized cross- over study.  Europace  2006; 8 :51 \u0002 55. 348. Delnoy PP, Ottervanger JP, Vos DH, Elvan A, Misier AR, Beukema WP, Steendijk P, van Hemel NM. Upgrading to biventricular pacing guided by pres- sure \u0002 volume loop analysis during implantation.  J Cardiovasc Electrophysiol 2011; 22 :677 \u0002 683. 349. van Geldorp IE, Vernooy K, Delhaas T, Prins MH, Crijns HJ, Prinzen FW, Dijkman B. Beneficial effects of biventricular pacing in chronically right ventricu- lar paced patients with mild cardiomyopathy.  Europace  2010; 12 :223 \u0002 229. 350. Leclercq C, Cazeau S, Lellouche D, Fossati F, Anselme F, Davy JM, Sadoul N, Klug D, Mollo L, Daubert JC. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart fail- ure: the RD-CHF Study.  Pacing Clin Electrophysiol  2007; 30 Suppl 1 :S23 \u0002 S30. 351. Kosztin A, Vamos M, Aradi D, Schwertner WR, Kovacs A, Nagy KV, Zima E, Geller L, Duray GZ, Kutyifa V, Merkely B. De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis.  Heart Fail Rev  2018; 23 :15 \u0002 26. 352. Linde CM, Normand C, Bogale N, Auricchio A, Sterlinski M, Marinskis G, Sticherling C, Bulava A, Perez OC, Maass AH, Witte KK, Rekvava R, Abdelali S, Dickstein K. Upgrades from a previous device compared to  de novo  cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II.  Eur J Heart Fail  2018; 20 :1457 \u0002 1468. 353. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, Camm J. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association.  Europace  2017; 19 :ii1 \u0002 ii90. 354. Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a com- plete, nationwide cohort in Denmark.  Eur Heart J  2014; 35 :1186 \u0002 1194. 355. Boriani G, Diemberger I. Cardiac resynchronization therapy in the real world: need to upgrade outcome research.  Eur J Heart Fail  2018; 20 :1469 \u0002 1471. 356. Merkely B, Kosztin A, Roka A, Geller L, Zima E, Kovacs A, Boros AM, Klein H, Wranicz JK, Hindricks G, Clemens M, Duray GZ, Moss AJ, Goldenberg I, Kutyifa V. Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial.  Europace  2017; 19 :1549 \u0002 1555. 357. Kindermann M, Hennen B, Jung J, Geisel J, Bohm M, Frohlig G. Biventricular ver- sus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE).  J Am Coll Cardiol  2006; 47 :1927 \u0002 1937. 358. Martinelli Filho M, de Siqueira SF, Costa R, Greco OT, Moreira LF, D’Avila A, Heist EK. Conventional versus biventricular pacing in heart failure and bradyar- rhythmia: the COMBAT study.  J Card Fail  2010; 16 :293 \u0002 300. 359. Yu CM, Fang F, Luo XX, Zhang Q, Azlan H, Razali O. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial.  Eur J Heart Fail 2014; 16 :1016 \u0002 1025. 360. Albertsen AE, Mortensen PT, Jensen HK, Poulsen SH, Egeblad H, Nielsen JC. Adverse effect of right ventricular pacing prevented by biventricular pacing dur- ing long-term follow-up: a randomized comparison. Eur J Echocardiogr 2011; 12 :767 \u0002 772.\n",
      "keywords": [
        "resynchronization",
        "odaglia",
        "brignole",
        "crt",
        "donateo",
        "vitale",
        "aste",
        "benefits",
        "pacemaker",
        "modalities",
        "additional",
        "corallo",
        "therapy",
        "using",
        "coluccia",
        "atrial fibrillation",
        "cardiomyopathy",
        "cardiac",
        "bundle",
        "heart failure",
        "indication",
        "pacing",
        "ablation",
        "nonconventional",
        "oddone"
      ],
      "tables": []
    },
    {
      "number": "90",
      "title": "361. Chung ES, St John Sutton MG, Mealing S, Sidhu MK, Padhiar A, Tsintzos SI, Lu X, Verhees KJP, Lautenbach AA, Curtis AB. Economic value and cost- effectiveness of biventricular versus right ventric",
      "start_page": 79,
      "end_page": 81,
      "content": "80 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 378. Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A, Bertaglia E, Solimene F, Molon G, Accogli M, Tommasi C, Paoletti Perini A, Ciardiello C, Padeletti L. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry.  Europace  2013; 15 :1273 \u0002 1279. 379. Acosta J, Fernandez-Armenta J, Borras R, Anguera I, Bisbal F, Marti-Almor J, Tolosana JM, Penela D, Andreu D, Soto-Iglesias D, Evertz R, Matiello M, Alonso C, Villuendas R, de Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra L, Planes X, Greiser A, Ekinci O, Lasalvia L, Mont L, Berruezo A. Scar characterization to predict life-threatening arrhythmic events and sudden cardiac death in patients with cardiac resynchronization therapy: the GAUDI-CRT study.  JACC Cardiovasc Imaging  2018; 11 :561 \u0002 572. 380. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, Umar F, Patel K, Panting J, Marshall H, Qiu T. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy.  J Am Coll Cardiol  2017; 70 :1216 \u0002 1227. 381. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert JC. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial.  Eur J Heart Fail 2012; 14 :628 \u0002 634. 382. Barra S, Looi KL, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchroni- zation therapy.  Europace  2016; 18 :1187 \u0002 1193. 383. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML, MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunc- tion.  J Am Coll Cardiol  2008; 51 :288 \u0002 296. 384. Lumens J, Tayal B, Walmsley J, Delgado-Montero A, Huntjens PR, Schwartzman D, Althouse AD, Delhaas T, Prinzen FW, Gorcsan J 3rd. Differentiating electro- mechanical from non-electrical substrates of mechanical discoordination to identify responders to cardiac resynchronization therapy.  Circ Cardiovasc Imaging 2015; 8 :e003744. 385. Ploux S, Lumens J, Whinnett Z, Montaudon M, Strom M, Ramanathan C, Derval N, Zemmoura A, Denis A, De Guillebon M, Shah A, Hocini M, Jais P, Ritter P, Haissaguerre M, Wilkoff BL, Bordachar P. Noninvasive electrocardiographic mapping to improve patient selection for cardiac resynchronization therapy: beyond QRS duration and left bundle branch block morphology.  J Am Coll Cardiol  2013; 61 :2435 \u0002 2443. 386. Parsai C, Bijnens B, Sutherland GR, Baltabaeva A, Claus P, Marciniak M, Paul V, Scheffer M, Donal E, Derumeaux G, Anderson L. Toward understanding response to cardiac resynchronization therapy: left ventricular dyssynchrony is only one of multiple mechanisms.  Eur Heart J  2009; 30 :940 \u0002 949. 387. Adelstein EC, Tanaka H, Soman P, Miske G, Haberman SC, Saba SF, Gorcsan J 3rd. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchro- nization therapy.  Eur Heart J  2011; 32 :93 \u0002 103. 388. Taylor RJ, Umar F, Panting JR, Stegemann B, Leyva F. Left ventricular lead posi- tion, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization ther- apy: a feature-tracking and contrast-enhanced cardiovascular magnetic reso- nance study.  Heart Rhythm  2016; 13 :481 \u0002 489. 389. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, Oyenuga OA, Onishi T, Soman P, Gorcsan J 3rd. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial.  Circ Heart Fail  2013; 6 :427 \u0002 434. 390. Stephansen C, Sommer A, Kronborg MB, Jensen JM, Norgaard BL, Gerdes C, Kristensen J, Jensen HK, Fyenbo DB, Bouchelouche K, Nielsen JC. Electrically vs. imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial.  Europace  2019; 21 :1369 \u0002 1377. 391. Delgado-Montero A, Tayal B, Goda A, Ryo K, Marek JJ, Sugahara M, Qi Z, Althouse AD, Saba S, Schwartzman D, Gorcsan J 3rd. Additive prognostic value of echocardiographic global longitudinal and global circumferential strain to electrocardiographic criteria in patients with heart failure undergoing cardiac resynchronization therapy.  Circ Cardiovasc Imaging  2016; 9 . 392. Gorcsan J 3rd, Anderson CP, Tayal B, Sugahara M, Walmsley J, Starling RC, Lumens J. Systolic stretch characterizes the electromechanical substrate responsive to cardiac resynchronization therapy.  JACC Cardiovasc Imaging 2019; 12 :1741 \u0002 1752. 393. Khidir MJH, Abou R, Yilmaz D, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic value of global longitudinal strain in heart failure patients treated with cardiac resynchronization therapy.  Heart Rhythm  2018; 15 :1533 \u0002 1539. 394. Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, Haugaa KH, Charron P, Voigt JU, Cardim N, Masci PG, Galderisi M, Gaemperli O, Gimelli A, Pinto YM,\nLancellotti P, Habib G, Elliott P, Edvardsen T, Cosyns B, Popescu BA, EACVI Scientific Documents Committee. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging.  Eur Heart J Cardiovasc Imaging  2019; 20 :1075 \u0002 1093. 395. Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, van der Wall EE, Schalij MJ, Bax JJ. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation  2006; 113 :969 \u0002 976. 396. Ypenburg C, Roes SD, Bleeker GB, Kaandorp TA, de Roos A, Schalij MJ, van der Wall EE, Bax JJ. Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy.  Am J Cardiol  2007; 99 :657 \u0002 660. 397. van der Bijl P, Khidir M, Ajmone Marsan N, Delgado V, Leon MB, Stone GW, Bax JJ. Effect of functional mitral regurgitation on outcome in patients receiving cardiac resynchronization therapy for heart failure. Am J Cardiol 2019; 123 :75 \u0002 83. 398. Leong DP, Hoke U, Delgado V, Auger D, Witkowski T, Thijssen J, van Erven L, Bax JJ, Schalij MJ, Marsan NA. Right ventricular function and survival following cardiac resynchronisation therapy.  Heart  2013; 99 :722 \u0002 728. 399. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J 3rd, St John Sutton M, De Sutter J, Murillo J. Results of the Predictors of Response to CRT (PROSPECT) trial.  Circulation  2008; 117 :2608 \u0002 2616. 400. Beela AS, Unlu S, Duchenne J, Ciarka A, Daraban AM, Kotrc M, Aarones M, Szulik M, Winter S, Penicka M, Neskovic AN, Kukulski T, Aakhus S, Willems R, Fehske W, Faber L, Stankovic I, Voigt JU. Assessment of mechanical dyssyn- chrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging 2019; 20 :66 \u0002 74. 401. Delgado V, Ypenburg C, van Bommel RJ, Tops LF, Mollema SA, Marsan NA, Bleeker GB, Schalij MJ, Bax JJ. Assessment of left ventricular dyssynchrony by speckle tracking strain imaging comparison between longitudinal, circumferen- tial, and radial strain in cardiac resynchronization therapy.  J Am Coll Cardiol 2008; 51 :1944 \u0002 1952. 402. Risum N, Tayal B, Hansen TF, Bruun NE, Jensen MT, Lauridsen TK, Saba S, Kisslo J, Gorcsan J 3rd, Sogaard P. Identification of typical left bundle branch block contraction by strain echocardiography is additive to electrocardiography in prediction of long-term outcome after cardiac resynchronization therapy.  J Am Coll Cardiol  2015; 66 :631 \u0002 641. 403. Leenders GE, Lumens J, Cramer MJ, De Boeck BW, Doevendans PA, Delhaas T, Prinzen FW. Septal deformation patterns delineate mechanical dyssynchrony and regional differences in contractility: analysis of patient data using a com- puter model.  Circ Heart Fail  2012; 5 :87 \u0002 96. 404. Mafi-Rad M, Van’t Sant J, Blaauw Y, Doevendans PA, Cramer MJ, Crijns HJ, Prinzen FW, Meine M, Vernooy K. Regional left ventricular electrical activation and peak contraction are closely related in candidates for cardiac resynchroni- zation therapy.  JACC Clin Electrophysiol  2017; 3 :854 \u0002 862. 405. Maass AH, Vernooy K, Wijers SC, van ‘t Sant J, Cramer MJ, Meine M, Allaart CP, De Lange FJ, Prinzen FW, Gerritse B, Erdtsieck E, Scheerder COS, Hill MRS, Scholten M, Kloosterman M, Ter Horst IAH, Voors AA, Vos MA, Rienstra M, Van Gelder IC. Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. Europace 2018; 20 :e1-e10. 406. van der Bijl P, Vo NM, Kostyukevich MV, Mertens B, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic implications of global, left ventricular myocardial work efficiency before cardiac resynchronization therapy.  Eur Heart J Cardiovasc Imaging  2019; 20 :1388 \u0002 1394. 407. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, con- trolled trial.  J Am Coll Cardiol  2012; 59 :1509 \u0002 1518. 408. Sommer A, Kronborg MB, Norgaard BL, Poulsen SH, Bouchelouche K, Bottcher M, Jensen HK, Jensen JM, Kristensen J, Gerdes C, Mortensen PT, Nielsen JC. Multimodality imaging-guided left ventricular lead placement in car- diac resynchronization therapy: a randomized controlled trial.  Eur J Heart Fail 2016; 18 :1365 \u0002 1374. 409. Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C, Pouleur AC, Knappe D, Biering-Sorensen T, Kutyifa V, Moss A, Stein K, Solomon SD, Bijnens B. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.  Eur J Heart Fail 2019; 21 :74 \u0002 85. 410. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, Regoli F, Sorgente A, Spinucci G, Ricciardi G, Michelucci A, Perrotta L, Faletra F, Mlcochova H, Sedlacek K, Canby R, Sanchez JE, Horton R, Burkhardt JD,\nESC Guidelines 81\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Moccetti T, Padeletti L, Natale A. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation.  Europace  2011; 13 :829 \u0002 838. 411. Auricchio A, Schillinger W, Meyer S, Maisano F, Hoffmann R, Ussia GP, Pedrazzini GB, van der Heyden J, Fratini S, Klersy C, Komtebedde J, Franzen O. Correction of mitral regurgitation in nonresponders to cardiac resynchroniza- tion therapy by MitraClip improves symptoms and promotes reverse remodel- ing.  J Am Coll Cardiol  2011; 58 :2183 \u0002 2189. 412. D’Ancona G, Ince H, Schillinger W, Senges J, Ouarrak T, Butter C, Seifert M, Schau T, Lubos E, Boekstegers P, von Bardeleben RS, Safak E. Percutaneous treat- ment of mitral regurgitation in patients with impaired ventricular function: impact of intracardiac electronic devices (from the German Transcatheter Mitral Valve Interventions Registry).  Catheter Cardiovasc Interv  2019; 94 :755 \u0002 763. 413. Giaimo VL, Zappulla P, Cirasa A, Tempio D, Sanfilippo M, Rapisarda G, Trovato D, Grazia AD, Liotta C, Grasso C, Capodanno D, Tamburino C, Calvi V. Long- term clinical and echocardiographic outcomes of Mitraclip therapy in patients nonresponders to cardiac resynchronization. Pacing Clin Electrophysiol 2018; 41 :65 \u0002 72. 414. Seifert M, Schau T, Schoepp M, Arya A, Neuss M, Butter C. MitraClip in CRT non-responders with severe mitral regurgitation.  Int J Cardiol  2014; 177 :79 \u0002 85. 415. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation.  N Engl J Med 2018; 379 :2297 \u0002 2306. 416. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379 :2307 \u0002 2318. 417. Kaye GC, Linker NJ, Marwick TH, Pollock L, Graham L, Pouliot E, Poloniecki J, Gammage M, Protect-Pace trial investigators. Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.  Eur Heart J  2015; 36 : 856 \u0002 862. 418. Leclercq C, Sadoul N, Mont L, Defaye P, Osca J, Mouton E, Isnard R, Habib G, Zamorano J, Derumeaux G, Fernandez-Lozano I, SEPTAL CRT Study Investigators. Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrilla- tors: the SEPTAL CRT Study.  Eur Heart J  2016; 37 :473 \u0002 483. 419. Hussain MA, Furuya-Kanamori L, Kaye G, Clark J, Doi SA. The Effect of right ventricular apical and nonapical pacing on the short- and long-term changes in left ventricular ejection fraction: a systematic review and meta-analysis of randomized-controlled trials.  Pacing Clin Electrophysiol  2015; 38 :1121 \u0002 1136. 420. Cano O, Andres A, Alonso P, Osca J, Sancho-Tello MJ, Olague J, Martinez-Dolz L. Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a single- centre experience with over 3800 implanted leads.  Europace  2017; 19 :96 \u0002 102. 421. Sommer A, Kronborg MB, Norgaard BL, Gerdes C, Mortensen PT, Nielsen JC. Left and right ventricular lead positions are imprecisely determined by fluoro- scopy in cardiac resynchronization therapy: a comparison with cardiac com- puted tomography.  Europace  2014; 16 :1334 \u0002 1341. 422. Zanon F, Ellenbogen KA, Dandamudi G, Sharma PS, Huang W, Lustgarten DL, Tung R, Tada H, Koneru JN, Bergemann T, Fagan DH, Hudnall JH, Vijayaraman P. Permanent His-bundle pacing: a systematic literature review and meta-analy- sis.  Europace  2018; 20 :1819 \u0002 1826. 423. Keene D, Arnold AD, Jastrzebski M, Burri H, Zweibel S, Crespo E, Chandrasekaran B, Bassi S, Joghetaei N, Swift M, Moskal P, Francis DP, Foley P, Shun-Shin MJ, Whinnett ZI. His bundle pacing, learning curve, procedure char- acteristics, safety, and feasibility: insights from a large international observational study.  J Cardiovasc Electrophysiol  2019; 30 :1984 \u0002 1993. 424. Vijayaraman P, Dandamudi G, Zanon F, Sharma PS, Tung R, Huang W, Koneru J, Tada H, Ellenbogen KA, Lustgarten DL. Permanent His bundle pacing: recom- mendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up. Heart Rhythm  2018; 15 :460 \u0002 468. 425. Burri H, Jastrzebski M, Vijayaraman P. ECG analysis for His bundle pacing at implantation and follow-up.  JACC Clin Electrophysiol  2020; 6 :883 \u0002 900. 426. Teigeler T, Kolominsky J, Vo C, Shepard RK, Kalahasty G, Kron J, Huizar JF, Kaszala K, Tan AY, Koneru JN, Ellenbogen KA, Padala SK. Intermediate term performance and safety of His bundle pacing leads: a single center experience. Heart Rhythm  2021; 18 :743 \u0002 749. 427. Vijayaraman P, Naperkowski A, Subzposh FA, Abdelrahman M, Sharma PS, Oren JW, Dandamudi G, Ellenbogen KA. Permanent His-bundle pacing: long- term lead performance and clinical outcomes.  Heart Rhythm  2018; 15 :696 \u0002 702.\n",
      "keywords": [
        "effectiveness",
        "ejection fraction",
        "sidhu",
        "lautenbach",
        "biventricular",
        "crt",
        "sudden cardiac death",
        "valve repair",
        "guideline",
        "pacemaker",
        "systolic",
        "value",
        "mitral regurgitation",
        "economic",
        "sutton",
        "risk stratification",
        "chung",
        "verhees",
        "mealing",
        "tsintzos",
        "echocardiography",
        "cardiomyopathy",
        "ecg",
        "heart failure",
        "versus",
        "curtis",
        "right",
        "indication",
        "padhiar",
        "john"
      ],
      "tables": []
    },
    {
      "number": "91",
      "title": "428. Zanon F, Abdelrahman M, Marcantoni L, Naperkowski A, Subzposh FA, Pastore G, Baracca E, Boaretto G, Raffagnato P, Tiribello A, Dandamudi G, Vijayaraman P. Long term performance and safety of His ",
      "start_page": 81,
      "end_page": 83,
      "content": "82 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ ventricular pacemaker: results from the MARVEL 2 study. JACC Clin Electrophysiol  2019; 6 :94 \u0002 106. 449. Beurskens NE, Tjong FV, Knops RE. End-of-life management of leadless cardiac pacemaker therapy.  Arrhythm Electrophysiol Rev  2017; 6 :129 \u0002 133. 450. El-Chami MF, Johansen JB, Zaidi A, Faerestrand S, Reynolds D, Garcia-Seara J, Mansourati J, Pasquie JL, McElderry HT, Roberts PR, Soejima K, Stromberg K, Piccini JP. Leadless pacemaker implant in patients with pre-existing infections: results from the Micra postapproval registry.  J Cardiovasc Electrophysiol 2019; 30 :569 \u0002 574. 451. Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction.  N Engl J Med  2003; 348 :933 \u0002 940. 452. Pejkovic B, Krajnc I, Anderhuber F, Kosutic D. Anatomical aspects of the arterial blood supply to the sinoatrial and atrioventricular nodes of the human heart.  J Int Med Res  2008; 36 :691 \u0002 698. 453. Ritter WS, Atkins JM, Blomqvist CG, Mullins CB. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction.  Am J Cardiol 1976; 38 :205 \u0002 208. 454. Ginks WR, Sutton R, Oh W, Leatham A. Long-term prognosis after acute ante- rior infarction with atrioventricular block.  Br Heart J  1977; 39 :186 \u0002 189. 455. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction.  J Am Coll Cardiol  1984; 4 :35 \u0002 38. 456. Jim MH, Chan AO, Tse HF, Barold SS, Lau CP. Clinical and angiographic findings of complete atrioventricular block in acute inferior myocardial infarction.  Ann Acad Med Singapore  2010; 39 :185 \u0002 190. 457. Sutton R, Davies M. The conduction system in acute myocardial infarction com- plicated by heart block.  Circulation  1968; 38 :987 \u0002 992. 458. Gang UJ, Hvelplund A, Pedersen S, Iversen A, Jøns C, Abildstrøm SZ, Haarbo J, Jensen JS, Thomsen PE. High-degree atrioventricular block complicating ST- segment elevation myocardial infarction in the era of primary percutaneous coronary intervention.  Europace  2012; 14 :1639 \u0002 1645. 459. Auffret V, Loirat A, Leurent G, Martins RP, Filippi E, Coudert I, Hacot JP, Gilard M, Castellant P, Rialan A, Delaunay R, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Bedossa M, Boulmier D, Le Guellec M, Daubert JC, Le Breton H. High-degree atrioventricular block complicating ST segment elevation myo- cardial infarction in the contemporary era.  Heart  2016; 102 :40 \u0002 49. 460. Kim KH, Jeong MH, Ahn Y, Kim YJ, Cho MC, Kim W, Other Korea Acute Myocardial Infarction Registry Investigators. Differential clinical implications of high-degree atrioventricular block complicating ST-segment elevation myocar- dial infarction according to the location of infarction in the era of primary per- cutaneous coronary intervention.  Korean Circ J  2016; 46 :315 \u0002 323. 461. Kosmidou I, Redfors B, Dordi R, Dizon JM, McAndrew T, Mehran R, Ben- Yehuda O, Mintz GS, Stone GW. Incidence, predictors, and outcomes of high- grade atrioventricular block in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial).  Am J Cardiol  2017; 119 :1295 \u0002 1301. 462. Singh SM, FitzGerald G, Yan AT, Brieger D, Fox KA, L \u0002 opez-Send \u0002 on J, Yan RT, Eagle KA, Steg PG, Budaj A, Goodman SG. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.  Eur Heart J  2015; 36 :976 \u0002 983. 463. Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, Ohman EM, Topol E, Califf RM. Incidence, predictors, and out- comes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.  Am Heart J  2005; 149 :670 \u0002 674. 464. Hindman MC, Wagner GS, JaRo M, Atkins JM, Scheinman MM, DeSanctis RW, Hutter AH, Yeatman L, Rubenfire M, Pujura C, Rubin M, Morris JJ. The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up.  Circulation 1978; 58 :679 \u0002 688. 465. Melgarejo-Moreno A, Galcer \u0002 a-Tom \u0002 as J, Garci \u0002 a-Alberola A, Valde´s-Chavarri M, Castillo-Soria FJ, Mira-S \u0002 anchez E, Gil-S \u0002 anchez J, Allegue-Gallego J. Incidence, clinical characteristics, and prognostic significance of right bundle-branch block in acute myocardial infarction: a study in the thrombolytic era.  Circulation 1997; 96 :1139 \u0002 1144. 466. Vivas D, Pe´rez-Vizcayno MJ, Hern \u0002 andez-Antol \u0002 ın R, Fern \u0002 andez-Ortiz A, Ba ~ nuelos C, Escaned J, Jime´nez-Quevedo P, De Agust \u0002 ın JA, N \u0002 u ~ nez-Gil I, Gonz \u0002 alez-Ferrer JJ, Macaya C, Alfonso F. Prognostic implications of bundle branch block in patients undergoing primary coronary angioplasty in the stent era.  Am J Cardiol  2010; 105 :1276 \u0002 1283. 467. Xiong Y, Wang L, Liu W, Hankey GJ, Xu B, Wang S. The prognostic significance of right bundle branch block: a meta-analysis of prospective cohort studies.  Clin Cardiol  2015; 38 :604 \u0002 613. 468. Swart G, Brady WJ, DeBehnke DJ, MA OJ, Aufderheide TP. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospi- tal and ED treatment with atropine.  Am J Emerg Med  1999; 17 :647 \u0002 652. 469. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,\nLenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsk \u0002 y P, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST- segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).  Eur Heart J  2018; 39 :119 \u0002 177. 470. Watson RD, Glover DR, Page AJ, Littler WA, Davies P, de Giovanni J, Pentecost BL. The Birmingham Trial of permanent pacing in patients with intra- ventricular conduction disorders after acute myocardial infarction.  Am Heart J 1984; 108 :496 \u0002 501. 471. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, Hohnloser SH, Indik J, Lee R, Mehra MR, Menon V, Page RL, Shen WK, Slotwiner DJ, Stevenson LW, Varosy PD, Welikovitch L. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical tri- als.  Circulation  2014; 130 :94 \u0002 125. 472. Brodell GK, Cosgrove D, Schiavone W, Underwood DA, Loop FD. Cardiac rhythm and conduction disturbances in patients undergoing mitral valve surgery. Cleve Clin J Med  1991; 58 :397 \u0002 399. 473. Chung MK. Cardiac surgery: postoperative arrhythmias. Crit Care Med 2000; 28 :N136 \u0002 N144. 474. Jaeger FJ, Trohman RG, Brener S, Loop F. Permanent pacing following repeat cardiac valve surgery.  Am J Cardiol  1994; 74 :505 \u0002 507. 475. Reade MC. Temporary epicardial pacing after cardiac surgery: a practical review. Part 1: general considerations in the management of epicardial pacing. Anaesthesia  2007; 62 :264 \u0002 271. 476. Reade MC. Temporary epicardial pacing after cardiac surgery: a practical review. Part 2: selection of epicardial pacing modes and troubleshooting. Anaesthesia  2007; 62 :364 \u0002 373. 477. Leyva F, Qiu T, McNulty D, Evison F, Marshall H, Gasparini M. Long-term requirement for pacemaker implantation after cardiac valve replacement sur- gery.  Heart Rhythm  2017; 14 :529 \u0002 534. 478. Merin O, Ilan M, Oren A, Fink D, Deeb M, Bitran D, Silberman S. Permanent pacemaker implantation following cardiac surgery: indications and long-term fol- low-up.  Pacing Clin Electrophysiol  2009; 32 :7 \u0002 12. 479. Glikson M, Dearani JA, Hyberger LK, Schaff HV, Hammill SC, Hayes DL. Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery.  Am J Cardiol  1997; 80 :1309 \u0002 1313. 480. Kim MH, Deeb GM, Eagle KA, Bruckman D, Pelosi F, Oral H, Sticherling C, Baker RL, Chough SP, Wasmer K, Michaud GF, Knight BP, Strickberger SA, Morady F. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation.  Am J Cardiol  2001; 87 :649 \u0002 651, A610. 481. Hill TE, Kiehl EL, Shrestha NK, Gordon SM, Pettersson GB, Mohan C, Hussein A, Hussain S, Wazni O, Wilkoff BL, Menon V, Tarakji KG. Predictors of perma- nent pacemaker requirement after cardiac surgery for infective endocarditis. Eur Heart J Acute Cardiovasc Care  2021; 10 :329 \u0002 334. 482. DiBiase A, Tse TM, Schnittger I, Wexler L, Stinson EB, Valantine HA. Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers.  Am J Cardiol  1991; 67 :1385 \u0002 1389. 483. Melton IC, Gilligan DM, Wood MA, Ellenbogen KA. Optimal cardiac pacing after heart transplantation.  Pacing Clin Electrophysiol  1999; 22 :1510 \u0002 1527. 484. Jacquet L, Ziady G, Stein K, Griffith B, Armitage J, Hardesty R, Kormos R. Cardiac rhythm disturbances early after orthotopic heart transplantation: prev- alence and clinical importance of the observed abnormalities.  J Am Coll Cardiol 1990; 16 :832 \u0002 837. 485. Holt ND, McComb JM. Cardiac transplantation and pacemakers: when and what to implant.  Card Electrophysiol Rev  2002; 6 :140 \u0002 151. 486. Burger H, Pecha S, Hakmi S, Opalka B, Schoenburg M, Ziegelhoeffer T. Five- year follow-up of transvenous and epicardial left ventricular leads: experience with more than 1000 leads.  Interact Cardiovasc Thorac Surg  2020; 30 :74 \u0002 80. 487. Noheria A, van Zyl M, Scott LR, Srivathsan K, Madhavan M, Asirvatham SJ, McLeod CJ. Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease.  Europace  2018; 20 :636 \u0002 642. 488. Sharma PS, Subzposh FA, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing in patients with prosthetic cardiac valves.  Heart Rhythm  2017; 14 :59 \u0002 64. 489. Martins RP, Galand V, Leclercq C, Daubert JC. Cardiac electronic implantable devices after tricuspid valve surgery.  Heart Rhythm  2018; 15 :1081 \u0002 1088. 490. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363 :1597 \u0002 1607. 491. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ,\nESC Guidelines 83\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Anderson WN, Wang D, Pocock SJ. Transcatheter versus surgical aortic-valve replacement in high-risk patients.  N Engl J Med  2011; 364 :2187 \u0002 2198. 492. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.  N Engl J Med  2016; 374 :1609 \u0002 1620. 493. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.  N Engl J Med 2019; 380 :1695 \u0002 1705. 494. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370 :1790 \u0002 1798. 495. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients.  N Engl J Med 2019; 380 :1706 \u0002 1715. 496. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.  N Engl J Med  2017; 376 :1321 \u0002 1331. 497. Barbash IM, Finkelstein A, Barsheshet A, Segev A, Steinvil A, Assali A, Ben Gal Y, Vaknin Assa H, Fefer P, Sagie A, Guetta V, Kornowski R. Outcomes of patients at estimated low, intermediate, and high risk undergoing transcath- eter aortic valve implantation for aortic stenosis. Am J Cardiol 2015; 116 :1916 \u0002 1922. 498. Bekeredjian R, Szabo G, Balaban U, Bleiziffer S, Bauer T, Ensminger S, Frerker C, Herrmann E, Beyersdorf F, Hamm C, Beckmann A, Mollmann H, Karck M, Katus HA, Walther T. Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY).  Eur Heart J  2019; 40 :1323 \u0002 1330. 499. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetche D, Carrie D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Van Belle E, Laskar M. Registry of transcatheter aortic-valve implan- tation in high-risk patients.  N Engl J Med  2012; 366 :1705 \u0002 1715. 500. Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel T, Gray H, Mullen MJ. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry.  J Am Coll Cardiol  2011; 58 :2130 \u0002 2138. 501. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H, Eggebrecht H, Rubino P, Michev I, Lange R, Anderson WN, Wendler O. Thirty- day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.  Circulation  2010; 122 :62 \u0002 69. 502. Werner N, Zahn R, Beckmann A, Bauer T, Bleiziffer S, Hamm CW, Berkeredjian R, Berkowitsch A, Mohr FW, Landwehr S, Katus HA, Harringer W, Ensminger S, Frerker C, Mollmann H, Walther T, Schneider S, Lange R. Patients at intermediate surgical risk undergoing isolated interventional or surgi- cal aortic valve implantation for severe symptomatic aortic valve stenosis. Circulation  2018; 138 :2611 \u0002 2623. 503. Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, Elgin E, Donato A. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry.  JACC Cardiovasc Interv  2016; 9 :2189 \u0002 2199.\n",
      "keywords": [
        "tiribello",
        "safety",
        "bradycardia",
        "electrocardiogram",
        "tavi",
        "pacemaker",
        "marcantoni",
        "naperkowski",
        "tricuspid",
        "boaretto",
        "dandamudi",
        "subzposh",
        "aortic",
        "term",
        "valve replacement",
        "baracca",
        "abdelrahman",
        "zanon",
        "pastore",
        "long",
        "stenosis",
        "raffagnato",
        "performance",
        "aortic stenosis",
        "vijayaraman"
      ],
      "tables": []
    },
    {
      "number": "92",
      "title": "504. Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, Campelo-Parada F, Puri R, Urena M, Philippon F, Rodes-Cabau J. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker",
      "start_page": 83,
      "end_page": 84,
      "content": "84 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 520. Guetta V, Goldenberg G, Segev A, Dvir D, Kornowski R, Finckelstein A, Hay I, Goldenberg I, Glikson M. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System.  Am J Cardiol  2011; 108 :1600 \u0002 1605. 521. Mangieri A, Lanzillo G, Bertoldi L, Jabbour RJ, Regazzoli D, Ancona MB, Tanaka A, Mitomo S, Garducci S, Montalto C, Pagnesi M, Giannini F, Giglio M, Montorfano M, Chieffo A, Rodes-Cabau J, Monaco F, Paglino G, Della Bella P, Colombo A, Latib A. Predictors of advanced conduction disturbances requiring a late (>_48 h) permanent pacemaker following transcatheter aortic valve replacement.  JACC Cardiovasc Interv  2018; 11 :1519 \u0002 1526. 522. Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S, Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph TK. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 2016; 9 :2200 \u0002 2209. 523. Mouillet G, Lellouche N, Yamamoto M, Oguri A, Dubois-Rande JL, Van Belle E, Gilard M, Laskar M, Teiger E. Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve V R  devices: results from the FRANCE 2 Registry.  Catheter Cardiovasc Interv  2015; 86 :E158 \u0002 E166. 524. Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, El-Chami MF, Herrmann HC, Mack M, Makkar RR, Miller DC, Pichard A, Tuzcu EM, Szeto WY, Webb JG, Moses JW, Smith CR, Williams MR, Leon MB, Kodali SK. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry.  JACC Cardiovasc Interv  2015; 8 :60 \u0002 69. 525. Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P, Windecker S. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis.  J Am Coll Cardiol 2014; 64 :129 \u0002 140. 526. van der Boon RM, Houthuizen P, Urena M, Poels TT, van Mieghem NM, Brueren GR, Altintas S, Nuis RJ, Serruys PW, van Garsse LA, van Domburg RT, Cabau JR, de Jaegere PP, Prinzen FW. Trends in the occurrence of new conduc- tion abnormalities after transcatheter aortic valve implantation.  Catheter Cardiovasc Interv  2015; 85 :E144 \u0002 E152. 527. Gonska B, Seeger J, Kessler M, von Keil A, Rottbauer W, Wohrle J. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve.  Clin Res Cardiol 2017; 106 :590 \u0002 597. 528. Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat G, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Friedman J, Berman D, Makkar RR, Jilaihawi H. A highly predictive risk model for pacemaker implantation after TAVR.  JACC Cardiovasc Imaging  2017; 10 :1139 \u0002 1147. 529. Giustino G, Van der Boon RM, Molina-Martin de Nicolas J, Dumonteil N, Chieffo A, de Jaegere PP, Tchetche D, Marcheix B, Millischer D, Cassagneau R, Carrie D, Van Mieghem NM, Colombo A. Impact of permanent pacemaker on mortality after transcatheter aortic valve implantation: the PRAGMATIC (Pooled Rotterdam-Milan-Toulouse in Collaboration) Pacemaker substudy. EuroIntervention  2016; 12 :1185 \u0002 1193. 530. Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, Goitein O, Segev A, Barbash I, Fefer P, Spiegelstein D, Goldenberg I, Schwammenthal E. Inverse relationship between membranous septal length and the risk of atrio- ventricular block in patients undergoing transcatheter aortic valve implantation. JACC Cardiovasc Interv  2015; 8 :1218 \u0002 1228. 531. Ledwoch J, Franke J, Gerckens U, Kuck KH, Linke A, Nickenig G, Krulls-Munch J, Vohringer M, Hambrecht R, Erbel R, Richardt G, Horack M, Zahn R, Senges J, Sievert H. Incidence and predictors of permanent pacemaker implantation fol- lowing transcatheter aortic valve implantation: analysis from the German trans- catheter aortic valve interventions registry. Catheter Cardiovasc Interv 2013; 82 :E569 \u0002 E577. 532. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM, Kastrati A, Schunkert H, Hengstenberg C. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 2016; 9 :244 \u0002 254. 533. Toggweiler S, Stortecky S, Holy E, Zuk K, Cuculi F, Nietlispach F, Sabti Z, Suciu R, Maier W, Jamshidi P, Maisano F, Windecker S, Kobza R, Wenaweser P, Luscher TF, Binder RK. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring.  JACC Cardiovasc Interv  2016; 9 :1269 \u0002 1276. 534. Urena M, Webb JG, Cheema A, Serra V, Toggweiler S, Barbanti M, Cheung A, Ye J, Dumont E, DeLarochelliere R, Doyle D, Al Lawati HA, Peterson M, Chisholm R, Igual A, Ribeiro HB, Nombela-Franco L, Philippon F, Garcia Del Blanco B, Rodes-Cabau J. Impact of new-onset persistent left bundle branch block on late clinical outcomes in patients undergoing transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2014; 7 :128 \u0002 136.\n",
      "keywords": [
        "left",
        "impact",
        "electrocardiogram",
        "pacemaker",
        "puri",
        "altisent",
        "parada",
        "periprocedural",
        "cabau",
        "aortic",
        "jawad",
        "philippon",
        "permanent",
        "valve replacement",
        "rodes",
        "regueiro",
        "onset",
        "abdul",
        "bundle",
        "block",
        "urena",
        "campelo",
        "stenosis",
        "tavr",
        "branch",
        "trigo",
        "aortic stenosis"
      ],
      "tables": []
    },
    {
      "number": "93",
      "title": "535. Mouillet G, Lellouche N, Lim P, Meguro K, Yamamoto M, Deux JF, Monin JL, Bergoend E, Dubois-Rande JL, Teiger E. Patients without prolonged QRS after TAVI with CoreValve device do not experience h",
      "start_page": 84,
      "end_page": 85,
      "content": "ESC Guidelines 85\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Cleveland JC Jr, Fullerton D, Carroll JD, Messenger J, Sauer WH, Aleong RG, Tzou WS. Ambulatory rhythm monitoring to detect late high-grade atrioven- tricular block following transcatheter aortic valve replacement.  J Am Coll Cardiol 2019; 73 :2538 \u0002 2547. 550. Kostopoulou A, Karyofillis P, Livanis E, Thomopoulou S, Stefopoulos C, Doudoumis K, Theodorakis G, Voudris V. Permanent pacing after transcatheter aortic valve implantation of a CoreValve prosthesis as determined by electro- cardiographic and electrophysiological predictors: a single-centre experience. Europace  2016; 18 :131 \u0002 137. 551. Khairy P, Landzberg MJ, Gatzoulis MA, Mercier L-Ae, Fernandes SM, Coˆte´ J-M, Lavoie J-P, Fournier A, Guerra PG, Frogoudaki A, Walsh EP, Dore A. Transvenous pacing leads and systemic thromboemboli in patients with intra- cardiac shunts.  Circulation  2006; 113 :2391 \u0002 2397. 552. Anand N. Chronotropic incompetence in young patients with late postopera- tive atrial flutter: a case \u0002 control study.  Eur Heart J  2006; 27 :2069 \u0002 2073. 553. Fishberger SB, Wernovsky G, Gentles TL, Gauvreau K, Burnetta J, Mayer JE, Walsh EP. Factors that influence the development of atrial flutter after the Fontan operation.  J Thorac Cardiovasc Surg  1997; 113 :80 \u0002 86. 554. Gillette PC, Shannon C, Garson A, Porter C-BJ, Ott D, Cooley DA, McNamara DG. Pacemaker treatment of sick sinus syndrome in children.  J Am Coll Cardiol 1983; 1 :1325 \u0002 1329. 555. Kay R, Estioko M, Wiener I. Primary sick sinus syndrome as an indication for chronic pacemaker therapy in young adults: incidence, clinical features, and long-term evaluation.  American Heart Journal  1982; 103 :338 \u0002 342. 556. Ragonese P, Drago F, Guccione P, Santilli A, Silvetti MS, Agostino DA. Permanent overdrive atrial pacing in the chronic management of recurrent postoperative atrial reentrant tachycardia in patients with complex congenital heart disease.  Pacing Clin Electrophysiol  1997; 20 :2917 \u0002 2923. 557. Opic P, Yap SC, Van Kranenburg M, Van Dijk AP, Budts W, Vliegen HW, Van Erven L, Can A, Sahin G, De Groot NM, Witsenburg M, Roos-Hesselink JW. Atrial-based pacing has no benefit over ventricular pacing in preventing atrial arrhythmias in adults with congenital heart disease.  Europace  2013; 15 :1757 \u0002 1762. 558. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR, Gent M, Thorpe KE, Roberts RS, Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators.  J Am Coll Cardiol  2001; 38 :167 \u0002 172. 559. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Circulation  2019; 140 :e333-e381. 560. Kramer CC, Maldonado JR, Olson MD, Gingerich JC, Ochoa LA, Law IH. Safety and efficacy of atrial antitachycardia pacing in congenital heart disease.  Heart Rhythm  2018; 15 :543 \u0002 547. 561. Stephenson EA, Casavant D, Tuzi J, Alexander ME, Law I, Serwer G, Strieper M, Walsh EP, Berul CI, ATTEST Investigators. Efficacy of atrial antitachycardia pac- ing using the Medtronic AT500 pacemaker in patients with congenital heart dis- ease.  Am J Cardiol  2003; 92 :871 \u0002 876. 562. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal, or childhood diagnosis of isolated congenital atrioventricular block: a single institution’s experience of 30 years.  ACC Current Journal Review  2002; 11 :95. 563. Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC, Bonnet D. Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status.  J Am Coll Cardiol  2006; 48 :1682 \u0002 1687. 564. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med  1987; 316 :835 \u0002 839. 565. Karpawich PP, Gillette PC, Garson A Jr, Hesslein PS, Porter CB, McNamara DG. Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion.  Am J Cardiol  1981; 48 :1098 \u0002 1102. 566. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioven- tricular block in adult life. A prospective study.  Circulation  1995; 92 :442 \u0002 449. 567. Beaufort-Krol GC, Schasfoort-van Leeuwen MJ, Stienstra Y, Bink-Boelkens MT. Longitudinal echocardiographic follow-up in children with congenital complete atrioventricular block.  Pacing Clin Electrophysiol  2007; 30 :1339 \u0002 1343. 568. Breur JM, Udink Ten Cate FE, Kapusta L, Cohen MI, Crosson JE, Boramanand N, Lubbers LJ, Friedman AH, Brenner JI, Vetter VL, Sreeram N, Meijboom EJ. Pacemaker therapy in isolated congenital complete atrioventricular block. Pacing Clin Electrophysiol  2002; 25 :1685 \u0002 1691. 569. Bonatti V, Agnetti A, Squarcia U. Early and late postoperative complete heart block in pediatric patients submitted to open-heart surgery for congenital heart disease.  Pediatr Med Chir  1998; 20 :181 \u0002 186.\n",
      "keywords": [
        "device",
        "yamamoto",
        "bradycardia",
        "guideline",
        "tavi",
        "pacemaker",
        "tachycardia",
        "rande",
        "experience",
        "aortic",
        "thromboemboli",
        "valve replacement",
        "without",
        "atrial fibrillation",
        "prolonged",
        "bergoend",
        "monin",
        "patients",
        "mouillet",
        "after",
        "indication",
        "corevalve",
        "lellouche",
        "teiger",
        "dubois",
        "deux",
        "meguro"
      ],
      "tables": []
    },
    {
      "number": "94",
      "title": "570. Gross GJ, Chiu CC, Hamilton RM, Kirsh JA, Stephenson EA. Natural history of postoperative heart block in congenital heart disease: implications for pacing intervention.  Heart Rhythm  2006; 3 :60",
      "start_page": 85,
      "end_page": 86,
      "content": "86 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 589. Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy.  Eur J Heart Fail  2008; 10 :507 \u0002 513. 590. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardio- myopathy: Executive Summary: a Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation  2020; 142 :e533-e557. 591. Cappelli F, Morini S, Pieragnoli P, Targetti M, Stefano P, Marchionni N, Olivotto I. Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria.  J Am Coll Cardiol  2018; 71 :464 \u0002 466. 592. Killu AM, Park JY, Sara JD, Hodge DO, Gersh BJ, Nishimura RA, Asirvatham SJ, McLeod CJ. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy.  Europace  2018; 20 :82 \u0002 88. 593. Gu M, Jin H, Hua W, Fan XH, Niu HX, Tian T, Ding LG, Wang J, Xue C, Zhang S. Clinical outcome of cardiac resynchronization therapy in dilated-phase hyper- trophic cardiomyopathy.  J Geriatr Cardiol  2017; 14 :238 \u0002 244. 594. Fruh A, Siem G, Holmstrom H, Dohlen G, Haugaa KH. The Jervell and Lange \u0002 Nielsen syndrome; atrial pacing combined with  b -blocker therapy, a favorable approach in young high-risk patients with long QT syndrome?  Heart Rhythm  2016; 13 :2186 \u0002 2192. 595. Aziz PF, Tanel RE, Zelster IJ, Pass RH, Wieand TS, Vetter VL, Vogel RL, Shah MJ. Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.  Heart Rhythm  2010; 7 :781 \u0002 785. 596. Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo SJ, American Heart Association Pediatric Heart Failure Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Radiology Intervention, Council on Functional Genomics Translational Biology, Stroke Council. Management of cardiac involvement associated with neuromuscular diseases: a Scientific Statement from the American Heart Association.  Circulation  2017; 136 :e200-e231. 597. Arbustini E, Di Toro A, Giuliani L, Favalli V, Narula N, Grasso M. Cardiac phe- notypes in hereditary muscle disorders: JACC State-of-the-Art Review.  J Am Coll Cardiol  2018; 72 :2485 \u0002 2506. 598. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm 2012; 9 :1890 \u0002 1895. 599. Bhakta D, Shen C, Kron J, Epstein AE, Pascuzzi RM, Groh WJ. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population.  J Cardiovasc Electrophysiol  2011; 22 :1369 \u0002 1375. 600. Wahbi K, Meune C, Porcher R, Becane HM, Lazarus A, Laforet P, Stojkovic T, Behin A, Radvanyi-Hoffmann H, Eymard B, Duboc D. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease.  JAMA  2012; 307 :1292 \u0002 1301. 601. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow- up of arrhythmias in patients with myotonic dystrophy treated by pacing: a mul- ticenter diagnostic pacemaker study.  J Am Coll Cardiol  2002; 40 :1645 \u0002 1652. 602. Laurent V, Pellieux S, Corcia P, Magro P, Pierre B, Fauchier L, Raynaud M, Babuty D. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices.  Int J Cardiol  2011; 150 :54 \u0002 58. 603. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, Pourmand R, Otten RF, Bhakta D, Nair GV, Marashdeh MM, Zipes DP, Pascuzzi RM. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1.  N Engl J Med  2008; 358 :2688 \u0002 2697. 604. Ha AH, Tarnopolsky MA, Bergstra TG, Nair GM, Al-Qubbany A, Healey JS. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II.  Pacing Clin Electrophysiol 2012; 35 :1262 \u0002 1269. 605. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W, McDonough B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction- system disease.  N Engl J Med  1999; 341 :1715 \u0002 1724. 606. Arbustini E, Pilotto A, Repetto A, Grasso M, Negri A, Diegoli M, Campana C, Scelsi L, Baldini E, Gavazzi A, Tavazzi L. Autosomal dominant dilated cardiomy- opathy with atrioventricular block: a lamin A/C defect-related disease.  J Am Coll Cardiol  2002; 39 :981 \u0002 990. 607. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di Lenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky GL, Boucek MM, Lascor J, Moss AC, Li WL, Stetler GL, Muntoni F, Bristow MR, Mestroni L, Familial Dilated Cardiomyopathy Registry Research Group. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41 :771 \u0002 780.\n",
      "keywords": [
        "natural",
        "guideline",
        "heart",
        "intervention",
        "pacemaker",
        "disease",
        "rhythm",
        "chiu",
        "implications",
        "stephenson",
        "history",
        "hereditary",
        "postoperative",
        "kirsh",
        "hamilton",
        "cardiomyopathy",
        "congenital",
        "heart failure",
        "block",
        "pacing",
        "gross"
      ],
      "tables": []
    },
    {
      "number": "95",
      "title": "608. Sanna T. Cardiac features of Emery \u0002 Dreifuss muscular dystrophy caused by lamin A/C gene mutations.  Eur Heart J  2003; 24 :2227 \u0002 2236. 609. Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch",
      "start_page": 86,
      "end_page": 90,
      "content": "ESC Guidelines 87\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 621. Limongelli G, Tome-Esteban M, Dejthevaporn C, Rahman S, Hanna MG, Elliott PM. Prevalence and natural history of heart disease in adults with primary mito- chondrial respiratory chain disease.  Eur J Heart Fail  2010; 12 :114 \u0002 121. 622. Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, Osame M, Tanaka H. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects.  Circulation  1995; 91 :955 \u0002 961. 623. Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns \u0002 Sayre syndrome: a case series of 35 adults and children.  Int J Gen Med  2014; 7 :325 \u0002 332. 624. Kabunga P, Lau AK, Phan K, Puranik R, Liang C, Davis RL, Sue CM, Sy RW. Systematic review of cardiac electrical disease in Kearns \u0002 Sayre syndrome and mitochondrial cytopathy.  Int J Cardiol  2015; 181 :303 \u0002 310. 625. Polak PE, Zijlstra F, Roelandt JR. Indications for pacemaker implantation in the Kearns \u0002 Sayre syndrome.  Eur Heart J  1989; 10 :281 \u0002 282. 626. Nordenswan HK, Lehtonen J, Ekstrom K, Kandolin R, Simonen P, Mayranpaa M, Vihinen T, Miettinen H, Kaikkonen K, Haataja P, Kerola T, Rissanen TT, Kokkonen J, Alatalo A, Pietila-Effati P, Utriainen S, Kupari M. Outcome of car- diac sarcoidosis presenting with high-grade atrioventricular block.  Circ Arrhythm Electrophysiol  2018; 11 :e006145. 627. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA, Davis D, Ohira H, Gollob MH, Leung E, Healey JS, Birnie DH. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.  J Cardiovasc Electrophysiol  2014; 25 :875 \u0002 881. 628. Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block.  Am Heart J  1997; 134 :382 \u0002 386. 629. Mankad P, Mitchell B, Birnie D, Kron J. Cardiac sarcoidosis.  Curr Cardiol Rep 2019; 21 :152. 630. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review.  Can J Cardiol  2013; 29 :1034 \u0002 1041. 631. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11 :1305 \u0002 1323. 632. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, Sweiss NJ, Nguyen DT, Aleong RG, Varosy PD, Weinberger HD, Sauer WH. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis.  J Cardiovasc Electrophysiol  2012; 23 :925 \u0002 929. 633. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA. Efficacy and safety of implant- able cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.  Europace  2013; 15 :347 \u0002 354. 634. Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart 2016; 102 :411 \u0002 414. 635. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.  Eur Heart J 2018; 39 :3165 \u0002 3241. 636. Tuzcu V, Gul EE, Erdem A, Kamali H, Saritas T, Karadeniz C, Akdeniz C. Cardiac interventions in pregnant patients without fluoroscopy.  Pediatr Cardiol 2015; 36 :1304 \u0002 1307. 637. Gudal M, Kervancioglu C, Oral D, Gurel T, Erol C, Sonel A. Permanent pace- maker implantation in a pregnant woman with the guidance of ECG and two- dimensional echocardiography.  Pacing Clin Electrophysiol  1987; 10 :543 \u0002 545. 638. Traykov V, Bongiorni MG, Boriani G, Burri H, Costa R, Dagres N, Deharo JC, Epstein LM, Erba PA, Snygg-Martin U, Nielsen JC, Poole JE, Saghy L, Starck C, Strathmore N, Blomstrom-Lundqvist C. Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association.  Europace  2019; 21 :1270 \u0002 1279. 639. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G, Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S, People Study Group. Risk factors related to infections of implanted pacemakers and cardioverter- defibrillators: results of a large prospective study.  Circulation  2007; 116 :1349 \u0002 1355. 640. Enzler MJ, Berbari E, Osmon DR. Antimicrobial prophylaxis in adults.  Mayo Clin Proc  2011; 86 :686 \u0002 701. 641. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis.  Europace 2015; 17 :767 \u0002 777. 642. Blomstrom-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Saghy L, Snygg-Martin\nU, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).  Eur Heart J 2020; 41 :2012 \u0002 2032. 643. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA, Costa R, D’Avila A, Danik SB. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial.  Circ Arrhythm Electrophysiol  2009; 2 :29 \u0002 34. 644. Madadi S, Kafi M, Kheirkhah J, Azhari A, Kiarsi M, Mehryar A, Fazelifar A, Alizadehdiz A, Emkanjoo Z, Haghjoo M. Postoperative antibiotic prophylaxis in the prevention of cardiac implantable electronic device infection.  Pacing Clin Electrophysiol  2019; 42 :161 \u0002 165. 645. Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, Rinne C, Coutu B, Low RA, Essebag V, Morillo C, Redfearn D, Toal S, Becker G, Degrace M, Thibault B, Crystal E, Tung S, LeMaitre J, Sultan O, Bennett M, Bashir J, Ayala-Paredes F, Gervais P, Rioux L, Hemels MEW, Bouwels LHR, van Vlies B, Wang J, Exner DV, Dorian P, Parkash R, Alings M, Connolly SJ. Prevention of arrhythmia device infection trial: the PADIT trial.  J Am Coll Cardiol 2018; 72 :3098 \u0002 3109. 646. Haines DE, Beheiry S, Akar JG, Baker JL, Beinborn D, Beshai JF, Brysiewicz N, Chiu-Man C, Collins KK, Dare M, Fetterly K, Fisher JD, Hongo R, Irefin S, Lopez J, Miller JM, Perry JC, Slotwiner DJ, Tomassoni GF, Weiss E. Heart Rythm Society expert consensus statement on electrophysiology laboratory standards: process, protocols, equipment, personnel, and safety.  Heart Rhythm  2014; 11 :e9- 51. 647. Mimoz O, Lucet J-C, Kerforne T, Pascal J, Souweine B, Goudet V, Mercat A, Bouadma L, Lasocki S, Alfandari S, Friggeri A, Wallet F, Allou N, Ruckly S, Balayn D, Lepape A, Timsit J-F. Skin antisepsis with chlorhexidine \u0002 alcohol versus povi- done iodine \u0002 alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, rand- omised, controlled, two-by-two factorial trial.  Lancet  2015; 386 :2069 \u0002 2077. 648. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. Chlorhexidine \u0002 alcohol versus povidone-iodine for surgical-site antisepsis.  N Engl J Med  2010; 362 :18 \u0002 26. 649. Essebag V, Verma A, Healey JS, Krahn AD, Kalfon E, Coutu B, Ayala-Paredes F, Tang AS, Sapp J, Sturmer M, Keren A, Wells GA, Birnie DH, BRUISE CONTROL Investigators. Clinically significant pocket hematoma increases long- term risk of device infection: BRUISE CONTROL INFECTION Study.  J Am Coll Cardiol  2016; 67 :1300 \u0002 1308. 650. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TLL, Essebag V, BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of antico- agulation.  N Engl J Med  2013; 368 :2084 \u0002 2093. 651. Malagu M, Trevisan F, Scalone A, Marcantoni L, Sammarco G, Bertini M. Frequency of ‘pocket’ hematoma in patients receiving vitamin K antagonist and antiplatelet therapy at the time of pacemaker or cardioverter defibrillator implantation (from the POCKET Study).  Am J Cardiol  2017; 119 :1036 \u0002 1040. 652. Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, Becker G, Verma A, Philippon F, Kalfon E, Eikelboom J, Sandhu RK, Nery PB, Lellouche N, Connolly SJ, Sapp J, Essebag V. Continued vs. interrupted direct oral anticoa- gulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J 2018; 39 :3973 \u0002 3979. 653. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era.  Circ Arrhythm Electrophysiol 2010; 3 :312 \u0002 318. 654. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010; 55 :2376 \u0002 2382. 655. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines, ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease devel- oped in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of\n88 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ the European Association for Cardio-Thoracic Surgery (EACTS).  Eur Heart J 2018; 39 :213 \u0002 260. 656. Rossini R, Musumeci G, Visconti LO, Bramucci E, Castiglioni B, De Servi S, Lettieri C, Lettino M, Piccaluga E, Savonitto S, Trabattoni D, Capodanno D, Buffoli F, Parolari A, Dionigi G, Boni L, Biglioli F, Valdatta L, Droghetti A, Bozzani A, Setacci C, Ravelli P, Crescini C, Staurenghi G, Scarone P, Francetti L, D’Angelo F, Gadda F, Comel A, Salvi L, Lorini L, Antonelli M, Bovenzi F, Cremonesi A, Angiolillo DJ, Guagliumi G, Italian Society of Invasive Cardiology, Italian Association of Hospital Cardiologists, Italian Society for Cardiac Surgery, Italian Society of Vascular and Endovascular Surgery, Italian Association of Hospital Surgeons, Italian Society of Surgery, Italian Society of Anaesthesia, Intensive Care Medicine, Lombard Society of Surgery, Italian Society of Maxillofacial Surgery, Italian Society of Reconstructive Plastic Surgery and Aesthetics, Italian Society of Thoracic Surgeons, Italian Society of Urology, Italian Society of Orthopaedics and Traumatology, Italian Society of Periodontology, Italian Federation of Scientific Societies of Digestive System Diseases Lombardia, Association of Obstetricians Gynaecologists Italian Hospital Lombardia, Society of Ophthalmology Lombardia. Perioperative man- agement of antiplatelet therapy in patients with coronary stents undergoing car- diac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.  EuroIntervention  2014; 10 :38 \u0002 46. 657. Essebag V, Healey JS, Joza J, Nery PB, Kalfon E, Leiria TLL, Verma A, Ayala- Paredes F, Coutu B, Sumner GL, Becker G, Philippon F, Eikelboom J, Sandhu RK, Sapp J, Leather R, Yung D, Thibault B, Simpson CS, Ahmad K, Toal S, Sturmer M, Kavanagh K, Crystal E, Wells GA, Krahn AD, Birnie DH. Effect of direct oral anticoagulants, warfarin, and antiplatelet agents on risk of device pocket hematoma: combined analysis of BRUISE CONTROL 1 and 2.  Circ Arrhythm Electrophysiol  2019; 12 :e007545. 658. Kirkfeldt RE, Johansen JB, Nohr EA, Moller M, Arnsbo P, Nielsen JC. Pneumothorax in cardiac pacing: a population-based cohort study of 28 860 Danish patients.  Europace  2012; 14 :1132 \u0002 1138. 659. Liu P, Zhou Y-F, Yang P, Gao Y-S, Zhao G-R, Ren S-Y, Li X-L. Optimized axil- lary vein technique versus subclavian vein technique in cardiovascular implant- able electronic device implantation.  Chin Med J  2016; 129 :2647 \u0002 2651. 660. Liccardo M, Nocerino P, Gaia S, Ciardiello C. Efficacy of ultrasound-guided axil- lary/subclavian venous approaches for pacemaker and defibrillator lead implan- tation: a randomized study.  J Interv Card Electrophysiol  2018; 51 :153 \u0002 160. 661. Chan NY, Kwong NP, Cheong AP. Venous access and long-term pacemaker lead failure: comparing contrast-guided axillary vein puncture with subclavian puncture and cephalic cutdown.  Europace  2017; 19 :1193 \u0002 1197. 662. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano I, Golzio PG, Hansky B, Kennergren C, Manolis AS, Mitkowski P, Platou ES, Love C, Wilkoff B. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper.  Europace 2012; 14 :124 \u0002 134. 663. Migliore F, Zorzi A, Bertaglia E, Leoni L, Siciliano M, De Lazzari M, Ignatiuk B, Veronese M, Verlato R, Tarantini G, Iliceto S, Corrado D. Incidence, manage- ment, and prevention of right ventricular perforation by pacemaker and implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol 2014; 37 :1602 \u0002 1609. 664. Segreti L, Di Cori A, Soldati E, Zucchelli G, Viani S, Paperini L, De Lucia R, Coluccia G, Valsecchi S, Bongiorni MG. Major predictors of fibrous adherences in transvenous implantable cardioverter-defibrillator lead extraction.  Heart Rhythm  2014; 11 :2196 \u0002 2201. 665. Behar JM, Bostock J, Zhu Li AP, Chin HMS, Jubb S, Lent E, Gamble J, Foley PWX, Betts TR, Rinaldi CA, Herring N. Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mor- tality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry.  J Cardiovasc Electrophysiol  2015; 26 :540 \u0002 546. 666. Forleo GB, Di Biase L, Panattoni G, Mantica M, Parisi Q, Martino A, Pappalardo A, Sergi D, Tesauro M, Papavasileiou LP, Santini L, Cal \u0004 o L, Tondo C, Natale A, Romeo F. Improved implant and postoperative lead performance in CRT-D patients implanted with a quadripolar left ventricular lead. A 6-month follow-up analysis from a multicenter prospective comparative study.  J Interv Card Electrophysiol  2015; 42 :59 \u0002 66. 667. Jackson KP, Faerestrand S, Philippon F, Yee R, Kong MH, Kloppe A, Bongiorni MG, Lee SF, Canby RC, Pouliot E, van Ginneken MME, Crossley GH. Performance of a novel active fixation quadripolar left ventricular lead for car- diac resynchronization therapy: Attain Stability Quad Clinical Study results.  J Cardiovasc Electrophysiol  2020; 31 :1147 \u0002 1154. 668. Ziacchi M, Diemberger I, Corzani A, Martignani C, Mazzotti A, Massaro G, Valzania C, Rapezzi C, Boriani G, Biffi M. Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads. Sci Rep  2018; 8 :13262. 669. Ziacchi M, Giannola G, Lunati M, Infusino T, Luzzi G, Rordorf R, Pecora D, Bongiorni MG, De Ruvo E, Biffi M. Bipolar active fixation left ventricular lead or\nquadripolar passive fixation lead? An Italian multicenter experience.  J Cardiovasc Med (Hagerstown)  2019; 20 :192 \u0002 200. 670. Shimony A, Eisenberg MJ, Filion KB, Amit G. Beneficial effects of right ventricu- lar non-apical vs. apical pacing: a systematic review and meta-analysis of randomized-controlled trials.  Europace  2012; 14 :81 \u0002 91. 671. Ng ACT, Allman C, Vidaic J, Tie H, Hopkins AP, Leung DY. Long-term impact of right ventricular septal versus apical pacing on left ventricular synchrony and function in patients with second- or third-degree heart block.  Am J Cardiol 2009; 103 :1096 \u0002 1101. 672. Hattori M, Naruse Y, Oginosawa Y, Matsue Y, Hanaki Y, Kowase S, Kurosaki K, Mizukami A, Kohno R, Abe H, Aonuma K, Nogami A. Prognostic impact of lead tip position confirmed via computed tomography in patients with right ventricu- lar septal pacing.  Heart Rhythm  2019; 16 :921 \u0002 927. 673. Domenichini G, Sunthorn H, Fleury E, Foulkes H, Stettler C, Burri H. Pacing of the interventricular septum versus the right ventricular apex: a prospective, randomized study.  Eur J Intern Med  2012; 23 :621 \u0002 627. 674. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD, Hayes DL. Incidence and predictors of cardiac perforation after permanent pacemaker placement.  Heart Rhythm  2005; 2 :907 \u0002 911. 675. Biffi M, de Zan G, Massaro G, Angeletti A, Martignani C, Boriani G, Diemberger I, Ziacchi M. Is ventricular sensing always right, when it is left?  Clin Cardiol 2018; 41 :1238 \u0002 1245. 676. Burri H, Muller H, Kobza R, Sticherling C, Ammann P, Zerlik H, Stettler C, Klersy C, Prinzen F, Auricchio A. RIght VErsus Left Apical transvenous pacing for bradycardia: results of the RIVELA randomized study.  Indian Pacing Electrophysiol J  2017; 17 :171 \u0002 175. 677. Tanabe K, Kotoda M, Nakashige D, Mitsui K, Ikemoto K, Matsukawa T. Sudden onset pacemaker-induced diaphragmatic twitching during general anesthesia.  JA Clin Rep  2019; 5 :36. 678. Khan AA, Nash A, Ring NJ, Marshall AJ. Right hemidiaphragmatic twitching: a com- plication of bipolar atrial pacing.  Pacing Clin Electrophysiol  1997; 20 :1732 \u0002 1733. 679. Shali S, Su Y, Ge J. Interatrial septal pacing to suppress atrial fibrillation in patients with dual chamber pacemakers: a meta-analysis of randomized, con- trolled trials.  Int J Cardiol  2016; 219 :421 \u0002 427. 680. Zhang L, Jiang H, Wang W, Bai J, Liang Y, Su Y, Ge J. Interatrial septum versus right atrial appendage pacing for prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.  Herz  2018; 43 :438 \u0002 446. 681. Magnusson P, Wennstrom L, Kastberg R, Liv P. Placement Of Cardiac PacemaKEr Trial (POCKET)—rationale and design: a randomized controlled trial.  Heart Int  2017; 12 :e8-e11. 682. Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutane- ous and submuscular approaches.  J Am Coll Cardiol  1996; 28 :1278 \u0002 1282. 683. Lakshmanadoss U, Nuanez B, Kutinsky I, Khalid R, Haines DE, Wong WS. Incidence of pocket infection postcardiac device implantation using antibiotic versus saline solution for pocket irrigation. Pacing Clin Electrophysiol 2016; 39 :978 \u0002 984. 684. Mueller TC, Loos M, Haller B, Mihaljevic AL, Nitsche U, Wilhelm D, Friess H, Kleeff J, Bader FG. Intra-operative wound irrigation to reduce surgical site infec- tions after abdominal surgery: a systematic review and meta-analysis. Langenbeck’s Arch Surg  2015; 400 :167 \u0002 181. 685. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, Gallastegui J, Pickett RA, Evonich R, Philippon F, McComb JM, Roark SF, Sorrentino D, Sholevar D, Cronin E, Berman B, Riggio D, Biffi M, Khan H, Silver MT, Collier J, Eldadah Z, Wright DJ, Lande JD, Lexcen DR, Cheng A, Wilkoff BL, WRAP-IT Investigators. Antibacterial envelope to prevent cardiac implantable device infection.  N Engl J Med  2019; 380 :1895 \u0002 1905. 686. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A, Isaaz K, Touboul P. Antibiotic prophylaxis for permanent pacemaker implanta- tion: a meta-analysis.  Circulation  1998; 97 :1796 \u0002 1801. 687. Leyva F, Zegard A, Qiu T, Acquaye E, Ferrante G, Walton J, Marshall H. Cardiac resynchronization therapy using quadripolar versus non-quadripolar left ventricular leads programmed to biventricular pacing with single-site left ventricular pacing: impact on survival and heart failure hospitalization.  J Am Heart Assoc  2017; 6 :e007026. 688. Henrikson CA, Sohail MR, Acosta H, Johnson EE, Rosenthal L, Pachulski R, Dan D, Paladino W, Khairallah FS, Gleed K, Hanna I, Cheng A, Lexcen DR, Simons GR. Antibacterial envelope is associated with low infection rates after implant- able cardioverter-defibrillator and cardiac resynchronization therapy device replacement: results of the Citadel and Centurion studies. JACC Clin Electrophysiol  2017; 3 :1158 \u0002 1167. 689. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, Good E, Chugh A, Oral H, Bogun F, Morady F, Pelosi F Jr. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridg- ing therapy during implantation of cardiac rhythm devices.  Am J Cardiol 2012; 110 :1482 \u0002 1488.\nESC Guidelines 89\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 690. Udo EO, Zuithoff NP, van Hemel NM, de Cock CC, Hendriks T, Doevendans PA, Moons KG. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study.  Heart Rhythm  2012; 9 :728 \u0002 735. 691. Koneru JN, Jones PW, Hammill EF, Wold N, Ellenbogen KA. Risk factors and temporal trends of complications associated with transvenous implantable car- diac defibrillator leads.  J Am Heart Assoc  2018; 7 :e007691. 692. Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunas JL, Love JC, Hadjis TA, Lee KL, Lamas GA. Complications arising after implantation of DDD pacemakers: the MOST experience.  Am J Cardiol  2003; 92 :740 \u0002 741. 693. Parsonnet V, Bernstein AD, Lindsay B. Pacemaker-implantation complication rates: an analysis of some contributing factors. J Am Coll Cardiol 1989; 13 :917 \u0002 921. 694. Ranasinghe I, Labrosciano C, Horton D, Ganesan A, Curtis JP, Krumholz HM, McGavigan A, Hossain S, Air T, Hariharaputhiran S. Institutional variation in quality of cardiovascular implantable electronic device implantation: a cohort study.  Ann Intern Med  2019; 171 :309 \u0002 317. 695. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, Shinn T, Dan D, Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell K, Holcomb R, REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replace- ments and upgrade procedures: results from the REPLACE registry.  Circulation 2010; 122 :1553 \u0002 1561. 696. Biffi M, Ammendola E, Menardi E, Parisi Q, Narducci ML, De Filippo P, Manzo M, Stabile G, Potenza DR, Zanon F, Quartieri F, Rillo M, Saporito D, Zaca V, Berisso MZ, Bertini M, Tumietto F, Malacrida M, Diemberger I. Real-life out- come of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry.  Europace  2019; 21 :1527 \u0002 1536. 697. Hosseini SM, Moazzami K, Rozen G, Vaid J, Saleh A, Heist KE, Vangel M, Ruskin JN. Utilization and in-hospital complications of cardiac resynchronization ther- apy: trends in the United States from 2003 to 2013. Eur Heart J 2017; 38 :2122 \u0002 2128. 698. Zeitler EP, Patel D, Hasselblad V, Sanders GD, Al-Khatib SM. Complications from prophylactic replacement of cardiac implantable electronic device genera- tors in response to United States Food and Drug Administration recall: a sys- tematic review and meta-analysis.  Heart Rhythm  2015; 12 :1558 \u0002 1564. 699. Nowak B, Tasche K, Barnewold L, Heller G, Schmidt B, Bordignon S, Chun KR, Furnkranz A, Mehta RH. Association between hospital procedure volume and early complications after pacemaker implantation: results from a large, unse- lected, contemporary cohort of the German nationwide obligatory external quality assurance programme.  Europace  2015; 17 :787 \u0002 793. 700. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of random- ized clinical trials.  J Am Coll Cardiol  2011; 58 :995 \u0002 1000. 701. Wiegand UK, Bode F, Bonnemeier H, Eberhard F, Schlei M, Peters W. Long- term complication rates in ventricular, single lead VDD, and dual chamber pac- ing.  Pacing Clin Electrophysiol  2003; 26 :1961 \u0002 1969. 702. Olsen T, Jorgensen OD, Nielsen JC, Thogersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982 \u0002 2018).  Eur Heart J  2019; 40 :1862 \u0002 1869. 703. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz SM. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008.  J Am Coll Cardiol 2011; 58 :1001 \u0002 1006. 704. Rennert-May E, Chew D, Lu S, Chu A, Kuriachan V, Somayaji R. Epidemiology of cardiac implantable electronic device infections in the United States: a population-based cohort study.  Heart Rhythm  2020; 17 :1125 \u0002 1131. 705. Ozcan C, Raunso J, Lamberts M, Kober L, Lindhardt TB, Bruun NE, Laursen ML, Torp-Pedersen C, Gislason GH, Hansen ML. Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study.  Europace  2017; 19 :1007 \u0002 1014. 706. Dai M, Cai C, Vaibhav V, Sohail MR, Hayes DL, Hodge DO, Tian Y, Asirvatham R, Cochuyt JJ, Huang C, Friedman PA, Cha YM. Trends of cardiovascular implantable electronic device infection in 3 decades: a population-based study. JACC Clin Electrophysiol  2019; 5 :1071 \u0002 1080. 707. Palmisano P, Accogli M, Zaccaria M, Luzzi G, Nacci F, Anaclerio M, Favale S. Rate, causes, and impact on patient outcome of implantable device complica- tions requiring surgical revision: large population survey from two centres in Italy.  Europace  2013; 15 :531 \u0002 540. 708. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med  2011; 171 :1821 \u0002 1828. 709. Cantillon DJ, Dukkipati SR, Ip JH, Exner DV, Niazi IK, Banker RS, Rashtian M, Plunkitt K, Tomassoni GF, Nabutovsky Y, Davis KJ, Reddy VY. Comparative\nstudy of acute and mid-term complications with leadless and transvenous car- diac pacemakers.  Heart Rhythm  2018; 15 :1023 \u0002 1030. 710. Chahine J, Baranowski B, Tarakji K, Gad MM, Saliba W, Rickard J, Cantillon DJ, Diab M, Kanj M, Callahan T, Dresing T, Bhargava M, Chung M, Niebauer MJ, Varma N, Tchou P, Wilkoff BL, Wazni O, Hussein AA. Cardiac venous injuries: procedural profiles and outcomes during left ventricular lead placement for car- diac resynchronization therapy.  Heart Rhythm  2020; 17 :1298 \u0002 1303. 711. Seifert M, Schau T, Moeller V, Neuss M, Meyhoefer J, Butter C. Influence of pacing configurations, body mass index, and position of coronary sinus lead on frequency of phrenic nerve stimulation and pacing thresholds under cardiac resynchronization therapy.  Europace  2010; 12 :961 \u0002 967. 712. Biffi M, Moschini C, Bertini M, Saporito D, Ziacchi M, Diemberger I, Valzania C, Domenichini G, Cervi E, Martignani C, Sangiorgi D, Branzi A, Boriani G. Phrenic stimulation: a challenge for cardiac resynchronization therapy.  Circ Arrhythm Electrophysiol  2009; 2 :402 \u0002 410. 713. Rijal S, Wolfe J, Rattan R, Durrani A, Althouse AD, Marroquin OC, Jain S, Mulukutla S, Saba S. Lead related complications in quadripolar versus bipolar left ventricular leads.  Indian Pacing Electrophysiol J  2017; 17 :3 \u0002 7. 714. Nichols CI, Vose JG. Incidence of bleeding-related complications during primary implantation and replacement of cardiac implantable electronic devices.  J Am Heart Assoc  2017; 6 :e004263. 715. Wiegand UKH, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H, Bode F. Pocket hematoma after pacemaker or implantable cardioverter defibrilla- tor surgery: influence of patient morbidity, operation strategy, and perioperative anti- platelet/anticoagulation therapy.  Chest  2004; 126 :1177 \u0002 1186. 716. Van De Heyning CM, Elbarasi E, Masiero S, Brambatti M, Ghazal S, Al-Maashani S, Capucci A, Leong D, Shivalkar B, Saenen JB, Miljoen HP, Morillo CA, Divarakarmenon S, Amit G, Ribas S, Baiocco E, Maolo A, Romandini A, Maffei S, Connolly SJ, Healey JS, Dokainish H. Prospective study of tricuspid regurgitation associated with permanent leads after cardiac rhythm device implantation.  Can J Cardiol  2019; 35 :389 \u0002 395. 717. Cho MS, Kim J, Lee JB, Nam GB, Choi KJ, Kim YH. Incidence and predictors of moderate to severe tricuspid regurgitation after dual-chamber pacemaker implantation.  Pacing Clin Electrophysiol  2019; 42 :85 \u0002 92. 718. Lee RC, Friedman SE, Kono AT, Greenberg ML, Palac RT. Tricuspid regurgita- tion following implantation of endocardial leads: incidence and predictors. Pacing Clin Electrophysiol  2015; 38 :1267 \u0002 1274. 719. Link MS, Hellkamp AS, Estes NA 3rd, Orav EJ, Ellenbogen KA, Ibrahim B, Greenspon A, Rizo-Patron C, Goldman L, Lee KL, Lamas GA, MOST Study Investigators. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST).  J Am Coll Cardiol  2004; 43 :2066 \u0002 2071. 720. van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman MV. Incidence and risk factors of early venous thrombosis associated with per- manent pacemaker leads.  J Cardiovasc Electrophysiol  2004; 15 :1258 \u0002 1262. 721. Da Costa SSdC, Scalabrini Neto A, Costa R, Caldas JG, Martinelli Filho M. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study.  Pacing Clin Electrophysiol  2002; 25 :1301 \u0002 1306. 722. Ascoeta MS, Marijon E, Defaye P, Klug D, Beganton F, Perier M-C, Gras D, Algalarrondo V, Deharo J-C, Leclercq C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Boveda S, Piot O, DAI-PP Investigators. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention.  Heart Rhythm  2016; 13 :1045 \u0002 1051. 723. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, Simon AW. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators.  J Am Coll Cardiol  2006; 47 :2493 \u0002 2497. 724. Sridhar AR, Yarlagadda V, Yeruva MR, Kanmanthareddy A, Vallakati A, Dawn B, Lakkireddy D. Impact of haematoma after pacemaker and CRT device implanta- tion on hospitalization costs, length of stay, and mortality: a population-based study.  Europace  2015; 17 :1548 \u0002 1554. 725. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska- Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL, ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).  Eur Heart J  2015; 36 :3075 \u0002 3128. 726. Clementy N, Carion PL, Leotoing L, Lamarsalle L, Wilquin-Bequet F, Brown B, Verhees KJP, Fernandes J, Deharo JC. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study.  Europace  2018; 20 :1974 \u0002 1980.\n90 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ 727. Rattanawong P, Kewcharoen J, Mekraksakit P, Mekritthikrai R, Prasitlumkum N, Vutthikraivit W, Putthapiban P, Dworkin J. Device infections in implantable car- dioverter defibrillators versus permanent pacemakers: a systematic review and meta-analysis.  J Cardiovasc Electrophysiol  2019; 30 :1053 \u0002 1065. 728. Prutkin JM, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal S, Uslan DZ. Rates of and factors associated with infection in 200 909 Medicare implant- able cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry.  Circulation  2014; 130 :1037 \u0002 1043. 729. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, Wilson WR, Steckelberg JM, Baddour LM. Permanent pacemaker and implantable cardi- overter defibrillator infection: a population-based study.  Arch Intern Med 2007; 167 :669 \u0002 675. 730. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction fol- lowing pacemaker or cardioverter-defibrillator implantation.  J Am Coll Cardiol 2017; 69 :2331 \u0002 2341. 731. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long- term survival.  J Am Coll Cardiol  2004; 43 :405 \u0002 409. 732. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, Schalij MJ, Bax JJ, Delgado V, Marsan NA. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up.  Heart 2014; 100 :960 \u0002 968. 733. Mutlak D, Aronson D, Lessick J, Reisner SA, Dabbah S, Agmon Y. Functional tri- cuspid regurgitation in patients with pulmonary hypertension: is pulmonary artery pressure the only determinant of regurgitation severity? Chest 2009; 135 :115 \u0002 121. 734. Schleifer JW, Pislaru SV, Lin G, Powell BD, Espinosa R, Koestler C, Thome T, Polk L, Li Z, Asirvatham SJ, Cha YM. Effect of ventricular pacing lead position on tricuspid regurgitation: a randomized prospective trial.  Heart Rhythm 2018; 15 :1009 \u0002 1016. 735. Cheng Y, Gao H, Tang L, Li J, Yao L. Clinical utility of three-dimensional echo- cardiography in the evaluation of tricuspid regurgitation induced by implantable device leads.  Echocardiography  2016; 33 :1689 \u0002 1696. 736. Beurskens NEG, Tjong FVY, de Bruin-Bon RHA, Dasselaar KJ, Kuijt WJ, Wilde AAM, Knops RE. Impact of leadless pacemaker therapy on cardiac and atrioven- tricular valve function through 12 months of follow-up.  Circ Arrhythm Electrophysiol  2019; 12 :e007124. 737. Addetia K, Harb SC, Hahn RT, Kapadia S, Lang RM. Cardiac implantable elec- tronic device lead-induced tricuspid regurgitation.  JACC Cardiovasc Imaging 2019; 12 :622 \u0002 636. 738. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodes-Cabau J, Schafer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation.  J Am Coll Cardiol  2019; 74 :2998 \u0002 3008. 739. Auricchio A, Gasparini M, Linde C, Dobreanu D, Cano O, Sterlinski M, Bogale N, Stellbrink C, Refaat MM, Blomstrom-Lundqvist C, Lober C, Dickstein K, Normand C. Sex-related procedural aspects and complications in CRT Survey II: a multicenter European experience in 11,088 patients.  JACC Clin Electrophysiol 2019; 5 :1048 \u0002 1058. 740. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness.  Milbank Q  1996; 74 :511 \u0002 544. 741. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation.  Eur Heart J 2012; 33 :2692 \u0002 2699. 742. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R, Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: a system- atic review and meta-analysis.  Heart  2017; 103 :1947 \u0002 1953. 743. Wijtvliet E, Tieleman RG, van Gelder IC, Pluymaekers N, Rienstra M, Folkeringa RJ, Bronzwaer P, Elvan A, Elders J, Tukkie R, Luermans J, Van Asselt A, Van Kuijk SMJ, Tijssen JG, Crijns H, RACE Investigators. Nurse-led vs. usual-care for atrial fibrillation.  Eur Heart J  2020; 41 :634 \u0002 641. 744. Russo RJ, Costa HS, Silva PD, Anderson JL, Arshad A, Biederman RW, Boyle NG, Frabizzio JV, Birgersdotter-Green U, Higgins SL, Lampert R, Machado CE, Martin ET, Rivard AL, Rubenstein JC, Schaerf RH, Schwartz JD, Shah DJ, Tomassoni GF, Tominaga GT, Tonkin AE, Uretsky S, Wolff SD. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator.  N Engl J Med  2017; 376 :755 \u0002 764.\n",
      "keywords": [
        "haas",
        "echo",
        "bradycardia",
        "crt",
        "heart",
        "muscular",
        "frese",
        "pacemaker",
        "anticoagulation",
        "mutations",
        "tricuspid",
        "keller",
        "dystrophy",
        "hypertension",
        "pulmonary hypertension",
        "emery",
        "arrhythmia",
        "sex",
        "lamin",
        "mri",
        "kloos",
        "caused",
        "dreifuss",
        "atrial fibrillation",
        "echocardiography",
        "cardiac",
        "ecg",
        "heart failure",
        "primary prevention",
        "gene"
      ],
      "tables": []
    },
    {
      "number": "96",
      "title": "745. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke GD, Dickfeld TL, Froelich JW, Grant J, Hayes DL, Heidbuchel H, Idriss SF, Kanal E, Lampert R, Machado CE, Mandrola JM,",
      "start_page": 90,
      "end_page": 93,
      "content": "ESC Guidelines 91\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ comprehensive practical guideline in The Netherlands. Dutch Society of Radiotherapy and Oncology (NVRO).  Radiat Oncol  2012; 7 :198. 763. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R, Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors.  Int J Radiat Oncol Biol Phys  2013; 87 :570 \u0002 575. 764. Tjong FVY, de Ruijter UW, Beurskens NEG, Knops RE. A comprehensive scop- ing review on transvenous temporary pacing therapy. Neth Heart J 2019; 27 :462 \u0002 473. 765. Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit.  Mayo Clin Proc  1983; 58 :122 \u0002 126. 766. Ferri LA, Farina A, Lenatti L, Ruffa F, Tiberti G, Piatti L, Savonitto S. Emergent transvenous cardiac pacing using ultrasound guidance: a prospective study ver- sus the standard fluoroscopy-guided procedure.  Eur Heart J Acute Cardiovasc Care  2016; 5 :125 \u0002 129. 767. Lang R, David D, Klein HO, Di Segni E, Libhaber C, Sareli P, Kaplinsky E. The use of the balloon-tipped floating catheter in temporary transvenous cardiac pacing.  Pacing Clin Electrophysiol  1981; 4 :491 \u0002 496. 768. Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters.  Lancet  1997; 349 :1883. 769. Austin JL, Preis LK, Crampton RS, Beller GA, Martin RP. Analysis of pacemaker malfunction and complications of temporary pacing in the coronary care unit. Am J Cardiol  1982; 49 :301 \u0002 306. 770. Hill PE. Complications of permanent transvenous cardiac pacing: a 14-year review of all transvenous pacemakers inserted at one community hospital. Pacing Clin Electrophysiol  1987; 10 :564 \u0002 570. 771. Murphy JJ. Current practice and complications of temporary transvenous car- diac pacing.  BMJ  1996; 312 :1134. 772. Bjornstad CC, Gjertsen E, Thorup F, Gundersen T, Tobiasson K, Otterstad JE. Temporary cardiac pacemaker treatment in five Norwegian regional hospitals. Scand Cardiovasc J  2012; 46 :137 \u0002 143. 773. Lopez Ayerbe J, Villuendas Sabate R, Garcia Garcia C, Rodriguez Leor O, Gomez Perez M, Curos Abadal A, Serra Flores J, Larrousse E, Valle V. [Temporary pace- makers: current use and complications].  Rev Esp Cardiol  2004; 57 :1045 \u0002 1052. 774. Ng ACC, Lau JK, Chow V, Adikari D, Brieger D, Kritharides L. Outcomes of 4838 patients requiring temporary transvenous cardiac pacing: a statewide cohort study.  Int J Cardiol  2018; 271 :98 \u0002 104. 775. Metkus TS, Schulman SP, Marine JE, Eid SM. Complications and outcomes of temporary transvenous pacing: an analysis of >360,000 patients from the National Inpatient Sample.  Chest  2019; 155 :749 \u0002 757. 776. Lever N, Ferguson JD, Bashir Y, Channon KM. Prolonged temporary cardiac pacing using subcutaneous tunnelled active-fixation permanent pacing leads. Heart  2003; 89 :209 \u0002 210. 777. Rastan AJ, Doll N, Walther T, Mohr FW. Pacemaker dependent patients with device infection—a modified approach. Eur J Cardiothorac Surg 2005; 27 :1116 \u0002 1118. 778. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using trans- venous active fixation leads and external re-sterilized pulse generators.  J Am Coll Cardiol  2006; 47 :1487 \u0002 1489. 779. Kawata H, Pretorius V, Phan H, Mulpuru S, Gadiyaram V, Patel J, Steltzner D, Krummen D, Feld G, Birgersdotter-Green U. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pace- makers after lead extraction.  Europace  2013; 15 :1287 \u0002 1291. 780. Timothy PR, Rodeman BJ. Temporary pacemakers in critically ill patients: assessment and management strategies.  AACN Clin Issues  2004; 15 :305 \u0002 325. 781. Abd Elaziz ME, Allama AM. Temporary epicardial pacing after valve replace- ment: incidence and predictors.  Heart Surg Forum  2018; 21 :E049 \u0002 E053. 782. Lazarescu C, Mertes PM, Longrois D. [Temporary epicardial pacing following cardiac surgery: practical aspects].  Ann Fr Anesth Reanim  2013; 32 :592 \u0002 601. 783. Bektas F, Soyuncu S. The efficacy of transcutaneous cardiac pacing in ED.  Am J Emerg Med  2016; 34 :2090 \u0002 2093. 784. Quast ABE, Beurskens NEG, Ebner A, Wasley R, Vehmeijer JT, Marcovecchio A, Sanghera R, Knops RE, Burke MC. Feasibility of an entirely extracardiac, minimally invasive, temporary pacing system.  Circ Arrhythm Electrophysiol  2019; 12 :e007182. 785. Sherbino J, Verbeek PR, MacDonald RD, Sawadsky BV, McDonald AC, Morrison LJ. Prehospital transcutaneous cardiac pacing for symptomatic brady- cardia or bradyasystolic cardiac arrest: a systematic review.  Resuscitation 2006; 70 :193 \u0002 200. 786. American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pace- makers and implantable cardioverter-defibrillators: an updated report by the American Society of Anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. Anesthesiology 2011; 114 :247 \u0002 261. 787. Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK, Ferguson TB, Gallagher JD, Gold MR, Hoyt RH, Irefin S, Kusumoto FM,\nMoorman LP, Thompson A. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perio- perative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS).  Heart Rhythm  2011; 8 :1114 \u0002 1154. 788. Healey JS, Merchant R, Simpson C, Tang T, Beardsall M, Tung S, Fraser JA, Long L, van Vlymen JM, Manninen P, Ralley F, Venkatraghavan L, Yee R, Prasloski B, Sanatani S, Philippon F, Canadian Cardiovascular Society, Canadian Anesthesiologists’ Society, Canadian Heart Rhythm Society. Canadian Cardiovascular Society/Canadian Anesthesiologists’ Society/Canadian Heart Rhythm Society joint position statement on the perioperative management of patients with implanted pacemakers, defibrillators, and neurostimulating devi- ces.  Can J Cardiol  2012; 28 :141 \u0002 151. 789. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A, Dan GA, Genovesi S, Israel C, Joung B, Kalarus Z, Lampert R, Malavasi VL, Mansourati J, Mont L, Potpara T, Thornton A, Lip GYH, ESC Scientific Document Group. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS) . Europace  2019; 21 :7 \u0002 8. 790. Schulman PM, Treggiari MM, Yanez ND, Henrikson CA, Jessel PM, Dewland TA, Merkel MJ, Sera V, Harukuni I, Anderson RB, Kahl E, Bingham A, Alkayed N, Stecker EC. Electromagnetic interference with protocolized electrosurgery dispersive electrode positioning in patients with implantable cardioverter defib- rillators.  Anesthesiology  2019; 130 :530 \u0002 540. 791. Gifford J, Larimer K, Thomas C, May P. ICD-ON Registry for perioperative management of CIEDs: most require no change.  Pacing Clin Electrophysiol 2017; 40 :128 \u0002 134. 792. Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, Delise P, Blomstrom-Lundqvist C, Vanhees L, Ivarhoff P, Dorwarth U, Pelliccia A, Study Group on Sports Cardiology of the European Association for Cardiovascular Prevention Rehabilitation. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: supraventricular arrhythmias and pacemakers.  Eur J Cardiovasc Prev Rehabil  2006; 13 :475 \u0002 484. 793. Lampert R. Managing with pacemakers and implantable cardioverter defibrilla- tors.  Circulation  2013; 128 :1576 \u0002 1585. 794. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G. Recommendations for competitive sports par- ticipation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.  Eur Heart J 2005; 26 :1422 \u0002 1445. 795. Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, Solberg EE, Wilhelm M, Pelliccia A. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and poten- tially arrhythmogenic conditions: Part 1: supraventricular arrhythmias. A posi- tion statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology.  Eur J Prev Cardiol  2020;doi: 10.1177/2047487320925635 796. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.  Eur Heart J  2020; 42 :17 \u0002 96. 797. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C, Broos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D. Safety of sports for athletes with implantable cardioverter-defibrillators: long- term results of a prospective multinational registry. Circulation 2017; 135 :2310 \u0002 2312. 798. Heidbuchel H, Arbelo E, D’Ascenzi F, Borjesson M, Boveda S, Castelletti S, Miljoen H, Mont L, Niebauer J, Papadakis M, Pelliccia A, Saenen J, Sanz de la\n92 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. ............................................................................................................................................................................ Garza M, Schwartz PJ, Sharma S, Zeppenfeld K, Corrado D. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace  2021; 23 :147 \u0002 148. 799. Hauser RG, Hayes DL, Kallinen LM, Cannom DS, Epstein AE, Almquist AK, Song SL, Tyers GF, Vlay SC, Irwin M. Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm  2007; 4 :154 \u0002 160. 800. Merchant FM, Tejada T, Patel A, El-Khalil J, Desai Y, Keeling B, Lattouf OM, Leon AR, El-Chami MF. Procedural outcomes and long-term survival associated with lead extraction in patients with abandoned leads. Heart Rhythm 2018; 15 :855 \u0002 859. 801. Diemberger I, Mazzotti A, Giulia MB, Biffi M, Cristian M, Massaro G, Matteo M, Martignani C, Letizia ZM, Ziacchi M, Reggiani B, Reggiani ML, Battistini P, Boriani G. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. Expert Rev Med Devices  2013; 10 :551 \u0002 573. 802. Bongiorni MG, Kennergren C, Butter C, Deharo JC, Kutarski A, Rinaldi CA, Romano SL, Maggioni AP, Andarala M, Auricchio A, Kuck KH, Blomstro¨m- Lundqvist C, ELECTRa Investigators. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J 2017; 38 :2995 \u0002 3005. 803. Segreti L, Rinaldi CA, Claridge S, Svendsen JH, Blomstrom-Lundqvist C, Auricchio A, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Kempa M, Magnani A, Casteigt B, Bongiorni MG, ELECTRa Investigators. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry sub-analysis.  Europace  2019; 21 :645 \u0002 654. 804. Parthiban N, Esterman A, Mahajan R, Twomey DJ, Pathak RK, Lau DH, Roberts-Thomson KC, Young GD, Sanders P, Ganesan AN. Remote monitoring of implantable cardioverter-defibrillators: a systematic review and meta-analysis of clinical outcomes.  J Am Coll Cardiol  2015; 65 :2591 \u0002 2600. 805. Garcia-Fernandez FJ, Osca Asensi J, Romero R, Fernandez Lozano I, Larrazabal JM, Martinez Ferrer J, Ortiz R, Pombo M, Tornes FJ, Moradi Kolbolandi M. Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE).  Eur Heart J  2019; 40 :1837 \u0002 1846. 806. Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A, Binet D, Daubert JC, COMPAS Trial Investigators. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J 2012; 33 :1105 \u0002 1111. 807. Vogtmann T, Stiller S, Marek A, Kespohl S, Gomer M, Ku¨hlkamp V, Zach G, Lo¨scher S, Baumann G. Workload and usefulness of daily, centralized home monitoring for patients treated with CIEDs: results of the MoniC (Model Project Monitor Centre) prospective multicentre study. Europace 2013; 15 :219 \u0002 226. 808. Nielsen JC, Kautzner J, Casado-Arroyo R, Burri H, Callens S, Cowie MR, Dickstein K, Drossart I, Geneste G, Erkin Z, Hyafil F, Kraus A, Kutyifa V, Marin E, Schulze C, Slotwiner D, Stein K, Zanero S, Heidbuchel H, Fraser AG. Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles—ESC Regulatory Affairs Committee/EHRA joint task force report.  Europace  2020; 22 :1742 \u0002 1758. 809. Perl S, Stiegler P, Rotman B, Prenner G, Lercher P, Anelli-Monti M, Sereinigg M, Riegelnik V, Kvas E, Kos C, Heinzel FR, Tscheliessnigg KH, Pieske B. Socio-eco- nomic effects and cost saving potential of remote patient monitoring (SAVE- HM trial).  Int J Cardiol  2013; 169 :402 \u0002 407. 810. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation.  Europace  2009; 11 :54 \u0002 61. 811. McCance T, McCormack B, Dewing J. An exploration of person-centredness in practice.  Online J Issues Nurs  2011; 16 :1. 812. Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient-centred care? A narrative review and synthesis of the literature from health policy, medicine and nursing.  J Adv Nurs  2013; 69 :4 \u0002 15. 813. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, Carlsson J, Dahlin-Ivanoff S, Johansson IL, Kjellgren K, Liden E, Ohlen J, Olsson LE, Rosen H, Rydmark M, Sunnerhagen KS. Person-centered care—ready for prime time. Eur J Cardiovasc Nurs  2011; 10 :248 \u0002 251. 814. Kiesler DJ, Auerbach SM. Optimal matches of patient preferences for informa- tion, decision-making and interpersonal behavior: evidence, models and inter- ventions.  Patient Educ Couns  2006; 61 :319 \u0002 341. 815. Alston C, Paget L, Halvorson G, Novelli B, Guest J, McCabe P, Hoffman K, Koepke C, Simon M, Sutton S, Okun S, Wicks P, Undem T, Rohrbach V, von Kohorn I.  Communicating with Patients on Health Care Evidence . Washington, DC:\nInstitute of Medicine of the National Academies; 2012. http://www.iom.edu/ evidence. 816. Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs.  Health Aff (Millwood)  2013; 32 :207 \u0002 214. 817. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encoun- ter: what does it mean? (or it takes at least two to tango).  Soc Sci Med 1997; 44 :681 \u0002 692. 818. Towle A, Godolphin W. Framework for teaching and learning informed shared decision making.  BMJ  1999; 319 :766 \u0002 771. 819. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters.  Patient Educ Couns  2006; 60 :301 \u0002 312. 820. Pitcher D, Soar J, Hogg K, Linker N, Chapman S, Beattie JM, Jones S, George R, McComb J, Glancy J, Patterson G, Turner S, Hampshire S, Lockey A, Baker T, Mitchell S. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care.  Heart  2016; 102 Suppl 7 :A1-a17. 821. The SHARE Approach. https://www.ahrq.gov/health-literacy/professional-train ing/shared-decision/index.html (25 May 2021) 822. International Patient Decision Aid Standards (IPDAS). IPDAS Collaboration Background Document,. ipdas.ohri.ca/IPDAS_Background.pdf (25 May 2021) 823. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for people facing health treatment or screening decisions.  Cochrane Database Syst Rev  2017; 4 :Cd001431. 824. De Oliveira GS Jr, McCarthy RJ, Wolf MS, Holl J. The impact of health literacy in the care of surgical patients: a qualitative systematic review.  BMC Surg 2015; 15 :86. 825. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Viera A, Crotty K, Holland A, Brasure M, Lohr KN, Harden E, Tant E, Wallace I, Viswanathan M. Health literacy interventions and outcomes: an updated systematic review.  Evid Rep Technol Assess (Full Report)  2011:1 \u0002 941. 826. Wolf A, Vella R, Fors A. The impact of person-centred care on patients’ care experiences in relation to educational level after acute coronary syndrome: sec- ondary outcome analysis of a randomised controlled trial.  Eur J Cardiovasc Nurs 2019; 18 :299 \u0002 308. 827. Marcus C. Strategies for improving the quality of verbal patient and family edu- cation: a review of the literature and creation of the EDUCATE model.  Health Psychol Behav Med  2014; 2 :482 \u0002 495. 828. Friedman AJ, Cosby R, Boyko S, Hatton-Bauer J, Turnbull G. Effective teaching strategies and methods of delivery for patient education: a systematic review and practice guideline recommendations.  J Cancer Educ 2011; 26 :12 \u0002 21. 829. Sustersic M, Gauchet A, Foote A, Bosson JL. How best to use and evaluate Patient Information Leaflets given during a consultation: a systematic review of literature reviews.  Health Expect  2017; 20 :531 \u0002 542. 830. Elwyn G, Lloyd A, Joseph-Williams N, Cording E, Thomson R, Durand MA, Edwards A. Option grids: shared decision making made easier.  Patient Educ Couns  2013; 90 :207 \u0002 212. 831. Dwamena F, Holmes-Rovner M, Gaulden CM, Jorgenson S, Sadigh G, Sikorskii A, Lewin S, Smith RC, Coffey J, Olomu A. Interventions for providers to pro- mote a patient-centred approach in clinical consultations.  Cochrane Database Syst Rev  2012; 12 :Cd003267. 832. Olsson LE, Jakobsson Ung E, Swedberg K, Ekman I. Efficacy of person-centred care as an intervention in controlled trials—a systematic review.  J Clin Nurs 2013; 22 :456 \u0002 465. 833. McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, Wheeler AJ. Patient- centered approaches to health care: a systematic review of randomized con- trolled trials.  Med Care Res Rev  2013; 70 :567 \u0002 596. 834. Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Swedberg K. Effects of person-centred care in patients with chronic heart failure: the PCC- HF study.  Eur Heart J  2012; 33 :1112 \u0002 1119. 835. Ulin K, Olsson LE, Wolf A, Ekman I. Person-centred care—an approach that improves the discharge process.  Eur J Cardiovasc Nurs  2016; 15 :e19 \u0002 e26. 836. Dudas K, Olsson LE, Wolf A, Swedberg K, Taft C, Schaufelberger M, Ekman I. Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care. Eur J Cardiovasc Nurs 2013; 12 :521 \u0002 528. 837. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United Kingdom after removal of financial incentives. N Engl J Med 2018; 379 :948 \u0002 957. 838. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 years into global payment.  N Engl J Med  2019; 381 :252 \u0002 263. 839. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P, Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of\nESC Guidelines 93\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n. .................................... Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes.  Eur Heart J Qual Care Clin Outcomes  2020;TO BE UPDATED:doi: 10.1093/ehjqcco/qcaa1069. Online ahead of print. 840. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT, Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T, Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N, Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R, Providencia R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer TV, Martins Oliveira M. Quality indicators for the care and outcomes of adults with atrial fibrillation.  Europace  2021; 23 :494 \u0002 495. 841. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients pre-\nsenting without persistent ST-segment elevation. Eur Heart J 2021; 42 :1289 \u0002 1367. 842. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European unified registries on heart care evaluation and randomized trials.  Eur Heart J 2019; 40 :2745 \u0002 2749. 843. Zhang S, Gaiser S, Kolominsky-Rabas PL. Cardiac implant registries 2006 \u0002 2016: a systematic review and summary of global experiences.  BMJ Open 2018; 8 :e019039. 844. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomstro¨m-Lundqvist C, Boriani G, Defaye P, Deharo J-C, Drossart I, Foldager D, Gold MR, Johansen JB, Leyva F, Linde C, Michowitz Y, Kronborg MB, Slotwiner D, Steen T, Tolosana JM, Tzeis S, Varma N, Glikson M, Nielsen J-C, Gale CP. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing Developed by the Working Group for Cardiac Pacing Quality Indicators in col- laboration with the European Heart Rhythm Association of the European Society of Cardiology.  Europace  2021;doi:10.1093/europace/euab193.\n94 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/35/3427/6358547 by guest on 14 January 2026\n",
      "keywords": [
        "clarke",
        "alkmim",
        "guideline",
        "physical activity",
        "pacemaker",
        "hayes",
        "indik",
        "dickfeld",
        "birgersdotter",
        "machado",
        "idriss",
        "arrhythmia",
        "icd",
        "heidbuchel",
        "mandrola",
        "atrial fibrillation",
        "froelich",
        "grant",
        "heart failure",
        "kanal",
        "exercise",
        "gimbel",
        "lampert",
        "teixeira",
        "green"
      ],
      "tables": []
    }
  ]
}